FORM 2 The Patents Act, 1970 (39 of 1970) & The Patent Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) 'N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS" ABBOTT LABORATORIES, a company incorporated in U.S.A. having its Registered Office at Dept. 377 Bldg. AP6A-1,100 Abbott Park Road, Abbott Park, Illinois, 60064-6008, (US). The following specification particularly describes the invention and the manner in which it is to be performed WO2005/049594 PCTAJS2004/037911 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS FIELD OF THE INVENTION This invention pertains to compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds, and uses of the compounds for preparing medicaments for treating diseases during which are expressed of one or more than one of an anti-apoptotic protein family member. BACKGROUND OF THE INVENTION Anti-apoptotic protein family members are associated with a number of diseases. There is therefore an existing need in the therapeutic arts for compounds which inhibit the activity of one of more than one of an anti-apoptotic protein family member. - 1 - WO2005/049594 PCT/US2004/037911 SUMMARY OF THE INVENTION One embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as inhibitors one or more than one anti-apoptotic protein family member, the compounds having formula (I) 0 0 0 E1 zlArVrYl (I), wherein A1 is N or C(A2); one or two or three or each of A , B , D and E are independently selected R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)OR1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHCtOR1, NHC(O)R1, NR-fOJNHR1, NR1C (O)N (R1) 2, SO2NHR1, SO2N(R1)2, NHSO2R1, NHSO2NHR1 or N(CH3)SO2N(CH3)R1, and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(O)OH, C(O)NH2 or C(O)OR1A; and Y1 is H, CN, NO2, C(O)OH, F, CI, Br, I, CF3, OCF3/ CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, NH2, NHR17, N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C (O) N (R17) 2, NHS(O)R17 or NHSO2R17; or B1and Y1 , together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of selected R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)R1, OC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2f NHC(O)R1, NHC(O)OR1, NHC(O)NHR1 N(CH3)C(O)N(CH3)R1, SO2NHR1, SO2N(R1)2/ NHSO2R1, NHSO2NHR1 or N(CH3)SO2N(CH3)R1, and the remainder are - 2 - WO2005/049594 PCT/US2004/037911 independently selected H, F, CI, Br, I, CF3, C(O)OH, C(O)NH2 or C(O)OR1A; R1 is RZ, R3, R4 or R5; R1A is C1-C6-alkyl, C3-C6-alkenyl or C3-C6-alkynyl; R2 is phenyl which is unfused or fused with arene, heteroarene or R2A ; R2A is cycloalkane or heterocycloalkane; R is heteroaryl which is unfused or fused with benzene, heteroarene or R3A ; R3A is cycloalkane or heterocycloalkane; R is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R4A ; R4A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R5 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R6, NC(R6A) (R6B), R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)0R7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC (O) NHR7, NHC (O) CH (CH3)NHC (O) CH (CH3) NH2, NHC(O)CH(CH3)NHC(O),CH(CH3)NHR1, OH, (O), C(O)OH, (O) , N3, CN, NH2, CF3, CF2CF3f F, CI, Br or I substituents; R6 is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, .CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R6A and R6A are independently selected alkyl or, together with the N to which they are attached, R ; R6C is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH; - 3 - WO2005/049594 PCT/US2004/037911 R7 is R8, R9, R10 or R11; R8 is phenyl which is unfused or fused with arene, heteroarene or R8A ; R8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; , R9 is heteroaryl which is unfused or fused with arene, heteroarene or R9A ; R9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R10 is C3-C10-cycloalkyl or C4-C10-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S (O) , SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R1A; R1A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R11 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R12, OR12, NHR12, N(R12)2, C(O)NH2, C(O)NHR12, C(O)N(R12)2, OH, (O) , C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R12 is R13, R14, R15 or R16; R13 is phenyl which is unfused or fused with arene, heteroarene or R13A; R 13A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; . • R14 is heteroaryl, each of which is unfused or fused with arene, heteroarene or R14A ; R14A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R15 is cycloalkane, cycloalkene, heterocycloalkene, each of which is unfused or fused with WO2005/049594 PCT/US2004/037911 arene, heteroarene or R15A ; R15A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R16 is alkyl, alkenyl or alkynyl; R17 is R18, R19, R20 or R21; . R18 is phenyl which is unfused or fused with arene, heteroarene or R18 ; R18 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R19 is heteroaryl which is unfused or fused with arene, heteroarene or R19 ; R19 is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R20 is C3-C10-cycloalkyl or C4-C10-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene,, heteroarene or R A; R A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R21 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R22,. OR22, NHR22, N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R22 is R23, R24 or R25; R23 is phenyl which is unfused or fused with arene, heteroarene or R2A; R2A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R24 is heteroarene which is unfused or fused with arene, heteroarene or R24A; R24A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -5- WO2005/049594 PCT/US2004/037911 R25 is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R25A ; R25A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z1 is R or R , each of which is substituted with R28, R29 or R30 , each of which is substituted with F, CI, Br, I, CH2R37, CH(R31) (R37), C(R31) (R31A) (R37) , C(O)R37, OR37, SR37, S(O)R37, SO2R37, NHR37 or N(R32)R37; R26 is phenyl which is unfused or fused with arene or heteroarene; R27 is heteroarene which is unfused or fused with arene or heteroarene; R28 is phenyl which is unfused or fused with arene, heteroarene or R28A ; R28A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene R29 is heteroaryl or R29A ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R30 is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R31 and R31A are independently F, CI, Br or alkyl or are taken together and are C2-C5-spiroalkyl; - 6 - WO2005/049594 PCT/US2004/037911 R32 is R33, C(O)R33 or C(O)OR33; R33 is R34 or R35 ; R is phenyl which is unfused or fused with aryl, 34A heteroaryl or R34A ; R34A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R35 is alkyl which is unsubstituted or substituted with R36; R36 is phenyl which is unfused or fused with arene, heteroarene or R36A; R36A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R37 is R38, R39 or R40, each of which is substituted with F, CI, Br, I, R41, OR41, NHR41, N(R41)2, NHC(O)OR41, SR41, S(O)R41 or SO2R41; R38 is phenyl which is unfused or fused with arene, heteroarene or R ; R A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R39 is heteroaryl which is unfused or fused with arene, heteroarene or R39A ; R39A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R40 is C3-C8-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 41 -42 43 44 45 R is R , R , R or R ; WO2005/049594 PCT/US2004/037911 R42 is phenyl which is unfused or fused with arene, 42A 42A heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R43 is heteroaryl which is unfused or fused with arene, 43A 43A heteroarene or R ,; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R43 is C3-C5-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R45 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R46, OR46, NHR46, N(R46)2, C(O)NH2, C(O)NHR46, C(O)N(R46)2, OH, (O), C<0)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I substituents; R46 is R47, R48 or R49; R is phenyl which is unfused or fused with arene, heteroarene or R47A ; R47A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R48 is heteroaryl or R48A; R48A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R49 is C3-C6-cycloalkyl or C3-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene - 8 - WO2005/049594 PCT/US2004/037911 or R49A ; R49A is cycloalkane,cycloalkene, heterocycloalkane or heterocycloalkene; wherein each foregoing cyclic moiety is independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R50, OR50, SR50, S(O)R50, SO2R5°, C(O)R50,' CO(O)R50, OC(O)R5°, OC(O)OR5°, NH2, NHR50, N(R50)2, C(O)NH2, C(O)NHR50, C(O)N(R50)2, C(O)NHOH, C(O)NH0R50, C (O) NHSO2R5°, C(O)NR55SO2R5°, SO2NH2, SO2NHR50, SO2N(R50)2, CF3, CF2CF3, C(O)H, C(O)OH, C(N)NH2, C(N)NHR50, C(N)N(R50)2, OH, (O), N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R50 is R51, R52, R53 or R54; R 1 is phenyl which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R52 is heteroaryl or R52A; R52A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R53 is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3f S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R53A ; R53A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R54 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R55, OR55, SR55, S(O)R5S, SO2R55, NHR55, N(R55)2, C(O)R55, C(O) NH2/ C(O)NHR55, NHC(O)R55, NHSO2R55, NHC(O)OR55, SO2NH2, SO2NHR55, SO2N(R55)2, NHC(O)NH2, NHC(O)NHR55, - 9 - WO2005/049594 PCT/US2004/037911 OH,(O), C(O)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R55 is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R56 ; R56 is C3-C6-cycloalkyl or C4-C6-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Still another embodiment pertains to compounds having formula (I)-a 0 o 0 E1 zi-H-SrS"YlR5a (I)-a, or therapeutically acceptable salts, prodrugs or salts of: prodrugs thereof, wherein R5a is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R6, NC (R6A) (R6B), R7, OR7, SR7, S(O)R7, ,SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC (O) NHR7, NHC (O) CH (CH3) NHC (O) CH (CH3) NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NHR1, OH, (O), C(O)OH, (O) , N3, CN, NH2, CF3f CF2CF3, Fr Cl, Br or I substituents. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A. is N or C(A ); A2 is H, F, CN, C(O)OH, C(O)NH2 or C(O)0R1A; B1 is R1, OR1, SR1, S(O)R1, SO2R1, C(O)R1, C(O)0R1, OC(O)R1, NHR1, NCR1) 2, C(O)NHR1, C(O)N{R1)2, NHCCOJR1, NHC (O) OR1, - 10 - WO2005/049594 PCT/US2004/037911 NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NHR1, SO2N(R1)2, NHSO2R1, NHSOzNHR1 or N(CH3)SO2N(CH3)R1; D1 is H, F, CI or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(O)R17, C(O)OR17, SR17, NH2, NHR17, N(R17)2, NHC(O)R17, C(O)NH2, C(O)NHR17, C(O)N{R17)2, NHS(O)R17 or NHSO2R17; or B1 and Y , together with the atoms to which they are attached, are imidazole or triazole; R1 is R2, R3, R4 or R5; R1A is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl, C6-alkyl; R2 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine I or 1,2,3-triazole; R3 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl/ each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R4 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, Ce-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or - 11 - WO2005/049594 PCT/US2004/037911 C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O/ C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R5 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl, C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl, C6-alkenyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R6, R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)0R7, SO2NH2, SO2NHR7r SO2N(R7)2/ NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, OH, (O), C(O)OH, (O), N3/ CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R6 is C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl or C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O) , N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R7 is R8, R9, R10 or R11; R is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R ; R8A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O),.CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; - 12 - WO2005/049594 PCT/US2004/037911 R9 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R10 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, Ce-cycloalkyl, C6-cycloalkyl, C10-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl, C8-cycloalkenyl, C9-cycloalkenyl, C10-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R11 is Cr-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl Ce-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R , OR , NHR , N(R12)2, C(O)NH2, C(O)NHR12, C (O) N (R12) 2, OH, (O) , C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R12 is R13, R14, R15 or R16; R13 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R13A ; - 13 - WO2005/049594 PCT/US2004/037911 R13A is C4-cycloalkane, C5-cycloalkanef C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R4 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl, 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R15 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R16 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C3-alkynylf C4-alkynyl, C5-alkynyl or C6-alkynyl; R17 is R18, R19, R20 or R21; R18 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; - 14 - WO2005/049594 PCT7US2004/037911 R19 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R20 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, C8-cycloalkyl, C9-cycloalkyl, C10-4cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl, C8-cycloalkenyl, C9-cycloalkenyl, C10-4cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or,two CH moieties unreplaced or replaced with N; R21 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R22 , OR22 , NHR22 , N(R22)2, C(O)NH2, C(O)NHR22, C(O)N(R22)2f OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R22 is R23, R24 or R25; R23 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine,' pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; - 15 - WO2005/049594 PCT/US2004/037911 R24I s furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl, 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R25 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; Z is R or R , each of which is substituted with R , 29 30 » R or R , each of which is substituted with F, CI, Br, I, CH2R37, CH(R31) (R37), C(R31) (R31A) (R37), C(O)R37, OR37, SR37, S(O)R37, SO2R37, NHR37 or N(R32)R37; R26 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R27 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, - 16 - WO2005/049594 PCT/US2004/037911 pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R28 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R29 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R30 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, C8-cycloalkyl, C9-cycloalkyl, C10-cycloalkyl, Cn-cycloalkyl, C12-cycloalkyl, C13-cycloalkyl, C14-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl, Ce-cycloalkenyl, C6-cycloalkenyl or C10-4cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R31 and R31A are independently F, CI, Br, Ca-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl or are taken together and are C6-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl or C5-spiroalkyl; R32 is R33, C(O)R33 or C(O)OR33; - 17 - WO2005/049594 PCT/US2004/037911 R33 is R34 or R35; R34 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R35 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is unsubstituted or substituted with R36; R36 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R37 is R38, R39 or R40, each of which is substituted with F, CI, Br, I, R41, OR41, NHR41, N(R41)2, NHC(O)OR41, SR41, S(O)R41 or SO2R41; R is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R39 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or lr2,3-triazole; - 18 - WO2005/049594 PCT/US2004/037911 R40 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, C5-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7~cycloalkenyl or Ca-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R41 is R42, R43, R44 or R45; R42 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R ; R42A is C4-cycloalkane, C5-Gycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycl.oalkene,seach having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R43 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R44 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced - 19 - WO2005/049594 PCT/US2004/037911 or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R45 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two independently selected R46, OR46, NHR46, N(R46)2, C(O)NH2, C(O)NHR46, C(O)N(R46)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R46 is R47, R48 or R49; R47 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R48 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; - 20 WO2005/049594 PCT/US2004/037911 R49 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C5-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; 1 1 wherein the moieties represented by B and Y together are substituted with C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyi or C6-alkyl, each of which is substituted with one or two independently selected SR55 or N(R55)2 substituents, wherein R55 is independently selected phenyl, C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl; 2 3 4 the moieties represented by R , R and R are unsubstituted or substituted with one or two independently selected R50, OR50, SR50, SO2R5°, CO(O)R5° or OCF3 substituents, wherein R50 is phenyl, C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl; 8 9 10 the moieties represented by R , R and R are unsubstituted or substituted with one or two independently selected R50, OR50, C (O) NHSO2R5°, CO(O)R50, C(O)R50, C(O)OH, C(O)NHOH, OH, NH2, F, CI, Br or I substituents, wherein R50 is phenyl, tetrazolyl or R 4, wherein R is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is uns,ubstituted or substituted with phenyl; the moieties represented by R26 and R27 are further unsubstituted or substituted with one or two independently selected F, Br, Cl or I substituents; the moieties represented by R28 , R29 and R30 are further unsubstituted or substituted with OR54 , wherein R54 is - 21 - WO2005/049594 PCT/US2004/037911 d-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is unsubstituted or substituted with R , wherein R5 is C3-cycloalkyl, C4-cycloalkyl C5-cycloalkyl or C6-cycloalkyl, each having one or two CH2 moieties replaced with independently selected O or NH and one CH moiety unreplaced or replaced with N; the moieties represented by R38 , R39 and R40 are unsubstituted or substituted with one or two independently selected R54, F, Br, CI or I substituents, wherein R4 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl; and the moieties represented by R42 , R43 , R44 and R45 are unsubstituted or substituted with one or two independently selected R50, OR50, SR50, N(R50)2, SO2R5°, CN, CF3, F, Cl, Br or I substituents, wherein R50 is phenyl or R54 , wherein R54 is C1.-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is unsubstituted or substituted with N(R55)2 or R56 , wherein R is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl and R56 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl or. C6-cycloalkyl, each having one CH2 moiety unreplaced or replaced with independently selected O>. C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A is C(A ); A2 is H, F, CN, C(O)OH, C(O)NH2 or C(O)OR1A; B1 is R1, OR1, SR1, S(O)R1, SO2R1, CCOJR1, C(O)0R1, OCC(O)R1, NHR1, N(R1)2, C(O)NHR1, C(O)N(R1)2, NHCCOR1, NHC(O)0R1, - 22 - WO2005/049594 PCT/US2004/037911 NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NHR1, SO2N(R1)2. NHSO2R1, NHSO2NHR1 or N(CH3)SO2N(CH3)R1; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, C(O)OH, F, CI, Br, CF3, OCF3/ NH2, C(O)NH2 or B1 and Y , together with the atoms to which they are attached, are imidazole or triazole; R1 is R2, R3, R4 or R5; R1R is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl, C6-alkyl; R2 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiopheile, triazine or 1,2,3-triazole; R3 is furanyl, imidazolyl, isothiazolyl, isoxazplyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R4 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), 'SO2 or NH and one or two CH moieties unreplaced or replaced with N; , R5 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl, C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl, C6-alkenyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, - 23 - WO2005/049594 PCT/US2004/037911 each of which is unsubstituted or substituted with one or two or three independently selected R6, R7, OR7, SR7, S(O)R7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)0R7, SO2NH2, SO2NHR7, SO2N(R7)2, NHC(O)NH2, NHC(O)NHR7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, OH, (O), C(O)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R6 is C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl or C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R7 is R8, R9, R10 or R11; R8 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R ; R8A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or.C6-cycloalkene, each having one or two CH2 moieties unreplaced or. replaced with independently selected O, C(O), S, S (O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R9 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazblyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R9 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C5-cycloalkyl, C?-cycloalkyl, C8-cycloalkyl, C9-cycloalkyl, Cxo~cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, - 24 - WO2005/049594 PCT/US2004/037911 C6-cycloalkenyl, C7-cycloalkenyl, C6-cycloalkenyl, C6-cycloalkenyl, C10-4cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R11 is Cx-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R12 , OR12 , NHR12 , N(R12)2, C(O)NH2/ C(O)NHR12, C(O)N(R12)2, OH, (O), C(O)OH, N3, CN, NH2/ CF3, CF2CF3, F, CI, Br or I substituents; R12 is R13 , R14 , R15 or R16 ; R is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or Ra3A; R13A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R14 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2, 3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl, 1,2,3-triazolyl, each of which is unfused or fused with benzene; - 25 - WO2005/049594 PCT/US2004/037911 R15 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6_cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6_cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R16 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or Cg--alkynyl; Z1 is R26 or R27 , each of which is substituted with R , R29 or R30, each of which is substituted with CI, Br, CH2R37, C(R31) (R31A) (R37) , C(O)R37, OR37, SR37, S(O)R37, SO2R37 or NHR37; 2 6 R is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R27 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl,. pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R28 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R29 is furanyl, imidazolyl, isothiazolyl, isoxazolyl,1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, - 26 - WO2005/049594 PCT7US2004/037911 tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R30 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, d-cycloalkyl, C8-cycloalkyl, C6-cycloalkyl, C10-4cycloalkyl, Cu-cycloalkyl, C12-cycloalkyl, C13-cycloalkyl, C14-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl, C8-cycloalkenyl, C6-cycloalkenyl or Ci0-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R31 and R3lA are independently F, CI, Br, .d-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or Ce-alkyl or are taken together and are C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl or C5-spiroalkyl; R37 is R38 , R39 or R40 , each of which is substituted with F, CI, Br, I, R41, OR41, NHR41, N(R41)2r NHC(O)OR41, SR41, S(O)R41 or SO2R41; R38 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R39 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl; oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R40 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C5-cycloalkyl, C7-cycloalkyl, C8-cycloalkyl, C4-cycloalkenyl, WO2005/049594 PCT/US2004/037911 C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R41 is R42, R43, R44 or R45; R42 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R42A; R42A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R43 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R44 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, - 28 - WO2005/049594 PCT/US2004/037911 pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R45 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenylf C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two independently selected R , OR , NHR , N(R )zt C(O)NH2, C(O)NHR46, C(O)N(R46)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I substituents; R46 is R47, R48 or R49; R47 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R48 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R49 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SQ2 or NH and one or two CH moieties unreplaced or replaced with N; wherein the moieties represented by B and Y together are substituted with C2-alkylf C3-alkyl or C4-alkyl, each of which is substituted with one or two independently selected SR55 or - 29 - WO2005/049594 PCT/US2004/037911 N(R55)2 substituents, wherein R55 is independently selected phenyl or C1-alkyl; the moieties represented by R2 , R3 and R4 are unsubstituted or substituted with one or two independently selected R50, OR50, SR50, SO2RSO, C0(O)R5° or OCF3 substituents, wherein R50 is phenyl, C1-alkyl, C2-alkyl, C3-alkyl or C4-,alkyl; the moieties represented by R8 , R9 and R10 are unsubstituted or substituted with one or two independently selected R50, OR50, C(O)NHSO2R5°, CO(O)R5°, C(O)R5°, C(O)OH, C(O)NHOH, OH, NH2, F, CI, Br or I substituents, wherein R50 is phenyl, tetrazolyl or R54, wherein R is C1-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with phenyl; the moieties represented by R26 and R27 are further unsubstituted or substituted with one or two independently selected F, Br, CI or I substituents; the moieties represented by R28 , R29 and R30 are further unsubstituted ox substituted with OR54 , wherein R54 is C1-alkyl or C2-alkyl, each of which is unsubstituted or substituted with N(R55)2 or R56, wherein R55 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, and R is _C5-cycloalkyl or C6-cycloalkyl, each having one or two CH2 moieties replaced with independently selected O or NH and one CH moiety unreplaced or replaced with N; the moieties, represented by R38 , R39 and R40 are unsubstituted or substituted with one or two independently selected C1-alkyl, F, Br, CI or I substituents; and - 30 - WO2005/049594 PCT/US2004/037911 the moieties represented by R42 , R43 , R44 and R4 are unsubstituted or substituted with one or two independently selected R50, OR50, SR50, N(R50)2, SO2R50, CN, CF3, F, Cl, Br or I substituents, wherein R is phenyl or R , wherein R 4 is C1-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with N(C1-alkyl)2 or C6-cycloalkyl having one CH2 moiety replaced with 0 and one CH moiety replaced with N. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A)2; A2 is H, F, CN, C(O)OH, C(O)NH2 or C(O)OCH3; . B1 is R1, OR1, NHR1, N(R1)2 or NR1-(O)N (R1) 2; D1 is H, F, Cl or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2, C(O)NH2, or B1 and Y1, together with the atoms to which they are attached, are imidazole or triazole; R1 is phenyl, pyrrolyl, cyclopentyl, cyclohexyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl or R5 ; R5 is C].-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is unsubstituted or substituted with one or two or three independently selected C4-spiroalkyl, C5-spiroalkyl, R7, OR7, SR7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)OR7, NHC(O)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, OH, C(O)OH or NH2 substituents; R is phenyl, furanyl, imidazolyl, pyridinyl, tetrazolyl, thiazolyl, thienyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,3- - 31 - WO2005/049594 PCT/US2004/037911 benzothiazole, cyclopropyl, cyclobutyl, cyclohexyl/ azetidinyl, morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, thiomorpholinyl sulfone 7-azabicyclo[2.2.l]heptanyl, 8-azabicyclo[3.2.1]octanyl, 4,5- dihydro-lH-imidazolyl 2-oxa-5-azabicyclo[2.2.1]heptanyl, 1,4,5,6-tetrahydropyrimidinyl or R ; R11 is C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl, each of which is unsubstituted or substituted with one or two or three independently selected R12, OR12, N(R12)2, C(O)N(R12)2, OH, C(O)OH, NH2/ CF3, F, CI, Br or I substituents; R12 is 1,3-benzodioxolyl, pyridinyl, morpholinyl or C1-alkyl; Z1 is phenyl or pyridinyl, each of which is substituted with cyclohexenyl, piperazinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl or octahydropyrrolo[3, 4- c]pyrrolyl, each of which is substituted with CH2R37 , C(C2-spiroalkyl) (R37) or C(O)R37; R37 is phenyl, naphthyl, imidazolyl, pyrazolyl, pyridinyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl or 3, 6-dihydro-2H-pyranyl, each of which is substituted with F, CI, Br, I, R41, NHR41, N(R41)2, NHC(O)OR41 or SR41; R41 is phenyl, naphthyl, cyclohexyl, morpholinyl, piperidinyl, thienyl, pyridinyl, quinolinyl, benzofuranyl, 1,3-benzodioxolyl, isoindolinyl, 1,3-oxazolidin-2-onyl or R45 R45 is C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl, each of which is unsubstituted or substituted with phenyl; wherein the moieties represented by B and Y together are substituted with C2-alkyl, C3-alkyl or C4-alkyl, each of which is substituted with one or two independently selected SR or - 32 - WO2005/049594 PCT/US2004/037911 N(R55)2 substituents, wherein R55 is independently selected phenyl or C1-alkyl; the moieties represented by R are unsubstituted or substituted with one or two independently selected R5 , OR50, SR50, SO2R50, CO(O)R5° or OCF3 substituents, wherein R50 is phenyl, C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl; 7 the moieties represented by R are unsubstituted or substituted with one or two independently selected R , OR5 , C(O)NHSO2R5°, CO(O)R50, C(O)R5°, C(O)OH, C(O)NHOH, OH, NH2, F, CI, Br or I substituents, wherein R is phenyl, tetrazolyl or R , wherein R is C1-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with phenyl; the phenyl and pyridinyl moieties of Z are further unsubstituted or substituted with one or two independently selected F, Br, CI or I substituents; the cyclohexenyl, piperazinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl and octahydropyrrolo[3,4-c]pyrrolyl moieties of Z are further unsubstituted or substituted with OR54, wherein R54 is C1-alkyl or C2-alkyl, each of which is unsubstituted or substituted with N (C1-alkyl) 2, morpholinyl, piperidinyl or piperidinyl; the moieties represented by R are unsubstituted or substituted with one or two independently selected C1-alkyl, F, Br, CI or I substituents; and the moieties represented by R41 are unsubstituted or substituted with one or two independently selected R , OR , SR50, N(R50)2, SO2R50, CN, CF3, F, Cl, Br or I substituents, wherein R is phenyl or R54, wherein R54 is C1-alkyl, C2-alkyl - 33 - WO2005/049594 PCT/US2004/037911 or C3-alkyl, each of which is unsubstituted or substituted with N(C1-alkyl)2 or morpholinyl. Still another embodiment pertains to compounds having salts of prodrugs thereof, wherein A1 is C(A2 ); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (IR)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (IR)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-((2,2-difluoro-ethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamine, (lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamine (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl) propylamino, (IR)-3-(dimethylamino).-l-( ((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(2,4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)pentylamino, 1-(1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,l-dimethyl-2- - 34 - WO2005/049594 PCT/US2004/037911 (phenylsulfonyl) ethylamino, (1, l-dimethyl-2- (phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2- (phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3- (2,6-dimethylpiperidin-l-yl) -i- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,6S)-2, 6- dimethylpiperidin-1-yl)-1—((phenylsulfanyl)methyl)- propylamino, 1,l-dimethyl-2-(pyrimidin-2- ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethylpyrrolidin- l-yl)-l-((phenylsulfanyl)methyl)butylamino, (IR)-3-((2R,5R)- 2,5-dimethylpyrrolidin-l-yl)-1- v ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5- dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl) -1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimefhyl-2-(thien-2-ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2, 2-trifluoroethyl)amino)-l-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (lR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl) propylamino; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3r NH2 or C(O)NH2; and Z1 is 4-(4-(2-(1,3-benzodioxol-5-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(benzofuran-2- ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-bromocyclohex-l-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-bromocyclopent-l-en-l-ylmethyl)piperazin-1- - 35 - WO2005/049594 PCT/US2004/037911 Yl)phenylcarbonyl, 4- (2- (4-bromophenyl) phenylmethyl) piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4-chlorophenyl)cyclohept-l-en-1-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(1-(2- (4-chlorophenyl)cyclohex-1-en-l-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)cyclohex-1-en-l-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)cyclopent-l-en-1-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4-(2- (4-chlorophenyl)cyclooct-1-en-l-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)-piperazin-1-yl)phenylcarbonyl, 4-(l-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohex-1-en-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylmethyl, 4-(4-(2-(4-chlorophenyl)naphth-3-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)pyridin-3-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(3-(4-chlorophenyl)pyridin-4-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)pyridin-5-yl)methyl)-piperazin-1-yl)phenylcarbonyl, 4-(4- (2- (4-chlorophenyl)phenylcarbonyl)piperazin-l-yl)phenylcarbonyl, 4- (1-(2-(4-chlorophenyl)phenylcycloprop-1-yl)piperazin-1- yl)phenylcarbonyl or 4-(4-(2-(4- chlorophenyl)phenylmethyl)cyclohex-1-en-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1- ((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1- ( (phenylsulfanyl)methyl) propylamino, (1R) -3- ( (2, 2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1- - 36 - WO2005/049594 PCT/US2004/037911 ( (phenylsulfanyl)methyl)propylamine), (lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamine, (IR) -2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (IR)-2-(2-(dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyDpropylamino, (IR) -3- (dimethylamino) -3-oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-l-( (l,3-thiazol-2-yl)methyl)propylamino, (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-1-(((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(2,4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (lR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)-pentylamino, 1-(1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,6S)-2,6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethyl-pyrrolidin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (IR)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(2,5-dimethyl-pyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, - 37 - WO2005/049594 PCT/US2004/037911 (lR)-3-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2S,5S)-2, 5-dimethylpyrrolidin-1-yl)-1- ( (phenylsulfanyl)methyl) propylaminor 1, l-dimethyl-2- (thien-2-ylsulfanyl)ethylamino, (IR)-3-(l,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, l-(ethoxycarbonyl)piperidin-4-yloxy, (lR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, Cl or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(5-(2-(4-chlorophenyl)phenylmethyl)hexahydropyrrolo[3,4-c]pyrrol-2(lH)-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)-piperazin-1-yl)-3, 5-difluorophenylcarbonyl, 4- (4-(2-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)-2-fluorophenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)piperazin-l-yl)-3-fluorophenylcarbonyl, 2-(4-(2- (4- chlorophenyl)phenylmethyl)piperazin-l-yl)pyridin-5-ylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylmethyl)piperidin-4-yl)phenylcarbonyl, 5-(4-(2-(4-chlorophenyl)phenylmethyl)-piperazin-l-yl)pyridin-2-ylcarbonyl, 4-(l-(2-(4-chlorophenyl)phenylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4-(4-(2-(cyclohex-1- ylamino)phenylmethyl)piperazin-1-yl)phenylcarbonyl4-(4-(2-cyclohex-l-ylphenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4- - 38 - WO2005/049594 PCT/US2004/037911 (2-(3-cyanophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2,4-dichlorophenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(3,4- dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4-(2-(2,4-difluorophenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(2-(1,3-dihydro-2H-isoindol-2- yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(1,1- dimethylethoxycarbonylamino)phenyl)piperazin-1- yl)phenylcarbonyl, 4-(2-(4-(2- (dimethylamino)ethoxy)phenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl or 4-(4-(3-(dimethylamino)phenyl)piperazin- 1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((pheny1sulfany1)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-((2,2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-2-((2-(dimethylamino)ethyl) (methyl) amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-( (dimethylamino)methylcarbonyl) amino) --1-((phenylsulfanyl)methyl)pentylamino, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (1R)-3-(dimethylamino) -1-((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3-oxo-l-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (lR)-3- r (dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, - 39 - WO2005/049594 PCT/US2004/037911 (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-1-(((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(2, 4-dimethyl-4,5-dihydro-lH-iiaidazol-l-yl)-l- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)-pentylamino, 1-(1,l-dimethylethoxycarbonyl)piperidin-4-yloxy, 1, l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-l- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,6S)-2,6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethyl-pyrrolidin-l-yl)-1-( (phenylsulfanyl)methyl)butylamino, (IR)-3-((2R, 5R)-2, 5--dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (IR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, - 40 - WO2005/049594 PCT/US2004/037911 (lR)-l-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamine; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(2-(4-(dimethylamino)phenyl)phenylcarbonyl)piperazin-1-yDphenylcarbonyl, 4-(4-(2-(4- (dimethylamino)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-(dimethylamino)phenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(5,5-dimethyl-2-oxo-l,3-oxazolidin-3-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-.(4-fluorophenyl)-3-fluorophenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4- ((2-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(2- (isopropylamino)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4-(isopropylsulfanyl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2- ('4-methoxyphenyl) cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(3-methoxyphenyl)phenylmethy1)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4-methoxyphenyl)phenylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-((2- (4-methoxyphenyl)pyridin-3- yl)methyl) piperazin-1-yl)phenylcarbonyl, 4- (4-methoxy-4r- (2- (pyridin-3-yl)phenylmethyl)piperidin-1-yl)phenylcarbonyl, 4- (4-(2-(2-methyl-4-dichlorophenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(2- methylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4- (2-(4-(methylsulfonyl)phenyl)methyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(4- methylsulfonylphenyl)phenylmethyl)piperazin-1- - 41 - WO2005/049594 PCT/US2004/037911 Yl)phenylcarbonyl or 4- (4- ( (2- (4-methylsulfonylphenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamine (1R)-3-((2,2-difluoroethyl)amino)-1-{(phenylsulfanyl)methyl)propylamine (1R) -3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenyisulfanyl)methyl)propylamino, (lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamine, (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylanu.no) methylcarbonyl)amino)-1-((phenylsulfanyl)methyl)pentylamino, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (1R)-3-(dimethylamino)-1-( (phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3-oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (1R)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-l-<((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (1R)-3-(2,4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)-pentylamino, 1-(1,l-dimethylethoxycarbonyl)piperidin-4-yloxy, 1, l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2- - 42 - WO2005/049594 PCT/US2004/037911 (phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,6S)-2,6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethyl-pyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)butylamino, (lR)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,5S)-2, 5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (IR) -3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2, 2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (IR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2/ F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(5-methylthien-2-yl)phenylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-(2-(4-methylsulfanylphenyl)cyclohex-1-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4-methylsulfanylphenyl)phenylcarbonyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((2-(4-methylsulfanylphenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4- - 43 - WO2005/049594 PCT/US2004/037911 methylsulfanylphenyl)phenylmethyl)piperazin-1-yl)- phenylcarbonyl, 4-(4-(2-(4-(2-(morpholin-1-yl)ethoxy)- phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4- (2-(morpholin-1-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(naphth-1-yl)phenylmethyl)piperazin-l-yl) phenylcarbonyl, 4-(4-(2-(naphth-2-yl)phenylmethyl)-piperazin-1- yl)phenylcarbonyl or4-(4-(2-(4- phenoxyphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((l-phenyl-lH-imidazol-2-yl)methyl)piperazin-l-yl) phenylcarbonyl, 4-(4-((l-phenyl-lH-imidazol-5- yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-{2-((phenylmethyl)amino)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(dimethylamino)ethoxy))piperidin-1-yl)phenylcarbonyl, 4- ((2-(phenyl)phenylmethyl)-4-methoxypiperidin-1-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(morpholin-1-yDethoxy) )piperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4- (2-(4-(phenyl)phenyl)phenylmethyl)piperaziri-1-yl)phenylcarbonyl or 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(piperidin-1-yl)ethoxy))piperidin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamine (1R)-3-((2,2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-(diisopropylamino) -1- ( (phenylsulfanyl) methyl )'propylamino, - 44 - WO2005/049594 PCT/US2004/037911 (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1- ((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2- (dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino)-1- ((phenylsulfanyl)methyl)pentylandno, (1R)-3-(dimethylamino)-1- ((phenylsulfanyl)methylJpropoxy, (1R)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3- oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (1R)-3- (dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (1R)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-l-{( (4- (trifluoromethoxy)phenyl)sulfany1)methyl)propylamino, (1R)-3- (2,4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-l- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(4,4-dimethyl-4,5- dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-5-((1,1- dimethylethoxy)carbonylamino)-1- ((phenylsulfanyl)methyl)pentylamino, 1-(1,1- dimethylethoxycarbonyl)piperidin-4-yloxy, 1,l-dimethyl-2- (phenylsulfonyl)ethylamino, (1,l-dimethyl-2- (phenylsulf anyl) ethyl) amino, 1,' l-dimethyl-2- (phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (1RJ-3- (2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,6S)-2,6- dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (lR)-4- ((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1- ((phenylsulfanyl)methyl)butylamino, (1R)-3-((2R,5R)-2,5- dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5- dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-((2R,5S)-2,5- - 45 - WO2005/049594 PCT/US2004/037911 dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyDmethyl)propylamino, (IR) -3- ((2S, 5S) -2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamine, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamine, 1-(ethoxycarbonyl)piperidin-4-yloxy, (lR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamine, (lR)-l-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamine; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(pyrrolidin-l-yl)ethoxy))piperidin-1-yl)phenylcarbonyl, 4-(4-((2-(phenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((1-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-{2-(piperidin-l-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(pyrid-3-yl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(quinolin-3- ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2-(quinolin-8-ylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)-4-methoxypiperazin-l-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)-piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-trifluoromethoxyphenyl)phenylmethyl)piperazin-1-yDphenylcarbonyl or 4-(4-(2-(4-trifluoromethylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or - 46 - WO2005/049594 PCT/US2004/037911 salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-{(phenylsulfanyl)methyl)propylamino, (lR)-3-((2,2-difluoroethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(5, 6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-(diisopropylamino)1-((phenylsulfanyl) methyl)propylamino, (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1- ( (phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino) methylcarbonyl)amino)-1-((phenylsulfanyl)methyl)pentylamino, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3-oxo-l-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (lR)-3-(dimethylamino)-3-oxo-l- ( (l,3-thiazol-2-yljmethyl)propylamino, (1R)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-1-(((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (1R)-3-(2,4-dimethyl-4r5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)p'entylamino, 1-(1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-1- - 47 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propylamino (1R) -3- ((2R, 6S) -2, 6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamine, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (1R)-4-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)butylamino, (1R)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamine (lR)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamine, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (1R)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl) propylaird.no, (1R) -3- (dipropylamino) -1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dipropylamino)-1-((phenyisulfanyl)methyl)propylamino, (1R)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, l-(ethoxycarbonyl)'piperidin~4-yloxy, (lR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, Cl or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(1, 3-benzodioxol-5-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(benzofuran-2- ylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(2-bromocyclohex-1-en-l-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(2-bromocyclopent-l-en-l-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(2-(4-bromophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2- (4-chlorophenyl)cyclohept-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(1- (2-(4-chlorophenyl)cyclohex-1-en-l-ylmethyl)-1, 2,3,6- - 48 - WO2005/049594 PCT/US2004/037911 tetrahydropyridin-4-yl)phenylcarbonyl, 4- (4-(2-(4- chlorophenyl)cyclohex-1-en-l-ylmethyl)piperazin-1- yl)phenylcarbonyl, 4- (4-(2-(4-chlorophenyl)cyclopent-l-en-1- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4- chlorophenyl)cyclooct-l-en-l-ylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-{(4-(4-chlorophenyl)-5,6-dihydro-2H- pyran-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-{4-((4-(4- chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l- yl)phenylcarbonyl, 4-(1-((2-(4-chlorophenyl)-5,5-dimethyl-l- cyclohex-1-en-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4- yl)phenylmethyl, 4-(4-(2-(4-chlorophenyl)naphth-3- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)pyridin-3-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(4-chlorophenyl)pyridin-4-ylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)pyridin-5- yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4—(2-(4- chlorophenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4- (1-(2-(4-chlorophenyl)phenylcycloprop-1-yl)piperazin-1- yl)phenylcarbonyl or 4-(4-(2-(4- chlorophenyl)phenylmethyl)cyclohex-1-en-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamine, (1R)~3-((2,2-dif luoroethyl) amino) -1- ((phenylsulfanyl)methyl).propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (1RJ-3- . (diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2- - 49 - WO2005/049594 PCT/US2004/037911 (dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamine, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-1-(((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(2, 4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)-pentylamino, 1- (1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,1-dimethy1-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-diraethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2R,6S)-2,6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (IR) -3- ((2R,'5R) -2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(2,5-dimethyl-pyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2- - 50 - WO2005/049594 PCT/US2004/037911 ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (IR)-3-((2-fluoroethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, CI or CF3; B1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(5-(2-(4-chloropheny.l) phenylmethyl) hexahydropyrrolo [3, 4-c]pyrrol-2(1H)-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2- (4--chlorophenyl) phenylmethyl) -4-methoxypiperidin-l-yDphenylcarbonyl, 4- (4- (2- (4-chlorophenyl) phenylmethyl) -piperazin-1-yl)-3,5-difluorophenylcarbonyl, 4- (4-(2- (4-chlorophenyl)phenylmethyl)piperazin-1-yl)-2-fluorophenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)-3-fluorophenylcarbonyl, 2-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)pyridin-5-ylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylmethyl)piperidin-4-yDphenylcarbonyl, 5- (4- (2- (4-chlorophenyl) phenylmethyl) -piperazin-l-yl)pyridin-2-ylcarbonyl, 4-(l-(2-(4-chlorophenyl)phenylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4- (4-(2-(cyclohex-1- ylamino)phenylmethyl)piperazin-1-yl)phenylcarbonyl4-(4-(2-cyclohex-l-ylphenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(3-cyanophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2, 4-dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2-(3,4-dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- - 51 - WO2005/049594 PCT/US2004/037911 (4-(2-(2,4-difluorophenyl)phenylmethyl)piperazin-l-yDphenylcarbonyl, 4- (2- (1, 3-rdihydro-2H-isoindol-2-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(3-(1,1-dimethylethoxycarbonylamino)phenyl)piperazin-1-yDphenylcarbonyl, 4-(2-(4-(2- (dimethylamino)ethoxy)phenyl)phenylmethyl)piperazin-1-yUphenylcarbonyl or 4- (4- (3- (dimethylamino) phenyl) piperazin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or 1 salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN,C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (IR)-2-(diethylamino)-1- ((phenylsulfanyl)methyl)ethylamino, (lR)-3-(diethylamino)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-((2,2- difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3- (diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1- ((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2- (dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino)-1- ((phenylsulfanyl)methyl)pentylamino, (IR)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propoxy, (IR)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3- oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (IR)-3- (dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-1-(((4- (trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3- (2, 4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1- - 52 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propylamino, (IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)pentylamino, 1-(1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,1-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,1-dimethyl-2-(phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl) -1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,6S)-2,£-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2- (pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)butylamino, (IR)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(2, 5-- dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R, 5S)-2, 5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2S, 5S) -2, 5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR) -3- (dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (IR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is - 53 - WO2005/049594 PCT/US2004/037911 H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(2-(4-(dimethylamino)phenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4- (dimethylamino)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-(dimethy1amino)phenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4- (2-(5,5-dimethyl-2-oxo-l,3-oxazolidin-3-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4-(2-(4-fluorophenyl)cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)-3-fluorophenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4- fluorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(2-(isopropylamino)phenylmethyl)-piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(isopropylsulfanyl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methoxyphenyl)cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(3-methoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methoxyphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-( (2-(4-methoxyphenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-methoxy-4-(2-(pyridin-3-yl)phenylmethyl)piperidin-l-yl)phenylcarbonyl, 4-(4-(2-(2-methyl-4-dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2- methylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(methylsulfonyl)-phenyl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methylsulfonylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-((2-(4-methylsulfonylphenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl. - 54 - WO2005/049594 PCT/US2004/037911 Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-((2,2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1-{(phenylsulfanyl)methyl)ethylamino, (3R)-5-(N-((dimethylamino)methylcarbonyl)amino) -1-((phenylsulfanyl)methyl)pentylamino, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-3-oxo-l-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (lR)-3-(dimethylamino)-3-oxo-l-((1,3-thiazol-2-yl)methyl)propylamino, (1R)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl)propylamino, (1R)-3-(dimethylamino)-1-(((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (1R)-3-(2,4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1-( (phenylsulfanyl)methyl)propylamino, (lR)-3- (4, 4-dimethyl-4, 5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-5-((1,1-dimethylethoxy)carbonylamino)-1-((phenylsulfanyl)methyl)pentylamino, 1-(1,1-dimethylethoxycarbonyl)piperidin-4-yloxy, 1,l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2- - 55 - WO2005/049594 PCT/US2004/037911 (phenylsulfanyl)ethyl, 4,4-dimethylpiperidin-l-yl, (lR)-3-(2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl) propylamine), (IR) -3- ((2R, 6S) -2, 6-dimethylpiperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 1, l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)butylamino, (IR)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ( (phenyl sulf anyl) methyl) propylamine), (lR)-3-(2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino,- (lR)-3-((2S,5S)-2,5-dimethylpyrrolidih-1-yl) -1- ((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (IR)-3-(1,l-dioxothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(ethyl(2, 2, 2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (lR)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-1-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, CI or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(5-methylthien-2-yl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(4-methylsulfanylphenyl)cyclohex-1-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2-(4-methylsulfanylphenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-methylsulfanylphenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4- (4-(2-(4-methylsulfanylphenyl)phenylmethyl)piperazin-1-yl)- - 56 - WO2005/049594 PCT/US2004/037911 phenylcarbonyl, 4- (4-(2-(4-(2-(morpholin-1- yl) ethoxy)phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2- (morpholin-1-yl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4- (4-(2-(naphth-1- yl) phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2- (naphth-2-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl or 4- (4-(2-(4-phenoxyphenyl)phenylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-((l-phenyl-lH-imidazol-2- yl)methyl)piperazin-1-yl) phenylcarbonyl, 4-(4-((1-phenyl-lH- imidazol-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(2- ((phenylmethyl)amino)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4- (4-(2-(phenyl)phenylmethyl)-4-(2- (dimethylamino)ethoxy))piperidin-1-yl)phenylcarbonyl, 4-((2- (phenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(morpholin-1- yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-(2- (phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(3- (phenyl")phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2- (4-(phenyl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(piperidin-1- yl)ethoxy))piperidin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethylamino, (1R)-3-(diethylamino)-1-((phenylsulfanyl) methyl)propylamine, (1R)-3-((2,2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(5,6-dihydro-l(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propylamine, (lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1- - 57 - WO2005/049594 PCI7US2004/037911 ((phenylsulfanyl)methyl)ethylamino, (lR)-2-(2-(dimethylamino)ethoxy)-1-((phenylsulfanyl)methyl)ethylamino, (3R) -5- (N- ( (dimethylamino) methylcarbonyl) amino) -1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propoxy, (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(dimethylamino)-3-oxo-1-((pyrimidin-2-ylsulfanyl)methyl)propylamino, (lR)-3-(dimethylamino)-3-oxo-l- ((1,3-thiazol-2-yl)methyl)propylamino, (IR)-3-(dimethylamino)-1-((thien-2- ylsulfanyl)methyl) propylamine (IR) -3- (dimethylamino) -1- (((4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(2, 4-dimethyl-4,5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-5-((1,1-dimethylethoxy)carbonylamiho)-1-((phenylsulfanyl)methyl)pentylamino, 1-(1,1-dimethylethoxycarbonyl) piperidin-4-yloxy, 1, l-dimethyl-2-(phenylsulfonyl)ethylamino, (1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino, 1,l-dimethyl-2-(phenylsulfany1)ethyl, 4,4-dimethylpiperidin-l-yl, (1RJ-3-(2,6-dimethylpiperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,6S)-2,6-dimethylpiperidin~l-yl)-1-((phenylsulfanyl)methyl)propylamino, 1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethylamino, (IR)-4-((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (lR)-3-((2R,5R)-2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(2,5-dimethylpyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1- - 58 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propylamine, (1R)-3-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)-propylamino, 1,l-dimethyl-2-(thien-2-ylsulfanyl)ethylamino, (1R)-3-(1,l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, 1-(ethoxycarbonyl)piperidin-4-yloxy, (1R)-3-((2-fluoroethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-1- (((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propylamino; D1 is H, F, Cl or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-{4-(2-(phenyl)phenylmethyl)-4-(2-(pyrrolidin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-((2-(phenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((1-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(piperidin-l-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(pyrid-3-yl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(quinolin-3- ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(quinolin-8-ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yi)phenylmethyl)-4-methoxypiperazin-l-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2-(4-trifluoromethoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-(2-(4-trifluoromethylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, - 59 - WO2005/049594 PCT/US2004/037911 C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (lR)-3-(4-(hydroxyaminocarbonyl)piperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(2-hydroxy-2-methylpropyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(4-hydroxypiperidin-l-yl)-1-((pheny1sulfany1)methyl)propylamine, (3R)-3-(3-hydroxypyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, isopropylamino, (lR)-3-(isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)-propylamino, (4-methoxycyclohex-l-yl)methyl)amino, (lR)-3-(4-(methoxyimino)piperidin-l-yl)-1-((phenylsulfanyl)methyl)-propylamino, (1R)-3-(N-methyl-N-carboxymethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (methyl)(cyclohexyl)amino, (methyl)(cyclohexylmethyl)amino, (1R)-3-(2-methyl-4,5-dihydro-lH-imidazol-l-yl)-1-( (phenylsulfanyl)methyl)propylamino, (3R)-3-(N-methyl-N-(dimethylcarbonylmethyl))-1- ((phenylsulfanyl)methyl)propylamino, (1R) -3-(N-methyl-N-(1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(1,2-diphenyl)amino)carbonyl)-N-methyl amino, (N-methyl-N-((diphenylmethyl)amino)carbonyl)-N-methylamino, (2-methylfuran-3-yl)sulfanyl)(1,1-spirobutyl)ethylamino, (lR)-3-(N-methyl-N-(2-hydroxyethyl))amino)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(N-methyl-N-isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(4-methoxyphenyl)amino)carbonyl)-N-methylamino, 1-methyl-4-(phenylsulfanyl)pyrrolidin-3-ylamino, (N-methyl-N-(4-methylphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(2-methylphenyl)amino)carbonyl)-N-methylamino, (1R)-3-(4-methylpiperazin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, - 60 - WO2005/049594 PCT/US2004/037911 l-methylpiperidin-4-yloxy, (N-methyl-N-((S)-1-phenylethyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(1-phenyl-2-(4-methylpiperazin-4-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(morpholin-1-yl) ) amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(N,N-dimethylamino)amino)carbonyl)-N-methylamino, (IR)-1-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IS)-l-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IR)-4-(4-methylpiperazin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (lR)-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propylamine, (lR)-5-((methylsulfonylamino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(4-(methylsulfonylaminocarbonyl)piperidin-l-yl)-1-((phenylsulfanyl)methyl)-propylamino, 2-((4-methyl-l,3-thiazol-2-yl)sulfanyl)ethylamino, (N-methyl-N-(4-trifluoromethoxyphenyl)amino)carbonyl)-N-methylamino, (IR)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2-(morpholin-4-yl)ethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl)methyl)-propylamino, (lR)-3-(morpholin-4-yl)-1-((1,3-thiazol-2- ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((thien-2-ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl) -1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-(((4-(methoxy)phenyl)sulfanyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-l-(((4- (methyl)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((phenylsulfonyl)methyl)propylamino, (lR)-3- (morpholin-4-yl)-1-( ((4- (trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino; D is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(1,3-benzodioxol-5- - 61 - WO2005/049594 PCT/US2004/037911 yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2- (benzofuran-2-ylphenyl)phenylmethyl)piperazin-1- yDphenylcarbonyl, 4- (2-bromocyclohex-l-en-l- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-bromocyclopent-l- en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-(4- bromophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2-(4-chlorophenyl)cyclohept-l-en-l-ylmethyl)piperazin-l- yl)phenylcarbonyl, 4- (1- (2-(4-chlorophenyl)cyclohex-l-en-1- ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4-(4- (2-(4-chlorophenyl)cyclohex-l-en-l-ylmethyl)piperazin-l- yl)phenylcarbonyl, 4- (4- (2-(4-chlorophenyl)cyclopent-l-en-1- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)cyclooct-l-en-l-ylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-( (4-(4-chlorophenyl)-5,6-dihydro-2H- pyran-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4- (4-((4-(4- t chlorophenyl)-5, 6-dihydrd-2H-pyran-3-yl)methyl)piperazin-1- yl)phenylcarbonyl, 4-(l-( (2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohex-1-en-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylmethyl, 4-(4-(2-(4-chlorophenyl)naphth-3-ylmethyl)piperazin-l-yl)-phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)pyridin-3-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(3-(4-chlorophenyl)pyridin-4-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-( (4-(4-chlorophenyl)pyridin-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2- (4-chlorophenyl)phenylcarbonyl)pipera-zin-1-yl)phenylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylcycloprop-1-yl)piperazin-1-yl)phenylcarbonyl or 4-(4-(2-(4-chlorophenyl)phenylmethyl)cyclohex-1-en-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (lR)-3-(4- - 62 - WO2005/049594 PCT/US2004/037911 (hydroxyaminocarbonyl)piperidin-l-yl)-1- ( (phenylsulfanyl)methyl) propylamino, (1R) -3- (2-hydroxy-2-methylpropyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(4-hydroxypiperidin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (3R)-3-(3-hydroxypyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, isopropylamino, (1R)-3-(isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-(lH-imidazol-1-yl)-l-((phenylsulfanyl)methyl)propylamino, (lR)-3-{isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)-propylamino, (4-methoxycyclohex-l-yl)methyl)amino, (lR)-3-(4-(methoxyimino)piperidin-l-yl)-1-((phenylsulfanyl)methyl)-propylamino, (1R)-3-(N-methyl-N-carboxymethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (methyl)(cyclohexyl)amino, (methyl)(cyclohexylmethyl)amino, (1R)-3-(2-methyl-4,5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (3R)-3-(N-methyl-N-(dimethylcarbonylmethyl))-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(1,2-diphenyl)amino)carbonyl)-N-methy1amino, (N-methyl-N-((diphenylmethyl)amino)carbonyl)-N-methylamino, (2-methylfuran-3-yl)sulfanyl)-(1,1-spirobutyl)ethylamino, (lR)-3-(N-methyl-N-(2-hydroxyethyl))amino)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-(N-methyl-N-isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(4-methoxyphenyl)amino)carbonyl)-N-methylamino, 1-methyl-4-(phenylsulfanyl)pyrrolidin-3-ylamino, (N-methyl-N-(4-methylphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(2-methylphenyl)amino)carbonyl)-N-methylamino, (1R)-3- (4-methylpiperazin-1-yl)-1-((phenylsulfany1)methyl)propylamino, l-methylpiperidin-4-yloxy, (N-methyl-N-((S) -1-phenylethyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(1- - 63 - WO2005/049594 PCT/US2004/037911 phenyl-2-(4-methylpiperazin-4-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(morpholin-1-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(N,N-dimethylamino))amino)carbonyl)-N-methylamino, (IR)-1-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IS)-l-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IR)-4-(4-methylpiperazin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (lR)-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-5-((methylsulfonylamino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(4-(methylsulfonylaminocarbonyl)piperidin-l-yl)-1-((phenylsulfanyl)methyl)-propylamino, 2- ((4-methyl-l,3-thiazol-2-yl)sulfanyl)ethylamino, (N-methyl-N-(4-trifluoromethoxyphenyl)amino)carbonyl)-N-methylamino, (IR)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2-(morpholin-4-yl)ethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR) -3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl) methyl)-propylamino, (IR)-3-(morpholin-4-yl)-1-((1,3-thiazol-2- ylsuLfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((thien-2-ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-(((4-(methoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-(((4- (methyl)phenyl)sulfanyl)methyl)propylamino, (IR) -3- (morpholin-4-yl) -1- ('(phenylsulfonyl) -methyl) propylamino, (IR) -3-(morpholin-4-yl)-1-(((4- (trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino; D is H, F, CI or CF3; E1 is H, F or Cl; Y1 is H, CNr NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(5-(2-(4- chlorophenyl)phenylmethyl)hexahydropyrrolo[3,4-c]pyrrol-2(IH)-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)- - 64 - WO2005/049594 PCT/US2004/037911 piperazin-1-yl)phenylcarbonyl, 4- (4- (2- (4-chlorophenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(4- i chlorophenyl)phenylmethyl)piperazin-1-yl)-3,5- difluoropheny1carbonyl, 4-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl) -2- fluorophenylcarbonyl, 4- (4-(2-(4- chlorophenyl)phenylmethyl)piperazin-1-yl) -3- fluorophenylcarbonyl, 2-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)pyridin-5-ylcarbonyl, 4- (l-.(2- (4-chlorophenyl)phenylmethyl)piperidin-4- yl)phenylcarbonyl, 5-(4-{2-(4- chlorophenyl)phenylmethyl)piperazin-1-yl)pyridin-2-ylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylmethyl)-1,2,3,6- tetrahydropyridin-4-yl)phenylcarbonyl, 4- (4- (2- (cyclohex-1- ylamino)phenylmethyl)piperazin-l-yl)phenylcarbonyl4-(4-(2- cyclohex-l-ylphenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4- (2-(3-cyanophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2,4-dichlorophenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-(2-(3,4- dichlorophenyl)phenylmethyl)piperazin~l-yl)phenylcarbonyl, 4- (4-(2-(2, 4-difluorophenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl, 4- (2-(1,3-dihydro-2H-isoindol-2- yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(3-(1,1- dimethylethoxycarbonylamino)phenyl)piperazin-1- yl)phenylcarbonyl, 4-(2-(4-(2- (dimethylamino)ethoxy)phenyl)phenylmethyl)piperazin-1- yl)phenylcarbonyl or 4-(4-(3-(dimethylamino)phenyl)piperazin- 1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1isC(A2 );A2 is H, F, CN, - 65 - WO2005/049594 PCT/US2004/037911 C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (lR)-3-(4-(hydroxyaminocarbonyl)piperidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(2-hydroxy-2-methylpropyl)amino)-1- ( (phenylsulfanyl)methyl)propylamino, (IR)-3-(4-hydroxypiperidin-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (3R)-3-(3-hydroxypyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, isopropylamino, (IR)-3- (isopropylamino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3- (isopropyl(methyl)amino) -1- ((phenylsulfanyl)methyl)propylamino, (4-methoxycyclohex-l-yl)methyl)amino, (IR)-3- (4-(methoxyimino)piperidin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-carboxymethyl)amino)-1- ( (phenylsulfanyl)methyl)propylamino, (methyl)(cyclohexyl)amino, (methyl)(cyclohexylmethy1)amino, (IR)-3-(2-methyl-4,5-dihydro-lH-imidazol-l-yl)-1- ((phenylsulfanyl)methyl) propylamino, (3R) -3- (N-methyl-N- (dimethylcarbonylmethyl))-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- ( (phenylsulfanyl)methyl)propylamino, (N-methyl-N-(1,2-diphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-((diphenylmethyl)amino)carbonyl)-N-methylamino, (2-methylfuran-3-yl)sulfanyl)-(1,1-spirobutyl)ethylamino, (IR)-3- (N-methyl-N-(2-hydroxyethyl)) amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(4-methoxyphenyl)amino)carbonyl)-N-methylamino, 1-methyl-4-(phenylsulfanyl)pyrrolidin-3-ylamino, (N-methyl-N-(4-methylphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(2-methylphenyl)amino)carbonyl)-N-methylamino, (lR)-3-(4-methylpiperazin-1-yl)-1- ( (phenylsulfanyl)methyl)propylamino, - 66 - WO2005/049594 PCT/US2004/037911 l-methylpiperidin-4-yloxy, (N-methyl-N-((S)-l-phenylethyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(1-phenyl-2-(4-methylpiperazin-4-yl))amino)carbonyl)-N-raethylamino, (N-methyl-N-(l-phenyl-2-(morpholin-1-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(N,N-dimethylamino))amino)carbonyl)-N-methylamino, (IR)-1-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IS)-l-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IR)-4-(4-methylpiperazin-l-yl)-l-((phenylsulfanyl)methylJbutylamino, (lR)-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propylamine, (lR)-5- ((methylsulfonylamino) -1- ( (phenylsulfanyl)methyl)pentylamino, (IR)-3-(4-(methylsulfonylaminocarbonyl)piperidin-1-yl)-1-((phenylsulfanyl) methyl)propylamino, 2- ((4-methyl-l, 3-thia'zol-2-yl)sulfanyl)ethylamino, (N-methyl-N-(4- trifluoromethoxyphenyl)amino)carbonyl)-N-methylamino, (lR)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyljpropylanu.no, (IR)-3-((2-(morpholin-4-yl)ethyl)amino)-1- ((phenylsulfanyl)methyl)propylamine (IR)-3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl)methylJpropylamino, (lR)-3-(morpholin-4-yl)-1-((1,3-thiazol-2- ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl) -1-((thien-2-ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-(((4-(methoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1- (((4- (methyl)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((phenylsulfonyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-(((4- (trifluoromethoxy)phenyl)sulfany1)methyl)propylamino; D is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, Cl, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(2-(4- - 67 - WO2005/049594 PCT/US2004/037911 (dimethylamino)phenyl)phenylcarbonyl)piperazin-1-yDphenylcarbonyl, 4-(4-(2-(4-(dimethylamino)phenyl)phenylmethyl)piperazin-1-yl") phenylcarbonyl, 4-(4-( (2-(4-(dimethylamino)phenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(5,5-dimethyl-2-oxo-l,3-oxazolidin-3-yl)phenylmethyl)-piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)-3-fluorophenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- fluorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4-((2-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(2-(isopropylamino)phenylmethyl)-piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(isopropylsulfanyl)phenyl)phenylmethyl)piperazin-1-yl) phenylcarbonyl, 4-(4- (2- (4-methoxyphenyl) cycl.opent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(3-methoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-methoxyphenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-methoxy-4-(2-(pyridin-3-yl)phenylmethyl)piperidin-1-yl)phenylcarbonyl, 4-(4-(2-(2-methyl-4-dichlbrophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2-methylphenyl)phenylmethyl)-piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(methylsulfonyl)-phenyl)methyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(4-methylsulfonylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-((2-(4-methylsulfonylphenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, - 68 - WO2005/049594 PCT/US2004/037911 C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (lR)-3-(4-(hydroxyaminocarbonyl)piperidin-1-yl)-1- ((phenylsulfanyl) methyl)propylamino, (IR)-3-(2-hydroxy-2-methylpropyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(4-hydroxypiperidin-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (3R)-3-(3-hydroxypyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, isopropylamino, (lR)-3-(isopropylamino)-1- ((phenylsulfanyl) methyl)propylamine, (IR)-3-(lH-imidazol-1-yl)-l-((phenylsulfanyl)methyl)propylamino, (lR)-3-(isopropyl(methyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (4-methoxycyclohex-l-yl)methyl)amino, (lR)-3-(4-(methoxyimino)piperidin-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-carboxymethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (methyl)(cyclohexyl)amino, (methyl)(cyclohexylmethyl)amino, (IR)-3-(Z-methyl-4,5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl)methyl)propylamino, (3R)-3-(N-methyl-N-(dimethylcarbonylmethyl))-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(1,2-diphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-((diphenylmethyl)amino)carbonyl)-N-methylamino, (2-methylfuran-3-yl)sulfanyl)-(1,1-spirobutyl)ethylamino, (IR)-3-(N-methyl-N-(2-hydroxyethyl))amino) -1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(N-methyl-N-isopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (N-methyl-N-(4-methoxyphenyl)amino)carbonyl)-N-methylamino, 1-methyl-4-(phenylsulfanyl)pyrrolidin-3-ylamino, (N-methyl-N- (4-methylphenyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(2-methylphenyl)amino)carbonyl)-N-methylamino, (IR)-3-(4-methylpiperazin-1-yl)-1-((phenylsulfanyl) methyl)propylamino, - 69 - WO2005/049594 PCT/US2004/037911 l-methylpiperidin-4-yloxy, (N-methyl-N-((S)-1-phenylethyl)amino)carbonyl)-N-methylamino, (N-methyl-N-(1-phenyl-2-(4-methylpiperazin-4-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(morpholin-1-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(N,N-dimethylamino))amino)carbonyl)-N-methylamino, (IR)-1-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IS)-l-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IR)-4-(4-methylpiperazin-l-yl)-l-((phenylsulfanyl)methyl)butylamino, (1RJ-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-5-((methylsulfonylamino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(4-(methylsulfonylaminocarbonyl)piperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 2-((4-methyl-l,3-thiazol-2-yl)sulfanyl)ethylamino, (N-methyl-N-(4- trifluoromethoxyphenyl)amino)carbonyl)-N-methylamino, (IR)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2-(morpholin-4-yl)ethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-l-((l,3-thiazo1-2- ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((thien-2-ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-(((4-(methoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-(((4- (methyl)phenyl)sulfanyl)methylpropylamino, (IR)-3-(morpholin-4-yl)-l-((phenylsulfonyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-1-(((4- (trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino; D is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(5-methylthien-2- - 70 - WO2005/049594 PCT/US2004/037911 yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-methylsulfanylphenyl)cyclohex-1-en-l-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4- methylsulfanylphenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-methylsulfanylphenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methylsulfanylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(2-(morpholin-1-y1)ethoxy)phenyl)phenylmethyl)pipera z in-1-y1)phenylcarbony1, 4-(4-(2-(morpholin-1-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(naphth-1- yl)phenylmethyl)piperazin-1-y1)phenylcarbonyl, 4-(4-(2-(naphth-2-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-(2-(4-phenoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((l-phenyl-lH-imidazol-2-yl)methyl)piperazin-l-yl) phenylcarbonyl, 4-(4-((1-phenyl-lH-imidazol-5-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(2-((phenylmethyl)amino)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(dimethylamino)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-((2-(phenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(morpholin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2-(4-(phenyl)phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl or 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(piperidin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (lR)-3-(4- - 71 - WO2005/049594 PCT/US2004/037911 phenyl-2-(4-methylpiperazin-4-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(morpholin-1-yl))amino)carbonyl)-N-methylamino, (N-methyl-N-(l-phenyl-2-(N,N-dimethylamino))amino)carbonyl)-N-methylamino, (IR)-1-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IS)-l-methyl-2-((phenylsulfanyl)methyl)ethylamino, (IR)-4-(4-methylpiperazin-1-yl)-1-((phenylsulfanyl)methyl)butylamino, (IR)-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-5- ((methylsulfonylamino)-1-((phenylsulfanyl)methyl)pentylamino, (IR)-3-(4-(methylsulfonylaminocarbonyl)piperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, 2-((4-methyl-l,3-thiazol-2-yl)sulfanyl)ethylamino, (N-methyl-N-(4- trifluoromethoxyphenyl)amino)carbonyl)-N-methylamino, (IR)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-((2-(morpholin-4-yl)ethyl) amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-l-((l,3-thiazol-2- ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((thien-2-ylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-l-(((4-(methoxy)phenyl)sulfanyl)methyl)propylamino, (IR)-3-(morpholin-4-yl)-1-(((4- (methyl)phenyl)sulfanyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-1-((phenylsulfonyl)methyl)propylamino, (lR)-3-(morpholin-4-yl)-1-(((4- (trifluoromethoxy)phenyl)sulfanyl)methyl)propylamino; D is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(phenyl)phenylmethyl)- 4-(2-(pyrrolidin-l-yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-((2-(phenyl)pyridin-3-yl)methyl)piperazin-1- - 73 - WO2005/049594 PCT/US2004/037911 Yl)phenylcarbonyl, 4-(4-( (l-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2- (piperidin-1-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(pyrid-3-yl)phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(quinolin-3-ylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(quinolin-8- ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(thien-2-yl)phenylmethyl)-4-methoxypiperazin-l-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-trifluoromethoxyphenyl)phenylmethyl)piperazin-1-yDphenylcarbonyl or 4-(4-(2-(4-trifluoromethyl-phenyl) pheny lmethyl) piperazin-1-yl) phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-3-((IS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfany1)methyl)propylamino, (1R)-3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(azetidin-1-yl)-l-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(cyclobutylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-(cyclopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(dimethylamino)-1- ( (phenylsulf onylmethyl)methyl) propylamino., (1R) -3-oxo-3-(dimethylamino)-1-((pyrimidin-l-ylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-((1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)-propylamino, - 74 - WO2005/049594 PCT/US2004/037911 (IR)-3-OXO-3-(1, l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(piperidin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-amino-1-((phenylsulfany1)methyl)propylamino, (IR)-3-oxo-3-(methylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(4-methylpiperazin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(morpholin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(2-(morpholin-1-yl)ethyl)-1-((phenylsulfanyl)methyl)propylamino, (2-phenoxyethyl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)methylamino, (4-phenyl-1,3-thiazol-2-ylsulfanyl)ethylamino, (IR,2S)-2-(phenylsulfanyl)cyclohex-1-ylamino, (IS,2R)-2-(phenylsulfanyl)cyclohex-1-ylamino, 2- (phenylsulfanyl)cyclopentylamino, 2-(phenylsulfanyl)ethoxy, 2-(phenylsulfanyl)ethylamino, 2-(phenylsulfonyl)ethylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(morpholin-4-yl)propylamino, (1R)-1-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylamino, 4-(phenylsulfonyl)tetrahydrofuran-3-ylamino, 4-(phenylsulfanyl)tetrahydrofuran-3-ylamino, (IR)-1-((phenylsulfanyl)methyl)-3-( (2,2,2-trifluoroethyl)amino)propylamino, (IS)-1-((phenylsulfanyl)methyl)propylamino, (1R)-1- ((phenylsulfanyl)methyl)-3-(pyridin-4-ylsulfanyl)propylamino, (1R)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-(piperazin-1-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((2-(pyridin-2-yl)ethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((pyridin-4-ylmethyl)amino)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3- - 75 - WO2005/049594 PCT/US2004/037911 (pyridin-3-ylamino) propylami.no, (1R)-1- {(phenylsulfanyl)methyl)-3-(pyrrolidin-1-ylaminb)propylamino), (IR)-1-((phenylsulfanyl)methyl)-3-(2H-tetrazol-5-yl)propylamine, (IR) -1-((phenylsulfanyl)methyl)-3-(pyrrolidin-l-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)3-((pyridin-2-ylmethyl)amino)propylamino, (IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethylamino, (3S,4R)- (phenylsulfanyl)pyrrolidin-4-ylamino, 2-(phenylsulfanyl)-1,1-spirobutylethylamino, 2-(phenylsulfanyl)-1,1-spiroethylethylamino', 2- (phenylsulfanyl) -1,1-spiropentylethylamino, piperidin-4-yloxy, (1-propylpiperidin-4-yl)methylamino, pyran-4-ylamino, 2-(pyridin-4-ylsulfanyl)ethylamino, 2-(pyrimidin-2-ylsulfanyl)ethylamino, 1,l-spirobutyl-2-(phenylsulfanyl)ethyl, 2-(thien-2-ylsulfanyl)ethylamino, sulfanylpyran-4-ylamino, (IR)-3-(2-(2H-tetrazol-3-yl)pyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (lR)-3-(3-(2H-tetrazol-3-yl)azetidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino or 2-(l,3-thiazol-2-ylsulfanyl) ethylamino; D1 is. H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2-(1,3-benzodioxol-5-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(benzofuran-2-ylphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-bromocyclohex-l-en-l- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-bromocyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(2-(4-bromophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)cyclohept-l-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(1-(2-(4-chlorophenyl)cyclohex-l-en-1-ylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)cyclohex-l-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)cyclopent-l-en-1- - 76 - WO2005/049594 PCT/US2004/037911 ylraethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)cyclooct-l-en-l-ylmethyl)piperazin-l- yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H- pyran-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((4-(4- chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1- yl) phenylcarbonyl, 4-(l-( (2-(4-chlorophenyl)-5,5-dimethyl-l- cyclohex-1-en-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4- yl)phenylmethyl, 4-(4-(2-(4-chlorophenyl)naphth-3- ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)pyridin-3-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(4-chlorophenyl)pyridin-4-ylmethyl)piperazin-1- yl)phenylcarbonyl, 4-(4-((4-(4-chlorophenyl)pyridin-5- yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4- (1-(2-(4-chlorophenyl)phenylcycloprop-1-yl)piperazin-1- yl)phenylcarbonyl or 4-(4-(2-(4- chlorophenyl)phenylmethyl)cyclohex-1-en-l-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or 1 2 2 salts of prodrugs thereof, wherein A1isC(A2 );A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-3-((IS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(azetidin-1-yl)-l-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3- (cyclobutylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-(cyclopropylamino)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3- (dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(dimethylamino)-1- ((phenylsulfonylmethyl)methyl)propylamino, (1R)-3-oxo-3- - 77 - WO2005/049594 PCT/US2004/037911 (dimethylamino)-1-((pyrimidin-1-ylsulfanyl)methyl)propylamino, (IR)-3-OXO-3-((1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)-propylamino, (IR)-3-oxo-3-(1, l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- • ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(piperidin-l-yl)-l-( (phenylsulfanyl)methyl)propylamino,. (IR)-3-oxo-3-amino-l-((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(methylamino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(4-methylpiperazin-l-yl)-1-((phenylsulfanyl)methyl)-propylamino, (IR)-3-oxo-3- (morpholin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(2- . (morpholin-1-yl)ethyl)-1-((phenylsulfanyl)methyl)propylamino, (2-phenoxyethyl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)methylamino, (4-phenyl-1,3-thiazol-2-ylsulfanyl)ethylamino, (1R,2S)-2-(phenylsulfanyl)cyclohex-1-ylamino, (IS,2R)-2-(phenylsulfanyl)cyclohex-1-ylamino, 2- (phenylsulfanyl)cyclopentylamino, 2-(phenylsulfanyl)ethoxy, 2-(phenylsulfanyl)ethylamino, 2-(phenylsulfonyl)ethylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(morpholin-4-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylamino, 4-(phenylsulfonyl)tetrahydrofuran-3-ylamino, 4-(phenylsulfanyl)tetrahydrofuran-3-ylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)-amino)propylamino, (lS)-l-( (phenylsulfanyl)methyl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyridin-4-ylsulfanyl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-yl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(piperazin-1-yl)propylamino, (1R)- - 78 - WO2005/049594 PCT/US2004/037911 1-((phenylsulfanyl)methyl)-3-((2-(pyridin-2- yl)ethyl)amino)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((pyridin-4-ylmethyl)amino)propylamino, (1R)-1-((phenylsulfanyl)methyl)-3-(pyridin-3-ylandno)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-ylamino)propylamino), (IR)-1-((phenylsulfanyl)methyl)-3-(2H-tetrazol-5-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propylamino, (IR)-1-((phenylsulfanyl)methyl)3-((pyridin-2-ylmethyl)amino)propylamino, (IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethylamino, (3S,4R)- (phenylsulfanyl)pyrrolidin-4-ylamino, 2-(phenylsulfanyl)-1,1-spirobutylethylamino, 2--(phenylsulfanyl)-1,1-spiroethylethylamino, 2- (phenylsulfanyl) -1,1-spiropentylethylamino, piperidin-4-yloxy, (1-propylpiperidin-4-yl)methylamino, pyran-4-ylamino, 2-(pyridin-4-ylsulfanyl)ethylamino, 2-(pyrimidin-2-ylsulfanyl)ethylamino, 1,l-spirobutyl-2-(phenylsulfanyl)ethyl, 2-(thien-2-ylsulfanyl)ethylamino, sulfanylpyran-4-ylamino, (IR)-3-(2-(2H-tetrazol-3-yl)pyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(3-(2H-tetrazol-3-yl)azetidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino or 2-(l,3-thiazol-2-ylsulfanyl)ethylamino; D1 is H, F, CI or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(5-(2-(4- chlorophenyl)phenylmethyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)phenylcarbonyl, 4-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)-piperazin-1-yl)-3,5-difluorophenylcarbonyl, 4-(4-(2-(4-chlorophenyl)phenylmethyl)piperazin-l-.yl) -2- - 79 - WO2005/049594 PCT/US2004/037911 fluorophenylcarbonyl, 4- (4-(2-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)-3-fluorophenylcarbonyl, 2- (4- (2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)pyridin-5-ylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylmethyl)piperidin-4-yDphenylcarbonyl, 5-(4-(2-(4- chlorophenyl)phenylmethyl)piperazin-l-yl)pyridin-2-ylcarbonyl, 4-(1-(2-(4-chlorophenyl)phenylmethyl)-1,2,3,6-tetrahydropyridin-4-yl)phenylcarbonyl, 4-(4-(2-(cyclohex-1-ylamino)phenylmethyl)piperazin-l-yl)phenylcarbonyl4-(4-(2-cyclohex-l-ylphenylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4-(2-(3-cyanophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2- (2,4-dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(3,4- dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2,4-difluorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(2-(l,3-dihydro-2H-isoindolT2-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4-(3-(1,1-dimethylethoxycarbonylamino)phenyl)piperazin-1-yl)phenylcarbonyl, 4-(2-(4-(2- (dimethylamino)ethoxy)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-(3-(dimethylamino)phenyl)piperazin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-3-((IS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamine, (lR)-3-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)-propylamino, (1R)-3-oxo-3-(azetidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3- - 80 - WO2005/049594 PCT/US2004/037911 (cyclobutylamino)-l-( (phenylsulfanyl)methyl)propylamino, (IR) -3-OXO-3- (cyclopropylami.no) -1-((phenylsulfanyl)methyl)propylamine, (IR)-3-oxo-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(dimethylamino)-1- ((phenylsulfonylmethyl)methyl)propylamino, (IR)-3-oxo-3-(dimethylamino)-1-((pyrimidin-1-ylsulfanyl)methyl)propylamino, (IR)-3-OXO-3-((1,1-dimethylethyl)amino)-1- . ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)-propylamino, (IR)-3-oxo-3-(1,l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(piperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-amino-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(methylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(4-methylpiperazin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(morpholin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(2-(morpholin-1-yl)ethyl)-1-((phenylsulfanyl)methyl)propylamino, (2-phenoxyethyl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)methylamino, (4-phenyl-1,3-thiazol-2-ylsulfanyl)ethylamino, (IR,2S)-2-(phenylsulfanyl)cyclohex-1-ylamino, (lS,2R)-2-(phenylsulfanyl)cyclohex-1-ylamino, 2- (phenylsulfanyl)cyclopentylamino, 2-(phenylsulfanyl)ethoxy, 2-(phenylsulfanyl)ethylamino, 2-(phenylsulfonyl)ethylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(morpholin-4-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylamino, 4-(phenylsulfonyl)tetrahydrofuran-3-ylamino, 4-(phenylsulfanyl)tetrahydrofuran-3-ylamino, (IR)-1- - 81 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylaraino, (1S)-1-((phenylsulfanyl)methyl)propylaraino, (1R)-1-((phenylsulfanyl)methyl)-3-(pyridin-4-ylsulfanyl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-yl)propylamino, (IR)-1- ( (phenylsulfanyl)methyl)-3-(piperazin-1-yl)propylamino, (lR)-l-( (phenylsulfanyl)methyl)-3-((2-(pyridin-2-yl)ethyl)amino)propylamino, (IR)-1-((phenylsulfanyl) methyl)-3-((pyridin-4- ylmethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyridin-3-ylamino)propylamino, (IR)-1- ((phenylsulfanyl)methyl)-3- (pyrrolidin-1-ylamino)propylamino), (IR)-1-((phenylsulfanyl) methyl)-3-(2H-tetrazol-5-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propylamino, (lR)-l-( (phenylsulfanyl)methyl)-3-((pyridin-2-ylmethyl)amino)propylamino, (IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethylamino, (3S,4R)- (phenylsulfanyl)pyrrolidin-4-ylamino, 2-(phenylsulfanyl)-1,1-spirobutylethylamino, 2-(phenylsulfanyl)-1,1-spiroethylethylamino, 2-(phenylsulfanyl)-1,1-spiropentylethylamino, piperidin-4-yloxy, (1-propylpiperidin-4-yl)methylamino, pyran-4-ylamino, 2-(pyridin-4-ylsulfanyl)ethylamino, 2- (pyrimidin-2-ylsulfanyl)ethylamino, 1,l-spirobutyl-2-(phenylsulfanyl)ethyl, 2-(thien-2-ylsulfanyl)ethylamino, sulfanylpyran-4-ylamino, (IR)-3-(2-(2H-tetrazol-3-yl)pyrrolidin-1-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-(3-(2H-tetrazol-3-yl)azetidin-1-yl)-1-( (phenylsulfanyl)methyl)propylamino or 2-(1,3-thiazol-2-ylsulfanyl) ethylamino; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, Cl, CF3/ OCF3, NH2 or C(O)NH2; and Z1 is 4-(2-(4-(dimethylamino)phenyl)phenylcarbonyl)piperazin-1- - 82 - WO2005/049594 PCT/US2004/037911 yl)phenylcarbonyl, 4-(4-(2-(4- (dimethylamino)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-((2-(4-(dimethylamino)phenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(5,5-dimethyl-2-oxo-l,3-oxazolidin-3-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-fluorophenyl)cyclopent-l-en-1-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4- (4- (2- (4-fluorophenyl)-3-fluorophenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- fluorophenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((2-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(2- (isopropylamino)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4-(isopropylsulfanyl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methoxyphenyl)cyclopent-l-en-1-ylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(3-methoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-methoxyphenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-{(2-(4-methoxyphenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-methoxy-4-(2-(pyridin-3-yl)phenylmethyl)piperidin-1-yl)phenylcarbonyl, 4-(4- (2-(2-methyl-4-dichlorophenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(2- methylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-(methylsulfonyl)phenyl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4- methylsulfonylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-((2-(4-methylsulfonylphenylJpyridin-3-yl)methyl)piperazin-1-yl)phenylcarbonyl. Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C(A2); A2 is H, F, CN, - 83 - WO2005/049594 PCT/US2004/037911 C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (IR)-3-((IS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- t ((phenylsulfanyl)methyl)propylamino, (lR)-3-((IR,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(azetidin-1-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(cyclobutylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-OXO-3-(cyclopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(dimethylamino)-1- ((phenylsulfonylmethy1)methyl)propylamino, (IR)-3-oxo-3-(dimethylamino)-1-((pyrimidin-1-ylsulfanyl)methyl)propylamino, (IR) -3-OXO-3- ( (1,1-dimethylethyl) amino) *-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-OXO-3-(l,l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(piperidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-amino-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(methylamino)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(4-methylpiperazin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(morpholin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (IR)-3-oxo-3-(2-(morpholin-1-yl)ethyl)-1-((phenylsulfanyl)methyl)propylamino, (2-phenoxyethyl)amino, 4-(1-(phenylmethyl)piperidin-4-yDamino, 4- (1- (phenylmethyl)piperidin-4-yl)methylamino, (4-phenyl-1,3-thiazol-2-ylsulfanyl)ethylamino, (IR,2S)-2-(phenylsulfanyl)cyclohex-1-ylamino, (IS,2R)-2-(phenylsulfanyl)cyclohex-1-ylamino, 2- - 84 - WO2005/049594 PCT/US2004/037911 (phenylsulfanyl)cyclopentylamino, 2-(phenylsulfanyl)ethoxy, 2-(phenylsulfanyl)ethylamino, 2-(phenylsulfonyl)ethylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(morpholin-4-yl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylamino, 4-(phenylsulfonyl)tetrahydrofuran-3-ylamino, 4-(phenylsulfanyl)tetrahydrofuran-3-ylamino, (IR)-1-((phenylsulfanyl) methyl)-3-((2,2,2-trifluoroethyl)-amino)propylamino, (1S)-1-((phenylsulfanyl)methyl)propylamino, (IR) -1-( (phenylsulfanyl)methyl)-3-(pyfidin-4-ylsulfanyl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-yl)propylamino, (1R)-1- ((phenylsulfanyl)methyl)-3-(piperazin-1-yl)propylamino, (IR)-1-((phenylsulfanyl) methyl)-3-((2-(pyridin-2- yl)ethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((pyridin-4-ylmethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyridin-3-ylamino)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-ylamino)propylamino), (lR)-l-((phenylsulfanyl)methyl)-3-(2H-tetrazol-5-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((pyridin-2-ylmethyl)amino)propylamino, (IS)-2-(phenylsulfanyl)-1- (pyridin-3-ylmethyl)ethylamino, (3S,4R)-(phenylsulfanyl)pyrrolidin-4-ylamino, 2-(phenylsulfanyl)-1,1-spirobutylethylamino, 2-(phenylsulfanyl)-1,1-spiroethylethylamino, 2-(phenylsulfanyl)-1,1- spiropentylethylamino, piperidin-4-yloxy, (1-propyl-piperidin-4-yl)methylamino, pyran-4-ylamino, 2-(pyridin-4-ylsulfanyl)ethylamino, 2-(pyrimidin-2-ylsulfanyl)ethylamino, 1,l-spirobutyl-2-(phenylsulfanyl)ethyl, 2-(thien-2-ylsulfanyl)ethylamino, sulfanylpyran-4-ylamino, (IR)-3-(2-(2H-tetrazol-3-yl)pyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propylamino, (IR)-3-(3-(2H-tetrazol-3- - 85 - WO2005/049594 PCT/US2004/037911 yl)azetidin-l-yl)-l- ( (phenylsulfanyl)methyl)propylami.no or 2-(l,3-thiazol-2-ylsulfanyl)ethylamino; D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3, NH2 or C(O)NH2; and Z1 is 4-(4-(2- (5-methylthien-2-yl)phenylmethyl)piperazin-l-yl) phenylcarbonyl, 4-(4-(2-(4-methylsulfanylphenyl)cyclohex-l-en-l-ylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(4- methylsulfanylphenyl)phenylcarbonyl)piperazin-1-yl)phenylcarbonyl, 4- (4- ((2- (4-methylsulfanylphenyl)pyridin-3-yl)methyl)piperazin-l-yl) phenylcarbonyl, 4-(4- (2-(4-methylsulf anylphenyl) phenylmethyl) piperazin-1-yDphenylcarbonyl, 4- (4- (2- (4-(2-(morphdlin-1-yl) ethoxy) phenyl) phenylmethyl) piperazin-1-yl) phenylcarbonyl, 4-(4-(2-(morpholin-1-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4- (4- (2-(naphth-1- yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(naphth-2-yl)phenylmethyl)piperazin-l-yl)phenylcarbonyl 4-(4-(2- (4-phenoxyphenyl) phenylmethyl) piperazin-1-yl)phenylcarbonyl, 4- (4-( (l-phenyl-lH-imidazol-2-yl)methyl)piperazin-1-yl) phenylcarbonyl, 4-(4-((1-phenyl-lH-imidazol-5-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(2-((phenylmethyl) amino) phenylmethyl) piperazin-1-yl)phenylcarbonyl, 4- (4-(2-(phenyl)phenylmethyl)-4-(2-(dimethylamino)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-( (2-(phenyl)phenylmethyl)-4-methoxypiperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(morpholin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-(2-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(3-(phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4- (2-(4-(phenyl)phenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(piperidin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl. - 86 - WO2005/049594 PCT/US2004/037911 Still another embodiment pertains to compounds having formula (I), or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, wherein A1 is C (A2 ) ; A2 is H, F, CN,C(O)OH, C(O)OCH3 or C(O)NH2; B1 is (1R)-3-((IS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3-((1R,4R)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3- (azetidin-1- yl)-l-((phenylsulfanyl)methyl)propylamino, (lR)-3-oxo-3-(cyclobutylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-(cyclopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-qxo-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propylamino, (lR)-3- oxo-3-(dimethylamino)-1- ((phenylsulfonylmethyl)methyl)propylamino, (1R)-3-oxo-3-(dimethylamino)-1-((pyrimidin-1-ylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-((1,1-dimethylethyl)amino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-OXO-3-(l,l-dioxothiomorpholin-4-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(N-methyl-N-(1,1-dimethylethyl)amino)-1- ((phenylsulfanyl)methyl)propylamino, {lR)-3-oxo-3-(piperidin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-amino-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(methylamino)-1-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(4-methylpiperazin-l-yl)-1- ((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(morpholin-l-yl)-l-((phenylsulfanyl)methyl)propylamino, (1R)-3-oxo-3-(2-(raorpholin-1-yl)ethyl)-1-((phenylsulfanyl)methyl)propylamino, (2-phenoxyethyl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)amino, 4-(1-(phenylmethyl)piperidin-4-yl)methylamino, (4- - 87 - WO2005/049594 PCT/US2004/037911 phenyl-1,3-thiazol-2-ylsulfanyl)ethylamino, (1R,2S)-2-(phenylsulfanyl)cyclohex-1-ylamino, (IS,2R)-2-(phenylsulfanyl)cyclohex-1-ylamino, 2- (phenylsulfanyl)cyclopentylamino, 2-(phenylsulfanylJethoxy, 2-(phenylsulfanyl)ethylamino, 2-(phenylsulfonyl)ethylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(morpholin-4-yl)propylamine, (IR)-1-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propylamino, 4-(phenylsulfonyl)tetrahydrofuran-3-ylamino, 4-(phenylsulfanyl)tetrahydrofuran-3-ylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl) amino) propylamino, (11S)-1-((phenylsulfanyl)methyl)propylamino, (1R)-1-((phenylsulfanyl)methyl)-3-(pyridin-4-ylsulfanyl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-yl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(piperazin-1-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((2-(pyridin-2-yl)ethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-((pyridin-4-ylmethyl)amino)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyridin-3-ylamino)propylamino, (1R)-1- ((phenylsulfanyl)methyl)-3-(pyrrolidin-l-ylamino)propylamino), (IR)-1-((phenylsulfanyl)methyl)-3-(2H-tetrazol-5-yl)propylamino, (IR)-1-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propylamino, (lR)-l-((phenylsulfanyl)methyl)-3-((pyridin-2-ylmethyl)amino)propylamino, (IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethylamino, (3S,4R)- (phenylsulfanyl)pyrrolidin-4-ylamino, 2-(phenylsulfanyl)-1,1-spirobutylethylamino, 2-(phenylsulfanyl)-1,1-spiroethylethylamino, 2-(phenylsulfanyl)-1,1-spiropentylethylamino, piperidin-4-yloxy, (1-propylpiperidin-4-yl)methylamino, pyran-4-ylamino, 2-(pyridin-4-ylsulfanyl)ethylamino, 2-(pyrimidin-2-ylsulfanyl)ethylamino, - 88 - WO2005/049594 PCT/US2004/037911 l,l-spirobutyl-2-(phenylsulfanyl*) ethyl, 2-(thien-2-ylsulfanyl)ethylamino, sulfanylpyran-4-ylamino, (IR)-3-(2-(2H-tetrazol-3-yl)pyrrolidin-1-yl)-1- ((phenylsulfanyl) methyl) propylartd.no, (IR)-3-(3-(2H-tetrazol-3-yl)azetidin-l-yl)-l-((phenylsulfanyl)methyl)propylamino or 2-(l,3-thiazol-2-ylsulfanyl)ethylamino; D1 is H, F, CI or CF3; E1 is H, F or Cl; Y1 is H, CN, NO2, F, CI, CF3, OCF3/ NH2 or C(O)NH2 and Z1 is 4-(4-(2-(phenyl)phenylmethyl)-4-(2-(pyrrolidin-1-yl)ethoxy))piperidin-l-yl)phenylcarbonyl, 4-(4-((2-(phenyl)pyridin-3-yl)methyl)piperazin-l-yl)phenylcarbonyl, 4-(4-((l-phenyl-lH-pyrazol-5-yl)methyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(piperidin-1- yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(pyrid-3-yl)phenyl)phenylmethyl)piperazin-l-yl)phenylcarbonyl, 4-(4-(2-(quinolin-3-ylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(quinolin-8- ylphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)-4-methoxypiperazin-l-yl)phenylcarbonyl, 4-(4-(2-(thien-2-yl)phenylmethyl)piperazin-1-yl)phenylcarbonyl, 4-(4-(2-(4-trifluoromethoxyphenyl)phenylmethyl)piperazin-1-yl)phenylcarbonyl or 4-{4-(2-(4-trifluoromethyl-phenyl) phenylmethyl) piperazin-1-yl) phenylcarbonyl . Still another embodiment pertains to compounds having formula (I) which are N-(4-(4-{(1,1 *-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-l-{(phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonartd.de, N-(4-(4-((4-chloro(1,1 -biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1- - 89 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4- methoxy(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-fluoro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino) -1-((phenylsulfanyl)methyl)propyl) amino)-N-(4-(4-((4-(methylsulfany1)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-((4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-(4-phenyl-1,1 *-biphenyl-2-ylmethyl)piperazin-1-yl)benzamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((4-phenoxy(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4- ((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, - 90 - WO2005/049594 PCT/US2004/037911 N- (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-4-(dimethylamino)-1-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, N- (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-5-(dimethylamino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-fluoro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4-(4-((4-chloro-4-fluoro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1- - 91 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(l,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(1,3-thiazol-2-ylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N- (4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((1,3-thiazol-2-ylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4 *-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((thien-2-ylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)pipera zin-l-yl)benzoyl)-4-(((IR)-2-(2-(dimethylamino)ethoxy--1-((phenylsulfanyl)methyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,l'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IS)-3-(dimethylamino)-1-methyl-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(methylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, (3R)-3-(4-(((A-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butanoic acid, (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-isopropyl-4-(phenylsulfanyl)butanamide, - 92 - WO2005/049594 PCT/US2004/037911 N-(4-(4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((lR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(azetidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((4-(phenylsulfanyl)tetrahydro-3-furanyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4- ((4’-chloro(1,1'-biphenyl)-2-yl)methyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-hydroxy-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(isopropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(2-naphthyl)benzyl)piperazin-1-yl)benzoyl) -3-nitrobenzenesulfonamide, 4-(((lR)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(1- - 93 - WO2005/049594 PCT/US2004/037911 naphthyl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide N-(4-(4-((3'-cyano(l,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((3'-methoxy(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((3'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((2'-chloro (1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-(2-(l,3-benzodioxol-5-yl)benzyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(3-thienyl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(pyridin-3-yl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(quinolin-8-yl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, - 94 - WO2005/049594 PCTAJS2004/037911 N-(4-(4-(2-(l-benzofuran-2-yl)benzyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2'-methyl(1,1'-biphenyl)-2-yl) methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(quinolin-3-yl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, N-(4-(4-((1-(4-chlorophenyl)-2-naphthyl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-( (2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1-(4-chlorophenyl)-2-naphthyl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1-(4-chlorophenyl)-2-naphthyl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)cyclopentyl)amino)benzenesulfonamide, N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-l-yl)benzoyl)-3-nitro-4- ( (2-(phenylsulfanyl)cyclopentyl)amino)benzenesulfonamide, N-(4-(4-((4-fluoro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-( (2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, - 95 - WO2005/049594 PCT/US2004/037911 N- (4-(4-((3', 4 '-dichloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((3»,4 »-diehloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((3•,4-dichloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)-N-(4-(4-((4-(trifluoromethyl)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)benzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((4-(trifluoromethyl) (1,1 *-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)benzenesulfonamide, 4-(( (IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((4 -(trifluoromethyl)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)benzenesulfonamide, 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)-N-(4-(4-((4-(trifluoromethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)-N-(4-(4-((4-(trifluoromethoxy)(1,1'-biphenyl)-2-yl)raethyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((4-(trifluoromethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)benzenesulfonamide, - 96 - WO2005/049594 PCT/US2004/037911 3-nitro-N- (4- (4-((4-phenoxy(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((4-phenoxy(1,l'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfonyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2',4-dichloro(1,1'-biphenyl)-2- yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino) - s 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(2-thienyl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, N-(4-(4-((4-chlqro-2'-methyl(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino) -1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-( (2',4•-difluoro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfonyl)ethyl)amino)benzenesulfonamide, - 97 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4-chloro (1,l'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfonyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1 *-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((4-(phenylsulfanyl)tetrahydro-3-furanyl)amino)benzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(5-methyl-2-thienyl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4 '-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((4-(phenylsulfonyl)tetrahydro-3-furanyl)amino)benzenesulfonamide, N- (4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((4-(phenylsulfonyl)tetrahydro-3-furanyl) amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((l-methyl-4-(phenylsulfanyl)pyrrolidin-3-yl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-l-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((2- (4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((4-bromo(1,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ( (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-(1-(4-chloro(1,1'-biphenyl)-2-yl)cyclopropyl)piperazin-l-yl)benzoyl)-4-(((1R)-3- - 98 - WO2005/049594 PCT/US2004/037911 (dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-2-(dimethylamino)-1-((phenylsulfanyl)methyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-2-(dimethylamino)-1-((phenylsulfanyl)methyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-2-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)ethyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-2-(diethylamino)-1-((phenylsulfanyl)methyl)ethyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yDmethyl) piperazin-1-yl)benzoyl)-4-( ( (IR) -2- (morpholin-4-yl)-1-((phenylsulfanyl)methyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(cyclopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1- - 99 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-(2-(pyridin-3-yl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- ( ( (IR) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-(2-(pyridin-4-yl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- ( ( (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl) propyl) amino) -N- (4- (4-methoxy-4-.(2-(2-thienyl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-{2-(3-thienyl)benzyl)piperidin-1-yl)benzoyl)-3- nitrobenzenesulfonamide, 4-(((IR)-3-(azetidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-((2,2,2-trifluoroethyl)amino)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(methyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(l,l'-biphenyl)-2-yl)methyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 100 - WO2005/049594 PCT/US2004/037911 N-(4-(4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)-4-methoxypiperidin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(ethyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4- {(4 *-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR)-3-((2-fluoroethyl)amino)-1-{(phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4- (4- ((4 »-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR)-3-((2,2-difluoroethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro{1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-1-((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)-lH-benzimidazole-5-sulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-1-((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)-1H-1,2,3-benzotriazole-5-sulfonamide, 5-{((4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzamide, N-(4-(4-((4-(dimethylamino)(1,1'-biphenyl)-2-yl)carbonyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4- ((4- - 101 - WO2005/049594 PCT/US2004/037911 {(phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4- (((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-(2-(pyridin-3-yl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- (((IR) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-(2-(pyridin-4-yl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino) -N- (4- (4-methoxy-4-(2- (2-thienyl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-methoxy-4-(2-(3-thienyl)benzyl)piperidin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(azetidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-((2,2, 2-trifluoroethyl)amino)propyl)aminoJbenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(methyl(2,2,2-trifluoroethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(l,l'-biphenyl)-2-yl)methyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 100 - WO2005/049594 PCT/US2004/037911 (methylsulfanyl) (1,1' -biphenyl)-2-yl)carbonyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- (((IR)-3-(dimethylamino)-1-( (phenylsulfanyl)methyl)propyl)amino)-N-{4-(4-( (41 -(methylsulfanyl) (1,1'-biphenyl)-2-yl)carbonyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-cyano-4-( ((IR)-3-(dimethylamino) -1-( (phenylsulfanyl)methyl)propyl) amino)benzenesulf onamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)oxy)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4- ( ((IR) -3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- ( ( (IR)-3-(5,6-dihydro-l(4H)-pyrimidin-l-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4 *-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(2-methyl-4,5-dihydro-lH-imidazol-l-yl)-l-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- ( ( (IR)-3-(5,6-dihydro-l(4H)-pyrimidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(2,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, - 102 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4-chloro (1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR) -3- (2-methyl-4,5-dihydro-lH-imidazol-l-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro (1,1»-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(4,4-dimethyl-4,5-dihydro-lH-imidazol-1-yl) -1- ((phenylsulfanyl)methyl) propyl) amino) -3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl) benzoyl) -4- ( ((IR) -3- (dimethylamino) -1- ( (phenylsulfanyl)methyl)propyl) oxy) -3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)cyclohept-l-en-1-yl)methyl) piperazin-1-yl) benzoyl) -4- (( (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino) -3-(trifluoromethyl)benzenesulfonamide, 4-(((IR)-3-(bis (2-methoxyethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(bis (2-methoxyethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-(trifluoromethyl)benzenesulfonamide, 4-(((IR)-5-amino-l-( (phenylsulfanyl)methyl)pentyl)amino)-N-(4-(4-((4 *-chloro(1,1'-biphenyl)-4-yl)methyl)-1-piperazinyl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((IR)-4-methyl-l-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrobenzenesulfonamide, - 103 - WO2005/049594 PCT/US2004/037911 tert-butyl(5R)-5-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-6-(phenylsulfanyl)hexylcarbamate, 4-(((1R)-5-amino-l-((phenylsulfanyl)methyl)pentyl)amino)-N-(4-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-5-((methylsulfonyl)amino)-1-((phenylsulfanyl)methyl)pentyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-5-((aminocarbonyl)amino)-1-((phenylsulfanyl)methyl)pentyl)amino)-N-(4-(4-((4-chloro (1,1'-biphenyl)-2-yl) methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- (((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(methylsulfanyl)benzyl)piperazin-1-yl)benzoyl)-3- nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4- (4- (2-(methylsulfonyl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- (((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(5,5-dimethyl-2-oxo-l, 3-oxazolidin-3-yl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N- (4-(4-(2-cyclohexylbenzyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(morpholin-4-yl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, - 104 - WO2005/049594 PCT/US2004/037911 4-(((IR)-3-(dimethylamino)-1-((phenylsulfany1)methyl)propyl)amino)-N-(4-(4-(2-(isopropylsulfanyl)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl) methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dipropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-3-ylmethyl)piperazin-l-yl)benzoyl)~3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-3-ylmethyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 105 - WO2005/049594 PCI7US2004/037911 N-(4-(4-((1,1'-biphenyl)-3-ylmethyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)-3-fluorobenzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)piperazin-l-yl)-3-fluorobenzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)-3-fluorobenzoyl)-4- ( ( (1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazln-1-yl)-3,5-difluorobenzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide N- (4- (4- ( (1,1’-biphenyl) -2-ylmethyl)piperazin-1-y-L) -3, 5-difluorobenzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)-3,5-difluorobenzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 3-nitro-N-(4-(4-((l-phenyl-lH-imidazol-2-yl)methyl)piperazin-l-yl)benzoyl)-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((lR)-3-(morpholin-4-yl)-l-((phenylsulfanyl) methyl)propyl)amino)-3-nitro-N-(4-(4-((1- - 106 - WO2005/049594 PCT/US2004/037911 phenyl-lH-imidazol-2-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 3-nitro-N-(4-(4-((l-phenyl-lH-pyrazol-5-yl)methyl)piperazin-1-yl)benzoyl)-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((1-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 4-(((1R)-3-(morpholin-4-yl)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((1-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide 4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((1-phenyl-lH-imidazol-5-yl) methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 1-((3R)-3-(4- (((4- (4- ((4‘-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butyl)-3-azetidinecarboxylic acid, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-( (2-hydroxy-2-methylpropyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzene- sulfonamide, (((3R)-3-(4-(((4-(4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl) -2-nitroanilino)-4-(phenylsulfanyl)butyl)(methyl)amino)acetic acid, (2R)-l-((3R)-3-(4-( ( (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butyl)-2-pyrrolidinecarboxylic acid - 107 - WO2005/049594 PCT/US2004/037911 1-((3R)-3-(4-(((4-(4-((4-chloro(1,1•-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)--2-nitroanilino)-4-(phenylsulfanyl)butyl)-4-piperidinecarboxylic acid N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-((2-hydroxyethyl)(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide (2S)-l-((3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butyl)-2-pyrrolidinecarboxylic acid, N-(4-(4-((4-chloro(1,1•-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-(3-(2H-tetrazol-5-yl)azetidin-1-yl)propyl)amino)benzenesulfonamide, (2S)-2-amino-N-((IS)-2-(((3R)-3-(4-(((4-(4-((4-chloro (1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butyl)amino)-l-methyl-2-oxoethyl)propanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(2-(2H-tetrazol-5-yl)pyrrolidin-l-yl)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(4- (((methylsulfonyl)amino)carbonyl)piperidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4"-chloro (1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, - 108 - WO2005/049594 PCT/US2004/037911 l-((3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butyl)-N-hydroxy-4-piperidinecarboxamide, 2-chloro-N-(4-(4-((4•-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, 2,6-dichloro-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, 4-(((lR)-3-((lR,5S)-8-azabicyclo[3.2.1]oct-8-yl)-l-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(7-azabicyclo[2.2.1]hept-7-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(2-(phenylsulfanyl)ethoxy)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl) methyl)piperazin-1-yl)benzoyl)-4-(2-(phenylsulfanyl)ethoxy)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl) methylJpiperazin-l-yl)benzoyl)-3-nitro-4-(((IR)-3-((IS,4S)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, N- (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-3-((IR,4R)-2-oxa-5-azabicyclo [2 . 2,-. 1] hept-5-yl) -1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, - 109 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl) methyl) piperazin-1-yl) benzoyl) -3-nitro-4- ( ((lR)-3-((1S,4S)-2-oxa-5-azabicyclo[2.2.l]hept-5-yl)-1-((phenylsulfanyl) methyl)propyl)amino)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IR)-3-((IR,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl)-1-((phenylsulfanyl) methyl)propyl)amino)benzenesulfonamide, 4-(((lR)-3-(7-azabicyclo[2.2.1]hept-7-yl)-l-((phenylsulfanyl) methyl)propyl)amino)-N-(4-(4-((2- (4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-( (2- (4-chlorophenyl)-1-cyclohexen-l-yl) methyl) piperazin-1-yl) benzoyl) -4-(((IR)-3-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, N-(4-(4- ( (4 '-chloro(l,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IR)-3-((IR,4R)-2-oxa-5-azabicyclo[2.2.1]hept-5-yl) -1-((phenylsulfanyl) methyl)propyl)amino)benzenesulfonamide, N-(4-(4-((l,l*-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4- (cyclohexyloxy)-3-nitrobenzenesulfonamide, N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)piperazin-1-yl) benzoyl)-4-(cyclohexylmethoxy)-3-nitrobenzenesulfonamide, N-(4-(4-((l,l’-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4- (2-cyclohexylethoxy)-3-nitrobenzenesulfonamide, N-(4-(4- ( (1,l'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-(tetrahydro-2H-pyran-4-ylamino)benzenesulfonamide, N-(4- (4- ( (1,l'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4- ( (2-cyclohexylethyl)amino)-3-nitrobenzenesulfonamide, - 110 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((1,1’ -biphenyl)-2-ylmethyl)piperazin-1-yl]benzoyl)-4-(cyclohexyl(methyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(4,4-dimethylpiperidin-l-yl) -3-nitrobenzenesulfonamide, tert-butyl 4-(4-( ((4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)amino)sulfonyl) -2-nitrophenoxy)-1-piperidinecarboxylate, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-3-nitro-4-(piperidin-4-yloxy)benzenesulfonamide, N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((l-methylpiperidin-4-yl)oxy)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-((cyclohexylmethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((cyclohexylmethyl)(propyl)amino)-3-nitrobenzenesulfonamide, 4-(((l-benzylpiperidin-4-yl)methyl) amino) -N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((cyclohexylmethyl)(methyl)amino)-3-nitrobenzenesulfonanmide 4-((l-benzylpiperidin-4-yl)amino)-N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-(tetrahydro-2H-sulfanylpyran-4-ylamino)benzenesulfonamide, - Ill - WO2005/049594 PCT/US2004/037911 ethyl 4-(4-( ( (4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-1-piperidinecarboxylate, N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((l-propylpiperidin-4-yl)methyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(isopropylamino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4- ({2- (1,3-thiazol-2-ylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-((4-phenyl-l, 3-thiazol-2-yl)sulfanyl)ethyl)amino)benzenesulfonamide, 4-((2-(l,3-benzothiazol-2-ylsulfanyl)ethyl)amino)-N-(4-(4- ( (1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(l,3-thiazol-2-ylsulfanyl)ethyl)amino)benzenesulfonamide, 4-((2-(1,3-benzoxazol-2-ylsulfanyl)ethyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-((2-(1,3-benzothiazol-2-ylsulfanyl)ethyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(pyrimidin-2-ylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((1R)-3-(morpholin-4-yl)-1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((1-phenyl-lH-pyrazol-5-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, - 112 - WO2005/049594 PCT/US2004/037911 4-(((l-benzylpiperidin-4-yl)methyl)amino)-N-(4-(4-( (4'-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4- ( (2-bromoethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((2-((4-methyl-l,3-thiazol-2-yl)sulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1•-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((4-methoxycyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(2-thienylsulfanyl)ethyl)amino)benzenesulfonamide, N- (4- (4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(2-thienylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N- (4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl) -4- ( ( (IR) -3- (morpholin-4-yl) -1- ( (1, 3-thiaz,ol-2-ylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, (3R)-3-(4-(((4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N,N-dimethyl-4-(pyrimidin-2-ylsulfanyl)butanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-3-oxo-l-((2-thienylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(pyrimidin-2-ylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2- - 113 - WO2005/049594 PCT/US2004/037911 nitroanilino)-N,N-dimethyl-4-(1,3-thiazol-2-ylsulfanyl)butanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR)-3-(morpholin-4-yl)-1-((2-thienylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((4 *-chloro(1,1 *-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR)-3-(dimethylamino)-1-(( (4-(trifluoromethdxy)phenyl)sulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-phenoxyethyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- (((IR)-3-(morpholin-4-yl)-1-( ( (4-(trifluoromethoxy)phenyl)sulfanyl)methyl)propyl)amino)-3-nitrobenzen'esulf onamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4- ( ( (IR)-1-(((4-methoxyphenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl) benzoyl) -4- ( ((IR) -1- ( ((4-methylphenyl) sulfanyDmethyl) -3-(morpholinr4-yl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ((IR)-3-(dimethylamino)-1-((2-thienylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl) benzoyl)-4-( ( (lR)-l-( ( (4-chlorophenyl) sulfanyDmethyl)-3-(morpholin-4-yl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ( (IR)-3-(dimethylamino)-1-(((4- - 114 - WO2005/049594 PCT/US2004/037911 fluorophenyl)sulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-l-(((4-fluorophenyl)sulfanyl)methyl)-3-(morpholin-4-yl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)-2-fluorobenzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-3r-nitrobenzenesulfonamide, N-(4-(1-((4’-chloro(1,1'-biphenyl)-2-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(1-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)-2-fluorobenzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzene sulfonamide, N-((6-(4-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)pyridin-3-yl)carbonyl)-4-(((IR)-3-{dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(1-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperidin-4-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulf ona.mide, N-(4-(1-((4-ehloro(1,1'-biphenyl)-2-yl)methyl)piperidin-4-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 115 - WO2005/049594 PCT/US2004/037911 N-(4-(1-((4-chloro(1,1'-biphenyl)-2-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(diraethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-((6-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)pyridin-3-yl)carbonyl)-4-(((lR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- ( (6-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-l-yl)pyridin-3-yl)carbonyl)-4-(((lR)-3-(diraethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro (1,1'-biphenyl)-2-yl)methyl)piperidin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-nitrobenzenesulfonamide N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperidin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-((5-(4-((4-chloro(1,1*-biphenyl)-2-yDmethyl) piperazin-1-yl) pyridin-2-yl) carbonyl) -4- (((IR) -3-(diraethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-((5-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)pyridin-2-yl)carbonyl)-4- ( ( (IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(1-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 116 - WO2005/049594 PCT/US2004/037911 N-(4- (1-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (1-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)-1,2,3, 6-tetrahydropyridin-4-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4- (l-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl)methyl)-1,2,3,6-tetrahydropyridin-4-yl)benzoyl)-4-(((lR)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4-((4-chloro(1,1 *-biphenyl)-2-yl)methyl)-1-cyclohexen-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4- (4- ( (4 '-chloro(1,1'-biphenyl)-2-yl)methyl)-1-cyclohexen-1-yljbenzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- ( (3aR,6aS)-5-((4-chloro(1,1'-biphenyl)-2-yl)methyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(methyl((methyl-4-(trifluoromethoxy)anilino)carbonyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(((2-dimethylanilino)carbonyl)(methyl)amino)-3-nitrobenzenesulfonamide, - 117 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((4- methoxy(methyl)anilino)carbonyl)(methyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4- ((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((4-dimethylanilino)carbonyl)(methyl)amino)-3-nitrobenzenesulfonamide, 4-(((benzhydryl(methyl)amino)carbonyl)(methyl)amino)-N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4- (4- ((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(methyl((methyl((IS)-1-phenylethyl)amino)carbonyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(methyl((methyl(2-(4-methylpiperazin-l-yl)-1-phenylethyl)amino)carbonyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(methyl((methyl(2-(morpholin-4-yl)-1-phenylethyl)amino)carbonyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((((1,2- diphenylethyl)(methyl)amino)carbonyl)(methyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((((2-(dimethylamino)-1-phenylethyl)(methyl)amino)carbonyl)(methyl)amino)-3-nitrobenzenesulfonamide, 3-amino-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-1-(2-(phenylsulfanyl)ethyl)-1H-1,2,3-benzotriazole-5-sulfonamide, - 118 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-1-(2-(phenylsulfanyl)ethyl)-lH-benzimidazole-5-sulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-((cyclohexylmethyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(cyclohexylamino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,l1-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-((1- ((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((1,1*-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-3-nitro-4-((1- ((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((1- ((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IS)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-l-yl)benzoyl)-3-nitro-4-(((1S)-1-((phenylsulfanyl)methyl)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methylJpiperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IS)-3-methyl-l- - 119 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-(((IS)-3-methyl-l-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((1-((phenylsulfanyl)methyl)cyclopropyl)amino)benzene-sulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((1-((phenylsulfanyl)methyl)cyclohexyl)amino)benzene-sulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-l-methyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N- (4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((IS)-l-methyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1, l1-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR,2S)-2-(phenylsulfanyl)cyclohexyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, 4-(((1R)-5-amino-l-((phenylsulfanyl)methyl)pentyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethyl)amino)benzenesulfonamide, - 120 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-l-yl)benzoyl)-3-nitro-4-(((IS)-2-(phenylsulfanyl)-l-(pyridin-3-ylmethyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-3-nitro-4-(((IS,2R)-2-(phenylsulfanyl)cyclohexyl)amino)benzenesulfonamide, N-(4-(4-{(1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-((1-(((2-methyl-3-furyl)sulfanyl)methyl)cyclopentyl)amino)-3-nitrobenzenesulfonamide, N- (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-((1-(((2-methyl-3-furyl)sulfanyl)methyl)cyclopentyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IS)-2-(phenylsulfanyl)-1-(pyridin-3-ylmethyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-3-pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 3-nitro-N-(4-(4-((2-phenylpyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, 4- ( ((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((2- - 121 - WO2005/049594 PCT/US2004/037911 phenylpyridin-3-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((2-phenylpyridin-3-yl)methyl)piperazin-l-yl)benzoyl)benzenesulfonamide, 4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-(methylsulfanyl)phenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4- ( ( (lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-methoxyphenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-(dimethylamino)phenyl)pyridin-3-' yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-fluorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-(methylsulfonyl)phenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(l,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-((2-(pyridin-4-ylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-(methylsulfonyl)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, - 122 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitroben zenesulfonamide, N-(4-(4-((2-bromo-l-cyclopenten-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl) methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4- (4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((2-bromo-l-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-l-( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4- ( ((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-methoxyphenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-fluorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, - 124 - WO2005/049594 PCT/US2004/037911 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-N-(4-(4-((2-phenyl-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cycloocten-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((2-(4-(methylsulfanyl)phenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohepten-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohepten-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl)methyl) piperazin-l.-yl) benzoyl) -4- (( (IR) -3- (dimethylamino) -1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-l-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((l,l'-biphenyl)-2-ylmethyl)-4-(2-(morpholin-4-yl)ethoxy)piperidin-1-yl)benzoyl)-4-((1, l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, - 125 - WO2005/049594 PCT/US2004/037911 N- (4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(morpholin-4-yl)ethoxy)piperidin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N- (4T (4- ((1,1'-biphenyl)-2-ylmethyl)-4-(2-(pyrrolidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(pyrrolidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1 *-biphenyl)-2-ylmethyl)-4-(2-(pyrrolidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((1-((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(dimethylamino)ethoxy)piperidin-1-yl)benzoyl)-4-((1,1-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(dimethylamino)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N- (4- (4-( (1,1'-biphenyl)-2-ylmethyl)-4-(2-(dimethylamino)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((1-((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(piperidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(piperidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-(2-(piperidin-1-yl)ethoxy)piperidin-1-yl)benzoyl)-3-nitro-4-((1-((phenylsulfanyl)methyl)cyclopentyl)amino)benzene-sulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((IS)-3-(morpholin-4-yl)-1- - 126 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(2-(dimethylamino)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(2-(dimethylamino)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonaitrile, N-(4-(4-((4-(2-(dimethylamino)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(2-(dimethylamino)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-(2-(morpholin-4-yl)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(2-(morpholin-4-yl)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-N-(4-(4-((4-(2-(morpholin-4-yl)ethoxy)(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(2- (morpholin-4-yl)ethoxy) (1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ( (IR)-3-(lH-imidazol-1-yl)-1- - 127 - WO2005/049594 PCT7US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-(lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,1'-biphenyl)-2-ylmethyl)-4-methoxy-piperidin-1-yl)benzoyl)-4-(((1R)-3- (lH-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-4-(4-methylpiperazin-l-yl)-1-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, N-(4-{4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-2-((2-(dimethylamino)ethyl)(methyl)amino)-1-((phenylsulfany1)methyl)ethyl)amino) -3-nitrobenzenesulfonamide, (4R)-4-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N,N-dimethyl-5-(phenylsulfanyl)pentanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-4-(dimethylamino)-1-((phenylsulfonyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, 2-(((3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl) -2-nitroanilino) -4- (phenylsulf a'nyl)butyl) (methyl) amino) -N,N-dimethylacetamide, (3R)-N-(tert-butyl)-3-(4-(((4-(4-((4 '-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-4-(phenylsulfanyl)butanamide, - 128 - WO2005/049594 PCT/US2004/037911 (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N,N-diisopropyl-4-(phenylsulfanyl)butanamide, (3R)-N-(tert-butyl)-3-(4-({(4-(4-((4 *-chloro(1,1«-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-methyl-4-(phenylsulfanyl)butanamide, (3R)-3-(4-{((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-isopropyl-N-methyl-4-(phenylsulfanyl)butanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IR)-3-oxo-l-((phenylsulfanyl)methyl)-3-(piperidin-1-yl)propyl)amino)benzenesulfonamide, N-((5R)-5-(4-(((4-(4-({4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-6-(phenylsulfanyl)hexyl)-2-(dimethylamino)acetamide, (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N,N-dimethyl-4-(phenylsulfanyl)butanamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(1,l-dioxidothiomorpholin-4-yl)-3-oxo-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, (3R)-3-(4-(((4-(4-((4’-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl) -2-nitroanilino)-4-(phenylsulfanyl)butanamide, (3R) -3- (4- ( ( (4- (4- ( (4' -chloro (1,1' -biphenyl) -2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-cyclopropyl-4-(phenylsulfanyl)butanamide, - 129 - WO2005/049594 PCT/US2004/037911 (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-cyclobutyl-4-(phenylsulfanyl)butanamide, N-(4-(4- ((4-chloro(1,1-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(4-methylpiperazin-l-yl)-3-oxo-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4-(4-((4 '-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-3-oxo-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(azetidin-1-yl)-3-oxo-l-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-(2-(morpholin-4-yl)ethyl)-4-(phenylsulfanyl)butanamide, (3R)-3-(4-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)amino)sulfonyl)-2-nitroanilino)-N-methyl-4-(phenylsulfanyl)butanamide, 4-(((1R)-3-amino-l-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-{(4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-cyano-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((1R)-3-(tert-butylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(A-{(4f-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitrobenzenesulfonamide, - 130 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(cyclopropylamino)-1-((phenyls ulfany1)methyl)propyl)amino)-3- nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(cyclobutylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1, l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N- (4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(isopropyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(tert-butyl(methyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-( (4*-chloro(l,l'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl) -3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1, l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IR)-1-( (phenylsulfanyl)methyl)-3-(piperidin-1-yl) propyl) amino) benzenesulfonamide, N- (4-,(4- ( (4 ' -chloro (1,1' -biphenyl) -2-yl) methyl) piper a zin-l-yl)benzoyl)-4-(((IR)-3-(4-hydroxypiperidin-l-yl) -1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(4-acetylpiperazin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chlorod, l'-biphenyl) -2-yl)methyl)piperazin- 1-yl)benzoyl) -3-nitrobenzenesulfonamide, - 131 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4- (((IR)-1-((phenylsulfanyl)methyl)-3-(thiomorpholin-4-y1)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-((2-(morpholin-4-yl)ethyl)amino)-1-((phenylsulfanyl)methyl)propyl) amino) -3-nitrobenzenesulfonamide; N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-( ( (lR)-l-((phenylsulfanyl)methyl)-3-(piperazin-1-yl)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3- ((3R)-3-hydroxypyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-((3R)-3-aminopyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(3-hydroxyazetidin-l-yl) -1-((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-3- (4-methylpipefazin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl) benzoyl)-4-(((IR)-3-(1,l-dioxidothiomorpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(1,3-benzodioxol-5-ylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4- - 132 - WO2005/049594 PCT/US2004/037911 chloro (1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, 4-(((1R)-3-((1,3-benzodioxol-4-ylmethyl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-( (4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N- (4- (4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-((pyridin-2-ylmethyl)amino)propyl)amino)benzenesulfonamide, N- (4-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-((2-(pyridin-2-yl)ethyl)amino)propyl)amino)benzenesulfonamide, N- (4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((1R)-1-((phenylsulfanyl)methyl)-3-((pyridin-4-ylmethyl) amino)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-ylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4*-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(methyl(pyridin-4-yl)amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1*-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((1R)-1-((phenylsulfanyl)methyl)-3-(pyridin-3-ylamino)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2,6-dimethylpiperidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-((2R,6S)-2,6-dimethylpiperidin-l-yl)- - 133 - WO2005/049594 PCT/US2004/037911 l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-bipheny1)-2-yl)methyl)piperazin-l-yl)benzoyl)-3-nitro-4-(((lR)-l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-ylamino)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((lR)-3-(4-(methoxyimino)piperidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1’-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitro-4-(((IR)-1-((phenylsulfanyl)methyl)-3-(2H-tetrazol-5-yl)propyl)amino)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(diisopropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulf onamide", N- (4- (4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(isopropylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, 4-(((lR)-3-(bis(2-hydroxyethyl)amino)-l-( (phenylsulfanyl)methyl.) propyl) amino) -N-(4- (4-( (4' -chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-((4*-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-4-(trifluoromethoxy)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(isopropyl(methyl) amino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, - 134 - WO2005/049594 PCT/US2004/037911 N-(4-(4- ((4*-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(diethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide, N-(4-(4- ( (4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((lR)-3-amino-l-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-(trifluoromethyl)benzenesulfonamide, N-(4- (4- ((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-2-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-fluorobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-2-(trifluoromethoxy)benzenesulfonamide, N-(4- (4- ((4-chloro(l,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-2,5-difluorobenzenesulfonamide, N-(4-(4-((4-chloro(1,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-methylbenzenesulfonamide, N-(4- (4- ((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3- - 135 - WO2005/049594 PCT/US2004/037911 (diisopropylamino)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-((2R,5R)-2, 5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3- ((2S,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4 *-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3- ((2R,5S)-2,5-dimethylpyrrolidin-l-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4’-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-5-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-5-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((2-(4-chlorophenyl)-1-cyclohepten-l-yDmethyl) piperazin-1-yl) benzoyl)-4-( ( (IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitro-5-(trifluoromethyl)benzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-3-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-4-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino) -1- - 136 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3,5-dif luorobenzenesulfonaird.de, methyl 5-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2- (((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzoate, 5-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl) methyl) piperazin-l-yl) benzoyl) amino) sulf onyl.) -2- (((IR) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzoic acid, 5-(((4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzoic acid, 5-(((4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((lR)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzoic acid, 5-(((4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzamide, 5-(((4-(4-((4*-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzamide, methyl 5-(((4-(4-((2-(4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-( ((lR)-3-(dimethylamino)rl-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzoate, methyl 5-(((4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((IR)-3-(dimethylamino)-1- - 137 - WO2005/049594 PCT/US2004/037911 ((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzoate, methyl 5-(((4-(4-((4«-chloro(1,l'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)amino)sulfonyl)-2-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzoate, N-(4-(4-((2-{4-chlorophenyl)-1-cyclohexen-l-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-4-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(4-chlorophenyl)-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((IR)-4-((2R,5S)-2,5-dimethylpyrrolidin-1-yl)-1-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, tert-butyl 3-((4-(4-((( (4-( ((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)amino)carbonyl)phenyl)piperazin-1-yl)carbonyl)phenylcarbamate, N-(4-(4-(3-(dimethylamino)benzoyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-methyl-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)piperazin-1-yl)benzoyl)-4-(((IS)-3-(dimethylamino)-1-methyl-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, - 138 - WO2005/049594 PCT/US2004/0379H N-(4-(4-(2-(l,3-dihydro-2H-isoindol-2-yl)benzyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-(2-(cyclohexylamino)benzyl)piperazin-l-yl)benzoyl)-4-( ((IR)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-N-(4-(4-(2-(isopropylamino)benzyl)piperazin-1-yl)benzoyl)-3-nitrobenzenesulfonamide, N-(4-(4-(2-(benzylamino)benzyl)piperazin-1-yl)benzoyl)-4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitro-N-(4-(4-(2-(piperidin-1-yl)benzyl)piperazin-1-yl)benzoyl)benzenesulfonamide, N-(4-(4- ( (1,l'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)piperazin-l-yl)benzoyl)-4- ((cyclohexylmethyl) amino) -3-nitrobenzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-4-( ( (IR)-3-(morpholin-4-yl)-1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide, N-(4-(4-((1,l'-biphenyl)-2-ylmethyl)-4-methoxypiperidin-1-yl)benzoyl)-3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, - 139 - WO2005/049594 PCT/US2004/037911 N-(4-(4-((4•-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lS)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ( (1R) -l-((phenylsulfanyl)methyl)-3-(pyrrolidin-1-yl)propyl)amino) -3-(trifluoromethyl) benzenesulfonamide, N-(4-(4-((4-(4-chlorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-l-((phenylsulfanyl)methyl) propyl) amino)-3-nitrobenzenesulfonamide, N-(4-(4-((4-(4-chlorophenyl)pyridin-3-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-l-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, and N-(4-(4-((4-chloro (1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-( ((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-2-fluoro-3-(trifluoromethyl)benzenesulfonamide, or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof. Still another embodiment pertains to compositions for treating diseases during which are expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (I) . Still another embodiment pertains to methods of treating disease in a patient during which is expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods - 140 - WO2005/049594 PCT/US2004/037911 i comprising administering to the patient a therapeutically effective amount of a compound having formula (I). Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or-B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (I). Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (I). Still another embodiment pertains to compositions for treating diseases during which are expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a'therapeutically effective amount of N- (4 - (4 - ((4 '-chloro(1,1'-biphenyl) -2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- - 141 - WO2005/049594 PCT/US2004/037911 nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof. Still another embodiment pertains to methods of treating disease in a patient during which is expressed one or more than one of antiapoptotic Bcl-X- protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4-chloro(l,l'-biphenyl)-2-yl) methyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof. Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic,leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1RJ-3-(dimethyl-amino)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof. Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous - 142 - WO2005/049594 PCT/US2004/037911 leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4 ' -chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-({(lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof. Still another embodiment pertains to compositions for treating diseases during which are expressed one or more than one of antiapoptotic BC1-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to methods of treating disease in a patient during which is expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of a compound having formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell - 143 - WO2005/049594 PCT/US2004/037911 lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of the compound having formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of the compound having formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to compositions for treating diseases during which are expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said compositions comprising an excipient and a therapeutically effective amount of N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. - 144 - WO2005/049594 PCT/US2004/037911 Still another embodiment pertains to methods of treating disease in a patient during which is expressed one or more than one of antiapoptotic Bcl-XL protein, antiapoptotic Bcl-2 protein or antiapoptotic Bcl-w protein, said methods comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4-chloro(1,l'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to compositions for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said compositions comprising an excipient and a therapeutically effective amount of N-(4-(4-((4-chloro(1,l'-biphenyl) -2-yl)methyl)piperazin-l-yl)benzoyl) -4-(((1R)-3-(dimethyl-amino)~l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Still another embodiment pertains to methods of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, - 145 - WO2005/049594 PCT/US2004/037911 lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said methods comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. DETAILED DESCRIPTION OF THE INVENTION Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied. It is meant to be understood that proper valences are maintained for all moieties and combinations thereof, that monovalent moieties having more than one atom are drawn from left to right and are attached through their left ends, and that divalent moieties are also drawn from left to right. It is also meant to be understood that a specific embodiment of a variable moiety herein may be the same or different as another specific embodiment having the same identifier. The term "cyclic moiety," as used herein, means arene, aryl, cycloalkane, cycloalkyl, cycloalkene, cycloalkenyl, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl, spiroalkyl, spiroalkenyl, spiroheteroalkyl and spiroheteroalkenyl. The term "arene," as used herein, means benzene. - 146 - WO2005/049594 PCT/US2004/037911 The term "aryl," as used herein, means phenyl. The term "cycloalkane," as used herein, means C3-cycloalkane, C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C7~cycloalkane, Ce-cycloalkane, C6-cycloalkane, C10-4cycloalkane, Cn-cycloalkane, C12-cycloalkane, C13-cycloalkane and C14-cycloalkane. The term "cycloalkyl," as used herein, means C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl Ce-cycloalkyl, C7~cycloalkyl, C8-cycloalkyl, C6-cycloalkyl, C10-cycloalkyl, Cn-cycloalkyl, C12-cycloalkyl, C13-cycloalkyl and C14-cycloalkyl. The term "cycloalkene," as used herein, means C4-cycloalkene, C5-cycloalkene, C6-cycloalkene, Cy-cycloalkene, C8-cycloalkene, C6-cycloalkene, C10-4cycloalkene, Cu-cycloalkene, C12-cycloalkene, C13-cycloalkene and C14-cycloalkene. The term "cycloalkenyl," as used herein, means C3-cycloalkenyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C-7-cycloalkenyl, C8-cycloalkenyl, C6-cycloalkenyl, C10-4cycloalkenyl, Cn-cycloalkenyl, C12-cycloalkenyl, C13-cycloalkenyl and C14_-cycloalkenyl. The term "heteroarene," as used herein, means furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine and 1,2,3-triazole. The term "heteroaryl," as used herein, means furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, - 147 - WO2005/049594 PCT/US2004/037911 pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl and 1,2,3-triazolyl. The term "heterocycloalkane," as used herein, means cycloalkane having one or two or three CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkane having one or two or three CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties replaced with N. The term "heterocycloalkyl," as used herein, means cycloalkyl having one or two or three CH2 moieties replaced with independently selected O, C(O), CNOH- CNOCH3/ S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkyl having one or two or three CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties replaced with N. The term "heterocycloalkene," as used herein, means cycloalkene having one or two or three CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one.or two CH moieties unreplaced or replaced with N and also means cycloalkene having one or two or three CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties replaced with N. The term "heterocycloalkenyl," as used herein, means cycloalkenyl having one or two or three CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N - 148 - WO2005/049594 PCT/US2004/037911 and also means cycloalkenyl having one or two or three CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties replaced with N. The term "spiroalkyl," as used herein, means C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl, C5-spiroalkyl, C6-spiroalkyl, Cy-spiroalkyl, C5-spiroalkyl and C6-spiroalkyl. The term "spiroalkenyl," as used herein, means C2-spiroalkenyl, C3-spiroalkenyl, C4-spiroalkenyl, C5-spiroalkenyl, C6-spiroalkenyl, C7-spiroalkenyl, C5-spiroalkenyl and C6-spiroalkenyl. The term "spiroheteroalkyl," as used herein, means spiroalkyl having one or two CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O) , SO2 or NH. .The term "spiroheteroalkenyl," as used herein, means spiroalkenyl having one or two CH2 moieties replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N and also means spiroalkenyl having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties replaced with N. The term "alkenyl," as used herein, means C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl and C6-alkenyl. The term "alkyl," as used herein, means C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl and C6-alkyl. The term "alkynyl," as used herein, means C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl and C6-alkynyl. - 149 - WO2005/049594 PCT/US2004/037911 The term "C2-alkenyl," as used herein, means ethenyl (vinyl). The term "C3-alkenyl," as used herein, means 1-propen-l-yl, l-propen-2-yl (isopropenyl) and l-propen-3-yl (allyl). The term "C4-alkenyl," as used herein, means 1-buten-l-yl, l-buten-2-yl, 1,3-butadien-l-yl, 1,3-butadien-2-yl, 2-buten-l-yl, 2-buten-2-yl, 3-buten-l-yl, 3-buten-2-yl, 2-methyl-l-propen-l-yl and 2-methyl-2-propen-1-yl. The term "C5-alkenyl," as used herein, means 2-methylene-3-buten-l-yl, 2-methylenebut-l-yl, 2-methyl-l-buten-l-yl, 2-methyl-l,3-butadien-l-yl, 2-methyl-2-buten-l-yl, 2-methyl-3-buten-l-yl, 2-methyl-3-buten-2-yl, 3-methyl-l-buten-l-yl, 3-methyl-l-buten-2-yl, 3-methyl-l,3-butadien-l-yl, 3-methyl-1,3-butadien-2-yl, 3-methyl-2-buten-l-yl, 3-methyl-2-buten-2-yl, 3-methyl-3-buten-l-yl, 3-methyl-3-buten-2-yl, 1-penten-l-yl, l-penten-2-yl, l-penten-3-yl, 1,3-pentadien-1-yl, 1,3-penta-dien-2-yl, 1,3-pentadien-3-yl, 1,4-pentadien-1-yl, 1,4-pentadien-2-yl, 1,4-pentadien-3-yl, 2-penten-l-yl, 2-penten-2-yl, 2-penten-3-yl, 2,4-pentadien-l-yl, 2,4-pentadien-2-yl, 3-penten-l-yl, 3-penten-2-yl, 4-penten-l-yl and 4-penten-2-yl. The term "C6-alkenyl," as used herein, means 2,2-dimethyl-3-buten-l-yl, 2,3-dimethyl-l-buten-l-yl, 2,3-dimethyl-l,3-butadien-l-yl, 2,3-dimethyl-2-buten-l-yl, 2,3-dimethyl-3-buten-l-yl, 2,3-dimethyl-3-buten-2-yl, 3,3-dimethyl-l-buten-l-yl, 3,3-dimethyl-l-buten-2-yl, 2-ethenyl-l,3-butadien-l-yl, 2-ethenyl-2-buten-l-yl, 2-ethyl-l-buten-l-yl, 2-ethyl-l,3-butadien-l-yl, 2-ethyl-2-buten-l-yl, 2-ethyl-3-buten-l-yl, 1-hexen-l-yl, - 150 - WO2005/049594 PCT/US2004/037911 1-hexen-2-yl, l-hexen-3-yl, 1,3-hexadien-l-yl, 1, 3-hexadien-2-yl, 1,3-hexadien-3-yl, 1,3,5-hexatrien-l-yl, l,3,5-hexatrien-2-yl, l,3,5-hexatrien-3-yl, 1,4-hexadien-l-yl, 1,4-hexadien-2-yl, 1,4-hexadien-3-yl/ 1,5-hexadien-l-yl, 1, 5-hexadien-2-yl, 1,5-hexadien-3-yl, 2-hexen-l-yl, 2-hexen-2-yl, 2-hexen-3-yl, 2,4-hexadien-l-yl, 2,4-hexadien-2-yl, 2,4-hexadien-3-yl, 2,5-hexadien-l-yl, 2,5-hexadien-2-yl, 2,5-hexadien-3-yl, 3-hexen-l-yl, 3-hexen-2-yl, 3-hexen-3-yl, 3,5-hexadien-l-yl, 3,5-hexadien-2-yl, 3,5-hexadien-3-yl, 4-hexen-l-yl, 4-hexen-2-yl, 4-hexen-3-yl, 5-hexen-l-yl, 5-hexen-2-yl, 5-hexen-3-yl, 2-methylene-3-methyl-3-buten-l-yl, 2-methylene-3-methylbut-l-yl, 2-methylene-3-penten-l-yl, 2-methylene-4-penten-l-yl, 2-methylenepent-l-yl, 2-methylenepent-3-yl, 3-methylene-l-penten-l-yl, 3-methylene-l-penten-2-yl, 3-methylenepent-l-yl, 3-methylene-1,4-pentadien-l-yl, 3-methylene-l,4-pentadien-2-yl, 3-methylene-pent-2-yl, 2-methyl-l-penten-l-yl, 2-methyl-l-penten-3-yl, 2-methyl-l,3-pentadien-l-yl, 2-methyl-l, 3-pentadien-3-yl, 2-methyl-l,4-pentadien-l-yl, 2-methyl-l,4-pentadien-3-yl, 2-methyl-2-penten-l-yl, 2-methyl-2-penten-3-yl, 2-methyl-2,4-pentadien-l-yl, 2-methyl-2,4-pentadien-3-yl, 2-methyl-3-penten-l-yl, 2-methyl-3-penten-2-yl, 2-methyl-3-penten-3-yl, 2-methyl-4-penten-l-yl, 2-methyl-4-penten-2-yl, 2-methyl-4-penten-3-yl, 3-methyl-l-penten-l-yl, 3-methyl-l-penten-2-yl, 3-methyl-l,3-pentadien-l-yl, 3-methyl-l,3-pentadien-2-yl, 3-methyl-l,4-pentadien-l-yl, 3-methyl-l,4-pentadien-2-yl, 3-methyl-2-penten-l-yl, 3-methyl-2-penten-2-yl,. 3-methyl-2,4-pentadien-l-yl, 3-methyl-3-penten-l-yl, 3-methyl-3-penten-2-yl, 3-methyl-4-penten-1-yl, 3-methyl-4-penten-2-yl, 3-methyl-4-penten-3-yl, 4-methyl-l-penten-l-yl, 4-methyl-l-penten-2-yl, 4-methyl-l-penten-3-yl, 4-methyl-l,3-pentadien-l-yl, 4-methyl-l, 3- - 151 - WO2005/049594 PCT/US2004/037911 pentadien-2-yl, 4-methyl-l,3-pentadien-3-yl, 4-methyl-l,4-pentadien-1-yl, 4-methyl-l,4-pentadien-2-yl, 4-methyl-l, 4-pentadien-3-yl, 4-methylene-2-penten-3-yl, 4-methyl-2-penten-1-yl, 4-methyl-2-penten-2-yl, 4-methyl-2-penten-3-yl, 4-methyl-2,4-pentadien-l-yl, 4-methyl-2,4-pentadien-2-yl, 4-methyl-3-penten-l-yl, 4-methyl-3-penten-2-yl, 4-methyl-3-penten-3-yl, 4-methyl-4-penten-l-yl and 4-methyl-4-penten-2-yl. The term "C1-alkyl," as used herein, means methyl. The term "C2-alkyl," as used herein, means ethyl. The term "C3-alkyl," as used herein, means prop-1-yl and prop-2-yl (isopropyl). The term "C4-alkyl," as used herein, means but-l-yl, but-2-yl, 2-methylprop-l-yl and 2-methylprop-2-yl (tert-butyl). The term "C5-alkyl," as used herein, means • 2,2-dimethylprop-l-yl (neo-pentyl), 2-methylbut-l-yl, 2-methylbut-2-yl, 3-methylbut-l-yl, 3-methylbut-2-yl, pent-1-yl, pent-2-yl and pent-3-yl. The term "C6-alkyl," as used herein, means 2,2-dimethylbut-l-yl, 2,3-dimethylbut-l-yl, 2,3-dimethylbut-2-yl, 3,3-dimethylbut-l-yl, 3,3-dimethylbut-2-yl, 2-ethylbut-l-yl, hex-l-yl, hex-2-yl, hex-3-yl, 2-methylpent-l-yl, 2-methylpent-2-yl, 2-methylpent-3-yl, 3-methylpent-l-yl, 3-methylpent-2-yl, 3-methylpent-3-yl, 4-methylpent-l-yl and 4-methylpent-2-yl. The term "C2-alkynyl," as used herein, means ethynyl (acetylenyl). The term "C3-alkynyl," as used herein, means 1-propyn-l-yl and 2-propyn-l-yl (propargyl). - 152 - WO2005/049594 PCT/US2004/037911 The term "C4-alkynyl," as used herein, means 1-butyn-l-yl, 1,3-butadiyn-l-yl, 2-butyn-l-yl, 3-butyn-l-yl and 3-butyn-2-yl. The term "C5-alkynyl," as used herein, means 2-methyl-3-butyn-l-yl, 2-methyl-3-butyn-2-yl, 3-methyl-l-butyn-l-yl, 1,3-pentadiyn-l-yl, 1,4-pentadiyn-l-yl, l,4-pentadiyn-3-yl, 2,4-pentadiyn-l-yl, 1-pentyn-l-yl, l-pentyn-3-yl, 2-pentyn-l-yl, 3-pentyn-l-yl, 3-pentyn-2-yl, 4-pentyn-l-yl and 4-pentyn-2-yl. The term "C6-alkynyl," as used herein, means 2,2-dimethyl-3-butyn-l-yl, 3,3-dimethyl-l-butyn-l-yl, 2-ethyl-3-butyn-l-yl, 2-ethynyl-3-butyn-l-yl, 1-hexyn-l-yl, l-hexyn-3-yl, 1,3-hexadiyn-l-yl, 1,3,5-hexatriyn-l-yl, 1,4-hexadiyn-l-yl, l,4-hexadiyn-3-yl, 1, 5-hexadiyn-l-yl, 1,5-hexadiyn-3-yl, 2-hexyn-l-yl, 2,5-hexadiyn-l-yl, 3-hexyn-l-yl, 3-hexyn-2-yl, 3,5-hexadiyn-2-yl, 4-hexyn-l-yl, 4-hexyn-2-yl, 4-hexyn-3-yl, 5-hexyn-l-yl, 5-hexyn-2-yl, 5-hexyn-3-yl, 2-methyl-3-pentyn-l-yl, 2-methyl-3-pentyn-2-yl, 2-methyl-4-pentyn-l-yl, 2-methyl-4-pentyn-2-yl, 2-methyl-4-pentyn-3-yl, 3-methyl-l-pentyn-l-yl, 3-methyl-4-pentyn-l-yl, 3-methyl-4-pentyn-2-yl, 3-methyl-1,4-pentadiyn-l-yl, 3-methyl-l,4-pentadiyn-3-yl, 3-methyl-4-pentyn-1-yl, 3-methyl-4-pentyn-3-yl, 4-methyl-l-pentyn-l-yl and 4-methyl-2-pentyn-l-yl. The term "C4-cycloalkane," as used herein, means cyclobutane. The term "C5-cycloalkane," as used herein, means cyclopentane. The term "C6-cycloalkane," as used herein, means cyclohexane. - 153 - WO2005/049594 PCT/US2004/037911 The term "C7-cycloalkane," as used herein, means cycloheptane. The term "C8-cycloalkane," as used herein, means cyclooctane. The term "C6-cycloalkane," as used herein, means cyclononane. The term "C10-4cycloalkane," as used herein, means cyclodecane. The term "Cn-cycloalkane," as used herein, means cycloundecane. The term "C12-cycloalkane," as used herein, means cyclododecane. The term "C13-cycloalkane," as used herein, means cyclotridecane. The term "C14-cycloalkane," as used herein, means cyclotetradecane. The term "C4-cycloalkene," as used herein, means cyclobutene and 1,3-cyclobutadiene. The term "C5-cycloalkene," as used herein, means cyclopentene and 1,3-cyclopentadiene. The term "C6-cycloalkene," as used herein, means cyclohexene, 1,3-cyclohexadiene and 1,4-cyclohexadiene. The term "C7-cycloalkene," as used herein, means cyclpheptene and 1,3-cycloheptadiene. The term "C8"~cydoalkene," as used herein, means cyclooctene, 1,3-cyclooctadiene, 1,4-cyclooctadiene, 1,5-cyclooctadiene, 1,3,5-cyclooctatriene and 1,3,6-cyclooctatriene. The term "C9-cycloalkene," as used herein, means cyclononene, 1,3-cyclononadiene, 1,4-cyclononadiene, 1,5- - 154 - WO2005/049594 PCT/US2004/037911 cyclononadiene, 1,3,5-cyclononatriene, 1,3,6-cyclononatriene, 1, 3,7-cyclononatriene and 1,3,5,7-cyclononatetraene. The term "C10-cycloalkene," as used herein, means cyclodecene, 1,3-cyclodecadiene, 1,4-cyclodecadiene, 1,5-cyclodecadiene, 1,6-cyclodecadiene, 1,3,5-cyclodecatriene, 1, 3, 6-cyclodecatriene, 1,3,5,7-cyclodecatetraene, 1,3,5,8-cyclodecatetraene and 1,3,6,8-cyclodecatetraene. The term "C12-cycloalkene," as used herein, means cycloundecene, 1,3-cycloundecadiene, 1,4-cycloundecadiene, 1,5-cycloundecadiene, 1,6-cycloundecadiene, 1,3,5-cycloundecatriene, 1,3,6-cycloundecatriene, 1,3,7-cycloundecatriene, 1,4,7-cycloundecatriene, 1,4,8-cycloundecatriene," 1, 3, 5, 7-cycloundecatetraene, 1,3,5,8-cycloundecatetraene, 1,3,6,8-cycloundecatetraene and 1,3,5,7,9-cycloundecapentaene. The term "C12-cycloalkene," as used herein, means cyclododecene, 1,3-cyclddodecadiene, 1,4-cyclododecadiene, 1,5-cyclododecadiene, 1,6-cyclododecadiene, 1,7-cyclododecadiene, 1,3,5-cyclododecatriene, 1,3,6-cyclododecatriene, 1,3,7-cyclododecatriene, 1,3,8-cyclododecatriene, 1,4,7-cyclododecatriene, 1,4,8-cyclododecatriene, 1,5,9-cyclododecatriene, 1,3,5,7-cyclododecatetraene, 1,3,5,8-cyclododecatetraene, 1,3,5,9-cyclododecatetraene, 1,3,6,8-cyclododecatetraene, 1,3,6,9-cyclododecatetraene, 1,3,6,10-cyclododecatetraene, 1,3,7,9-cyclododecatetraene, 1,4,7,10-cyclododecatetraene, 1,3,5,7,9-cyclododecapentaene, 1,3,5,7,10-cyclododecapentaene and 1,3,5,8,10-cyclododecapentaene. The term "C13-cycloalkene," as used herein, means 1,3-cyclotridecadiene, 1,4-cyclotridecadiene, 1,5-cyclotridecadiene, 1,6-cyclotridecadiene, 1,7-cyclotridecadiene, 1,3,5-cyclotridecatriene, 1,3,6- - 155 - WO2005/049594 PCT/US2004/037911 cyclotridecatriene, 1,3,7-cyclotridecatriene, 1,3,8-cyclotridecatriene, 1,4,7-cyclotridecatriene, 1,4,8-cyclotridecatriene, 1,4,9-cyclotridecatriene, 1,5,9-cyclotridecatriene, 1,3,5,7-cyclotridecatetraene, 1,3,5,8-cyclotridecatetraene, 1,3,5,9-cyclotridecatetraene, 1,3,6,8-cyclotridecatetraene, 1,3,6,9-cyclotridecatetraene, 1,3,6,10-cyclotridecatetraene, 1,3,6,11-cyclotridecatetraene, 1,3,7,9-cyclotridecatetraene, 1,3,7,10-cyclotridecatetraene, 1,4,7,10-cyclotridecatetraene, 1,3,6,11-cyclotridecatetraene, 1,3,, 5, 7, 9-cyclotridecapentaene, 1,3,5,7,10-cyclotridecapentaene, 1,3,5,8,10-cyclotridecapentaene, 1,3,5, 8,11-cyclotridecapentaene, 1,3,6,8,11-cyclotridecapentaene and 1,3,5,7,9,11-cyclotridecahexaene. The term "C14-cycloalkene," as used herein, means cyclotetradecene," 1,3-cyclotetradecadiene, 1,4-cyclotetradecadiene, 1,5-cyclotetradecadiene, 1,6-cyclotetradecadiene, 1,7-cyclotetradecadiene, 1,8-cyclotetradecadiene, 1,3,5-cyclotetradecatriene, 1,3,6-cyclotetradecatriene, 1,3,7-cyclotetradecatriene, 1,3,8-cyclotetradecatriene, 1,3,9-cyclotetradecatriene, 1,4,7-cyclotetradecatriene, 1,4,8-cyclotetradecatriene, 1,4,9-cyclotetradecatriene, 1,5,9-cyclotetradecatriene, 1,5,10-cyclotetradecatriene, 1,3,5,7-cyclotetradecatetraene, 1,3,5,8-cyclotetradecatetraene, 1,3,5,9-cyclotetradecatetraene, 1,3,5,10-cyclotetradecatetraene, 1,3,6,8-cyclotetradecatetraene, 1,3,6,9-cyclotetradecatetraene, 1,3,6,10-cyclotetradecatetraene, 1,3,6,11-cyclotetradecatetraene, 1,3,6,12-cyclotetradecatetraene, 1, 3, 7, 9-cyclotetradecatetraene, 1,3,7,10-cyclotetradecatetraene, 1,3,7,11-cyclotetradecatetraene, 1,3,8,10-cyclotetradecatetraene, 1,4,7,10-cyclotetradecatetraene, 1,4,7,11-cyclotetradecatetraene, - 156 - WO2005/049594 PCT/US2004/037911 1,4,8,ll-cyclotetfadecatetraene, 1,3,5,7,9-cyclotetradecapentaene, 1,3,5,7,10-cyclotetradecapentaene, 1,3, 5,7,11-cyclotetradecapentaene, 1,3,5,8,10-cyclotetradecapentaene, 1,3,5,8,11-cyclotetradecapentaene, 1,3,5, 8,12-cyclotetradecapentaene, 1,3,5,9,11-cyclotetradecapentaene , 1,3,5,8,11-cyclotetradecapentaene, 1,3,6,8,11-cyclotetradecapentaene, 1,3,6,9,11-cyclotetradecapentaene, 1,3,6,9,12-cyclotetradecapentaene, 1,3,5,8,11-cyclotetradecapentaene, 1,3,5,8,12-cyclotetradecapentaene , 1,3,5,7,9,11-cyclotetradecahexaene, 1,3,5,7,9,12-cyclotetradecahexaene, 1,3,5,7,10,12-cyclotetradecahexaene, 1,3,5,8,10,12-cyclotetradecahexaene and 1,3,5,7,9,11,13-cyclotetradecaheptaene. The term "C3-cycloalkenyl," as used herein, means cycloprop-1-en-l-yl and cycloprop-2-en-l-yl. The term "C4-cycloalkenyl," as used herein, means cyclobut-1-en-l-yl and cyclobut-2-en-l-yl. The term "C5-cycloalkenyl," as used herein, means cyclopent-1-en-l-yl, cyclopent-2-en-l-yl, cyclopent-3-en-l-yl and cyclopenta-1,3-dien-l-yl. The term "C6-cycloalkenyl," as used herein, means cyclohex-1-en-l-yl, cyclohex-2-en-l-yl, cyclohex-3-en-l-yl, cyclohexa-1,3-dien-l-yl, cyclohexa-1,'4-dien-l-yl, cyclohexa-1,5-dien-l-yl, cyclohexa-2,4-dien-l-yl and cyclohexa-2,5-dien-1-yl. The term "C7-cycloalkenyl," as used herein, means bicyclo[2.2.1]hept-2-en-l-yl, bicyclo[2.2.1]hept-2-en-2-yl, bicyclo[2.2.1]hept-2-en-5-yl, bicyclo[2.2.1]hept-2-en-7-yl, bicyclo[2.2.1]hepta-2,5-dien-l-yl, bicyclo[2.2.l]hepta-2,5-dien-2-yl, bicyclo[2.2.1]hepta-2,5-dien-7-yl, cyclohept-1-en-l-yl, cyclohept-2-en-l-yl, cyclohept-3-en-l-yl, cyclohept-4-en-l-yl, cyclohepta-1,3-dien-l-yl, - 157 - WO2005/049594 PCT/US2004/037911 cyclohepta-1,4-dien-l-yl, cyclohepta-1,5-dien-l-yl, cyclohepta-1,6-dien-l-yl, cyclohepta-2,4-dien-l-yl, cyclohepta-2,5-dien-l-yl, cyclohepta-2,6-dien-l-yl, cyclohepta-3,5-dien-l-yl, cyclohepta-1,3,5-trien-l-yl, cyclohepta-1,3,6-trien-l-yl, cyclohepta-1,4,6-trien-l-yl and cyclohepta-2,4,6-trien-l-yl. The term "C6-cycloalkenyl," as used herein, means bicyclo[2.2.2]oct-2-en-l-yl, bicyclo[2.2.2]oct-2-en-2-yl, bicyclo [2.2.2]oct-2-en-5-yl, bicyclo [2.2.2]oct-2-en-7-yl', bicyclo[2.2.2]octa-2,5-dien-l-yl, bicyclo[2.2.2]octa-2,5-dien-2-yl, bicyclo[2.2.2]octa-2,5-dien-7-yl, bicyclo[2.2.2]octa-2, 5,7-trien-l-yl, bicyclo[2.2.2]octa-2,5,7-trien-2-yl cyclooct-1-en-l-yl, cyclooct-2-en-l-yl, cyclooct-3-en-l-yl, cyclooct-4-en-l-yl, cycloocta-l,3-dien-l-yl, cycloocta- 1, 4-dien-l-yl, cycloocta-1,5-dien-l-yl, cycloocta-1,6-dien-1-yl, cyclooctal,7-dien-l-yl, cycloocta-2,4-dien-l-yl, cycloocta-2,5-dien-l-yl, cycloocta-2,6-dien-l-yl, cycloocta- 2, 7-dien-l-yl, cycloocta-3,5-dien-l-yl, cycloocta-3,6-dien-1-yl, cycloocta-1,3,5-trien-l-yl, cycloocta-1,3,6-trien-1-yl, cycloocta-1,3,7-trien-l-yl, cycloocta-1,4,6-trien-1-yl, cycloocta-1,4,7-trien-l-yl, cycloocta-1,5,7-trien-1-yl, cycloocta-2,4,6-trien-l-yl, cycloocta-2,4,7-trien-1-yl, cycloocta-2,5,7-trien-l-yl and cycloocta-1,3,5,7-tetraen-1-yl. The term "C6-cycloalkenyl," as used herein, means cyclonon-1-en-l-yl, cyclonon-2-en-l-yl, cyclonon-3-en-l-yl, cyclonon-4-en-l-yl, cyclonon-5-en-l-yl, cyclonona-1,3-dien-1-yl, cyclonona-1,4-dien-l-yl, cyclonona-1,5-dien-l-yl, cyclonona-1,6-dien-l-yl, cyclonona-1,7-dien-l-yl, cyclonona-1,8-dien-l-yl, cyclonona-2,4-dien-l-yl, cyclonona-2,5-dien-l-yl, cyclonona-2,6-dien-l-yl, cyclonona-2,7-dien-l-yl, cyclonona-2,8-dien-l-yl, - 158 - WO2005/049594 PCT/US2004/037911 cyclonona-3,5-dien-l-yl, cyclonona-3,6-dien-l-yl, cyclonona-3,7-dien-l-yl, cyclonona-4,6-dien-l-yl, cyclonona-1,3,5-trien-l-yl, cyclonona-1,3,6-trien-l-yl, cyclonona-1,3,7-trien-l-yl, cyclonona-1,3,8-trien-l-yl, cyclonona-1,4,6-trien-l-yl, cyclonona-1,4,7-trien-l-yl, cyclonona-1,4,8-trien-l-yl, cyclonona-1,5,7-trien-l-yl, cyclonona-1,5,8-trien-l-yl, cyclonona-1,6,8-trien-l-yl, cyclonona-2,4,8-trien-l-yl, cyclonona-2,4,6-trien-l-yl, cyclonona-2,4,7-trien-l-yl, cyclonona-2,4,8-trien-l-yl, cyclonona-2,5,7-trien-l-yl, cyclonona-2,5,8-trien-l-yl, cyclonona-1,3,5,7-tetraen-l-yl, cyclonona-1,3,5,8-tetraen-1-yl, cyclonona-1,3,6,8-tetraen-l-yl, cyclonona-1, 4, 6, 8-tetraen-l-yl and cyclonona-2,4,6,8-tetraen-l-yl. The term "C10-4cycloalkenyl," as used herein, means cyclodec-1-en-l-yl, cyclodec-2-en-l-yl, cyclodec-3-en-l-yl, cyclodec-4-en-l-yl, cyclodec-5-en-l-yl, cyclodeca-1,3-dien-1-yl, cyclodeca-1, 4-dien-l-yl, cyclodeca-1,5-dien-l-yl, cyclodeca-1,6-dien-l-yl, cyclodeca-1,7-dien-l-yl, cyclodeca-1,8-dien-l-yl, cyclodeca-1,9-dien-l-yl, cyclodeca-2,4-dien-l-yl, cyclodeca-2,5-dien-l-yl, cyclodeca-2,6-dien-l-yl, cyclodeca-2,7-dien-l-yl, cyclodeca-2,8-dien-l-yl, cyclodeca-2,9-dien-l-yl, cyclodeca-3, 5-dien-l-yl, cyclodeca-3,6-dien-l-yl, cyclodeca-3,7-dien-1-yl, cyclodeca-3,8-dien-l-yl, cyclodeca-4,6-dien-l-yl, cyclodeca-4,7-dien-l-yl, cyclodeca-1,3,5-trien-l-yl, cyclodeca-1,3,6-trien-l-yl, cyclodeca-1,3,7-trien-l-yl, cyclodeca-1,3,8-trien-l-yl, cyclodeca-1,3,9-trien-l-yl, cyclodeca-1,4,6-trien-l-yl, cyclodeca-1,4,7-trien-l-yl, cyclodeca-1,4,8-trien-l-yl, cyclodeca-1,4,9-trien-l-yl, cyclodeca-1,5,7-trien-l-yl, cyclodeca-1,5,8-trien-l-yl, cyclodeca-1,5,9-trien-l-yl, cyclodeca-1,6,8-trien-l-yl, cyclodeca-1,6,9-trien-l-yl, cyclodeca-1,7,9-trien-l-yl, - 159 - WO2005/049594 PCT/US2004/037911 cyclodeca-2,4,6-trien-l-yl, cyclodeca-2,4,7-trien-l-yl, cyclodeca-2,4,8-trien-l-yl, cyclodeca-2,4,9-trien-l-yl, cyclodeca-2,5,7-trien-l-yl, cyclodeca-2,5,8-trien-l-yl, cyclodeca-2,5,9-trien-l-yl, cyclodeca-2,6,8-trien-l-yl, cyclodeca-3,5,7-trien-l-yl, cyclodeca-3,5,8-trien-l-yl, cyclodeca-l,3,5,7-tetraen-l-yl, cyclodeca-1,3,5,8-tetraen-1-yl, cyclodeca-1,3,5,9-tetraen-l-yl, cyclodeca-1,3,6,8-tetraen-l-yl, cyclodeca-1,3,6,9-tetraen-l-yl, cyclodeca-1,3,7,9-tetraen-l-yl, cyclodeca-1,4, 6,8-tetraen-1-yl, cyclodeca-1,4,6,9-tetraen-l-yl, cyclodeca-1,4,7,9-tetraen-l-yl, cyclodeca-1,5,7,9-tetraen-l-yl, cyclodeca-2,4,6,8-tetraen-l-yl, cyclodeca-2,4,6,9-tetraen-l-yl, cyclodeca-2,4,7,9-tetraen-l-yl and cyclodeca-1,3,5,7, 9-pentaen-l-yl. The term "Cu-cycloalkenyl," as used herein, means cycloundec-1-en-l-yl, cycloundec-2-en-l-yl, cycloundec-3-en-l-yl, cycloundec-4-en-l-yl, cycloundec-5-en-l-yl, cycloundec-6-en-l-yl, cycloundeca-1,3-dien-l-yl, cycloundeca-1,4-dien-l-yl, cycloundeca-1,5-dien-l-yl, cycloundeca-1,6-dien-l-yl, cycloundeca-1,7-dien-l-yl, cycloundeca-1,8-dien-l-yl, cycloundeca-1,9-dien-l-yl, cycloundeca-1,10-dien-l-yl, cycloundeca-2,4-dien-l-yl, cycloundeca-2,5-dien-l-yl, cycloundeca-2,6-dien-l-yl, cycloundeca-2,7-dien-l-yl, cycloundeca-2,8-dien-l-yl, cycloundeca-2,9-dien-l-yl, cycloundeca-2,10-dien-l-yl, cycloundeca-3,5-dien-l-yl, cycloundeca-3,6-dien-l-yl, cycloundeca-3,7-dien-l-yl, cycloundeca-3,8-dien-l-yl, cycloundeca-3,9-dien-l-yl, cycloundeca-4, 6-dien-l-yl, cycloundeca-4,7-dien-l-yl, cycloundeca-4,8-dien-l-yl, cycloundeca-5,7-dien-l-yl, cycloundeca-1,3,5-trien-l-yl, cycloundeca-1,3,6-trien-l-yl, cycloundeca-1,3,7-trien-l-yl, cycloundeca-1,3,8-trien-l-yl, - 160 - WO2005/049594 PCT/US2004/037911 cycloundeca-1,3 cycloundeca-1,4, cycloundeca-1,4, cycloundeca-1,4, cycloundeca-1,5, cycloundeca-1,5, cycloundeca-1, 6, cycloundeca-1, 7, cycloundeca-1, 8, cycloundeca-2, 4, cycloundeca-2, 4, cycloundeca-2,5, cycloundeca-2,5, cycloundeca-2,6, cycloundeca-2,6, cycloundeca-3,5, cycloundeca-3,5, cycloundeca-3,6, cycloundeca-1,3, 9-trien-l-yl, cycloundeca-1,3,10-trien-l-yl, 6-trien-l-yl, cycloundeca-1,4,7-tri-en-l-yl, 8-trien-l-yl, cycloundeca-1,4,9-trien-l-yl, 10-trien-l-yl, cycloundeca-1,5,7-trien-l-yl, 8-trien-l-yl, cycloundeca-1,5,9-trien-l-yl, 10-trien-l-yl, cycloundeca-1,6,8-trien-l-yl, 9-trien-l-yl, cycloundeca-1,6,10-trien-l-yl, 9-trien-l-yl, cycloundeca-1,7,10-trien-l-yl, 10-trien-l-yl, cycloundeca-2,4,6-trien-l-yl, 7-trien-l-yl, cycloundeca-2,4,8-trien-l-yl, 9-trien-l-yl, cycloundeca-2,4,10-trien-l-yl, 7-trien-l-yl, cycloundeca-2,5,8-trien-l-yl, 9-trien-l-yl, cycloundeca-2,5,10-tri-en-l-yl, 8-trien-l-yl, cycloundeca-2,6,9-trien-l-yl, 10-trien-l-yl, cycloundeca-2,7,9-trien-l-yl, 7-trien-l-yl, cycloundeca-3,5,8-trien-l-yl, 9-trien-l-yl, cycloundeca-3,6,8-trien-l-yl, 9-trien-l-yl, cycloundeca-4,6,8-trien-l-yl, 5,7-tetraen-l-yl, cycloundeca-1,3,5,8 tetraen-1-yl, cycloundeca-1,3,5,9-tetraen-l-yl, cycloundeca-1,3,5,10-tetraen-l-yl, cycloundeca-1,3,6,8-tetraen-1-yl, cycloundeca-1,3,6,9-tetraen-l-yl, cycloundeca-1,3,6,10-tetraen-l-yl, cycloundeca-1,3,7,9-tetraen-l-yl, cycloundeca-1,3,7,10-tetraen-l-yl, cycloundeca-1,3,8,10-tetraen-l-yl, cycloundeca-1,4,6,8-tetraen-l-yl, cycloundeca-1,4,6,9-tetraen-l-yl, cycloundeca-1,4,6,10-tetraen-l-yl, cycloundeca-1,4,8,10-tetraen-l-yl, cycloundeca-1,5,7,9-tetraen-l-yl, cycloundeca-1,5,7,10-tetraen-l-yl, cycloundeca-1,5,8,10-tetraen-l-yl, cycloundeca-1,6,8,10-tetraen-l-yl, cycloundeca-2,4,6,8-tetraen-1-yl, cycloundeca-2,4,6,9-tetraen-l-yl, cycloundeca-2,4,6,10-tetraen-l-yl, cycloundeca-2,4,7,9-tetraen-1-yl, cycloundeca-2,5,7,9-tetraen-l-yl, cycloundeca- - 161 - WO2005/049594 PCT/US2004/037911 3,5,7,9-tetraen-l-yl, cycloundeca-1, 3, 5,7,9-pentaenyl, cycloundeca-1,3,5,7,10-pentaenyl, cycloundeca-1,3,5,8,10-pentaenyl, cycloundeca-1,3,6,8,10-pentaenyl, cycloundeca-1,4,6,8,10-pentaenyl and cycloundeca-2,4,6,8,10-pentaenyl. The term "C12-cycloalkenyl," as -used herein, means cyclododec-1-en-l-yl, cyclododec-2-en-l-yl, cyclododec-3-.en-l-yl, cyclododec-4-en-l-yl, cyclododec-5-en-l-yl, cyclododec--6-en-l-yl, cyclododeca-1,3-dien-l-yl, cyclododeca-1,4-dien-l-yl, cyclododeca-1,5-dien-l-yl, cyclododeca-1,6-dien-l-yl, cyclododeca-1,7-dien-l-yl, cyclododeca-1,8-dien-l-yl, cyclododeca-1,9-dien-l-yl, cyclododeca-1,10-dien-l-yl, cyclododeca-1,11-dien-l-yl, cyclododeca-2,4-dien-l-yl, cyclododeca-2,5-dien-l-yl, cyclododeca-2,6-dien-l-yl, cyclododeca-2,7-dien-l-yl, cyclododeca-2,8-dien-l-yl, cyclododeca-2,9-dien-l-yl, cyclododeca-2,10-dien-l-yl, cyclododeca-2,11-dien-l-yl, cyclododeca-3,5-dien-l-yl, cyclododeca-3,6-dien-l-yl, cyclododeca-3,7-dien-l-yl, cyclododeca-3,8-dien-l-yl, cyclododeca-3,9-dien-l-yl, cyclododeca-3,10-dien-l-yl, cyclododeca-3,11-dien-l-yl, cyclododeca-4,6-dien-l-yl, cyclododeca-4,7-dien-l-yl, cyclododeca-4, 8-dien-l-yl,1 cyclododeca-4, 9-dien-l-yl, cyclododeca-5,7-dien-l-yl, cyclododeca-5,8-dien-l-yl, cyclododeca-1,3,5-trien-l-yl, cyclododeca-1,3,6-trien-l-yl, cyclododeca-1,3,7-trien-1-yl, cyclododeca-1,3,8-trien-l-yl, cyclododeca-1,3,9-trien-l-yl, cyclododeca-1,3,10-trien-l-yl, cyclododeca-1,3,11-trien-l-yl, cyclododeca-1,4,6-trien-l-yl, cyclododeca-1,4,7-trien-l-yl, cyclododeca-1,4,8-trien-l-yl, cyclododeca-1,4,9-trien-l-yl, cyclododeca-1,4,10-trien-l-yl, cyclododeca-1,4,11-trien-l-yl, cyclododeca-1,5,7-trien-l-yl, cyclododeca-1,5,8-trien-l-yl, cyclododeca-1,5,9-trien-l-yl, cyclododeca-1,5,10-trien-l-yl, cyclododeca-1,5,11-trien-l-yl, - 162 - WO2005/049594 PCT/US2004/037911 cyclododeca-1,6 8-trien-l-yl, cyclododeca-1,6,9-trien-l-yl, cyclododeca-1,6, cyclododeca-1,7, cyclododeca-1,7, cyclododeca-1,8 cyclododeca-2,4 cyclododeca-2,4, cyclododeca-2,4, cyclododeca-2,5, cyclododeca-2,5, cyclododeca-2,5, cyclododeca-2,6, cyclododeca-2,6, cyclododeca-2,7, cyclododeca-3,5, cyclododeca-3,5, cyclododeca-3,6, cyclododeca-3,6, cyclododeca-4,6, cyclododeca-1,3, 10-trien-l-yl, cyclododeca-1,6,11-trien-l-yl, 9-trien-l-yl, cyclododeca-1,7,10-trien-l-yl, 11-trien-l-yl, cyclododeca-1,8,10-trien-l-yl, 11-trien-l-yl, cyclododeca-1,9,11-trien-l-yl, 6-trien-l-yl, cyclododeca-2,4,7-trien-l-yl, 8-trien-l-yl, cyclododeca-2,4,9-trien-l-yl, 10-trien-l-yl, cyclododeca-2,4,11-trien-l-yl, 7-trien-l-yl, cyclododeca-2,5,8-trien-l-yl, 9-trien-l-yl, cyclododeca-2,5,10-trien-l-yl, 11-trien-l-yl/ cyclododeca-2,6,8-trien-l-yl, 9-trien-l-yl, cyclododeca-2,6,10-trien-l-yl, 11-trien-l-yl, cyclododeca-2,7,9-trien-l-yl, 10-trien-l-yl, cyclododeca-2,8,10-trien-l-yl, 7-trien-l-yl, cyclododeca-3,5,8-trien-l-yl, 9-trien-l-yl, cyclododeca-3,5,10-trien-l-yl, 8-trien-l-yl, cyclododeca-3,6,9-trien-l-yl, 10-trien-l-yl, cyclododeca-3,7,9-trien-l-yl, 8-trien-l-yl, cyclododeca-4,6,9-trien-l-yl, 5,7-tetraen-l-yl, cyclododeca-1,3,5,8 tetraen-l-yl, cyclododeca-1,3,5,9-tetraen-l-yl, cyclododeca-1,3,5,10-tetraen-l-yl, cyclododeca-1, 3, 5,11-tetraen-1-yl, cyclododeca-1,3,6,8-tetraen-l-yl, cyclododeca-1,3,6,9-tetraen-l-yl, cyclododeca-1,3,6,10-tetraen-l-yl, cyclododeca-1,3,6,11-tetraen-l-yl, cyclododeca-1, 3,7,9-tetraen-1-yl, cyclododeca-1,3,7,10-tetraen-l-yl, cyclododeca-1,3,7,11-tetraen-l-yl, cyclododeca-1,3,8,10-tetraen-l-yl, cyclododeca-1,3,8,11-tetraen-l-yl, cyclododeca-1, 3, 9,11-tetraen-l-yl, cyclododeca-1,4,6,8-tetraen-l-yl, cyclododeca-1,4,6,9-tetraen-l-yl, cyclododeca-1,4,6,10-tetraen-l-yl, cyclododeca-1,4,6,11-tetraen-l-yl, cyclododeca-1,4,7,9-tetraen-l-yl, cyclododeca-1,4,7,10-tetraen-l-yl, cyclododeca-1,4,7,11-tetraen-l-yl, cyclododeca- - 163 - WO2005/049594 PCT/US2004/037911 1, 4, 8,10-tetraen-l-yl, cyclododeca-1, 4, 8,11-tetraen-l-yl, cyclododeca-1,4,9,11-tetraen-l-yl, cyclododeca-1,5,7,9-tetraen-1-yl, cyclododeca-1,5,7,10-tetraen-l-yl, cyclododeca-1,5,7,11-tetraen-l-yl, cyclododeca-1,5,8,10-tetraen-l-yl, cyclododeca-1,5,8,11-tetraen-l-yl, cyclododeca-1,5, 9,11-tetraen-l-yl, cyclododeca-1, 6, 8,10-tetraen-l-yl, cyclododeca-1,6,8,11-tetraen-l-yl, cyclododeca-1,6,9,11-tetraen-l-yl, cyclododeca-1-, 7, 9,11-tetraen-l-yl, cyclododeca-2,4,6,8-tetraen-l-yl, cyclododeca-2,4,6,9-tetraen-1-yl, cyclododeca-2,4,6,10-tetraen-l-yl, cyclododeca-2,4, 6, 11-tetraen-l-yl, cyclododeca-2,4,7,9-tetraen-l-yl, cyclododeca-2,4,7,10-tetraen-l-yl, cyclododeca-2,4,7,11-tetraen-l-yl, cyclododeca-2,4,8,10-tetraen-l-yl, cyclododeca-2,4,8,11-tetraen-l-yl, cyclododeca-2,4,9,11-tetraen-l-yl, cyclododeca-2,5,7,9-tetraen-l-yl, cyclododeca- 2, 5, 7,10-tetraen-l-yl, cyclododeca-2,5,7,11-tetraen-l-yl, cyclododeca-2,5,8,10-tetraen-l-yl, cyclododeca-2,5,8,11-tetraen-l-yl, cyclododeca-2,6,8,10-tetraen-l-yl, cyclododeca-3,5,7,9-tetraen-l-yl, cyclododeca-3,5,7,10-tetraen-l-yl, cyclododeca-3,5,8,10-tetraen-l-yl, cyclododeca-1,3,5,7,9-pentaen-l-yl, cyclododeca-1,3,5,7,10-pentaen-l-yl, cyclododeca-1,3,5,7,11-pentaen-l-yl, cyclododeca-1,3,5,8,10-pentaen-l-yl, cyclododeca-1,3,5,8,11-pentaen-l-yl, cyclododeca-1,3,5,9,11-pentaen-l-yl, cyclododeca-1,3,6,8,10-pentaen-l-yl, cyclododeca-1,3,6,8,11-pentaen-l-yl, cyclododeca-1,3,6,9,11-pentaen-l-yl, cyclododeca-1,3,7,9,11-pentaen-l-yl, cyclododeca-1,4,6,8,10-pentaen-l-yl, cyclododeca-1,4,6,8,11-pentaen-l-yl, cyclododeca-1,4,6,9,11-pentaen-l-yl, cyclododeca-1,4,7,9,11-pentaen-l-yl, cyclododeca-1,5,7,9,11-pentaen-l-yl, cyclododeca-2,4,6,8,10-pentaen-l-yl, cyclododeca-2,4,6,8,11-pentaen-l-yl, cyclododeca-2,4,6,9,11-pentaen-l-yl and cyclododeca- 1,3,5,7,9,11-hexaen-l-yl. - 164 - WO2005/049594 PCT/US2004/037911 The term "C13-cycloalkenyl," as used herein, means cyclotridec-1-en-l-yl, cyclotridec-2-en-l-yl, cyclotridec-3-en-l-yl, cyclotridec-4-en-l-yl, cyclotridec-5-en-l-yl, cyclotridec-6-en-l-yl, cyclotridec-7-en-l-yl, cyclotrideca-1,3-dien-l-yl, cyclotrideca-1,4-dieri-l-yl, cyclotrideca-1,5-dien-l-yl, cyclotrideca-1,6-dien-l-yl, cyclotrideca-1,7-dien-l-yl, cyclotrideca-1,8-dien-l-yl, cyclotrideca-1,9-dien-l-yl,' cyclotrideca-1,10-dien-l-yl, cyclotrideca-1,11-dien-l-yl, cyclotrideca-1,12-dien-l-yl, cyclotrideca-2,4-dien-l-yl, cyclotrideca-2,5-dien-l-yl, cyclotrideca-2,6-dien-l-yl, cyclotrideca-2,7-dien-l-yl, cyclotrideca-2,8-dien-l-yl, cyclotrideca-2,9-dien-l-yl, cyclotrideca-2,10-dien-l-yl, cyclotrideca-2,11-dien-l-yl, cyclotrideca-2,12-dien-l-yl, cyclotrideca-3,5-dien-l-yl, cyclotrideca-3,6-dien-l-yl, cyclotrideca-3,7-dien-l-yl, cyclotrideca-3,8-dien-l-yl, cyclotrideca-3,9-dien-l-yl, cyclotrideca-3,10-dien-l-yl, cyclotrideca-3,11-dien-l-yl, cyclotrideca-4,6-dien-l-yl, cyclotrideca-4,7-dien-l-yl, cyclotrideca-4,8-dien-l-yl, cyclotrideca-4,9-dien-l-yl, cyclotrideca-4,10-dien-l-yl, cyclotrideca-5,7-dien-l-yl, cyclotrideca-5,8-dien-l-yl, cyclotrideca-5,9-dien-l-yl, cyclotrideca-6,8-dien-l-yl, cyclotrideca-1,3,5-trien-l-yl, cyclotrideca-1, 3, 6-trien-l-yl, cyclotrideca-1,3, 7-trien-l-yl, cyclotrideca-1,3,8-trien-l-yl, cyclotrideca-1,3,9-trien-l-yl, cyclotrideca-1,3,10-trien-l-yl, cyclotrideca-1, 3,11-trien-l-yl, cyclotrideca-1, 3,12-trien-l-yl, cyclotrideca-1,4,6-trien-l-yl, cyclotrideca-1,4,7-trien-l-yl, cyclotrideca-1,4,8-trien-l-yl, cyclotrideca-1,4,9-trien-l-yl, cyclotrideca-1,4,10-trien-l-yl, cyclotrideca-1,4,11-trien-l-yl, cyclotrideca-1,4,12-trien-l-yl, cyclotrideca-1,5,7-trien-l-yl, cyclotrideca-1,5,8-trien-l-yl, cyclotrideca-1,5,9-trien-l-yl, cyclotrideca-1,5,10-trien-l-yl, cyclotrideca-1,5,11-trien-l-yl, - 165 - WO2005/049594 PCT/US2004/037911 cyclotrideca-1,5,12-trien-l-yl, cyclotrideca-1, 6, 8-trien-l-yl, cyclotrideca-1,6,9-trien-l-yl, cyclotrideca-1, 6,10-tri-en-l-yl, cyclotrideca-1,6,11-trien-l-yl, cyclotrideca-1,6,12-trien-l-yl, cyclotrideca-1,7,9-trien-l-yl, cyclotrideca-1,7,10-trien-l-yl, cyclotrideca-1,7,11-trien-l-yl, cyclotrideca-1,7,12-trien-l-yl, cyclotrideca-1,8,10-trien-l-yl, cyclotrideca-1,8,11-trien-l-yl, cyclotrideca-1,8,12-trien-l-yl, cyclotrideca-1,9,11-trien-l-yl, cyclotrideca-1,9,12-trien-l-yl, cyclotrideca-1,10,12-trien-l-yl, cyclotrideca-2, 4, 6-trien-l-yl, cyclotrideca-2,4,7-trien-1-yl, cyclotrideca-2,4,8-trien-l-yl, cyclotrideca-2,4,9-trien-1-yl, cyclotrideca-2,4,10-trien-l-yl, cyclotrideca-2,4,11-trien-l-yl, cyclotrideca-2,4,12-trien-l-yl, cyclotrideca-2,5,7-trien-l-yl, cyclotrideca-2, 5, 8-trien-l-yl, cyclotri-deca-2,5,9-trien-l-yl, cyclotri-deca-2,5,10-trien-l-yl, cyclotrideca-2,5,11-trien-l-yl, cyclotrideca-2,5,12-trien-l-yl, cyclotrideca-2,6,8-trien-l-yl/ cyclotrideca-2,6,9-trien-l-yl, cyclotrideca-2, 6,10-trien-l-yl, cyclotrideca-2,6,11-trien-l-yl, cyclotrideca-2,6,12-trien-l-yl, cyclotrideca-2,7,9-trien-l-yl, cyclotrideca-2,7,10-trien-l-yl, cyclotrideca-2,7,11-trien-l-yl, cyclotrideca-2,7,12-trien-l-yl, cyclotrideca-2,8,10-trien-l-yl, cyclotrideca-2,8,11-trien-l-yl, cyclotrideca-2,8,12-trien-l-yl, cyclotrideca-2,9,11-trien-l-yl, cyclotrideca-2,9,12-trien-l-yl, cyclotrideca-2, 10,12-trien-l-yl, cyclotrideca-3,5,7-trien-l-yl, cyclotrideca-3, 5, 8-trien-l-yl, cyclotrideca-3,5,9-trien-l-yl, cyclotrideca-3,5,10-trien-l-yl, cyclotrideca-3,5,11-trien-l-yl, cyclotrideca-3,6,8-trien-l-yl, cyclotrideca-3, 6, 9-trien-l-yl, cyclotrideca-3,6,10-trien-l-yl, cyclotrideca-3,6,11-trien-l-yl, cyclotrideca-3, 7,9-trien-l-yl, cyclotrideca-3,7,10-trien-l-yl, cyclotrideca-3, 7,11-trien-l-yl, cyclotrideca-3,8,10-trien-l-yl, cyclotrideca- - 166 - WO2005/049594 PCT/US2004/037911 4, 6,8-trien-l-yl, cyclotrideca-4,6,9-trien-l-yl, cyclotri-deca-4,6,10-trien-l-yl, cyclotrideca-4,7,9-trien-l-yl, cyclotrideca-4,7,10-trien-l-yl, cyclotrideca-1, 3, 5,7-tetraen-1-yl, cyclotrideca-1,3,5,8-tetraen-l-yl, cyclotrideca-1,3, 5, 9-tetraen-l-yl, cyclotrideca-1,3,5,10-tetraen-l-yl, cyclotrideca-1,3,5,11-tetraen-l-yl, cyclotrideca-1,3,5,12-tetraen-1-yl, cyclotrideca-1,3,6,8-tetraen-l-yl, cyclotrideca-1,3,6,9-tetraen-l-yl, cyclotrideca-1,3,6,10-tetraen-l-yl, cyclotrideca-1,3,6,11-tetraen-l-yl, cyclotrideca-1,3,6,12-tetraen-l-yl, cyclotrideca-1,3,7,9-tetraen-1-yl, cyclotrideca-1,3,7,10-tetraen-l-yl, cyclotrideca-1,3,7,11-tetraen-l-yl, cyclotrideca-1,3,7,12-tetraen-l-yl, cyclotri-deca-1,3,8,10-tetraen-l-yl, cyclotrideca-1,3,8,11-tetraen-l-yl, cyclotrideca-1,3,8,12-tetraen-l-yl, cyclotrideca-1,3,9,11-tetraen-l-yl, cyclotrideca-1,3,9,12-tetraen-l-yl, cyclotrideca-1,3,10,12-tetraen-l-yl, cyclotrideca-1,4,6,8-tetraen-l-yl, cyclotrideca-1,4,6,9-tetraen-l-yl, cyclotri-deca-1,4,6,10-tetraen-l-yl, cyclotrideca-1,4,6,11-tetraen-l-yl, cyclotrideca-1,4,6,12-tetraen-l-yl, cyclotrideca-1,4,7,9-tetraen-l-yl, cyclotrideca-1,4,7,10-tetraen-l-yl, cyclotrideca-1,4,7,llrtetraen-1-yl, cyclotrideca-1,4,7,12-tetraen-l-yl, cyclotri-deca-1,4,8,10-tetraen-l-yl, cyclotrideca-1, 4,8,11-tetraen-l-yl, cyclotrideca-1,4,8,12-tetraen-l-yl, cyclotrideca-1,4,9,11-tetraen-l-yl, cyclotrideca-1,4,9,12-tetraen-l-yl, cyclotrideca-1,4,10,12-tetraen-l-yl, cyclotrideca-1,5,7,9-tetraen-l-yl, cyclotrideca-1,5,7,10-tetraen-l-yl, cyclotri-deca-1,5,7,11-tetraen-l-yl, cyclotrideca-1, 5, 7, 12-tetraen-l-yl, cyclotrideca-1,5,8,10-tetraen-l-yl, cyclotrideca-1,5,8,11-tetraen-l-yl, cyclotrideca-1,5,8,12-tetraen-l-yl, cyclotrideca-1,5,9,11-tetraen-l-yl, cyclotrideca-1,5,9,12-tetraen-l-yl, cyclotrideca-1,5,10,12-tetraen-l-yl, cyclotrideca-1,6,8,10-tetraen-l-yl, cyclotri- - 167 - WO2005/049594 PCT/US2004/037911 deca-1, 6,8,11-tetraen-l-yl, cyclotrideca-1,6,8,12-tetraen-l-yl, cyclotrideca-1,6,9,11-tetraen-l-yl, cyclotrideca- 1, 6, 9,12-tetraen-l-yl, cyclotrideca-1,6,10,12-tetraen-l-yl, cyclotrideca-1,7,9,11-tetraen-l-yl, cyclotrideca-1,7,9,12-tetraen-l-yl, cyclotri-deca-1,7,10,12-tetraen-l-yl, cyclotrideca-1,8,10,12-tetraen-l-yl, cyclotrideca-2,4,6,8-tetraen-1-yl, cyclotrideca-2;4, 6,9-tetraen-l-yl, cyclotrideca-2, 4, 6,10-tetraen-l-yl, cyclotrideca-2,4,6,11-tetraen-l-yl, cyclotrideca-2, 4, 6,12-tetraen-l-yl, cyclotrideca-2,4,7,9-tetraen-l-yl, cyclotri-deca-2,4,7,10-tetraen-1-yl, cyclotrideca-2,4,7,11-tetraen-l-yl, cyclotrideca-2,4,7,12-tetraen-l-yl, cyclotrideca- 2, 4,8,10-tetraen-l-yl, cyclotri-deca-2,4,8,11-tetraen-l-yl, cyclotrideca-2,4,8,12-tetraen-l-yl, cyclotrideca-2,4,9,11-tetraen-l-yl, cyclotrideca-2,4, 9,12-tetraen-l-yl, cyclotrideca-2,4,10,12-tetraen-l-yl, cyclotrideca-2,5,7,9-tetraen-1-yl, cyclotrideca-2,5, 7,10-tetraen-l-yl, cyclotrideca-2,5,7,11-tetraen-l-yl, cyclotrideca- 2,5,7,12-tetraen-l-yl, cyclotrideca-2,5,8,10-tetraen-l-yl, cyclotrideca-2,5,8,11-tetraen-l-yl, cyclotrideca-2,5,8,12-tetraen-l-yl, cyclotri-deca-2,5,9,11-tetraen-l-yl, cyclotrideca-2,5,9,12-tetraen-l-yl, cyclotrideca-2,5,10,12-tetraen-l-yl, cyclotrideca-2,6,8,10-tetraen-l-yl, cyclotrideca-2, 6, 8, 11-tetraen-l-yl, cyclotrideca-2,6,8,12-tetraen-l-yl, cyclotrideca-2,6, 9,11-tetraen-l-yl, cyclotrideca-2,6,9,12-tetraen-l-yl, cyclotri-deca-2,6,10,12-tetraen-l-yl, cyclotrideca-2,7,9,11-tetraen-l-yl, cyclotrideca-2,7,9,12-tetraen-l-yl, cyclotrideca-2,7,10,12-tetraen-l-yl, cyclotri-deca-3,5,7,9-tetraen-l-yl, cyclotrideca-3,5,7,10-tetraen-l-yl, cyclotrideca-3,5,7,11-tetraen-l-yl, cyclotrideca-3,5,8,10-tetraen-l-yl, cyclotrideca-3, 5, 8,11-tetraen-l-yl, cyclotrideca-3,5,9,11-tetraen-l-yl, cyclotrideca-3,6,8,10-tetraen-l-yl, - 168 - WO2005/049594 PCT/US2004/037911 cyclotrideca-3, 6,8,11-tetraen-l-yl, cyclotrideca-3,7,9,11-tetraen-1-yl, cyclotrideca-1,3,5,7, 9-pentaen-l-yl, cyclotrideca-1, 3,5,7,10-pentaen-l-yl, cyclotrideca-1,3,5,7,11-pentaen-l-yl, cyclotrideca-1,3,5,7,12-pentaen-l-yl, cyclotrideca-1,3, 5,8,10-pentaen-l-yl, cyclotrideca-1,3,5,8,11-pentaen-l-yl, cyclotrideca-1,3,5,8,12-pentaen-l-yl, cyclotrideca-1,3,5,9,11-pentaen-l-yl, cyclotrideca-1,3,5,9,12-pentaen-l-yl, cyclotrideca-1,3, 6, 8,10-pentaen-l-yl, cyclotrideca-1, 3,6,8,11-pentaen-l-yl, cyclotrideca-1,3,6,8,12-pentaen-l-yl, cyclotrideca-1,3,6,9,11-pentaen-l-yl, cyclotrideca-1, 3, 6,9,12-pentaen-l-yl, cyclotrideca-1,3,7,9,11-pentaen-l-yl, cyclotrideca-1, 3,7, 9,12-pentaen-l-yl, cyclotrideca-1, 4, 6, 8,10-pentaen-l-yl, cyclotrideca-1,4,6,8,11-pentaen-l-yl, cyclotrideca-1, 4, 6, 8,12-pentaen-l-yl, cyclotrideca-1,4,6,9,11-pentaen-l-yl, cyclotrideca-1,4,6,9,12-pentaen-l-yl, cyclotrideca-1,4,7,9,11-pentaen-l-yl, cyclotrideca-1,4,7,9,12-pentaen-l-yl, cyclotrideca-1, 5,7,9,11-pentaen-l-yl, cyclotrideca-1,5,7,9,12-pentaen-l-yl, cyclotrideca-2,4,6,8,10-pentaen-l-yl, cyclotrideca-2, 4,6,8,11-pentaen-l-yl, cyclotrideca-2,4,6,8,12-pentaen-l-yl, cyclotrideca-2,4,6,9,11-pentaen-l-yl, cyclotrideca-2,5,7,9,11-pentaen-l-yl, cyclotrideca-2,5,7,9,12-pentaen-l-yl, cyclotrideca-1,3,5,7,9,11-hexaen-l-yl and cyclotrideca-2, 4,6,8,10,12-hexaen-l-yl. The terra "C14-cycloalkenyl," as used herein, means cyclotetradec-1-en-l-yl, cyclotetradec-2-en-l-yl, cyclotetradec-3-en-l-yl, cyclotetradec-4-en-l-yl, cyclotetradec-5-en-l-yl, cyclotetradec-6-en-l-yl, cyclotetradec-7-en-l-yl, cyclotetradec-8-en-l-yl, cyclotetradeca-1,3-dien-l-yl, cyclotetradeca-1,4-dien-l-yl, cyclotetradeca-1,5-dien-l-yl, cyclotetradeca-1,6-dien-l-yl, cyclotetradeca-1, 7-dien-l-yl, cyclotetradeca-1,8-dien-l-yl, - 169 - WO2005/049594 PCT/US2004/037911 cyclotetradeca-1,9-dien-l-yl, cyclotetradeca-1,10-dien-l-yl, cyclotetradeca-1,11-di-en-l-yl, cyclotetradeca-1,12-dien-l-yl, cyclotetradeca-1,13-dien-l-yl, cyclotetradeca-2,4-dien-l-yl, cyclotetradeca-2,5-dien-l-yl, cyclotetradeca-2,6-dien-l-yl, cyclotetradeca-2,7-dien-l-yl, cyclotetradeca-2,8-dien-l-yl, cyclotetradeca-2,9-dien-l-yl, cyclotetradeca-2,10-dien-l-yl, cyclotetradeca-2,11-dien-l-yl, cyclotetradeca-2,12-dien-l-yl, cyclotetradeca-2,13-dien-l-yl, cyclotetradeca-3,5-dien-l-yl, cyclotetradeca-3,6-dien-l-yl, cyclotetradeca-3,7-dien-l-yl, cyclotetradeca-3,8-dien-l-yl, cyclotetradeca-3,9-dien-l-yl, cyclotetradeca-3,10-dien-l-yl, cyclotetradeca-3,11-dien-l-yl, cyclotetradeca-3,12-dien-l-yl, cyclotetradeca-4,6-dien-l-yl, cyclotetradeca-4,7-dien-l-yl, cyclotetradeca-4,8-dien-l-yl, cyclotetradeca-4,9-dien-l-yl, cyclotetradeca-4,10-dien-l-yl, cyclotetradeca-4,11-dien-l-yl, cyclotetradeca-5,7-dien-l-yl, cyclotetradeca-5,8-dien-l-yl, cyclotetradeca-5,9-dien-l-yl, cyclotetradeca-5,10-dien-l-yl, cyclotetradeca-6,8-dien-l-yl, cyclotetra-deca-6,9-dien-l-yl, cyclotetradeca-1,3,5-tetraen-1-yl, cyclotetradeca-1,3,6-tetraen-l-yl, cyclotetradeca-1,3,7-tetraen-l-yl, cyclotetradeca-1,3,8-tetraen-l-yl, cyclotetradeca-1,3,9-tetraen-l-yl, cyclotetradeca-1,3,10-tetraen-1-yl, cyclotetradeca-1,3,11-tetraen-l-yl, cyclotetradeca-1,3,12-tetraen-l-yl, cyclotetradeca-1,3,13-tetraen-1-yl, cyclotetradeca-1,4,6-tetraen-l-yl, cyclotetradeca-1,4,7-tetraen-l-yl, cyclotetradeca-1,4,8-tetraen-1-yl, cyclotetradeca-1,4,9-tetraen-l-yl, cyclotetradeca-1,4,10-tetraen-l-yl, cyclotetradeca-1,4,11-tetraen-l-yl, cyclotetradeca-1,4,12-tetraen-l-yl, cyclotetradeca-1,4,13-tetraen-l-yl, cyclotetradeca-1,5,7-tetraen-l-yl, cyclotetradeca-1,5,8-tetraen-l-yl, cyclotetradeca-1,5,9-tetraen-l-yl, cyclotetradeca-1,5,10-tetraen-l-yl, cyclotetradeca-1,5,11-tetraen-l-yl, . - 170 - WO2005/049594 PCT/US2004/037911 cyclotetradeca-1,5,12-tetraen-l-yl, cyclotetradeca-1,5,13-tetraen-l-yl, cyclotetradeca-1,6,8-tetraen-l-yl, cyclotetradeca-1,6,9-tetraen-l-yl, cyclotetradeca-1, 6,10-tetraen-l-yl, cyclotetradeca-1,6,11-tetraen-l-yl, cyclotetradeca-1,6,12-tetraen-l-yl, cyclotetradeca-1,6,13-tetraen-l-yl, cyclotetradeca-1,7,9-tetraen-l-yl, cyclotetradeca-1,7,10-tetraen-l-yl, cyclotetradeca-1,7,11-tetraen-l-yl, cyclotetradeca-1,7,12-tetraen-l-yl, cyclotetradeca-1,7,13-tetraen-l-yl, cyclotetradeca-1,8,10-tetraen-l-yl, cyclotetradeca-1,8,11-tetraen-l-yl, cyclotetradeca-1,8,12-tetraen-l-yl, cyclotetradeca-1,8,13-tetraen-l-yl, cyclotetradeca-1,9,11-tetraen-l-yl, cyclotetradeca-1,9,12-tetraen-l-yl, cyclotetradeca-1,9,13-tetraen-l-yl, cyclotetradeca-1,10,12-tetraen-l-yl, cyclotetradeca-1,10,13-tetraen-l-yl, cyclotetradeca-1,11,13-tetraen-l-yl, cyclotetradeca-2,4,6-tetraen-l-yl, cyclotetradeca-2,4,7-tetraen-l-yl, cyclotetradeca-2,4,8-tetraen-1-yl, cyclotetradeca-2,4,9-tetraen-l-yl, cyclotetradeca-2,4,10-tetraen-l-yl, cyclotetradeca-2,4,11-tetraen-l-yl, cyclotetradeca-2,4,12-tetraen-l-yl, cyclotetradeca-2,4,13-tetraen-l-yl, cyclotetradeca-2,5,7-tetraen-1-yl, cyclotetradeca-2,5,8-tetraen-l-yl, cyclotetradeca-2,5,9-tetraen-l-yl, cyclotetradeca-2,5,10-tetraen-l-yl, cyclotetradeca-2,5,11-tetraen-l-yl, cyclotetradeca-2,5,12-tetraen-l-yl, cyclotetradeca-2,5,13-tetraen-l-yl, cyclotetradeca-2,6,8-tetraen-l-yl, cyclotetradeca-2,6,9-tetraen-l-yl, cyclotetradeca-2,6,10-tetraen-l-yl, cyclotetradeca-2,6,11-tetraen-l-yl, cyclotetradeca-2,6,12-tetraen-l-yl/ cyclotetradeca-2,6,13-tetraen-l-yl, cyclotetradeca-2,7,9-tetraen-l-yl, cyclotetradeca-2,7,10-tetraen-l-yl, cyclotetradeca-2,7,11-tetraen-l-yl, cyclotetradeca-2,7,12-tetraen-l-yl, cyclotetradeca-2,7,13-tetraen-l-yl, cyclotetradeca- - 171 - WO2005/049594 PCT/US2004/037911 2,8,10-tetraen-l-yl, cyclotetradeca-2,8,11-tetraen-l-yl, cyclotetradeca-2,8,12-tetraen-l-yl, cyclotetradeca-2,8,13-tetraen-1-yl, cyclotetradeca-2,9,11-tetraen-l-yl, cyclotetradeca-2,9,12-tetraen-l-yl, cyclotetradeca-2,9,13-tetraen-l-yl, cyclotetradeca-2,10,12-tetraen-l-yl, cyclotetradeca-2,10,13-tetraen-l-yl, cyclotetradeca-2,11,13-tetraen-l-yl, cyclotetradeca-3,5,7-tetraen-l-yl, cyclotetradeca-3,5,8-tetraen-l-yl, cyclotetradeca-3,5,9-tetraen-l-yl, cyclotetradeca-3, 5,10-tetraen-l-yl, cyclotetradeca-3,5,11-tetraen-l-yl, cyclotetradeca-3, 5,12-tetraen-l-yl, cyclotetradeca-3,6,8-tetraen-l-yl, cyclotetradeca-3,6,9-tetraen-l-yl, cyclotetradeca-3, 6,10-tetraen-l-yl, cyclotetradeca-3,6,11-tetraen-l-yl, cyclotetradeca-3,6,12-tetraen-l-yl, cyclotetradeca-3,7,9-tetraen-1-yl, cyclotetradeca-3,7,10-tetraen-l-yl, cyclotetradeca-3,7,11-tetraen-l-yl, cyclotetradeca-3,7,12-tetraen-l-yl, cyclotetradeca-3,8,10-tetraen-l-yl, cyclotetradeca-3,8,11-tetraen-l-yl, cyclotetradeca-3,9,11-tetraen-l-yl, cyclotetradeca-4,6, 8-tetraen-l-yl, cyclotetradeca-4,6,9-tetraen-l-yl, cyclotetradeca-4,6,10-tetraen-l-yl, cyclotetradeca-4,6,11-tetraen-l-yl, cyclotetradeca-4,7,9-tetraen-l-yl, cyclotetradeca-4,7,10-tetraen-l-yl, cyclotetradeca-4,7,11-tetraen-l-yl, cyclotetradeca-4,8,10-tetraen-l-yl, cyclotetradeca-1,3, 5, 7-tetraen-1-yl, cyclotetradeca-1,3, 5,8-tetraen-l-yl, cyclotetradeca-1,3,5,9-tetraen-l-yl, cyclotetradeca-1,3,5,10-tetraen-l-yl, cyclotetradeca-1,3,5,11-tetraen-l-yl, cyclotetradeca-1,3,5,12-tetraen-l-yl, cyclotetradeca-1,3,5,13-tetraen-l-yl, cyclotetradeca-1,3, 6,8-tetraen-l-yl, cyclotetradeca-1,3,6,9-tetraen-l-yl, cyclotetradeca-1,3,6,10-tetraen-l-yl, cyclotetradeca-1,3,6,11-tetraen-l-yl, cyclotetradeca-1,3,6,12-tetraen-l-yl, cyclotetradeca-1,3,6,13-tetraen-l-yl, cyclotetradeca-1, 3,7,9-tetraen-l-yl, - 172 - WO2005/049594 PCT/US2004/037911 cyclotetradeca-1,3,7,10-tetraen-l-yl, cyclotetradeca-1,3,7,11-tetraen-1-yl, cyclotetradeca-1,3,7,12-tetraen-l-yl, cyclotetradeca-1,3,7,13-tetraen-l-yl, cyclotetradeca-1, 3,8,10-tetraen-l-yl , cyclotetradeca-1,3,8,11-tetraen-1-yl, cyclotetradeca-1,3,8,12-tetraen-l-yl, cyclotetradeca-1,3,8,13-tetraen-l-yl, cyclotetradeca-1,3, 9,11-tetraen-l-yl, cyclotetradeca-1,3,9,12-tetraen-l-yl, cyclotetradeca-1,3,9,13-tetraen-l-yl, cyclotetradeca-1,3,10,12-tetraen-l-yl, cyclotetradeca-1,3,10,13-tetraen-l-yl, cyclotetradeca-1,3,11,13-tetraen-l-yl, cyclotetradeca-1,4,6,8-tetraen-l-yl, cyclotetradeca-1, 4, 6,9-tetraen-l-yl, cyclotetradeca-1,4,6,10-tetraen-l-yl, cyclotetradeca-1,4,6,11-tetraen-l-yl, cyclotetradeca-1,4,6,12-tetraen-l-yl, cyclotetradeca-1,4,6,13-tetraen-l-yl, cyclotetradeca-1,4,7,9-tetraen-l-yl, cyclotetradeca-1,4,7,10-tetraen-l-yl, cyclotetradeca-1,4,7,11-tetraen-l-yl, cyclotetradeca-1,4,7,12-tetraen-l-yl, cyclotetradeca-1, 4,7,13-tetraen-l-yl, cyclotetradeca-1,4,8,10-tetraen-l-yl, cyclotetradeca-1,4,8,11-tetraen-l-yl, cyclotetradeca-1,4,8,12-tetraen-l-yl, cyclotetradeca--1, 4, 8,13-tetraen-l-yl, cyclotetradeca-1,4,9,11-tetraen-l-yl, cyclotetradeca-1,4,9,12-tetraen-l-yl, cyclotetradeca-1,4,9,13-tetraen-l-yl, cyclotetradeca-1,4,10,12-tetraen-l-yl, cyclotetradeca-1,4,10,13-tetraen-l-yl, cyclotetradeca-1,4,11,13-tetraen-l-yl, cyclotetradeca-1,5,7,9-tetraen-l-yl, cyclotetradeca-1,5,7,10-tetraen-l-yl, cyclotetradeca-1,5,7,11-tetraen-l-yl, cyclotetradeca-1,5,7,12-tetraen-l-yl, cyclotetradeca-1,5,7,13-tetraen-l-yl, cyclotetradeca-1,5,8,10-tetraen-l-yl, cyclotetradeca-1,5,8,11-tetraen-l-yl, cyclotetradeca-1,5,8,12-tetraen-l-yl, cyclotetradeca-1,5,8,13-tetraen-l-yl, cyclotetradeca-1,5,9,11-tetraen-l-yl, cyclotetradeca-1,5,9,12-tetraen-l-yl, cyclotetradeca-1,5,9,13-tetraen-l-yl, cyclotetradeca-1,5,10,12-tetraen-l-yl, cyclotetradeca- - 173 - WO2005/049594 PCT/US2004/037911 1,5,10,13-tetraen-l-yl, cyclotetradeca-1,5,11,13-tetraen-l-yl, cyclotetradeca-1,6,8,10-tetraen-l-yl, cyclotetradeca-1,6,8,ll-tetraen-l-yl, cyclotetradeca-1,6, 8,12-tetraen-l-yl, cyclotetradeca-1,6,8,13-tetraen-l-yl, cyclotetradeca-1,6,9,ll-tetraen-l-yl, cyclotetradeca-1,6,9,12-tetraen-1-yl, cyclotetradeca-1,6,9,13-tetraen-l-yl, cyclotetradeca-1,6,10,12-tetraen-l-yl, cyclotetradeca-1,6,10,13-tetraen-l-yl, cyclotetradeca-1,6,11,13-tetraen-l-yl, cyclotetradeca-1,7,9,ll-tetraen-l-yl, cyclotetradeca-1,7,9,12-tetraen-l-yl, cyclotetradeca-1,7,9,13-tetraen-l-yl, cyclotetradeca-1,7,10,12-tetraen-l-yl, cyclotetradeca-1,7,10,13-tetraen-l-yl, cyclotetradeca-1,7,11,13-tetraen-l-yl, cyclotetradeca-1,8,10,12-tetraen-l-yl, cyclotetradeca-1,8,10,13-tetraen-l-yl, cyclotetradeca-1,8,11,13-tetraen-l-yl, cyclotetradeca-2,4,6,8-tetraen-l-yl, cyclotetradeca-2,4,6,9-tetraen-1-yl, cyclotetradeca-2,4,6,10-tetraen-l-yl, cyclotetradeca-2,4,6,ll-tetraen-l-yl, cyclotetradeca-2,4,6,12-tetraen-l-yl, cyclotetradeca-2,4,6,13-tetraen-l-yl, cyclotetradeca-2,4,7,9-tetraen-l-yl, cyclotetradeca-2,4,7,10-tetraen-l-yl, cyclotetradeca-2,4,7,ll-tetraen-l-yl, cyclotetradeca-2,4,7,12-tetraen-l-yl, cyclotetradeca-2,4,7,13-tetraen-l-yl, cyclotetradeca-2,4,8,10-tetraen-l-yl, cyclotetradeca-2, 4,8,ll-tetraen-l-yl, cyclotetradeca-2,4,8,12-tetraen-l-yl, cyclotetradeca-2,4,8,13-tetraen-l-yl, cyclotetradeca-2,4,9,ll-tetraen-l-yl, cyclotetradeca-2,4,9,12-tetraen-l-yl, cyclotetradeca-2,4,9,13-tetraen-l-yl, cyclotetradeca-2, 4,10,12-tetraen-l-yl, cyclotetradeca-2,4,10,13-tetraen-l-yl, cyclotetradeca-2,4,11,13-tetraen-l-yl, cyclotetradeca-2,5,7,9-tetraen-l-yl, cyclotetradeca-2,5,7,10-tetraen-l-yl, cyclotetradeca-2,5,7,ll-tetraen-l-yl, cyclotetradeca-2, 5,7,12-tetraen-l-yl, cyclotetradeca-2,5,7,13-tetraen-l-yl, cyclotetradeca-2,5,8,10-tetraen-l-yl, - 174 - WO2005/049594 PCT/US2004/037911 cyclotetradeca-2,5,8,11-tetraen-l-yl, cyclotetradeca-2,5,8,12-tetraen-l-yl, cyclotetradeca-2,5,8,13-tetraen-l-yl, cyclotetradeca-2,5,9,11-tetraen-l-yl, cyclotetradeca-2,5,9,12-tetraen-l-yl, cyclotetradeca-2,5,9,13-tetraen-l-yl, cyclotetradeca-2,5,10,12-tetraen-l-yl, cyclotetradeca-2,5,10,13-tetraen-l-yl, cyclotetradeca-2,6,8,10-tetraen-l-yl, cyclotetradeca-2,6,8,11-tetraen-l-yl, cyclotetradeca-2,6,8,12-tetraen-l-yl, cyclotetradeca-2,6,8,13-tetraen-l-yl, cyclotetradeca-2, 6, 9,11-tetraen-l-yl, cyclotetradeca-2,6,9,12-tetraen-l-yl, cyclotetradeca-2,6,9,13-tetraen-l-yl, cyclotetradeca-2, 6,10,12-tetraen-l-yl, cyclotetradeca-2,6,10,13-tetraen-l-yl, cyclotetradeca-2,6,11,13-tetraen-l-yl, cyclotetradeca-2,7,9,11-tetraen-l-yl, cyclotetradeca-2,7,9,12-tetraen-l-yl , cyclotetradeca-2,7,10,12-tetraen-l-yl, cyclotetradeca-3,5,7,9-tetraen-l-yl, cyclotetradeca-3,5,7,10-tetraen-1-yl, cyclotetradeca-3,5,7,11-tetraen-l-yl, cyclotetradeca-3,5,7,12-tetraen-l-yl, cyclotetradeca-3,5,8,10-tetraen-1-yl, cyclotetradeca-3,5,8,11-tetraen-l-yl, cyclotetradeca-3,5,8,12-tetraen-l-yl, cyclotetradeca-3,5,9,11-tetraen-l-yl, cyclotetradeca-3,5,9,12-tetraen-l-yl, cyclotetradeca-3,5,10,12-tetraen-l-yl, cyclotetradeca-3,6,8,10-tetraen-l-yl, cyclotetradeca-3,6,8,11-tetraen-l-yl, cyclotetradeca-3,6,8,12-tetraen-l-yl, cyclotetradeca-3,7,9,11-tetraen-l-yl, cyclotetradeca-1,3,5,7,9-pentaen-l-yl, cyclotetradeca-1, 3, 5, 7,10-pentaen-l-yl, cyclotetradeca-1,3, 5,7,11-pentaen-1-yl, cyclotetradeca-1,3,5,7,12-pentaen-l-yl, , cyclotetradeca-1,3,5,7,13-pentaen-l-yl, cyclotetradeca-1, 3,5,8,10-pentaen-l-yl, cyclotetradeca-1,3,5,8,11-pentaen-1-yl, cyclotetradeca-1,3,5,8,12-pentaen-l-yl, cyclotetradeca-1,3,5,8,13-pentaen-l-yl, cyclotetradeca-1,3,5,9,11-pentaen-l-yl, cyclotetradeca-1,3,5,9,12- - 175 - WO2005/049594 PCT/US2004/037911 pentaen-1-yl, cyclotetradeca-1,3,5,9,13-pentaen-l-yl, cyclotetradeca-1,3,5,10,12-pentaen-l-ylr cyclotetradeca-1, 3, 5,10,13-pentaen-l-yl, cyclotetradeca-1,3,5,11,13-pentaen-l-yl, cyclotetradeca-1,3,6,8,10-pentaen-l-yl, cyclotetradeca-1,3,6,8,11-pentaen-l-yl, cyclotetradeca-1,3,6,8,12-pentaen-l-yl, cyclotetradeca-1,3,6,8,13-pentaen-l-yl, cyclotetradeca-1,3,6,9,11-pentaen-l-yl, cyclotetradeca-1,3,6,9,12-pentaen-l-yl, cyclotetradeca-1,3, 6, 9,13-pentaen-l-yl, cyclotetradeca-1,3,7,9,11-pentaen-l-yl, cyclotetradeca-1,3, 7, 9,12-pentaen-l-yl, cyclotetradeca-1,3,7,9,13-pentaen-l-yl, cyclotetradeca- 1, 4,6,8,10-pentaen-l-yl, cyclotetradeca-1,4,6,8,11-pentaen-l-yl, cyclotetradeca-1,4,6,8,12-pentaen-l-yl, cyclotetradeca-1,4,6,8,13-pentaen-l-yl, cyclotetradeca-1,4,6,9,11-pentaen-l-yl, cyclotetradeca-1,4,6,9,12-pentaen-l-yl, cyclotetradeca-1, 4,6,9,13-pentaen-l-yl, cyclotetradeca-1,4,7,9,11-pentaen-l-yl, cyclotetradeca-1,4,7,9,12-pentaen-l-yl, cyclotetradeca-1,4,7,9,13-pentaen-l-yl, cyclotetradeca-1,5,7,9,11-pentaen-l-yl, cyclotetradeca-1,5,7,9,12-pentaen-l-yl, cyclotetradeca-1,5,7,9,13-pentaen-l-yl, cyclotetradeca-2,4,6,8,10-pentaen-l-yl, cyclotetradeca-2,4, 6,8,11-pentaen-l-yl, cyclotetradeca-2,4,6,8,12-pentaen-l-yl, cyclotetradeca- 2, 4, 6, 8,13-pentaen-l-yl, cyclotetradeca-2,4,6,9,11-pentaen-l-yl, cyclotetradeca-2,4,6,9,12-pentaen-l-yl, cyclotetradeca-2,4,6,9,13-pentaen-l-yl, cyclotetradeca-2, 4, 6,10,12-pentaen-l-yl, cyclotetradeca-2,4,6,10,13-pentaen-l-yl, cyclotetradeca-2,4,6,11,13-pentaen-l-yl, cyclotetradeca-2,4,7,9,11-pentaen-l-yl, cyclotetradeca-2,4,7, 9,12-pentaen-l-yl, cyclotetradeca-2,4,7,9,13-pentaen-l-yl, cyclotetradeca-2,4,7,10,12-pentaen-l-yl, cyclotetradeca-2,4,7,10,13-pentaen-l-yl, cyclotetradeca-2,4,7,11,13-pentaen-l-yl, cyclotetradeca-2,4,8,10,12- - 176 - WO2005/049594 PCT/US2004/037911 pentaen-1-yl, cyclotetradeca-2, 4,8,10,13-pentaen-l-yl, cyclotetradeca-2,5,7,9,11-pentaen-l-yl, cyclotetradeca-2,5,7,9,12-pentaen-l-yl, cyclotetradeca-2,5,7,9,13-pentaen-l-yl, cyclotetradeca-2, 5, 7,10,12-pentaen-l-yl, cyclotetradeca-2,5,7,10,13-pentaen-l-yl, cyclotetradeca-1,3,5,7,9,11-hexaen-l-yl, cyclotetradeca-1,3,5,7,9,12-hexaen-1-yl, cyclotetradeca-1,3,5,7,9,13-hexaen-l-yl, cyclotetradeca-2,4,6,8,10,12-hexaen-l-yl, cyclotetradeca-2,4,6,8,10,13-hexaen-l-yl, cyclotetradeca-2,4,6,8,11,13-hexaen-l-yl and cyclotetradeca-1,3,5,7, 9,11,13-heptaen-l-yl. The term "C3-cycloalkyl," as used herein, means cycloprop-1-yl. The term "C4-cycloalkyl," as used herein, means cyclobut-1-yl. The term "C5-cycloalkyl,"' as used herein, means cyclopent-1-yl. The term "C6-cycloalkyl," as used herein, means cyclohex-1-yl. The term "C7-cycloalkyl," as used herein, means bicyclo[2.2.1]hept-1-yl, bicyclo[2.2.1]hept-2-yl, cyclohept-1-yl, bicyclo[2.2.1]hept-7-yl and cyclohept-1-yl. The term "Ce-cycloalkyl," as used herein, means bicyclo[2.2.2]oct-l-yl, bicyclo[2.2.2]oct-2-yl, bicyclo[2.2.2]oct-7-yl, cyclooct-1-yl. The term "Ca-cycloalkyl," as used herein, means cyclonon-1-yl. The term "C10-4cycloalkyl," as used herein, means adamant-1-yl, adamant-2-yl and cyclodec-1-yl. The term "Cn-cycloalkyl," as used herein, means 3 8 cycloundec-1-yl, tricyclo[4.3.1.1 ' ]undec-l-yl (homoadamant-l- yl), tricyclo[4.3.1.138 ]undec-2-yl (homoadamant-2-yl), - 177 - WO2005/049594 PCT/US2004/037911 tricyclo[4.3.1.13,8]undec-3-yl (homoadamant-3-yl), tricyclo[4.3.1.13'8 ]undec-4-yl (homoadamant-4-yl), and tricyclo[4.3.1.13,8]undec-9-yl (homoadamant-9-yl)- The term "C12-cycloalkyl," as used herein, means cyclododec-1-yl. The term "C13-cycloalkyl," as used herein, means cyclotridec-1-yl. The term "C14-cycloalkyl," as used herein, means cyclotetradec-1-yl. The term "C2-spiroalkenyl," as used herein, means ethen-l,2-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C3-spiroalkenyl," as used herein, means prop-l-en-l,3-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C2-spiroalkenyl," as used herein, means but-l-en-l,4-ylene, but-2-en-l,4-ylene and buta-1,3-dien-l,4-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C5-spiroalkenyl," as used herein, means pent-l-en-1,5-yl-ene, pent-2-en-l,5-ylene, penta-1,3-dien-l,5-ylene and penta-1,4-dien-1,5-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C6-spiroalkenyl," as used herein, means hex-l-en-1,6-ylene, hex-2-en-l,6-ylene, hexa-1,3-dien-1,6-ylene, hexa-1, 4-di-en-l,6-ylene and hexa-1,3,5-trien-1,6-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C7-spiroalkenyl," as used herein, means hept-l-en-1,7-yl-ene, hept-2-en-l,7-ylene, hept-3-en- - 178 - WO2005/049594 PCT/US2004/037911 1,7-ylene, hepta-1,3-dien-l,7-ylene, hepta-1,4-dien-l,7-ylene, hepta-1,5-dien-l,7-ylene, hepta-2,4-dien-l,7- ylene, hepta-2,5-dien-l,7-ylene, hepta-1,3,5-trien-l,7-ylene and hepta-1,3,6-trien-l,7-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C6-spiroalkenyl," as used herein, means oct-l-en-l,8-ylene, oct-2-en-l,8-ylene, oct-3-en-l,8-ylenef octa-1, 3-dien-l,8-ylene, octa-1,4-dien-l,8-ylene, octa-1,5-dien-1,8-ylene, octa-1,6-dien-l,8-ylene, octa-2,4-dien-1,8-ylene, octa-2,5-dien-l,8-ylene, octa-3,5-dien-l,8-ylene, octa-1,3,5-trien-l,8-ylene, octa-1,3,6-trien-l,8-ylene and octa-2,4,6-tri-en-l,8-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C6-spiroalkenyl," as used herein, means nona-l-en-1,9-yl-ene, nona-2-en-l,9-ylene, nona-3-en-1,9-ylene, nona-4-en-l,9-ylene, nona-1,3-dien-l,-9-ylene, nona-1,4-dien-l,9-ylene, nona-1,5-dien-l,9-ylene, nona-1,6-dien-1,9-ylene, nona-1,7-dien-l,9-ylene, nona-1,8-dien-1,9-ylene, nona-2,4-dien-l,9-ylene, nona-2,5-dien-l,9-ylene, nona-2,6-dien-l,9-ylene, nona-2,7-dien-l,9-ylene, nona-3,5-dien-1,9-ylene, nona-3,6-dien-l,9-ylene, nona-4,6-dien-1,9-ylene, nona-1,3,5-trien-l,9-ylene, nona-1,3,6-trien-1,9-ylene, nona-1,3,7-trien-l,9-ylene, nona-1,3,8-trien-1,9-ylene, nona-1,4,6-trien-l,9-yl-ene, nona-1,4,7-trien-1,9-ylene, nona-1,4,8-trien-l,9-ylene, nona-1,5,7-trien-1,9-ylene, nona-2,4,6-trien-l,9-ylene, nona-2,4,7-trien-1,9-ylene, nona-1,3,5,7-tetraen-l,9-ylene, nona-1,3,5,8-tetraen-1,9-ylene and nona-1,3,6,9-tetraen-l,9-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C2-spiroalkyl," as used herein, means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. - 179 - WO2005/049594 PCT/US2004/037911 The term "C3-spiroalkyl," as used herein, means prop-1,3-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C4-spiroalkyl," as used herein, means fout-l,4-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C5-spiroalkyl," as used herein, means pent-1,5-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C6-spiroalkyl," as used herein, means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C7-spiroalkyl," as used herein, means hept-1,7-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C8-spiroalkyl," as used herein, means oct-1,8-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C6-spiroalkyl," as used herein, means non-1,9-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. Compounds of this invention contain asymmetrically substituted carbon atoms in the R or S configuration, in wJ-the terms "R" and "S" are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemist PureAppl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal ar R and S configurations are racemic at those carbon Atoms with an excess of one configuration over the assigned the configuration present in the higher - 180 - WO2005/049594 PCT/US2004/037911 preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers. Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term "Z" represents the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double bond and the term "E" represents the larger two substituents on opposite sides of a carbon-carbon or carbon-nitrogen double bond. The compounds may also exist as an equilibrium mixture of Z or E configurations. , Compounds of this invention containing NH, C(O)OH, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed hydroxyl, amino or carboxylic acid in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance. Metabolites of compounds having formula (I), produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with expression of an anti-apoptotic protein family member such as of BCl-Xl, protein, and Bcl-2 protein or Bcl-w protein. Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having formula (I) may also have utility for treating diseases associated with expression of an anti-apoptotic protein family member such as of BC1-XL protein, and Bcl-2 protein or Bcl-w protein. - 181 - WO2005/049594 PCT/US2004/037911 Compounds having formula (I) may exist as an acid addition salts, basic addition salts or zwitterions. Salts of the compounds are prepared during their isolation or following their purification. Acid addition salts of the compounds are those derived from the reaction of the compounds with an acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate, and undecanoate salts of the compounds and prodrugs thereof are contemplated as being embraced by this invention. Basic addition salts of the compounds are those derived from the reaction of the compounds with the hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium, and magnesium. The compounds having formula (I) may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperintoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally, or vaginally. > Therapeutically effective amounts of compounds having formula (I) depend on recipient of treatment, disorder being treated and severity thereof, composition containing it, time of administration, route of administration, duration of treatment, its potency, its rate of clearance and whether or not another drug is co-administered. The amount of a compound of this invention having formula (I) used to make a - 182 - WO2005/049594 PCT/US2004/037911 composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof. Compounds having formula (I) may be administered with or without an excipient. Excipients include, for example, encapsulating materials or additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents and mixtures thereof. Excipients for preparation of compositions comprising a compound having formula (I) to be administered orally in solid dosage form include, for example, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone, diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having formula (I) to be - 183 - WO2005/049594 PCT/US2004/037911 administered ophthalmically or orally in liquid dosage forms include, for example, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having formula (I) to be administered osmotically include, for example, chlorofluorohydrocarbons, ethanol, water and mixtures thereof., Excipients for preparation of compositions comprising a compound of this invention having formula (I) to be administered parenterally include, for example, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water and mixtures thereof. Excipients for preparation of compositions comprising a compound of this invention having formula (I) to be administered rectally or vaginally include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof. Compounds having formula (I) may also be administered with one or more than one additional therapeutic agents, wherein additional therapeutic agents include radiation or chemotherapeutic agents, wherein chemotherapeutic agents include, but are not limited to, carboplatin, cisplatin, cyclophosphamide, dacarbazine, dexamethasone, docetaxel, doxorubicin, etoposide, fludarabine, irinotecan, CHOP (C: Cytoxan® (cyclophosphamide); H: Adiamycin® (hydroxydoxorubicin); 0: Vincristine (Oncovin®); P: prednisone), paclitaxel, rapamycin, Rituxin® (rituximab) and vincristine. - 184 - WO2005/049594 PCT/US2004/037911 For determination of- the utility of compounds having formula (I) as inhibitors of the activity of anti-apoptotic Bcl-XL, representative examples in DMSO at concentrations between 100 mM and 1 pM and added to each well of a 96-well microtiter plate. A mixture totaling 125 mL per well of assay buffer (20 mM phosphate buffer, pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68) , 30 nM Bcl-Xl, protein (prepared as described in Science 1997, 275, 983-986), 15 nM fluorescein-labeled BAD peptide (prepared in-house), and the DMSO solution of the example was shaken for 2 minutes then placed in a LJL Analyst (LJL Bio Systems, CA) . A negative control (DMSO, 15 nM BAD peptide, assay buffer) and a positive control (DMSO, 15 nM BAD peptide, 30 nM Bcl-XL, assay buffer) were used to determine the range of the assay. Polarization was measured at 25°C with a continuous Fluorescein lamp (excitation 485 nm; emission 530 nm). Percentage of inhibition was determined by (l-((mP value of well-negative control)/range))*100%. IC50 values (concentration of example needed for 50% inhibition of BC1-XL) for the representative compounds having formula (I), calculated using Microsoft Excel, were 3.7 nM, 5.8 nM, 6.1 nM, 6.2 nM, 6.9 nM, 7.1 nM, 7.1 nM, 7.4 nM, 7.7 nM, 7.8 nM, 7.9 nM, 8.3 nM, 8.3 nM, 8.3 nM, 8 . 4 nM, 8.4 nM, 8 . 5 nM, 8.5 nM, 8.7 nM, 8.8 nM, 9.1 nM, 9.1 nM, 9.1 nM, 9.2 nM, 9.5 nM, 9.6 nM, 9.7 nM, 9.8 nM, 9.8 nM, 9.9 nM, 9.9 nM, 9.9 nM, 10.0 nM, 10.0 nM, 10.0 nM, 10.0 nM, 10.1 nM, 10.1 nM, 10.2 nM, 10.2 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.3 nM, 10.5 nM, 10.6 nM, 10.6 nM, 10.6 nM, 10.6 nM, 10.6 nM, 10.7 nM, 10.7 nM, 10.7 nM, 10.7 nM, 10.8 nM, 10.8 nM, - 185 - WO2005/049594 PCT/US2004/037911 10.8 nM, 10.8 11.0 nM, 11.0 11.1 nM, 11.1 11.1 nM, 11.1 11.2 nM, 11.2 11.3 nM, 11.4 11.5 nM, 11.6 11.6 nM, 11.6 11.9 nM, 11.9 12.1 nM, '12.1 12.3 nM, 12.3 12.5 nM, 12.5 12.6 nM, 12.6 12.8 nM, 12.8 12.8 nM, 12.9 13.0 nM, 13.1 13.3 nM, 13.4 13.6 nM, 13.6 13.7 nM, 13.7 13.8 nM, 13.9 13.9 nM, 13.9 14.1 nM, 14.1 14.2 nM, 14.3 14.5 nM, 14.6 14.7 nM, 14.7 14.8 nM, 14.8 14.9 nM, 15.0 15.2 nM, 15.3 15.5 nM, 15.5 15.7 nM, 15.8 15.9 nM, 15.9 16.0 nM, 16.1 nM, 10.9 nM, nM, 11.0 nM, nM, 11.1 nM, nM, 11.2 nM, nM, 11.2 nM, nM, 11.5 nM, nM, 11.6 nM, nM, 11.7 nM, nM, 11.9 nM, nM, 12.2 nM, nM, 12.4 nM, nM, 12.5 nM, nM, 12.7 nM nM, 12.8 nM nM, 12.9 nM nM, 13.2 nM nM, 13.4 nM nM, 13.6 nM nM, 13.7 nM nM, 13.9 nM nM, 14.0 nM nM, 14.1 nM nM, 14.3 nM nM, 14.6 nM nM, 14.7 nM nM, 14.9 nM nM, 15.0 nM nM, 15.3 nM nM, 15.5 nM nM, 15.9 nM nM, 16.0 nM nM, 16.1 nM 10.9 nM, 10.9 11.0 nM, 11.0 11.1 nM, 11.1 11.2 nM, 11.2 11.3 nM, 11.3 11.5 nM, 11.5 11.6 nM, 11.6 11.7 nM, 11.8 11.9 nM, 11.9 12.2 nM, 12.3 12.4 nM, 12.4 12.6 nM, 12.6 12.7 nM, 12.7 12.8 nM, 12.8 12.9 nM, 12.9 13.2 nM, 13.2 13.5 nM, 13.5 13.7 nM, 13.7 13.8 nM, 13.8 13.9 nM, 13.9 14.0 nM, 14.0 14.1 nM, 14.2 14.4 nM, 14.4 14.7 nM, 14.7 14.7 nM, 14.7 14.9 nM, 14.9 15.1 nM, 15.1 15.3 nM, 15.4 15.5 nM, 15.6 15.9 nM, 15.9 16.0 nM, 16.0 16.1 nM, 16.1 nM, 10.9 nM, nM, 11.1 nM, nM, 11.1 nM, nM, 11.2 nM, nM, 11.3 nM, nM, 11.5 nM, nM, 11.6 nM, nM, 11.8 nM, nM, 12.1 nM, nM, 12.3 nM, nM, 12.4 nM, nM, 12.6 nM, nM, 12.8 nM, nM, 12.8 nM, nM, 13.0 nM, nM, 13.3 nM, nM, 13.5 nM, nM, 13.7 nM, nM, 13.8 nM, nM, 13.9 nM, nM, 14.0 nM, nM, 14.2 nM, nM, 14.4 nM, nM, 14.7 nM, nM, 14.8 nM, nM, 14.9 nM, nM, 15.2 nM, nM, 15.4 nM, nM, 15.6 nM, nM, 15.9 nM, nM, 16.0 nM, nM, 16.1 nM, 186 - WO2005/049594 PCT/US2004/037911 16.2 nM, ltf.2 nM, 16.4 nM, 16.4 nM, 16.5 nM, 16.5 nM, 16.7 nM, 16.8 nM, 16.8 nM, 17.0 nM, 17.1 nM, 17.1 nM, 17.3 nM, 17.3 nM, 17.4 nM, 17.5 nM, 17.6 nM, 17.8 nM, 17.9 nM, 17.9 nM, 18.1 nM, 18.3 nM, 18.4 nM, 18.4 nM, 18.9 nM, 18.9 nM, 19.1 nM, 19.3 nM, 19.4 nM, 19.4 nM, 19.8 nM, 19.8 nM, 19.9 nM, 20.3 nM, 20.3 nM, 20.3 nM, 20.8 nM, 20.9 nM, 21.4 nM, 22.0 nM, 22.2 nM, 22.3 nM, 23.2 nM, 23.3 nM, 23.5 nM, 24.5 nM, 25.0 nM, 25.2 nM, 25.9 nM, 26.1 nM, 2 6.4 nM, 27.9 nM, 28.3 nM, 28.4 nM, 29.7 nM, 29.9 nM, 30.3 nM, 31.1 nM, 31.3 nM, 31.8 nM, 33.2 nM, 33.4 nM, 33.7 nM, 40.8 nM, 42.1 nM, 44.6 nM, 45.2 nM, 47.4 nM, 47.5 nM, 55.6 nM, 56.0 nM, 58.3 nM, 65.7 nM, 68.3 nM, 83.6 nM, 0.2 mM, 0.2 mM, 0.2 mM, 0.2 mM, 0.3 mM, 0.3 mM, 0.9 mM, 1.0 mM, 1.0 mM, 1.4 mM, 1.5 mM, 1.5 mM, 2.1 mM, 2.7 mM, 2.7 mM, 3.6 mM, 3.6 mM, 3.7 mM, 6.8 mM, 7.8 mM, 10.0 mM, 16.4 nM, 16.4 nM, 16.4 nM, 16.5 nM, 16.6 nM, 16.6 nM, 16.9 nM, 17.0 nM, 17.0 nM, 17.2 nM, 17.2 nM, 17.3 nM, 17.4 nM, 17.4 nM, 17.5 nM, 17.8 nM, 17.8 nM, 17.8 nM, 18.2 nM, 18.2 nM, 18.2 nM, 18.8 nM, 18.8 nM, 18.8 nM, 19.2 nM, 19.2 nM, 19.3 nM, 19.6 nM, 19.7 nM, 19.7 nM, 20.0 nM, 20.2 nM, 20.3 nM, 20.7 nM, 20.7 nM, 20.7 nM, 21.5 nM, 21.7 nM, 21.9 nM, 22.5 nM, 22.6 nM, 22.9 nM, 23.8 nM, 23.8 nM, 24.4 nM, 25.6 nM, 25.7 nM, 25.8 nM, 26.4 nM, 26.7 nM, 27.7 nM, 28.9 nM, 29.5 nM, 29.6 nM, 30.5 nM, 30.9 nM, 31.0 nM, 32.1 nM, 32.2 nM, 32.4 nM, 37.1 nM, 39.3 nM, 39.5 nM, 44.6 nM, 44.9 nM, 44.9 nM, 51.5 nM, .51.6 nM, 53.2 nM, 58.7 nM, 58.9 nM, 61.0 nM, 85.9 nM, 0.2 mM, 0.2 pM, 0.2 mM, 0.3 mM, 0.2 mM, 0.3 mM, 0.5 mM, 0.5 mM, 1.0 mM, 1.1 mM, 1.2 mM, 1.9 mM, 2.0 mM, 2.1 mM, 2.9 mM, 3.1 mM, 3.4 mM, 5.5 mM, 5.5 mM, 6.6 mM, 10.0 mM, 10.0 mM, 10.0 mM, 187 - WO2005/049594 PCT/US2004/037911 10.0 mM, 10.0 . mM and 13.5 mM. Determination of the utility of compounds having formula (I) as inhibitiors of anti-apoptotic Bcl-2 was also performed in 96-well microtiter plates. Representative examples were diluted in DMSO to concentrations between 10 pM and 10 pM and added to each well of the plate. A mixture totaling 125 uL per well of assay buffer (20 mM phosphate buffer, pH 7.4), 1 mM EDTA, 50 mM NaCl, 0.05% PF-68), 10 nM Bcl-2 protein (prepared as described in PNAS 2001, 98, 3012-3017) , 1 nM fluorescein-labeled BAX peptide (prepared in-house), and the DMSO solution of the example was shaken for 2 minutes and placed in the LJL Analyst. Polarization was measured at 25°C using a continuous Fluorescein lamp (excitation 485nm; emission 530nm). Ki values for the representative compounds having formula (I), calculated using Microsoft Excel, were <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM; <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM', <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, <1.0 nM, These binding and inhibitory data demonstrate the utility of compounds having formula (I) as inhibitors of anti-apopotic BC1-XL protein and anti-apopotic Bcl-2- - 190 - WO2005/049594 PCT/US2004/037911 It is expected that, because compounds having formula (I) bind to and inhibit the activity of BC1-XL and Bcl-2, they would also have utility as inhibitors of anti-apopotic protein family members having close structural homology to BC1-XL and Bcl-2, such as, for example, anti-apopotic Bcl-w protein. Accordingly, compounds having formula (I) are expected to have utility in treatment of diseases during which anti-apopotic Bcl-XL protein, anti-apopotic Bcl-2 protein, anti-apopotic Bcl-w protein or a combination thereof, are expressed. Diseases during which anti-apopotic protein family members such as BC1-XL protein, Bcl-2 protein and Bcl-w protein are expressed include cancer and autoimmune disorders, wherein cancer includes, but is not limited to, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer,lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer and small cell lung cancer (Cancer Res., 2000, 60, 6101-10); autoimmune disorders include, but are not limited to, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia (Current Allergy and Asthma Reports 2003, 3:378-384; Br. J. Haematol. 2000 Sep; 110(3): 584-90; Blood 2000 Feb 15;95(4):1283-92; and New England Journal of Medicine 2004 Sep; 351(14): 1409-1418). A representative compound having formula (I), EXAMPLE 2, displayed therapeutic utility against human tumor cell lines derived from small cell lung carcinomas and lymphoid malignancies of both T-cell and B-cell origin. - 191 - WO2005/049594 PCT/US2004/037911 EXAMPLE 2 also displayed therapeutic utility against acute lymphoblastoid leukemia, small cell lung cancer, prostate cancer, non-small cell lung cancer, and follicular lymphoma tumors (RS11380, DoHH2 and SuDHL-4) in xenograft models. EXAMPLE 2 also demonstrated anti-tumor activity in two murine models (H14 6 and SCLC xenograft) from human-derived small cell lung cancer isolated from smokers and nonsmokers, defective for Rb/p53 gene function, and expresseive of moderately high levels of Bcl-2. In the H146 model, treatment with EXAMPLE 2 resulted in complete regression of an established tumor with, in some cases, tumor disappearance after prolonged therapy. EXAMPLE 2 also prolonged survival in a systemic model of acute lymphoblastic leukemia and inhibited tumor growth in a model of follicular lymphoma (DOHH-2). Therapeutic utility was also observed in a prostate cancer model. Without being limited by theory, the genetic link between Bcl-2 and cancer comes from the observation that t(14;18) chromosomal translocations in B-cell lymphomas lead to ,overexpression of the protein. Aberrant Bcl-2 and Bcl-XL, expression is also seen in other lymphoid malignancies such as chronic lymphocytic leukemia and acute lymphocytic leukemia. EXAMPLE 2 e1Hibited significant activity in a CCRF-CEM T-cell acute lymphoblastoid leukemia model as well as in SuDHL4 and RS11380, two models of B-cell follicular lymphoma. CCRF-CEM is a p53-mutant acute lympoblastoid leukemia line of T-cell origin used as an animal (mouse) model of systemic leukemia involving intravenous inoculation of tumor cells. If left untreated, the mice succumb to disease within about 34 days post inoculation, at which time extensive tumor infiltration of spleen, liver, and bone marrow has occured. - 192 - WO2005/049594 PCT/US2004/037911 Administeration of EXAMPLE 2 increased the average survival of the mice and showed a significant decrease in average spleen weight relative to vehicle controls (indicative of a lower tumor burden in this organ). Subsequent histopahtological assessments revealed lower tumor infiltration in both the liver and spleen relative to controls. The therapeutic effect of EXAMPLE 2 on other human tumor cell lines is shown in TABLE 1 for which the ECso-s are the effective concentrations which cause a 50% reduction in cell viability. TABLE 1 Cell Line3 Tumor Type EC50(m mM)b Calu-6 Non- -Small Cell Lung 0.16 \ ± 0.07(6) NC1-H460 Non- -Small Cell Lung 2.3 ± 1.5(6) NC1-H226 Non- -Small Cell Lung 2.6 ± 1.1(2) NC1-H322M Non- -Small Cell Lung 4.1 ± 0.8(2) A549/ATCC Non- -Small Cell Lung 5.2 ± 0.2(2) HOP-62 Non- -Small Cell Lung 6.3 ± 6.7(2) NC1-H23 Non- -Small Cell Lung 7.4 + 0.6(2) COLO 205 Colorectal 0.51 ± 0.07(4) HCT-15 Colorectal 0.60 ± 0.34(4) HCT-15 Colorectal >11 (2) SW-620 Colorectal 0.69 ± 0.07(2) DLD-1 Colorectal 0.99 ± 0.45(4) HT-29 Colorectal 1.1 + 1.1(6) KM12 Colorectal 1.7 ± 0.2(2) HCT-116 Colorectal 2.1 ± 1.8(6) MCF7 Breast 2.0 ± 0.8(2) MDA-MB-4 35 Breast 2.4 (1) MDA-MB-436 Breast 3.9 ± 2.6(2) BT-549 Breast 6.5 ± 2.3(2) HS-578T Breast 7.2 ± 8.2(2) T47D Breast >10(2) NCI/ADR-RES Breast >10(2) U251 CNS 3.8 ± 2.0(2) SF-539 CNS 4.1 ± 0.6(2) SF-295 CNS 7.7 ± 2.3(2) SF-268 CNS 8.3 + 0.4(2) U87MG Glioma 2.7 ± 1.8(2) D54MG Glioma 3.1 ± 2.5(2) 193 - WO2005/049594 PCT/US2004/037911 LOX IMVI Melanoma 1.7 ± 0.4(2) MALME-3M Melanoma 1.9 ± 0.8(2) SK-MEL15 Melanoma 3.7 ± 0.8(2) SK-MEL-28 Melanoma 9.3 ± 0.1(2) OVCAR-5 Ovarian 1.1 ± 0(2) IGROV-1 Ovarian 1.7 ± 0.6(2) OVCAR-3 Ovarian 1.9 ± 0.3(2) OVCAR-8 Ovarian 3.4 ± 0.8(2) SK-OV-3 Ovarian 5.6 ± 1.0(2) OVCAR-4 Ovarian 22 ± 3 (2) MiaPaCa Pancreas 1.4 ± 0.6(2) PC3 Prostate 0.96 ± 0.38(4) DU-145 Prostate 8.2 ± 1.1(2) ACHN Renal 1(1) 786-0 Renal 2.9 ± 0.1(2) R1F-393 Renal 2.9 ±,0.4(2) SN12C Renal 3.2 ± 0.2(2) a Serum-free conditions, 48 hour treatment. b Mean ± SEM(n). The therapeutic effect of paclitaxel on A549 human non-small cell lung carcinoma cells was about 4.4-rfold more efficacious when administered with EXAMPLE 2. A similar increase (4.7-fold) in efficacy was demonstrated against PC-3 prostate carcinoma cells. The enantiomer of EXAMPLE 2 was less efficacious, indicating that the therapeutic effect of EXAMPLE 2 was the direct result of binding to anti-apoptotic Bcl-2 family proteins. The anti-tumor activity of EXAMPLE 2 was equivalent to slightly better than paclitaxel near the maximum tolerated dose in a small cell lung cancer xenograft tumor model and superior to cisplatin and etoposide. In a PC3 derived murine model of prostate cancer, EXAMPLE 2 e1Hibited about 40-50% inhibition of tumor growth rate. Studies pertaining to the efficacy of EXAMPLE 2 in combination with etoposide, vincristine, modified CHOP, doxorubicin, rapamycin and Rituxin® demonstrated that EXAMPLE 2 synergistically enhanced efficacy of these cytotoxic agents during combination therapy. In particular, combinations - 194 - WO2005/049594 PCT/US2004/037911 ocomprising EXAMPLE 2 and rapamycin and EXAMPLE 2 and Rituxin® resulted in complete regression of a significant percentage of established DoHH2 follicular lymphoma flank tumors for a sustained period of time. These data demonstrate the utility of compounds having formula (I) for treatment of diseases which are caused or exascerbated by expression of one or more than one of an anti-apoptotic protein family member. Furthermore, experiments with representative Bcl-XL-selective compounds demonstrated synergistic therapeutic effects with multiple chemotherapeutic agents against cell lines representative of diverse tumor types. Accordingly, the compounds having formula (I) are expected to be useful as chemotherapeutic agents alone or in combination with additional therapeutic agents. Compounds having formula (I) may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, reagents, solvents, and reaction conditions may be substituted for those specifically mentioned, and vulnerable moieties may be protected and deprotected, as necessary, by NH, C(O)OH, OH, SH protecting groups. The following abbraviations have the meanings indicated-ADDP means 1,1'-(azodicarbonyl)dipiperidine; AD-mix-p* means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2C03, and K2SO4) ; 9-BBN means 9-borabicyclo[3.3.1]nonane; Boc means tert-butoxycarbonyl; (DHQD-PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means - 195 - WO2005/049594 PCT/US2004/037911 N,N-dimethylformamide; dmpe means 1,2- bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane? EDAOHCl means l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means 0-(7-azabenzotriazol-1-yl) Ht-N'N'N'-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; ipA means isopropyl alcohol; MP-BH3 means macroporus triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine. The term "NH protecting group," as used herein, means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycarbonyl, para-nitrobenzylcarbonyl, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyl-oxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryl-oxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxy-carixmyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, Jeucyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl, be diphenylmethyl, triphenylmethyl, 2-nitrophenylthio, methanesulfonyl, para-toluenesulfonyl, N,N-dimethylaminomethylene-, benzylidene, 2-hydroxybenzylir 2-hydroxy-S-chlorobenzylidene, 2-hydroxy-l-naphthyl-1 3-hydroxy—pyridylmethylene, cyclohexylidine - 196 - WO2005/049594 PCT/US2004/037911 2-ethoxycarbonylcyclohexylidene, 2-ethoxycarbonylcyclopenty-lidene, 2-acetylcyclohexylidene, 3,3-dimethyl-5-oxycyclo-hexylidene, diphenylphosphoryl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-l,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl, and triphenylsilyl. The term "C(O)OH protecting group," as used herein, means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylntethyl, para-bromobenzoylmethyl, para-met hanesulfony lbenzoylme thy 1, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro-ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethy1, methoxyethoxymethy1, 2-(trimethylsilyl)ethoxymethy1, benzyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. The term "OH or SH protecting group," as used herein, means benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3, 4-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2- - 197 - WO2005/049594 PCT/US2004/037911 (phenylsulfonyl)ethoxycarbonyl, 2- (triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, vinyloxycarbonyl, allyloxycarbonyl, S-benzylthiocarbonyl, 4-ethoxy-l-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl,, 2,2,2-trichloro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. Compounds having formula (1) may be converted to compounds having formula (2) by reacting the former, chlorosulfonic acid, and ammonia. Compounds having formula (2) may be converted to compounds having formula (I) by reacting the former and compounds having formula Z1-CO2H and a coupling agent, with or - 198 - WO2005/049594 PCT/US2004/037911 without a first base. Examples of coupling agents include EDCI, CDI, and PyBop. Examples of first bases include TEA, DIEA, DMAP, and mixtures thereof. Compounds having formula (2) may be converted to compounds having formula (I) by reacting the former and compounds having formula Z1-COCl and the first base. Compounds having formula (4) may be converted to compounds having formula (I), wherein B and Y together are imidazole, by reacting the former, sodium nitrite, hydrochloric acid, and acetic acid. Compounds having formula (I), wherein B1 and Y1 together are imidazole, may be reacted with a second base and the appropriate electrophile to provide compounds having formula (I), wherein B and Y together are substituted imidazole. Examples of second bases include sodium hydride, potassium hydride, lithium diisopropylamide and sodium bis(trimethylsilyl)amide. WO2005/049594 PCT/US2004/037911 SCHEME 3 Compounds having formula (3), may be converted to compounds having formula (4) by reacting the former, hydrogen and a hydrogenation catalyst. Examples of hydrogenation catalysts include Pd on carbon, platinum on carbon, and Raney nickel. Compounds having formula (4) may be converted to compounds having formula (I), wherein B and Y together are triazole, by reacting the former, sodium nitrite, hydrochloric acid, and acetic acid. Compounds having formula (I), wherein B1 and Y1 together are triazole, may be reacted with the second base and the appropriate electrophile to provide compounds having formula (I), wherein B and Y together are substituted triazole. EXAMPLE 1A A mixture of piperazine (129.2 g), ethyl-4-fluorobenzoate (84 g), and K2C03 (103.65 g) in DMSO (200 mL) at 120°C was stirred for 6 hours, poured into water, stirred for 30 minutes, and filtered. - 200 - WO2005/049594 PCT/US2004/037911 EXAMPLE IB EXAMPLE 1A (200 mg) in dioxane at 40°C (4 mL) was treated with 2-(bromomethyl)-l,l'-biphenyl (232 mg) and DIEA (165 mg) and concentrated. The concentrate was flash chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE 1C EXAMPLE IB (340 mg) in 3:1:1 THF/methanol/water (4 mL) at 25°C was treated with LiOH-water (143 mg), stirred for 16 hours, and treated with 4M HC1 (850 uL) and dichloromethane. The extract was dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 20% methanol/dichloromethane. EXAMPLE ID EXAMPLE 1C (112 mg) in dichloromethane (2.5 mL) at 25°C was treated with 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in commonly-owned International Application No. PCT/USOl/29432, published as WO 02/24636, (115 mg), EDAC-HC1 (109 mg), and DMAP (49 mg), stirred for 16 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 20% methanol/dichloromethane. lU NMR (300 MHz, DMSO-d6) 8 8.45 (d, IH), 8.28 (d, IH), 7.78 (dd, IH), 7.72 (d, 2H), 7.54 (dd, IH), 7.45-7.41 (m, 4H), 7.40-7.28 (m, 6H), 7.25 (td, 2H), 7.17 (tt, IH), 6.88 (d, IH), 6.78 (d, 2H), 4.10-4.01 (m, IH), 3.41 (s, 2H), 3.33 (d, 2H), 3.14 (m, 4H), 2.82-2.62 (m, 2H), 2.44-2.35 (m, 10 H), 2.09-1.91 (m, 2H). EXAMPLE IE EXAMPLE 1C (112 mg) in dichloromethane (2.5 mL) at 25°C - 201 - WO2005/049594 PCT/US2004/037911 was treated with EXAMPLE ID (115 mg) , EDAC-HC1 (109 mg) , and DMAP (49 mg), stirred for 16 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 20% methanol/dichloromethane. 1H NMR (300 MHz, DMSO-d6) 8 8.45 (d, IH), 8.28 (d, IH), 7.78 (dd, IH), 7.72 (d, 2H), 7.54 (dd, IH), 7.45-7.41 (m, 4H), 7.40-7.28 (m, 6H), 7.25 (td, 2H), 7.17 (tt, IH), 6.88 (d, IH), 6.78 (d, 2H), 4.10-4.01 (m, IH) , 3.41 (s, 2H), 3.33 (d, 2H), 3.14 (m, 4H), 2:82-2.62 (m, 2H), 2.44-2.35 (m, 1OH), 2.09-1.91 (m, 2H). EXAMPLE 2A A mixture of EXAMPLE 1A (23.43 g), 2-bromobenzyl bromide (26.24 g), and DIEA (20.94 mL) in acetonitrile (200 mL) at 25°C was stirred for 2 hours and filtered. EXAMPLE 2B A mixture of EXAMPLE 2A (13.83 g), 4-chlorophenyl-boronic acid (7.04 g), bis(triphenylphosphine)palladium dichloride (481 mg) and 2M sodium carbonate (22.5 mL) in 7:3:2 DME/water/ethanol (200 mL) at 90°C was stirred for 4.5 hours and extracted with ethyl acetate. The extract was dried (MgSO4>, filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 5%-40% ethyl acetate/hexanes. EXAMPLE 2C A mixture of EXAMPLE 2B (13 g) and lithium hydroxide hydrate (3.78 g) in dioxane (250 mL) and water (100 mL) at 95°C was stirred for 16 hours and concentrated. The concentrate in water was heated at 80°C and filtered. The filtrate was treated with 1M HC1 (90 mL) and filtered. - 202 - WO2005/049594 PCT/US2004/037911 EXAMPLE 2D A mixture of EXAMPLE 2C (3.683 g), 4-(((lR)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide (3.53 g), EDAC-HC1 (3.32 g) and DMAP (2.12 g) in dichloromethane (500 mL) at 25°C was stirred for 8 hours, washed with saturated NH4C1 (330 mL), and dried (MgSO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 1%, 2%, 5%, 10%, and 15% methanol/NH3-saturated dichloromethane. 1H NMR (DMSO-d6) 5 12.10 (br s, IH), 11.18 (br s, IH), 10.40 (br s, IH), 8.54 (s, IH), 8.29 (d, IH), 8.10 (br s, IH), 7.85 (d, IH), 7.77 (d, 2H), 7.52 (d, 4H), 7.40-7.36 (m, 2H), 7.35-7.32 (m, IH), 7.26-7.21 (m, 2H), 7.16-7.09 (m, 3H), 6.93 (d, 2H), 4.34 (br s, 2H), 4.35-4.23 (m, IH), 3.88 (br s, 2H), 3.42-3.36 (m, 4H), 3.17-3.07 (m, 2H), 2.90-2.78 (m, 2H), 2.50 (s, 6H), 2.20-2.15 (m, 2H). EXAMPLE 3A This example was prepared by substituting 4-methoxyphenylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. EXAMPLE 3B This example was prepared by substituting EXAMPLE 3A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 3C This example was prepared by substituting EXAMPLE 3B for EXAMPLE 2C in EXAMPLE 2D. 1R NMR (400 MHz, DMSO-d6) 8 12.10 (br s, IH), 9.9 (br s, IH), 9.57 (s, IH), 8.54 (d, IH), 8.29 (d, IH), 7.86 (dd, IH), 7.77 (d, 2H), 7.72 (m, IH), 7.50 (m, 2H), 7.33 (m, IH), 7.29 (d, 2H), 7.23 (dd, 2H), 7.18 (d, IH) , - 203 - WO2005/049594 PCT/US2004/037911 7.11 (m, 2H), 7.03 (d, 2H), 6.93 (d, 3H), 4.36 (br s, 2H), 4.18 (m, IH), 3.80 (br s, 2H), 3.79 (s, 3H) , 3.39 (d, 2H), 3.07 (m, 6H), 2.75 (s, 3H), 2.74 (s, 3H), 2.14 (q, 2H). EXAMPLE 4A This example was prepared by substituting 4-fluorophenylboronic acid for 4-chlqrophenylboronic acid in EXAMPLE 2B. EXAMPLE 4B This example was prepared by substituting EXAMPLE 4A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 4C This example was prepared by substituting EXAMPLE 4B for EXAMPLE 2C in EXAMPLE 2D. lR NMR (400 MHz, DMSO-d6) 6 12.10 (br s, IH), 10.00 (br s, IH), 9.65 (s, IH), 8.54 (d, IH), 8.29 (d, IH), 7.86 (dd, IH), 7.77 (d, 2H), 7.74 (m, IH), 7.52 (m, 2H), 7.41 (m, 2H), 7.34 (m, IH), 7.29 (t, 2H), 7.23 (dd, 2H), 7.18 (d, IH), 7.12 (m, 3H), 6.93 (d, 2H), 4.29 (br s, 4H), 4.18 (m, IH), 3.84 (br s, 2H), 3.39 (d, 2H), 3.13 (m, 4H), 2.92 (m, 2H), 2.74 (s, 6H), 2.15 (m, 2H). EXAMPLE 5A This example was prepared by substituting 4-(methylsulfanyl)phenylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. EXAMPLE 5B This example was prepared by substituting EXAMPLE 5A for EXAMPLE 2B in EXAMPLE 2C. - 204 - WO2005/049594 PCT/US2004/037911 EXAMPLE 5C This example was prepared by substituting EXAMPLE 5B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 6 12.10 (s, IH), 9.9 (br s, IH), 9.54 (s, IH), 8.53 (d, IH), 8.27 (d, IH), 7.85 (dd, IH), 7.76 (d, 2H), 7.72 (m, IH), 7.51 (dd, 2H), 7.33 (d, 2H), 7.31 (m, IH), 7.29 (d, 2H), 7.21 (d, 2H), 7.16 (d, IH), 7.10 (m, 3H), 6.92 (d, 2H), 4.32 (br s, 2H), 4.17 (m, IH), 3.85 (br s, 4H), 3.38 (d, 2H), 3.11 (m, 5H), 2.90 (br s, IH) , 2.73 (s, 6H), 2.49 (s, 3H) , 2.14 (in, 2H) . EXAMPLE 6A This example was prepared by substituting 1,1'-biphenyl-4-ylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. EXAMPLE 6B This example was prepared by substituting EXAMPLE 6A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 6C This example was prepared by substituting EXAMPLE 6B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 12.10 (br s, IH), 9.9 (br s, IH), 9.56 (s, IH), 8.54 (d, IH), 8.28 (d, IH), 7.86 (dd, IH), 7.75 (m, 7H), 7.56 (m, 2H) , 7.48 (m, 4H), 7.39 (m, 2H), 7.22 (dd, 2H), 7.17 (d, IH), 7.11 (m, 3H), 6.93 (d, 2H), 4.42 (br s, 2H), 4.18 (m, IH), 3.83 (br s, 2H), 3.39 (d, 2H), 3.25 (br s, 2H), 3.13 (m, 4H), 2.91 (m, 2H), 2.74 (s, 6H), 2.14 (m, 2H). EXAMPLE 7A This example was prepared by substituting 4-phenoxyphenylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. - 205 - WO2005/049594 PO7US2004/037911 EXAMPLE 7B This example was prepared by substituting EXAMPLE 7A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 7C This example was prepared by substituting EXAMPLE 7B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 12.09 (br s, IH), 10.10 (br s, IH), 9.64 (s, IH), 8.55 (d, IH) , 8.29 (d, IH), 7.87 (dd, IH), 7.78 (d, 2H), 7.73 (m, IH), 7.51 (m, 2H), 7.38 (m, 5H), 7.23 (m, 2H), 7.14 (m, 5H) , 7.07 (d, 4H), 6.95 (d, 2H), 4.33 (br s, 2H), 4.20 (m, IH), 3.86 (br s, 2H), 3.39 (d, 2H), 3.25 (br s, 2H), 3.12 (m, 4H), 2.92 (m, 2H), 2.74 (s, 6H), 2.15 (m, 2H). EXAMPLE 8 This example was prepared by substituting 4-((1, l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, DMSO-d6) 8 12.05 (br s, IH), 9.8 (br s, IH), 8.53 (s, IH), 8.51 (d, IH), 7.83 (dd, IH), 7.79 (d, 2H), 7.72 (br s, IH), 7.52 (br s, 2H), 7.47 (t, 2H), 7.41 (t, IH), 7.36 (d, 2H) , 7.35 (m, 2H), 7.26 (d, 2H), 7.01 (t, 2H), 6.93 (d, 2H), 6.92 (d, IH), 4.32 (br s, 2H), 3.79 (br s, 2H), 3.49 (br s, 4H), 3,14 (br s, 2H), 2.80 (br s, 2H), 1.56 (s, 6H) . EXAMPLE 9 This example was prepared by substituting 4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- - 206 - WO2005/049594 PCT/US2004/037911 nitrobenzenesulfonamide, prepared as described in WO 02/24 636, for 4-(((lR)-3- (dimethylamino)-1-{ (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, DMSO-d6) 5 8.60 (d, IH), 8.40 (d, IH) , 7.89 (dd, IH), 7.79 (d, 2H), 7.64 (m, -7H), 7.62 (d, IH), 7.31 (d, 2H), 7.30 (d, IH), 7.24 (dd, 2H), 7.19 (dd, 2H), 6.94 (d, 2H), 4.24 (m, IH), 3.71 (m, 4H), 3.55 (m, 2H) , 3.41 (d, 2H), 3.31 (m, 4H), 2.80 (m, 4H) , 2.48 (m, 4H), 2.16 (m, IH), 2.06 (m, IH). EXAMPLE 10 This example was prepared by substituting 3-nitro~4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide), prepared as described in WO 02/24636, for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, DMSO-de) 5 11.87 (br s, IH), 8.74 (t, IH), 8.58 (d, IH), 7.89 (dd, IH), 7.72 (d, 2H), 7.55 (m, IH), 7.38 (m, 7H), 7.26 (m, 4H), 7.17 (m, 2H), 6.89 (d, 3H), 3.66 (m, 2H), 3.47 (m, 2H), 3.26 (m, 6H), 2.41 (m, 4H). EXAMPLE 11 This example was prepared by substituting 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, prepared as described in WO 02/24636, for 4-(((1R)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-de) 8 11.93 (s, IH), 8.66 . (t, .IH), 8.56 (d, IH), 7.89 (dd, IH), 7.73 (d, 2H), 7.51 (d, IH), 7.47 (m, 4H), 7.37 (m, 4H), 7.28 (t, 2H), 7.24 (m, IH), 7.18 (t, IH), 7.11 (d, IH), 6.86 (d, 2H), 3.64 (q, 2H), 3.40 (s, 2H), 3.27 (q, 2H), 3.21 (m, 4H), 2.40 (m, AH). - 207 - WO2005/049594 PCT/US2004/037911 EXAMPLE 12 This example was prepared by substituting. 4-(((1R)-3- (4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, prepared as described in WO 02/24 636, for 4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 12.07 (s, 1H), 9.98 (s, 2H) , 8.55 (d, 1H), 8.30 (d, 1H), 7.87 (dd, 1H), 7.77 (d, 2H), 7.72 (br s, 1H), 7.52 (d, 4H), 7.40 (d, 2H), 7.34 (m, 1H), 7.23 (d, 2H), 7.18 (d, 1H), 7.15 (t, 2H), 7.10 (m, 1H), 6.93 (d, 2H), 4.25 (br s, 2H), 4.19 (m, 1H), 3.95 (br s, 5H), 3.63 (br s, 4H), 3.40 (m, 4H), 3.18 (m, 4H), 3.02 (br s, 3H), 2.18 (m, 2H) . EXAMPLE 13 This example was prepared by substituting 4-((l,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((1R)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzene- sulfonamide in. EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 12.06 (br s, 1H), 9.69 (br s, 1H), 8.53 (s, 1H), 8.51 (d, 1H), 7.83 (dd, 1H), 7.80 (d, 2H), 7.71 (br s, 1H), 7.52 (d, 4H), 7.40 (d, 2H), 7.37 (d, 1H), 7.33 (m, 1H), 7.26 (d, 2H), 7.01 (t, 2H), 6.93 (m, 3H), 4.33 (br s, 2H), 3.73 (br s, 4H), 3.12 (br s, 4H), 2.85 (br s, 2H), .1.56 (s, 6H) . EXAMPLE 14 This example was prepared by substituting 4-(((lR)-4-(dimethylamino)-1-((phenylsulfanyl)methyl)butyl)amino)-3-nitrobenzenesulfonamide, prepared as described in WO 02/24636, - 208 - WO2005/049594 PCT/US2004/037911 for 4-(((lR)-3- (dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzene-sulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 12.07 (br s, IH), 9.75 (br s, IH), 9.26 (s, IH), 8.54 (d, IB), 8.29 (d, IH), 7.87 (dd, IH), 7.77 (d, 2H), 7.74 (m, IH), 7.52 (d, 4H), 7.39 (d, 2H), 7.34 (m, IH), 7.23 (m, 3H), 7.11 (m, 3H), 6.93 (d, 2H), 4.30 (br s, 2H), 4.14 (m, IH), 3.73 (br s, 6H), 3.37 4/()37911 5% aqueous citric acid, saturated NaHCO3, and brine, and dried (MgSO4), filtered, and concentrated. EXAMPLE 2IB A mixture of EXAMPLE 21A (980 mg), 2-mercaptothiazole (610 mg), and triphenylphosphine (1.5 g) in THF (12 mL) at 25°C was stirred for 20 minutes, cooled to 0°C, treated with diisopropylazodicarboxylate (1.1 mL) in THF (6 mL), stirred at 25°C for 3 days, treated with ethyl acetate, washed with water and brine, and dried (MgSO4-), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 2%-10% ethyl acetate/hexanes. EXAMPLE 21C EXAMPLE 21B (410 mg) in diethyl ether (.5 mL) at 25°C was treated with 4M HC1 in 1,4-dioxane (5 mL), stirred for 2.5 hours, and filtered. EXAMPLE 2ID A mixture of EXAMPLE 21C (300 mg) and 4-fluoro-3-nitrobenzenesulfonamide (300 mg), and DIEA (690 uL) in DMSO (2 mL) at 25°C was stirred for 18 hours, cooled to 15°C, treated with water (25 mL), acidified with 1M HC1, cooled to 0°C, stirred for 1 hour, and filtered. EXAMPLE 2IE This example was prepared by substituting EXAMPLE 21D for 4-(((1R)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500MHz, DMSO-d6) 5 8.59 (d, 1H), 8.49, (s, 1H), 7.90 (dd, 1H), 7.80 (d, 2H), 7.77 (s, 1H), 7.52 (d, 3H), 7.48 (d, 2H), 7.45 (dd, 2H) , - 216 - WO2005/049594 PCT/US2004/037911 EXAMPLE 22F This example was prepared by substituting EXAMPLE 22E for 4-(((lR)-3- (dimethylamino) -1- ((phenylsulfanyl)methyl)propyl) amino) -3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500MHz, DMSO-d6) 5 8.50 (d, IH), 8.22 (d, IH), 7.90 (dd, IH), 7.72 (dd, 2H), 7.61 (d, IH), 7.51 (m, 2H), 7.47 (s, 3H), 7.37 (m, 2H), 7.23, (m, 2H), 6.79 (d, 2H), 4.28 (m, IH) , 3.60 (m, 2H) , 3.39 (s, 2H), 3.14 (m, 4H), 3.00 (m, 2H), 2.62 (s, 6H), 2.40 (m, 4H), 2.10 (m, 2H).. EXAMPLE 23A This example was prepared by substituting 2-thienyldisulfide and THF for EXAMPLE 22A and toluene, respectively, in EXAMPLE 22B. EXAMPLE 23B This example was prepared by substituting EXAMPLE 23A for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 23C This example was prepared by substituting EXAMPLE 23B for EXAMPLE 19C in EXAMPLE 19D. EXAMPLE 23D This example was prepared by substituting EXAMPLE 23C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 23E This example was prepared by substituting EXAMPLE 23D for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- - 218 - WO2005/049594 PCT/US2004/037911 nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500MHz, DMSO~d6) 8 8.50 (d, 1H), 8.22 (d, 1H), 7.90 (dd, 1H), 7.82, (dd, 1H), 7.72 (d, 2H), 7.62 (dd, 1H), 7.51 (m, 1H) , 7.47 (s, 3H), 7.37 (m, 2H), 7.25 (dd, 1H), 7.14 (dd, 1H), 7.02 (dd, 1H), 6.80 (m, 3H), 3.99 (m, 1H), 3.31 (m, 2H), 3.18 (m, 6H), 2.95 (m, 3H), 2.59 (s, 6H), 2.40 (t, 3H), 2.11 (m, 1H), 2.02 (m, 1H) . EXAMPLE 24A N-tert-butoxycarbonyl-L-serine methyl ester (30 g) in dichloromethane (300 mL) at 0°C was treated with DIEA (59.7 mL) and methanesulfonylchloride (11.65 mL), stirred for 20 minutes, treated with thiophenol (15.5 mL), stirred at 25°C for 24 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 10-30% ethyl acetate/hexanes. EXAMPLE 24B EXAMPLE 24A (8.35 g) in dichloromethane (75 mL) was treated with IM DIBAL in dichloromethane (94 mL) stirred for 2 hours, treated with methanol, poured into saturated NaH2P04 (300 mL) . stirred for 30 minutes, and extracted with ethyl acetate. The extract was washed with brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 24C 60% Oily NaH (480 mg) in dioxane (30 mL) at 25°C was treated with EXAMPLE 24B (1.7 g) in dioxane (10 mL), stirred for 10 minutes, treated with N,N-dimethylchloroacetamide (1.23 mL) , heated at 70°C for 24 hours, poured into water, and extracted with ethyl acetate. The extract was washed with - 219 - WO2005/049594 PCT/US2004/037911 brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 24D EXAMPLE 24C (1.65 g) in THF (10 mL) at 25°C was treated with IM borane-THF (20 mL), stirred for 24 hours, treated with 5M HC1 (300 mL) and THF (300 mL), stirred for 2 days, cooled to 0°C, adjusted to pH 12 with KOH and extracted with ethyl acetate. The extract was washed with brine and dried (Na2SO4), filtered, and concentrated. The concentrate in DMF (30 mL) was treated with 4-fluoro-3-nitrobenzenesulfonamide (1 g) and TEA (627 uL) , heated at 55°C for 90 minutes, poured into water, and extracted with ethyl acetate. The extract was washed with water and brine and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with ethyl acetate, 10% methanol/ethyl acetate, and 10% methanol/10% acetonitrile/80% ethyl acetate. EXAMPLE 24E This example was prepared by substituting EXAMPLE 24D for 4-(((lR)-3- (dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 12.12 (s, 1H) , 10.90 (m, 1H), 9.90 (m, 1H), 8.56 (d, 1H), 8.52 (d, 1H), 8.04 (m, 1H), 7.86 (dd, 1H), 7.76 (d, 2H), 7.53 (m, 4H), 7.13-7.39 (m, 9H), 6.93 (d, 2H), 4.35 (m, 1H) , 3.87-3.79 (m, 2H), 3.74 (m, 4H), 3.47 (m, 8H), 3.23 (m, 4H), 2.75 (m, 6H). EXAMPLE 25A - 220 - WO2005/049594 PCT/US2004/037911 Diethylamine (4.15 mL) in THF (150 mL) at -78 °C was treated with 2.5M n-butyllithium in hexanes (15.4 mL), stirred for 5 minutes at 0°C, cooled to -78°C, treated with (2R, 4S)-3-((benzyloxy)carbonyl)-4-methyl-2-phenyl-l,3-oxazolidin-5-one, prepared as described in Helv. Chim. Acta 1991, 74, 800, (10 g) in THF (40 mL), stirred for 20 minutes, treated with allyl bromide (4.29 mL)., stirred for 1 hour, stirred at 25°C for 18 hours, poured into pH 7 buffer, and extracted with diethyl ether. The extract was washed with brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE 25B EXAMPLE 25A (8.18 g) in methanol (200 mL) and water (20 mL) at 25°C was treated with LiOH-water (1.95 g), stirred for 30 minutes, poured into saturated NaH2P04 (200 mL) , and extracted with ethyl acetate. The extract was washed with 1M NaOH and brine and dried (Na2SO4) , filtered, and concentrated. The base wash was acidified with 12M HC1 and extracted with ethyl acetate. The extract was concentrated, and the concentrate in 1:1 ethyl acetate/methanol (50 mL) at 25°C was treated with 2M (trimethylsilyl)diazomethane in THF (5 mL), stirred for 10 minutes, and concentrated. The concentrates were combined and flash chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 25C EXAMPLE 25B (5.03 g) in THF (75 mL) at 25°C was treated with 1M LiBH(CH2CH3)3 in THF (38 mL), stirred for 2 hours, treated with methanol (30 mL), poured into water, and extracted with ethyl acetate. The extract was washed with - 221 - WO2005/049594 PCT/US2004/0379H brine and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 30% ethyl acetate/hexanes. EXAMPLE 25D This example was prepared by substituting EXAMPLE 25C for EXAMPLE 18A in EXAMPLE' 18B. EXAMPLE 25E EXAMPLE 25D (2.9 g) in diethyl ether (45 mL) and tert-butanol (45 mL) at 25°C was treated with AD-mix-p" (12.74 g), stirred for 18 hours, poured into saturated Na2C03, and extracted with ethyl acetate. The extract was washed with brine and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 20-50% ethyl acetate/hexanes. The product in THF (30 mL) and water (30 mL) at 25°C was treated with NaI04 (2.75 g), stirred for 20 minutes, poured into water, and extracted with ethyl acetate. The extract was washed with brine and dried (Na2SO4), filtered, and concentrated. EXAMPLE 25F EXAMPLE 25E (1.92 g) in dichloromethane (30 mL) at 25°C was treated with dimethylamine hydrochloride (684 mg), sodium triacetoxyborohydride (1.9 g), and TEA (1.56 mL), stirred for 24 hours, treated with methanol and water, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 25G This example was prepared by substituting EXAMPLE 25F for EXAMPLE 18B in EXAMPLE 18C. - 222 - WO2005/049594 PCT/US2004/037911 EXAMPLE 25H A mixture of EXAMPLE 25G (600 mg) and 4-fluoro-3-nitrobenzene-sulfonamide (554 mg) in DMSO (7 mL) at 25°C was treated with TEA (351 uL) , heated at 60°C for 90 minutes, poured into water (30 mL), and extracted with ethyl acetate. The extract was washed with water and brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 0-10% methanol/ethyl acetate. EXAMPLE 251 This example was prepared by substituting EXAMPLE 25H for 4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 5 12.14 (s, 1H) , 10.90 (m, 1H) , 10.22 (m, -1H), 8.50 (d, 1H), 8.32 (s,lH), 8.04 (m, 1H), 7.83 (m, 3H), 7.54 (m, 4H), 7.36 (m, 4H), 7.23 (d, 2H), 6.98-6.85 (m, 5H), 4.35 (m, 2H), 3.92-3.87 (ra, 2H), 3.74 (m, 2H), 3.48 (m, 8H), 3.23 (m, 2H), 2.70 (m, 6H), 1.56 (s, 3H). EXAMPLE 26A This example was prepared by substituting methylamine for dimethylamine in EXAMPLE 18A. EXAMPLE 26B This example was prepared by substituting EXAMPLE 26A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 26C This example was prepared by substituting EXAMPLE 26B for EXAMPLE 18B in EXAMPLE 18C. - 223 - WO2005/049594 PCT/US2004/037911 EXAMPLE 26D This example was prepared by substituting EXAMPLE 26C for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 26E This example was prepared by substituting EXAMPLE 26D for EXAMPLE 18E in EXAMPLE 18F. EXAMPLE 26F EXAMPLE 26E (1.12 g) in THF (7 mL) and acetonitrile (7 mL) at 25°C was treated with di-tert-butyldicarbonate (572 mg) and TEA (276 mg), stirred for 16 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 26G This example was prepared by substituting EXAMPLE 26F for 4-(((1R) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 26H EXAMPLE 26G was flash chromatographed on silica gel with dichloromethane, 1:1 dichloromethane/ethyl acetate, and 10% (7M NH3 in methanol) in methanol. A mixture of the free base in dichloromethane at 25°C was treated with 1:1 2M HCl/diethyl ether (10 mL), stirred for 18 hours and concentrated. 1H NMR (500 MHz, DMSO-d6) 5 12.11 (s, IH), 10.94 (m, IH) , 8.71 (m, IH)', 8.53 (d, IH) , 8.28 (d, IH) , 8.05 (m, IH), 7.86 (dd, IH), 7.77 (d, 2H), 7.53 (m, 4H), 7.37 (m, 4H), 7.23 (m, 2H), 7.11 (m, 3H), 6.93 (d, 2H), 4.34 (m, IH) , 4.28 (m, IH), 4.12 (m, IH) , 3.92-3.87 (m, 2H) , 3.39 (m, 8H) , 3.27 -224 - WO2005/049594 PCT/US2004/037911 (m, 3H), 2.94 (m, 3H) , 2.11 (m, 2H) . EXAMPLE 27A A mixture of Fmoc-D-Asp(O-tert-butyl)-OH (10.25 g) and NMM (2.8 mL) in DME (30 mL) at -15°C was treated with isobutyl chloroformate (4.1 mL), stirred for 10 minutes, and filtered. The filtrate was cooled to 0°C, treated with NaBH4 (2.84 g) in water (15 mL), stirred for 5 minutes, treated with water, stirred at 25°C for 3 hours, and filtered. EXAMPLE 27B A mixture of EXAMPLE 27A (9.5 g) , diphenyl disulfide (7.86 g) and tributylphosphine (7.28 g) in toluene (200 mL) at 80°C was stirred for 5 hours and concentrated. The concentrate was flash chromatographed on silica gel with 5% to 20% ethyl acetate/hexanes. EXAMPLE 27C This example was prepared by substituting EXAMPLE 27B for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 27D This example was prepared by substituting EXAMPLE 27C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfany1)methyl)-propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 27E EXAMPLE 27D (1 g) in dichloromethane (5 mL) at 25°C was treated with TFA (5 mL), stirred for 3 hours, and concentrated. 1H NMR (500 MHz, DMSO-d6) 5 8.57 (d, 1H) , 8.52 (d, 1H), 7.84 (dd, 1H), 7.75 (d, 2H), 7.55-7.35 (m, 7H), 7.27-7.11 (m, 6H), 6.91 (d, 2H), 4.39 (m, 1H), 3.39 (2, 2H), 3.31 - 225 - WO2005/049594 PCT/US2004/037911 (s, 8H), 3.26 (m, 2H), 2.81 (d, 2H). EXAMPLE 28 A mixture of EXAMPLE 27E (160 mg) and N-methyl-morpholine (27 nL) in DMF (1 mL) at 25°C was treated with HATU (92 mg) and isopropylamine (50 uL), stirred for 5 hours, treated with ethyl acetate (200 mL) , washed with 1% HC1, saturated NaHC03, water, and brine, and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with dichloromethane, (1:1) dichloromethane/ethyl acetate, and 5% methanol/dichloromethane. H NMR (500 MHz, DMSO-d6), 8 8.73 (d, IH) , 8.52 (d, IH) , 7.93 (d, IH) , 7.83 (dd, IH), 7.76 (d, 2H) , 7.52 (m, 2H), 7.38 (m, 3H), 7.23 (m, 2H), 7.18-7.10 (m, 6H), 6.92 (d, 2H), 4.39 (m, IH), 3.75 (m, IH), 3.40 (m, 1OH), 3.34 (m, 2H), 2.54 (m,- 2H), 0.98 (d, 3H), 0.91 (d, 3H). EXAMPLE 29A EXAMPLE 27B (500 mg) in dichloromethane (3 mL) at 25°C was treated with TFA (3 mL), stirred for 3 hours, and concentrated with a dichloromethane azeotrope. EXAMPLE 29B A mixture of EXAMPLE 29A (450 mg) and NMM (140 uL) in DMF (3 mL) at 25°C was treated with HATU (464 mg) and diisopropylamine (283 mL) , stirred for 5 hours, treated with ethyl acetate, washed with 1% HC1, saturated NaHC03, water, and brine, and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with dichloromethane, 1:1 dichloromethane/ethyl acetate, 5% methanol/dichloromethane. - 226 - WO2005/049594 PCT/US2004/037911 EXAMPLE 29C EXAMPLE 29B (200 mg) in THF (5 mL) at 25°C was treated with 2M borane-THF in THF (1 mL), stirred for 4 hours, treated with methanol (3 mL) and concentrated HCl (1 mL), stirred for 2 hours, brought to pH 7 with saturated NaHCO3, and extracted with dichloromethane. The extract was washed with water and brine and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with dichloromethane and 5% methanol/dichloromethane. EXAMPLE 29D This example was prepared by substituting EXAMPLE 29C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 29E This example was prepared by substituting EXAMPLE 29D for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 8 11.88 (s, 1H) , 11.33 (s, 1H), 10.13 (s, 1H), 9.57 (s, 1H), 8.30 (d, 1H), 8.08 (d, 1H), 7.94 (m, 1H), 7.63 (dd, 1H), 7.55 (d, 2H), 7.30 4H). EXAMPLE 200A This example was made by substituting 2-mercaptobenzthiazole for 2-mercaptothiazole in EXAMPLE 198A. EXAMPLE 200B This example was made by substituting EXAMPLE 200A for EXAMPLE 2IB in EXAMPLE 21C. EXAMPLE 20OC This example was made by substituting EXAMPLE 200B for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 200D This example was made by substituting EXAMPLE 20OC for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, DMSO-d6) 8 8.86 (t, IH), 8.59 (d, IH), 7.76 (m, 4H), 7.54 (m, 2H), 7.48 (m, 2H), 7.43 (m, 2H), 7.36 (m, 4H), 6.92 (d, 2H), 4.31 (br s, 2H), 3.91 (m, 2H), 3.66 (t, 4H) , 2.97 (br s, 4H) . EXAMPLE 201 - 337 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 198C for 4- (((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 8.80 (m, IH) , 8.61 (d, IH) , 7.95 (dd, IH) , 7.74 (m, 4H), 7.71 (d, IH), 7.62 (d, IH), 7.52 (m, 4H), 7.40 (m, IH), 7.39 (m, 2H), 7.37 (m, IH), 7.33 (m, IH) , 6.91 (d, 2H), 3.81 (m, 4H), 3.50 (m, 4H), 3.32 (m, IH), 3.27 (m, IH), 2.49 (m, IH), 2.06 (s, IH). EXAMPLE 202A This example was made by substituting 2-mercaptobenzoxazole for 2-mercaptothiazole in EXAMPLE 198A. EXAMPLE 202B This example was made by substituting EXAMPLE 202A for EXAMPLE 2IB in EXAMPLE 21C. EXAMPLE 202C This example was made by substituting EXAMPLE 202B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 202D This example was made by substituting EXAMPLE 202C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 8.84 (m, IH) , 8.58 (d, IH), 8.00 (dd, IH), 7.76 (d, 2H), 7.71 (br s, IH), 7.57 (m, 2H), 7.50 (m, 4H), 7.39 (m, 2H), 7.29 (m, 3H), 6.91 (d, 2H), 4.22 (br s, 2H) , 3.92 (m, 2H), 3.60 (t, 4H), 2.97 (m, 4H). EXAMPLE 203 - 338 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 20OC for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1HNMR (500 MHz, DMSO-d6) 5 12.06 (br s, IH) , 8.85 (t, IH), 8.58 (d, IH), 8.01 (dd, IH), 7.97 (d, IH), 7.75 (m, 3H), 7.71 (br s, IH) , 7.51 (m, 4H), 7.37 (m, 4H) , 6.91 (d, 2H), 4.26 (br s, 2H) , 3.90 (m, 2H) , 3.64 (t, 4H), 2.96 (m, 6H) . EXAMPLE 204A This example was made by substituting 2-mercaptopyrimidine for 2-mercaptothiazole in EXAMPLE 198A. EXAMPLE 204B This example was made by substituting EXAMPLE 204A for EXAMPLE 2IB in EXAMPLE 21C. EXAMPLE 204C This example was made by substituting EXAMPLE 204B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 204D This example was made by substituting EXAMPLE 204C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl) -propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 6 12.07 (br s, IH) , 8.83 (t, IH) , 8.66 (d, 2H), 8.63 (d, IH), 8.04 (dd, IH), 7.76 (d, 2H), 7.72 (br s, IH), 7.52 (m, 5H), 7.40 (d, 2H), 7.33 (m, IH), 7.24 (t, IH) , 6.92 (d, 2H), 4.29 (br s, 2H), 3.78 (m, 4H), 3.39 (t, 4H) , 2.85 (br s, 2H). EXAMPLE 205A - 339 - WO2005/049594 PCT/US2004/037911 This example was made by substituting 2-bromoethylamine hydrochloride for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 205B EXAMPLE 205A and 2-mercaptoimidazole were subjected to the procedure described in J.Med.Chem. 1995, 38, 1067. .EXAMPLE 205C This example was made by substituting EXAMPLE 205B for 4-(((1R)-3-(dimethylamino)- 1-{(phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-de) 8 8.73 (t, IH), 8.63 (d, IH), 7.94 (dd, IH), 7.76 (d, 3H), 7.53 (m, 4H), 7.40 (d, 2H), 7.34 (m, IH), 7.30 (m, IH), 6.93 (d, 2H), 4.26 (br s, 2H), 3.72 (m, 4H), 3.42 (t, 4H), 2.98 (br s, 4H). EXAMPLE 206 This example was made by substituting EXAMPLE 191D for 4-( ((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 12.11 (br s, IH), 11.43 (br s, IH), 10.67 (br s, IH), 8.73 (t, IH), 8.63 (d, IH), 8.15 (m, IH), 7.92 (dd, IH), 7.76 (d, 2H), 7.59 (m, 2H), 7.53 (m, 4H), 7.44 (m, 4H) , 7.38 (d, 2H) , 7.33 (m, IH), 7.28 (d, IH), 6.93 (d, 2H), 4.34 (br s, 2H), 4.22 (d, 2H), 3.89 (d, 2H), 3.37 (m, 4H), 3.31 (d, 2H) , 3.25 (d, 2H), 2.84 (m, 4H), 1.88 (d, 3H), 1.61 (m, 2H). EXAMPLE 207 This example was made by substituting EXAMPLE 205A for 4-(( (1R)-3-(dimethylamino)- - 340 - WO2005/049594 PCT/US2004/037911 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, DMSO-d6) 5 12.12 (br s, IH), 8.75 (m, IH), 8.65 (d, IH), 7.96 (dd, IH), 7.75 (d, 3H), 7.53 (m, 2H) , 7.48 (m, 2H), 7.43 (m, IH), 7.36 (m, 4H), 6.92 (d, 2H), 4.29 (br s, 2H), 3.88 (m, 4H), 3.82 (m, 2H), 3.72 (t, 2H), 3.03 (m, 4H). EXAMPLE 208A This example was made by substituting 4-methylthiazole-2-thiol for 2-mercaptoimidazole in EXAMPLE 205B. EXAMPLE 208B This example was made by substituting EXAMPLE 208A for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1K NMR (500 MHz, DMSO-d6) 5 12.07 (br s, IH), 8.81 (t, IH), 8.63 (d, IH), 7.95 (dd, IH), 7.76 (d, 2H), 7.73 (br s, IH) , 7.52 (m, 3H) , 7.39 (d, 2H), 7.34 (m, IH), 6.93 (d, 2H), 4.25 (br s, 2H), 3.82 (m, 2H) , 3.48 (m, 4H) , 3.02 (rn, 4H) , 2.29 (s, 3H) , 2.07 (s, 2H) . EXAMPLE 209A This example was made by substituting benzylamine for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl) methyl)propyl)amino)-3- nitrobenzenesulfonamide and 4-methoxycyclohexane carboxylic acid for EXAMPLE 2C in EXAMPLE 2D. EXAMPLE 209B This example was made by subsituting EXAMPLE 209A for EXAMPLE 18E in EXAMPLE 18F. - 341 - WO2005/049594 PCT/US2004/037911 EXAMPLE 209C EXAMPLE 209B (710 mg) and Pd(OH)2 (0.28g) in methanol (70 mL) at 50°C was stirred under H2 (60 psi) for 22 hours, cooled to 25°, filtered, and concentrated. EXAMPLE 209D This example was made by substituting EXAMPLE 209C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 209E This example was made by substituting EXAMPLE 209D for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. XH NMR (400 MHz, DMSO-d6) 5 8.55 (d, IH), 8.48 (t, IH), 7.90 (dd, IH), 7.72 (d, 2H), 7.51 (m, IH), 7.47 (s, 3H), 7.37 (m, 2H), 7.25 (m, IH), 7.14 (d, IH), 6.84 (d, 2H) , 3.39 (s, 2H) , 3.36 (m, IH) , 3.27 (m, 4H), 3.19 (m, 5H), 2.40 (t, 4H), 1.80 (m, 2H), 1.69 (m, IH), 1.48 (m, 2H), 1.33 (m, 4H). EXAMPLE 210A This example was made by substituting 2-mercaptothiophene for 2-mercaptothiazole in EXAMPLE 198A. EXAMPLE 210B This example was made by substituting EXAMPLE 210A for EXAMPLE 2IB in EXAMPLE 21C. EXAMPLE 21OC This example was made by substituting EXAMPLE 210B for EXAMPLE 21C in EXAMPLE 2ID. - 342 - WO2005/049594 PCT/US2004/037911 EXAMPLE 210D This example was made by substituting EXAMPLE 21OC for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, DMSO-d6) 5 8.74 (t, IH), 8.62 (d, IH), 7.90 (dd, IH), 7.75 (m, 2H), 7.61 (dd, IH), 7.54 (m, 2H), 7.49 (m, 2H), 7.43 (m, IH), 7.36 (m, 2H), 7.21 (dd, IH), 7.13 (d, IH), 7.02 (dd, IH) , 6.92 (d, 2H), 4.36 (br s, 2H), 3.63 (m, 4H), 3.11 (t, 4H), 2.54 (s, 4H) - EXAMPLE 211A A mixture of Boc-2-amino-2-methylpropanol (633 mg) and 2-thienyldisulfide (l.g) in THF (12 mL) at 25°C was treated with tributylphosphine (1.1 mL), heated at 85°C for 2.5 hours, treated with ethyl acetate, washed with water, dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatograped on silica gel with 30-70% ethyl acetate/hexanes. EXAMPLE 211B This example was made by substituting EXAMPLE 211A for EXAMPLE 21B in EXAMPLE 21C. EXAMPLE 211C This example was made by substituting EXAMPLE 8030757B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 211D This example was made by substituting EXAMPLE 211C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- - 343 - WO2005/049594 PCT/US2004/037911 nitrobenzenesulfonamide in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 8 8.58 (d, IH), 8.54 (s, IH), 7.82 (dd, IH), 7.79 (d, 2H), 7.72 (br s, IH), 7.52 (m, 4H), 7.33 (d, 2H), 7.21 (dd, IH), 6.96 (dd, IH), 6.94 (d, 2H), 6.66 (dd, IH), 4.19 (br s, 4H), 2.90 (br s, 6H), 1.54 (s, 6H). EXAMPLE 212A This example was made by'sustituting EXAMPLE 19A for Boc-2-amino-2-methylpropanol and EXAMPLE 22A for 2-thienyldisulfide in EXAMPLE 211A. EXAMPLE 212B This example was made by substituting EXAMPLE 212A for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 212C This example was made by substituting EXAMPLE 212B for EXAMPLE 18E in EXAMPLE 18F. EXAMPLE 212D This example was made by substituting EXAMPLE 212C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 212E This example was made by substituting EXAMPLE 212D for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 9.97 (br s, IH), 8.61 (d, IH), 8.34 (d, IH) , 7.95 (dd, IH) , 7.75 (d, 2H), 7.72 (br s, IH), 7.66 (d, IH) , 7.59 (d, IH), 7.51 (d, 4H), 7.32 (m, IH), 6.92 (d, 2H), 4.35 (m, - 344 - WO2005/049594 PCT/US2004/037911 2H), 4.22 (br s, 2H) , 3.95 (br s, 4H) , 3.21 (m, 4H), 2.94 (m, 6H), 2.20 (m, 2H). EXAMPLE 213A This example was prepared by substituting 2-mercaptopyrimidine for 2-mercaptothiazole in EXAMPLE 22A. EXAMPLE 213B This example was made by sustituting EXAMPLE 18A for Boc-2-amino-2-methylpropanol and EXAMPLE 213A for 2-thienyldisulfide in EXAMPLE 211A. EXAMPLE 213C This example was made by substituting EXAMPLE 213B for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 213D This example was made by substituting EXAMPLE 213C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 213E This example was made by substituting EXAMPLE 212D for 4-( ( (1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-de) 5 12.08 (br s, IH), 9.86 (br s, IH), 8.97 (d, IH) 8.62 (d, 2H,) 8.60 (d, IH), 7.99 (dd, IH), 7.77 (d, 2H), 7.74 (br s, IH) , 7.53 (m, 5H) , 7.39 (d, 2H) , 7.34 (m, IH) , 7.22 (tf IH), 6.93 (d, 2H), 4.59 (m, IH), 4.29 (br s, 2H), 3.42 (dd, 3H), 3.04 (dd, 2H), 2.95 (s, 4H), 2.81 (m, 5H). EXAMPLE 214A - 345 - WO2005/049594 PCT/US2004/037911 This example was made by sustituting EXAMPLE 19A for Boc-2-amino-2-methylpropanol in EXAMPLE 211A. EXAMPLE 214B This example was made by substituting EXAMPLE 214A for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 214C This example was made by substituting EXAMPLE 214B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 214D This example was made by substituting EXAMPLE 214C for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. XH NMR (500 MHz, DMSO-d6) 8 12.06 (br s, IH) , 8.77 (d, IH), 7.86 (dd, IH), 7.74 (d, 2H), 7.71 (br s, IH), 7.55 (dd, IH), 7.51 (m, 4H), 7.38 (d, 2H), 7.32 (m, IH), 7.08 (d, IH), 7.04 (dd, IH), 6.94 (dd, IH) , 6.91 (d, 2H), 4.39 (m, 2H), 3.51 (m, 5H), 3.25 (m, 4H) , 2.99 (dd, 2H), 2.75 (dd, 2H). EXAMPLE 215A This example was made by substituting EXAMPLE 213A for 2-thienyldisulfide in EXAMPLE 211A. EXAMPLE 215B This example was made by substituting EXAMPLE 215A for EXAMPLE 21B in EXAMPLE 21C. EXAMPLE 215C - 346 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 215B for , EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 215D This example was made by substituting EXAMPLE 215C for 4- (((1R)-3-(dimethylamino)- 1-((phenylsulfanyl) methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 8.55 (d, IH), 8.53 (d, 2H), 8.49 (br s, IH), 7.97 (dd, IH), 7.74 (d, 2H), 7.53 (m, 2H), 7.47 (br s, 4H), 7.37 , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 0-2% methanol dichloromethane. EXAMPLE 231B This example was made by substituting EXAMPLE 231A for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 231C This example was made by substituting EXAMPLE 231B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 9.31 (br s, IH), 8.36 (d, IH), 8.28 (d, IH), 8.03 (d, IH) , 7.72 (dd, IH), 7.61 (dd, IH), 7.47 (br s, IH), 7.25 (d, 4H) , 7.13 (d, 2H) , 7.06 (m, IH), 6.98 (m, 2H), 6.89 (m, 4H) , 6.60 (d, IH), 3.94 (m, 4H), 2.88 (m, 4H), 2.49 (br s, 6H), 2.24 (m, 2H), 1.89 (m, 2H). EXAMPLE 232A This example was made by substituting l-benzyl-4-piperidohe for tert-butyl-4-oxo-l-piperidinecarboxylate in EXAMPLE 228A. EXAMPLE 232B - 358 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 232A for EXAMPLE 228A in EXAMPLE 228B. EXAMPLE 232C A mixture of EXAMPLE 232B (0.98 g) and 10%Pd/C (0.1 g) in ethanol (50 mL) at 50°C was stirred under hydrogen for 2 hours, cooled to 25°, filtered, and concentrated. EXAMPLE 232D This example was prepared by substituting EXAMPLE 232C for EXAMPLE 1A in EXAMPLE 2A. EXAMPLE 232E This example was made by substituting EXAMPLE 232D for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 232F This example was made by substituting EXAMPLE 232E for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 232G This example was made by substituting EXAMPLE 232F for EXAMPLE 2C in EXAMPLE 2D. -"-H NMR (500 MHz, DMSO-d6) 8 9.57 (br s, IH), 9.46 (br s, IH), 8.55 (d, IH), 8.28 (d, IH), 7.86 (dd, IH), 7.83 (d, 2H), 7.79 (m, IH), 7.55 (m, 4H), 7.40 (d, 2H), 7.35 (m, IH), 7.28 (d, 2H), 7.23 (d, 2H), 7.14 (m, 4H) , 4.32 (br s, 2H) , 4.19 (m, 2H), 3.39 (d, 2H), 3.29 (d, 2H), 3.13 (m, 2H), 2.81 (br s, 2H), 2.74 (br s, 6H), 2.14 (m, 2H), 1.84 (m, 3H) . EXAMPLE 233 - 359 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 232F for EXAMPLE 2C and 4-(((IR)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((IR)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 6 9.98 (m, 1H) , 9.51 (br s, 1H), 8.55 (d, 1H), 8.30 (d, 1H), 7.87 (dd, 1H), 7.83 (d, 2H), 7.79 (m, 1H), 7.56 (m, 4H), 7.40 (d, 2H), 7.35 (m, 1H), 7.28 (d, 2H), 7.24 (d, 2H), 7.14 (m, 4H) , 4.32 (br s, 2H), 4.19 (m, 1H), 3.93 (br s, 2H), 3.39 (d, 4H) , 3.29 (d, 3H), 3.18 (br s, 3H), 3.02 (br s, 2H), 2.80 (m, 3H), 2.17 (m, 2H), 1.84 (m, 3H). EXAMPLE 234 This example was prepared by substituting EXAMPLE 228F for EXAMPLE 2C and EXAMPLE 18F for 4-(((IR)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 9.32 (br s, 1H), 7.72 (d, 1H), 7.62 (d, 2H) , 7.59 (dd, 1H) , 7.53 (br s, 1H), 7.29 (m, 2H), 7.25 (d, 2H) , 7.20 (d, 2H), 7.16 (d, 2H), 7.11 (m, 1H), 7.04 (m, 4H), 6.94 (t, 1H), 6.63 (d, 1H), 5.86 (br s, 1H), 5.78 (d, 1H), 4.11 (br s, 1H), 3.69 (m, 1H), 2.90 (m, 2H), 2.75 (m, 2H), 2.49 (s, 6H), 2.25 (m, 2H), 1.86 (m, 2H). EXAMPLE 235 This example was made by substituting EXAMPLE 231B for EXAMPLE 2C and 4-(((IR)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((IR)-3-(dimethylamino)- - 360 - WO2005/049594 PCT/US2004/037911 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 9.91 (br s, 1H), 8.61 (d, 1H), 8.55 (d, 1H), 8.30 (d, 1H), 7.98 (dd, 1H), 7.87 (dd, 1H), 7.74 (br s, 1H), 7.51 (d, 4H), 7.39 (d, 2H), 7.33 (m, 1H), 7.24 (m, 2H) , 7.19 (d, 1H), 7.13 (m, 3H), 6.86 (d, 1H), 4.33 (br s, 2H), 4.20 (m, 2H), 3.96 (br s, 4H), 3.62 (br s, 4H), 3.40 (m, 4H) , 3.19 (m, 3H), 3.01 (br s, 2H), 2.80 (br s, 2H), 2.17 (m, 2H). EXAMPLE 848866 This example was prepared by substituting EXAMPLE 231B for EXAMPLE 2C and EXAMPLE 18F for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 9.60 (br s, 1H), 8.60 (d, 1H), 7.95 (m, 1H), 7.82 (dd, 1H), 7.73 (br s, 1H), 7.51 (d, 3H), 7.39 (d, 2H) , 7.30 (m, 4H), 7.19 (iti, 1H), 6.88 (d, 1H) , 6.85 (d, 1H) , 6.04 (d, 1H), 3.94 (m, 1H), 3.29 (m, 4H), 3.15 (m, 2H), 3.01 (m, 2H), 2.74 (s, 6H), 2.11 (m, 2H). EXAMPLE 237A 2.5M n-Butyllithium in hexanes (3 mL) at 25°C was treated with methyltriphenylphosphonium bromide (2.6 g) in diethyl ether (37 mL), stirred for 1.5 hours, treated with ethyl 4-(4-oxopiperidin-l-yl)benzoate, prepared as described in Synthesis 1981, 8, 606, (1.47 g), in diethyl ether (15 mL), stirred for 18 hours, and filtered. The filtrate was washed with water and dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 237B - 361 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 232 F for EXAMPLE 2C and 4-(((IR)-3-(4-morpholinyl)-1- ( (phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 9.98 (m, 1H), 9.51 (br s, 1H), 8.55 (d, 1H), 8.30 (d, 1H), 7.87 (dd, 1H), 7.83 (d, 2H), 7.79 (m, 1H), 7.56 (m, 4H), 7.40 (d, 2H), 7.35 (m, 1H), 7.28 (d, 2H), 7.24 (df 2H), 7.14 (m, 4H), 4.32 (br s, 2H), 4.19 (m, 1H), 3.93 (br s, 2H) , 3.39 (d, 4H), 3.29 (d, 3H), 3.18 (br s, 3H), 3.02 (br s, 2H), 2.80 (m, 3H) , 2.17 (m, 2H) , 1.84 (m, 3H) . EXAMPLE 234 This example was prepared by substituting EXAMPLE 228F for EXAMPLE 2C and EXAMPLE 18F for 4-(((IR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 6 9.32 (br s, 1H), 7.72 (d, 1H), 7.62 (d, 2H) , 7.59 (dd, 1H), 7.53 (br s, 1H), 7.29 (m, 2H), 7.25 (d, 2H), 7.20 (d, 2H), 7.16 (d, 2H), 7.11 (m, 1H), 7.04 (m, 4H), 6.94 (t, 1H), 6.63 (d, 1H), 5.86 (br s, 1H), 5.78 (d, 1H), 4.11 (br s, 1H), 3.69 (m, 1H) , 2.90 (m, 2H), 2.75 (m, 2H), 2.49 (s, 6H), 2.25 (m, 2H), 1.86 (m, 2H). EXAMPLE 235 This example was made by substituting EXAMPLE 231B for EXAMPLE 2C and 4-(((IR)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((IR)-3-(dimethylamino)- - 360 - WO2005/049594 PCT/US2004/037911 A mixture of EXAMPLE 237A (400 mg) and 0.5M 9-BBN (3.3 mL) in THF (2 mL) at 60°C was stirred for 1.5 hours, cooled to 25°C, treated dropwise with 2-bromo-4-chlorobiphenyl (434 mg) , K2C03 (296 mg) , and dichloro (1,1' -bis(diphenylphosphino)ferrocene)palladium(II) dichloromethane (24.5 mg) in water (0.36 mL) and DMF (3.6 mL) , stirred for 3 hours at 60°C, cooled to 25°C, and treated with water and ethyl acetate. The extract was washed with brine and dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 2-5% ethyl acetate/hexanes. EXAMPLE 237C This example was made by substituting EXAMPLE 237B for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 237D This example was made by substituting EXAMPLE 237C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 6 11.94 (br s, IH), 9.43 (br s, IH), 8.54 (d, IH), 7.87 (dd, IH), 7.70 (d, 2H) , 7.47 (d, 2H) , 7.32 (m, 3H) , 7.27 (dd, IH) , 7.25 (d, 2H), 7.17 (m, 3H), 7.11 (m, 2H), 6.84 (d, 2H) , 4.20 (m, IH), 3.78 (d, 2H), 3.39 (d, 2H), 3.14 (m, 2H), 2.74 (s, 6H) , 2.65 (t, 2H), 2.53 (m, 2H), 2.14 (m, 2H), 1.55 (m, IH) , 1.44 (d, 2H), 0.96 (m, 2H). EXAMPLE 238 This example was made by substituting EXAMPLE 237C for EXAMPLE 2C and 4-( ((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24 636, for 4-(((1R)-3-(dimethylamino)- - 362 - WO2005/049594 PCT/US2004/037911 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 11.95 (br s, IH) , 9.75 (br s, IH), 8.55 (d, IH), 8.29 (d, 'lH), 7.87 (dd, IH), 7.70 (d, 2H), 7.48 (m, 2H), 7.32 (m, 4H), 7.28 (m, IH), 7.25 (m, 2H), 7.17 (m, 4H), 7.11 (m, IH), 6.84 (d, 2H), 4.19 (m, IH), 3.96 (br s, 2H), 3.78 (d, 4H), 3.40 (d, 4H), 3.20 (m, 2H) , 3.02 (br s, 2H), 2.66 (t, 2H), 2.53 (m, 2H), 2.17 (m, 2H), 1.56 (m, IH), 1.45 (d, 2H), 0.98 (m, 2H). EXAMPLE 239A A mixture of, 2,5-dibromopyridine(2.4 g), dichloro(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloromethane (430 mg) , and TEA (2.9 mL) in methanol (10 mL), and DMF (10 mL) in a Parr shaker at 50°C was stirred under CO (200 psi) over 5.5 hours, cooled to 25°C, filtered, and concentrated. The concentrate was flash chromatographed on silca gel with 10-20% ethyl acetate/hexanes. EXAMPLE 239B A mixture of EXAMPLE 239A (900 mg), EXAMPLE 227C (1.6 g), and DIEA (2.1 mL) in DMSO (5.9 mL) was stirred at 130°C for 24 hours, cooled to 25°C, and concentrated. The concentrate was flash chromatagraphed on silica gel with 30-50% ethyl acetate/hexanes. EXAMPLE 239C This example was made by substituting EXAMPLE 239B for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 239D - 363 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 239C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 9.60 (br s, 1H), 8.59 (d, 1H), 8.30 (m, 2H), 7.90 (dd, 1H), 7.82 (d, 1H), 7.70 (br s, 1H), 7.51 (m, 4H), 7.41 (d, 2H), 7.38 (dd, 1H), 7.32 (m, 1H), 7.22 (d, 2H), 7.17 (d, 1H), 7.12 (m, 3H), 4.19 (m, 2H), 3.39 (d, 2H), 3.13 (m, 4H) , 2.74 (s, 6H), 2.14 (m, 2H). EXAMPLE 240 This example was made by substituting EXAMPLE 239C for EXAMPLE 2C and 4-(( (1R) -3-(4-morpholinyl)- 1-((phenylsulfanyl)methyl)propyl}amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((lR)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H .NMR (500 MHz, DMSO-d6) 8 9.89 (br s, 1H), 8.59 (d, 1H), 8.30 (m, 2H), 7.91 (dd, 1H), 7.83 (d, 1H), 7.73 (br s, 1H), 7.52 (d, 4H), 7.40' (m, 3H), 7.34 (m, 1H), 7.23 (d, 2H) , 7.18 (d, 1H), 7.12 (m, 3H), 4.20 (m, 2H), 3.96 (br s, 4H), 3.40 (d, 2H), 3.19 (m, 2H), 3.01 (br s, 4H) , 2.17 (m, 2H). EXAMPLE 24I A EXAMPLE 855947A (12.3 g) in propan-2-ol (57 mL) at 0°C was treated with NaBH4 (2.2 g) in 1:1 ethanol/propane-2-ol (100 mL) , stirred at 25°C for 18 hours, treated with NH4C1 and brine, and extracted with diethyl ether. The extract was dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 10-30% ethyl acetate/hexanes. EXAMPLE 24I B - 364 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 24I A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 24I C A mixture of EXAMPLE 24I B (420 mg) and TEA (0.95 mL) in dichloromethane (8.7 mL) at 0°C was treated with methanesulfonyl chloride (0.16 mL) , stirred for 0.5 hours, treated with EXAMPLE 228C (0.57 g) , stirred for 1 hour at 0°C and for 5 hours at 25 °C, treated with dichloromethane, washed with water and brine, and dried (MgSC-) , filtered, and •concentrated. The concentrate was flash chromatographed on silica gel with 0-2% methanol/dichloromethane. EXAMPLE 24I D This example was made by substituting EXAMPLE 24I C for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 24I E This example was made by substituting EXAMPLE 24I D for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 8.47 (d, IH), 8.17 (d, IH), 7.82 (m, 3H), 7.38 (d, 2H), 7.31 (d, 4H), 7.24 (m, 2H), 7.18 (m, IH), 7.14 (m, 2H), 6.90 (d, IH), 6.13 (br s, IH), 4.07 (m, IH), 2.93 (m, 6H), 2.61 (m, 6H), 2.39 (br s, 2H), 2.24 (m, 2H), 2.08 (m, 2H), 1.99 (m, 2H), 1.44 (t, 2H), 0.97 (br s, 2H). EXAMPLE 242A This example was made by substituting 2-bromo-cyclohex-1-enecarboxaldehyde, prepared as described in Collect. Czech. Chem. Commun. 1961, 26, 3059-3073, for EXAMPLE 855947A in EXAMPLE 24I A. - 365 - WO2005/049594 PCT/US2004/037911 EXAMPLE 242B This example was made by substituting EXAMPLE 242A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 242C This example was made by substituting EXAMPLE 242B for EXAMPLE 24I B in EXAMPLE 24I C. EXAMPLE 242D This example was made by substituting EXAMPLE 242C for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 242E This example was made by substituting EXAMPLE 242D for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 9.69 (br s, IH), 9.60 (br s, IH), 8.56 (d, IH), 8.30 (d, IH), 7.89 (m, 3H), 7.45 (d, 2H), 7.37 (m, 2H), 7.17 (m, 8H), 6.14 (br s, IH), 4.20 (m, IH), 3.89 (m, IH), 3.66 (d, 4H), 3.40 (d, 3H), 3.12 (m, 4H), 2.75 (br s, 6H), 2.69 (br s, IH), 2.29 (br s, 2H), 2.22 (br s, 2H), 2.15 (m, 2H), 1.71 (br s, 4H). EXAMPLE 243 This example was made by substituting EXAMPLE 242D for EXAMPLE 2C and 4-(((1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(( (lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 9.84 (br s, IH) , 9.60 (br s, Ik), 8.56 (d, IH), 8.30 (d, IH), 7.89 (m, 3H) , 7.45 (d, 2H), 7.37 (m, 2H) , 7.24 (m, 2H), 7.15 (m, 6H), 6.13 (br s, IH), 4.20 (m, IH), 3.92 (m, - 366 - WO2005/049594 PCT/US2004/037911 2H), 3.64 (m, 4H), 3.19 (m, 4H), 3.02 (br s, 4H), 2.70 (m, 2H) , 2.29 (br s, 2H), 2.18 (m, 4H) , 1.71 (br s, 4H). EXAMPLE 244 This example was made by substituting EXAMPLE 24I D for EXAMPLE 2C and 4- (( (1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 8.47 (d, IH), 8.27 (d, IH) , 7.84 (d, 2H), 7.79 (dd, IH), 7.39 (d, 2H), 7.32 (m, 4H), 7.24 (t, 2H), 7.16 (m, 3H), 6.93 (d, IH), 6.10 (br s, IH), 4.09 (m, IH), 3.55 (br s, 4H), 3.34 (m, 4H), 3.02 (m, 2H), 2.76 (s, IH), 2.27 (m, 2H) , 2.01 (br s, 3H), 1.86 (m, IH), 1.46 (t, 2H), 0.98 (s, 6H). EXAMPLE 245A This example was made by substituting 1,4-cyclohexanedione monoethylene ketal for ethyl 4-(4-oxopiperidin-l-yl)benzoate in EXAMPLE 237A. EXAMPLE 245B This example was made by substituting EXAMPLE 245A for EXAMPLE 237A in EXAMPLE 237B. EXAMPLE 245C A mixture of EXAMPLE 245B (1.9 g) and 35% aqueous TFA (42 mL) in chloroform (61 mL) was stirred at 25°C for 7 hours and treated with water and dichloromethane. The extract was washed with saturated NaHC03 and brine and dried (MgSO4) , filtered, and concentrated. - 367 - WO2005/049594 PCTYUS2004/037911 EXAMPLE 245D This example was made by substituting EXAMPLE 245C for tert-butyl-4-oxo-l-piperidinecarboxylate and by substituting 2-(N,N-bis(trifluoromethylsulfonyl)amino)-5-chloropyridine for N-phenylbis(trifluoromethanesulfonamide) in EXAMPLE 228A. EXAMPLE 245E This example was made by substituting EXAMPLE 245D for EXAMPLE 228A in EXAMPLE 228B. EXAMPLE 245F This example was made by substituting EXAMPLE 245E for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 245G This example was made by substituting EXAMPLE 245F for EXAMPLE 2C in EXAMPLE 2D. 1H. NMR (500 MHz, DMSO-d6) 5 9.45 (br s, IH), 8.56 (d, IH), 8.30 (d, IH), 7.88 (dd, IH) , 7.81 (d, 2H), 7.47 (d, 2H), 7.42 (d, 2H), 7.34 (m, 3H), 7.32 (s, IH) , 7.28 (m, IH), 7.24 (m, 2H), 7.16 (m, 4H), 7.11 (m, IH) , 6.16 (br s, IH), 4.19 (m, IH), 3.14 (m, 3H), 2.74 (s, 6H), 2.61 (m, 2H) , 2.24 (m, 2H) , 2.14 (m, 2H), 2.03 (m, IH), 1.68 (m, 3H) , 1.17 (m, IH). EXAMPLE 246 This example was made by substituting EXAMPLE 245F for EXAMPLE 2C and 4-( ( (1R)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for 4-(( (1R)-3-(dimethylamino –1-((phenylsulfanyl)methyl)propyl)amino)-3- - 368 - WO2005/049594 PCT/US2004/037911 nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 8.55 (d, IH), 8.29 (d, IH), 7.87 (dd, IH), 7.79 (d, 2H), 7.46 (d, 2H), 7.40 (d, 2H), 7.32 (m, 4H), 7.27 (m, IH), 7.23 (m, 2H), 7.15 (m, 4H), 7.10 (m, IH), 6.14 (br s, IH), 4.18 (m, IH), 3.77 (br s, 4H), 3.15 (m, 4H), 2.59 (m, 2H), 2.20 (m, 4H), 2.02 (d, IH), 1.67 (m, (3H), 1.15 (m, IH). EXAMPLE 247A This example was made by substituting methyl-4-fluorobenzoate for ethyl-2,4-difluorobenzoate and cis-octahydropyrrolo[3,4-c]pyrrole for EXAMPLE 227C in EXAMPLE 227D. EXAMPLE 247B This example was made by substituting EXAMPLE 247A for EXAMPLE 1A in EXAMPLE 2A. EXAMPLE 247C This example was made by substituting EXAMPLE 247B for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 247D This example was made by substituting EXAMPLE 247C for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 247E This example was made by substituting EXAMPLE 247D for EXAMPLE 2C in EXAMPLE 2D. 2H NM£ -(500 MHz, CDC13) 5 8.77 (br s, IH), 8.34 (d, IH), 7.96 (d, IH), 7.92 (br s, IH), 7.65 (brs, 2H), 7.49 (m, 4H), 7.38 (br s, 2H), 7.30 (m, 2H) , 7.19 (m, 6H), 6.83 (m, IH), 6.46 (m, 2H), 4.34 (br s, 2H), 3.84 (m, - 369 - WO2005/049594 PCT/US2004/037911 1H), 3.28 (m, 4H), 3.15 (m,.'4H) , 2.80 (m, 6H), 2.41 (br s, 2H) . EXAMPLE 248 A A mixture of 4-chloro-3-nitrobenzenesulfonyl chloride (10 g) , TEA (10.87 niL) , and bis (2, 4-dimethoxybenzyl) amine (12.38 g) in dichloromethane (200 mL) at 25°C was stirred for 12 hours, treated with dichloromethane (200 mL), washed with saturated sodium bicarbonate (100 mL) and brine, and concentrated. EXAMPLE 248B A mixture of EXAMPLE 248A (20.98 g) and 2M methylamine in THF (400 mL) at 80°C was stirred for 4 hours and concentrated. The concentrate was treated with ethyl acetate and saturated sodium bicarbonate. The extract was dried (MgaSO-) , filtered and concentrated. EXAMPLE 248C A mixture of EXAMPLE 248B (1 g) and 3.56 mmol/g polymer-supported N,N-DIEA (2.65 g) in dichloromethane (10 mL) was treated with 20% phosgene in toluene (10.1 mL), heated at 40°C for 24 hours, filtered and concentrated. EXAMPLE 248D A mixture of EXAMPLE 248C (200 mg), TEA (141 uL) and N-methyl-4-trifluoromethoxyphenyl aniline (129 mg) in dichloromethane (2 mL) at 50°C was heated for 12 hours and concentrated. The concentrate was flash chromatographed on silica gel with 70% ethyl acetate/hexane. EXAMPLE 248E - 370 - WO2005/049594 PCT/US2004/037911 EXAMPLE 248D (57 mg) in triethylsilane/TFA/dichloromethane (0.05 irtL/0.45 mL/0.5 mL) was stirred at 25°C for 30 minutes and concentrated. The concentrate was flash chromatographed on silica gel with 80% ethyl acetate/hexane. EXAMPLE 248F This example was made by substituting EXAMPLE 248E for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 5 8.26 (d, IH), 7.80 (d, 2H), 7.72 (br, IH), 7.41 (m, 8H) , 7.28 (d, IH), 6.92 (m, 6H), 4.26 (br, 2H), 3.74 (br, 2H), 3.13 (br, 2H), 2.96 (s, 6H), 2.82 (br, 2H) EXAMPLE 249A This example was made by substituting N-methyl-2-methylanaline for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 249B This example was made by substituting EXAMPLE 249A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 249C This example was made by substituting EXAMPLE 249B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 8.30 (d, IH) , 7.86 (d, IH), 7.83 (d, 2H), 7.75 (br, IH), 7.53 (m, 2H), 7.47 (d, 2H), 7.43 (q, IH), 7.37 (m, 3H) , 7.21 (d, IH), 6.97 (d, 2H), 6.83 (d, IH), 6.74 (t, IH) , 6.64 - 371 - WO2005/049594 PCT/US2004AI37911 (t, IH) , 6.56 (d, IH), 4.31 (br, 2H) , 3.80 (br, 2H) , 3.18 (s, 3H), 3.14 (br, 2H), 2.90 (s, 3H), 2.84 (br, 4H), 1.95 (s, 3H). EXAMPLE 250A This example was made by substituting N-methyl-4-methoxyanaline for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 25OB This example was made by substituting EXAMPLE 250A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 25OC This example was made by substituting EXAMPLE 250B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 5 8.28 (d, IH), 7.86 (dd, IH), 7.81 (d, 2H), 7.73 (br, IH), 7.52 (br, 2H), 7.47 (d, 2H), 7.43 (d, IH), 7.36 (m, 3H) , 7.20 (d, IH), 6.94 (d, 2H), 6.70 (d, 2H), 6.49 (d, 2H), 4.28 (br, 2H), 3.81 (br, 2H), 3.43 (s, 3H), 3.19 (s, 3H), 3.14 (br, 2H), 2.90 (s, 3H), 2.82 (br, 4H). EXAMPLE 251A This example was made by substituting N-methyl-4-methylanaline for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 25IB This example was made by substituting EXAMPLE 251A for EXAMPLE 248D in EXAMPLE 24 8E. - 372 - WO2005/049594 PCT/US2004/037911 EXAMPLE 251 C This example was made by substituting EXAMPLE 251B for 4- (((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 5 8.25 (d, IH), 7.83 (m, 3H), 7.73 (br, IH), 7.52 (m, 2H), 7.47 (d, 2H), 7.42 (d, IH), 7.36 (m, 3H), 7.20 (d, IH) , 6.96 (d, 2H), 6.71 (d, 2H), 6.66 (d, 2H), 4.28 (br, 2H), 3.80 (br, 2H), 3.22 (s, 3H), 3.14 (br, 2H), 2.91 (s, 3H), 2.82 (br, 4H), 1.90 (s, 3H) EXAMPLE 252A This example was made by substituting N-diphenylmethyl methylamine for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 252B This example was made by substituting EXAMPLE 252A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 252C This example was made by substituting EXAMPLE 252B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 8 8.35 (d, IH), 8.15 (dd, IH), 7.74 (dd, 4H), 7.50 (m, 4H), 7.43 (d, IH), 7.36 (m, 6H), 7.29 (m, 2H), 7.16 (d, 4H) , 6.92 (d, 2H), 6.30 (s, IH), 4.33 (br, 2H), 3.84 (br, 4H), 3.25 (s, 3H), 3.13 (br, 3H), 2.82 (br, 2H) , 2.69 (s, 3H) . EXAMPLE 253A - 373 - WO2005/049594 PCT/US2004/037911 This example was made by substituting (S)-(-)-N-methyl-1-phenethylamine for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 253B This example was made by substituting EXAMPLE 253A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 253C This example was made by substituting EXAMPLE 253B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 8 8.38 (d, IH), 8.19 (dd, IH), 7.76 (d, 2H), 7.70 (d, IH), 7.50 (br, 6H) , 7.33 (br, 8H), 6.93 (d, 2H), 5.17 ' (q, IH), 4.37 (br, 2H) 3.84 (br, 2H), 3.26 (s, 3H), 3.11 (br, 4H), 2.84 (br, 2H), 2.61 (s, 3H), 1.46 (d, 3H) EXAMPLE 254A This example was made by substituting 2-(4-methylpiperazinyl)-1-phenethyl methylamine for N-methyl-4-t'rifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 254B This example was made by substituting EXAMPLE 254A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 254C This example was made by substituting EXAMPLE 254B for 4-(((1R)-3-(dimethylamino)- 1- ( (phenylsulfanyl)methyDpropyl) amino) -3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, - 374 - WO2005/049594 PCT/US2004/037911 DMSO-dg) 5 8.37 (d, IH) , 8.20 (dd, IH), 7.76 (d, 3H), 7.65 (d, IH), 7.48 (m, 5H), 7.34 (m, 8H), 6.93 (d, 2H), 5.31 (dd, IH), 4.36 (br, 2H), 3.84 (br, 2H), 3.42 (br, 4H) , 3.30 (s, 3H) , ' 3.07 (br, 8H), 2.86 (m, 2H), 2.80 (s, 3H), 2.75 (s, 3H), 2.33 (m, 2H) . EXAMPLE 255A This example was made by substituting 2-morpholine-4-yl-1-phenethyl methylamine for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 255B This example was made by substituting EXAMPLE 255A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 255C This example was made by substituting EXAMPLE 255B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 8 8.40 (d, IH), 8.15 (dd, IH), 7.76 (m, 3H), 7.66 (d, IH) , 7.47 (m, 13H), 6.93 (d, 2H), 5.57 (br, IH), 4.37 (br, 2H), 3.83 (br, 8H), 3.25 (s, 3H), 3.13 (br, 6H), 2.84 (br, 4H), 2.64 (s, 3H) EXAMPLE 256A This example was made by substituting (1,2-diphenyl-ethyl)methylamine for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 256B - 375 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 256A for EXAMPLE 248D in EXAMPLE 24 8E. EXAMPLE 256C This example was made by substituting EXAMPLE 256B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (400MHz, DMSO-d6) 6 8.33 (d, IH), 8.05 (dd, IH), 7.75 (d, 3H), 7.38 (m, 18H), 7.22 (m, IH), 6.92 (d, 2H), 5.58 (dd, IH), 4.32 (br, 2H) , 3.65 (br, 6H), 3.40 (dd, IH), 3.22 (dd, IH) , 3.10 (br, 2H), 2.69 (s, 3H), 2.66 (s, 3H) EXAMPLE 257A This example was made by substituting (2-(methylamino)-2-phenylethyl)dimethylamine for N-methyl-4-trifluoromethoxyaniline in EXAMPLE 248D. EXAMPLE 257B This example was made by substituting EXAMPLE 257A for EXAMPLE 248D in EXAMPLE 248E. EXAMPLE 257C This example was made by substituting EXAMPLE 257B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. IH NMR (500MHz, DMSO-d6) 5 8.39 (d, IH), 8.12 (dd, IH), 7.74 (d, 3H), 7.64 (d, IH), 7.40 (m, 13H), 6-91 (d, 2H), 5.54 (dd, IH), 4.00 (br, 8H), 3.25 (s, 3H), 3.14 (br, 2H), 2.69 (s, 6H), 2.61 (s, 3H) EXAMPLE 258 - 376 - WO2005/049594 PCT/US2004/037911 A mixture of EXAMPLE 10 (400 mg) and 30% Pd/C (120 mg) in 1:1 methanol/ethyl acetate (10 mL) at 25°C was stirred under H2 (balloon) for 2 hours and filtered. The filtrate was concentrated and flash chromatographed on silica gel with 40% acetonitrile/dichloromethane. IH NMR (500MHz, CDC13) 8 7.87 (br, IH), 7.64 (m, 2H), 7.40 (m, 6H), 7.17 (m, 8H) , 6.38 (br, IH), 5.17 (br, 4H), 4.29 (s, 2H), 3.30 (m, 4H), 2.95 (s, 2H), 2.49 (br, 2H) EXAMPLE 259 A mixture of EXAMPLE 258 (50 mg) and sodium nitrite (7.2 mg) in water/hydrochloric acid/acetic acid (0.38 mL/0.562 mL/2 mL) at 0°C was stirred for 2 hours and concentrated. The concentrate in 1:1 DMSO/methanol (10.5 mL) and purified by HPLC with 0-70% acetonitrile/ water with 0.1% TFA. 1H NMR (500MHz, CDC13) 8 8.75 (s, IH) , 8.23 (dd, IH), 7.78 (dd, IH), 7.69 (d, 2H), 7.49 (m, 3H), 7.42 (d, 2H), 7.30 (m, IH) , 7.26 (m, 2H), 7.19 (m, 5H), 5.66 (d, 2H) , 4.82 (t, 2H), 4.39 (s, 2H), 3.50 (t, 2H), 3.42 (br, 8H) EXAMPLE 260 EXAMPLE 258 (60 mg) in formic acid (2 mL) was heated at 100°C for 3 hours, and concentrated. The concentrate was purified by HPLC with 0-70% acetonitrile/water with 0.1% TFA. IH NMR (400MHz, CDC13) 8 8.53 (s, IH) , 8.46 (s, IH), 8.13 (d, IH), 7.75 (dd, IH), 7.62 (d, 2H), 7.46 (m, 4H), 7.30 (dd, IH) , 7.16 (m, 8H), 6.63 (d, 2H), 4.48 (t, 2H) , 4.35 (s, 2H) , 3.42 (br, 4H), 3.35 (t, 2H), 3.00 (br, 4H) . EXAMPLE 261 This example was made by substituting EXAMPLE 9OC and 4-(cyclohexylmethylamino)-3-nitrobenzenesulfonamide, prepared as - 377 - WO2005/049594 PCT/US2004/037911 described in WO02/24636, for EXAMPLE 1C and 4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrbbenzenesulfonamide, respectively, in EXAMPLE ID. 1H NMR (300 MHz, DMSO-d6) 5 11.95 (m, IH), 8.61 (m, IH), 7.91 (dd, IH), 7.67 (d, 2H), 7.44 (m, IH), 7.39 (m, IH), 7.34 (m, 2H), 7.30 (m, 2H), 7.27 (m, 2H), 7.22 (m, IH), 7.16 (m, IH), 6.80 (m, 2H), 3.38 (m, 2ti); 3.27 (m, 3H), 3.03 (s, 3H) , 2.89 (s, i 2H), 2.84 (m, IH), 2.76 (m, IH), 1.77 (m, IH) , 1.66 (m, 5H) , 1.47 (m, 2H), 1.08 (m, 7H). EXAMPLE 262 This example was made by substituting EXAMPLE 9OC and 4-(cyclohexylamino)-3-nitrobenzenesulfonamide, prepared as described in WO02/24636, for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino) -1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, DMSO-d6) 5 8.62 (d, IH), 8.31 (d, IH), 7.92 (dd, IH), 7.66 (d, 2H), 7.34 (m, 9H), 7.15 (m, IH), 6.79 (d, 2H), 3.71 (m, IH), 3.39 (d, 2H), 3.02 (m, 3H), 2.84 (m, 4H), 1.94 (m, 2H), 1.65 (m, 3H), 1.30 (m, 9H). EXAMPLE 263 This example was made by substituting EXAMPLE 9OC and 4- ((1,l-dimethyl-2-(phenylsulfanyl)ethyl)amino)-3-nitrobenzenesulfonamide, prepared as described in WO02/24636, for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1- ((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, DMSO-d6) 5 11.96 (m, IH) , 8.51 (m, 2H) , 7.82 (dd, IH), 7.71 (d, 2H), 7.33 (m, 11H), 7.15 (m, IH), 7.00 (m, 2H), 6.92 (m, IH), 6.82 (d, 2H), 3.54 (s, 2H), 3.40 (m, 2H) , 3.03 - 378 - WO2005/049594 PCT/LS2004/037911 (s, 3H), 2.85 (m, 4H), 1.57 (s, 6H), 1.46 (m, 2H), 1.17 (m, 2H) . EXAMPLE 264A A mixture of thiophenol (0.2 mL), (1-amino-cyclopentyl)methanol (0.2 g), tributylphosphine (0.5 mL), and THF (30 mL) at 0°C was treated with ADDP (0.482g), stirred for 1 hour, stirred at 25°C for 18 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes and 5% methanol/dichloromethane. EXAMPLE 264B This example was prepared by substituting EXAMPLE 264A for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 264C This example was made by substituting EXAMPLE 264B for 4-(((lR)-3-(dimethylamino)- ‘ 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, DMSO-d6) 5 9.50 (s, IH) , 8.42 (s, IH), 8.35 (d, IH), 7.74 (m, • 4H), 7.39 (m, 8H), 7.11 (m, 3H), 6.79 (m, 5H), 4.33 (s, IH), 3.81 (s, IH), 3.50 (s, 2H), 3.07 (m, 4H), 2.35 (m, 4H), 1.98 (m, 4H), 1.64 (m, 4H). EXAMPLE 265 This example was made by substituting EXAMPLE 9OC and EXAMPLE 264B for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, DMSO-d6) 8 11.96 (s, IH), 8.49 (s, IH), 8.41 (d, IH), 7.82 (dd, IH), 7.73 (d, IH), 7.34 (m, 8H), 7.16 (m, 4H), 6.83 - 379 - WO2005/049594 PCT7US2004/037911 (m, 5H), 3.57 (s, 2H), 3.31 (s, 2H) , 3.02 (s, 3H) , 2.85 (m, 4H), 2.11 (m, 2H), 1.99 (m, 2H), 1.71 (m, 4H) , 1.47 (m, 2H), 1.18 (m, 2H). EXAMPLE 266 This example was made by substituting EXAMPLE 264B for 4-(((1R)-3-(dimethylamino) - 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. , 1H NMR (300 MHz, CD3OD) 8 8.52 (d, IH), 7.85 (m, 3H), 7.72 (m, IH), 7.58 (m, 2H), 7.51 (d, 2H) , 7.42 (m, IH), 7.35 (d, 2H), 7.12 (m, 2H), 6.99 (m, 3H), 6.72 (m, 3H), 4.46 (s, 2H), 3.50 (s, 2H), 3.31 (m, 4H), 3.17 (m, 4H), 2.13 (m, 4H), 1.80 (m, 4H). EXAMPLE 267A A mixture of (S)-2-aminobutan-l-ol (1 g) , tributylphosphine (3 mL) and phenyl disulfide (2.64 g) in toluene (20 mL) at 85°C was stirred for 16 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 1% methanol/dichloromethane. EXAMPLE 267B This example was prepared by substituting EXAMPLE 267A for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 267C This example was made by substituting EXAMPLE 267B for 4-(((1R)-3-(dimethylamino) - 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1HNMR (300 MHz, CD3OD) 5 8.30 (d, IH), 7.90 (dd, IH), 7.75 (d, 2H), 7.52 (m, IH), 7.38 (m, 6H), 7.24 (m, 3H) , 7.05 (m, 2H), 6.96 (d, IH) , 6.90 - 380 - WO2005/049594 PCT/US2004/037911 (d, 2H), 3.95 (m, IH) , 3.54 (s, 2H), 3.27 (m, 4H), 2.51 (ra, 4H), 1.81 (m, 2H), 1.00 (t, 3H). EXAMPLE 268 This example was made by substituting EXAMPLE 9OC and EXAMPLE 267B for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, CDC13) 5 8.79 (s, IH) , 8.37 (m, IH), 8.01 (d, IH), 7.57 (m, 2H), 7.35 (m, 1OH), 7.19 (m, 4H), 6.72 (d, 2H), 6.64 (d, IH) , 3.72 (m, IH), 3.36 (m, 2H), 3.13 (m, 5H), 2.99 (m, IH), 2.92 (s, 3H), 1.92 (m, IH), 1.58 (m, 3H), 1.31 (m, 2H), 0.98 (t, 3H). EXAMPLE 269 This example was made by substituting EXAMPLE 267B for 4-( ((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, CDC13) 6 8.80 (s, IH), 8.42 (m, IH), 8.03 (dd, IH), 7.67 (m, 3H) , 7.36 (m, 1OH), 7.19 (m, 3H), 6.74 (d, 2H), 6.65 (d, IH), 3.64 (m, 3H) , 3.31 (m, 4H), 3.11 (s, 2H), 2.53 (m, 4H), 1.69 (m, 2H), 0.98 (t, 3H). EXAMPLE 270A This example was prepared by substituting (S)- 2-amino-4-methyl-pentan-1-ol for (S)-2-Amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 270B This example was prepared by substituting EXAMPLE 270A for EXAMPLE 21C in EXAMPLE 21D. - 381 - WO2005/049594 PCT/LS2004/037911 EXAMPLE 27OC This example was made by substituting EXAMPLE 270B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.80 (d, IH), 8.38 (d, IH), 8.00 (dd, IH) , 7.63 (d, 2H), 7.49 (m, IH), 7.35 (m, 8H) , 7.22 (m, 4H), 6.79 (d, 2H), 6.60 (d, IH), 3.85 (m, IH), 3.42 (s, 2H), 3.28 (m, 4H), 3.09 (d, 2H), 2.47 (m, 4H), 1.73 (m, 3H), 0.96 (d, 3H), 0.86 (d, 3H). EXAMPLE 271 This example was made by substituting EXAMPLE 9OC and EXAMPLE 270B for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, CDC13) 8 8.77 (d, IH) , 8.36 (d, 2H), 7.98 (dd, IH), 7.60 (d, 2H), 7.35 (m, 9H), 7.20 (m, 4H), 6.64 (m, 3H), 3.80 (m, IH), 3.34 (s, 2H), 3.12 (s, 3H), 3.07 (m, 2H), 2.92 (m, 4H), 1.57 (m, 5H), 1.30 (m, 2H), 0.95 (d, 3H), 0.85 (d, 3H) . EXAMPLE 272A 1-Tert-butoxycarbonylaminocyclopropane carboxylic acid (1.018 g) in THF (6 mL) at 0°C was treated with IM borane-THF (15 mL), stirred at 25°C, treated with 3M NaOH, (5 mL), and extracted with diethyl ether. The extract was dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 272B This example was prepared by substituting EXAMPLE 272A for (S)-2-amino-butan-l-ol in EXAMPLE 267A. - 382 - WO2005/049594 PCT/US2004/037911 EXAMPLE 272C 272B (0.090 g) in dichloromethane/TFA at 25°C was stirred for 16 hours and concentrated. The concentrate was flash chromatographed on silica gel with 5% methanol/dichloromethane. EXAMPLE 272 D This example was prepared by substituting EXAMPLE 272C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 272E This example was made by substituting EXAMPLE 272D for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 6 8.74 (d, IH) , 8.60 (s, IH), 8.14 (dd, IH) , 7.63 (d, 2H), 7.49 (m, IH), 7.35 (m, 6H), 7.25 (m, 3H) , 7.06 (m, 3H) , 6.80 (d, 2H) , 3.41 (s, 2H), 3.28 (m, 4H), 3.22 (s, 2H) , 2.47 (m, ■ 4H) , 1.01 (m, 4H). EXAMPLE 273A This example was prepared by substituting (1-hydroxymethyl-cyclohexyl)carbamic acid tert-butyl ester, prepared as described in Bioorg. Med. Chem. Lett., 2003; 13; 1883, for (S)-2-amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 273B This example was prepared by substituting EXAMPLE 273A for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 273C - 383 - WO2005/049594 PCT/US2004/037911 This example was prepared by substituting EXAMPLE 273B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 273D This example was made by substituting EXAMPLE 273C for 4-(((1R) -3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.71 (s, IH), 8.63 (s, IH), 7.92 (d, IH), 7.68 (m, 2H) , 7.47 (m, 5H), 7.32 (m, IH), 7.20 (m, 4H), 6.94 (m, 6H), 6.78 (m, IH), 4.38 (s, 2H), 3.56 (m, 4H) , 3.38 (s, 2H), 2.31 (m, 4H), 1.47 (m, 1OH). EXAMPLE 274A This example was prepared by substituting (R)-2-amino-propan-1-ol for (S)-2-amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 274B This example was prepared by substituting EXAMPLE 274A for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 274C This example was made by substituting EXAMPLE 274B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 8 8.80 (br s, IH), 8.42 (br s, IH), 8.03 (d, IH), 7.65 (d, 2H), 7.50 (m, IH), 7.34 (m, 9H), 7.22 (m, 3H), 6.77 (d, 2H) , 6.63 (m, IH), 3.88 (m, IH), 3.42 (s, 2H), 3.26 (m, 4H), 3.10 (d, 2H), 2.48 (m, 4H), 1.43 (d, 3H). EXAMPLE 275A - 384 - WO2005/049594 PCT/US2004/037911 This example was prepared by substituting (S)-2-amino-propan-1-ol for (S)-2-amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 275B This example was prepared by substituting EXAMPLE 275A for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 275C This example was made by substituting EXAMPLE 275B for 4-(( (lR)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, CDC13) S 8.82 (d, IH), 8.45 (d, IH), 8.04 (dd, IH), 7.64 (d, 2H) , 7.56 (m, IH), 7.35 (m, 1OH) , 7.20 (m, 3H), 6.77 (d, 2H) , 6.65 (d, IH) , 3.91 (m, IH), 3.51 (s, 2H), 3.27 (t, 4H), 3.12 (m, 2H), 2.48 (t, 4H), 1.45 (d, 3H). EXAMPLE 276A This example was prepared by substituting (1R, 2R)-(2-hydroxycyclohexyl)carbamic acid tert-butyl ester, prepared as described in Synth.Commun. 1992, 22, 3003, for (S)-2-amino-butan-l-ol in EXAMPLE 267A. This example was prepared by substituting EXAMPLE 27 6A for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 276C This example was prepared by substituting EXAMPLE 276B for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 27 6D - 385 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 276C for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, CDC13) 5 8.92 (s, IH), 8.78 (s, IH), 8.07 (d, IH), 7.61 (m, 3H), 7.35 (m, 1OH), 7.09 (m, 3H), 6.76 (m, 3H), 3.84 (s, IH), 3.65 (s, IH), 3.48 (m, 2H), 3.25 (m, 4H), 2.47 (m, 4H), 1.73 (m, 8H). EXAMPLE 277 This example was made by substituting EXAMPLE 276C for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.92 (d, IH) , 8.80 (d, IH), 8.08 (dd, IH), 7.66 (d, 2H), 7.53 (m, IH) , 7.35 (m, 8H), 7.23 (m, IH), 7.11 (m, 3H), 6.78 (m, 3H), 3.87 (m, IH), 3.65 (m, IH), 3.46 (s, 2H), 3.28 (m, 4H), 2.49 (m, 4H), 1.75 (m, 8H). EXAMPLE 278A This example was prepared by substituting (lS,2R)-(2-hydroxycyclohexyl)carbamic acid tert-butyl ester, prepared as described in Eur. J. Org. Chem., 1998, 9, 1771, for (S)-2-amino-butan-1-ol in EXAMPLE 267A. EXAMPLE 278B This example was prepared by substituting EXAMPLE 278A for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 278C This example was prepared by substituting EXAMPLE 278B for EXAMPLE 21C in EXAMPLE 21D. - 386 - WO2005/049594 PCT/CS2004/037911 EXAMPLE 278D This example was made by substituting EXAMPLE 278C for 4-(((lR)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1ti NMR (300 MHz, CDC13) 8 8.93 (d, IH), 8.80 (d, IH), 8.09 (dd, IH), 7.64 (d, 2H), 7.53 (m, IH), 7.35 (m, 8H), 7.12 (m, 3H), 6.80 (m, 3H) , 3.87 (m, IH), 3.66 (m, IH), 3.50 (s, 2H), 3.32 (m, 4H), 2.50 (m, 4H), 1.85 (m, 8H). EXAMPLE 279A This example was prepared by substituting S-(l-hydroxymethyl-2-pyridin-3-yl-ethyl)-carbamic acid tert-butyl ester for (S)-2-amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 279B This example was prepared by substituting EXAMPLE 27 9A for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 279C This example was prepared by substituting EXAMPLE 27 9B for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 279D This example was made by substituting EXAMPLE 795333C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, CDC13) 5 8.74 (d, IH), 8.48' (m, 3H), 7.97 (dd, IH), 7.64 (d, 2H), 7.53 (m, 2H), 7.37 (m, 9H), 7.23 (m, 5H), 6.75 (d, 2H), 6.53 (d, IH), 4.00 (m, IH), 3.50 (s, 2H), 3.26 (m, 5H), 3.13 (d, 2H), 2.98 (m, IH) , 2.48 (m, 4H). - 387 - WO2005/049594 PCT/US2004/037911 EXAMPLE 280 This example was made by substituting EXAMPLE 9OC and EXAMPLE 279C for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE ID. 1H NMR (300 MHz, CDC13) 8 8.90 (s, IH) , 8.62 (s, IH), 8.53 (s, IH), 8.45 (d, IH), 8.15 (d, IH), 7.81 (d, IH), 7.69 (m, 3H) , 7.34 (m, 9H), 7.19 (m, 4H), 6.90 (d, 2H), 6.54 (d, IH), 4.18 (m, IH), 3.34 (m, 6H), 3.12 (s, 3H), 3.04 (m, 2H), 2.94 (s, 2H) , 1.61 (m, 2H), 1.45 (m, 2H). EXAMPLE 281 This example was made by substituting EXAMPLE 278C for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (300 MHz, CDC13) 8 8.95 (d, IH), 8.79 (d, IH), 8.06 (dd, IH), 7.69 (m, 3H), 7.41 (m, 8H), 7.24 (m, IH), 7.11 (m, 3H), 6.80 (d, IH), 6.74 (d, 2H), 3.86 (m, IH), 3.66 (m, IH), 3.29 (m, 8H), 2.52 (s, 2H), 2.07 (m, IH) , 1.81 (m, 5H), 1.51 (m, 2H). EXAMPLE 282A This example was prepared by substituting (1-amino-cyclopentyl)-methanol and bis(2-methyl-3-furyl)disulphide for (S)-2-amino-butan-l-ol and phenyl disulphide, respectively, in EXAMPLE 267A. EXAMPLE 282B This example was prepared by substituting EXAMPLE 282A for EXAMPLE 21C in EXAMPLE 21D. - 388 - WO2005/049594 PCT/US2004/037911 EXAMPLE 282C This example was made by substituting EXAMPLE 282B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500 MHz, CDC13) 5 8.82 (d, IH) , 8.68 (s, IH), 8.06 (dd, IH), 7.65 (d, 2H), 7.53 (m, IH), 7.33 (m, 7H), 6.91 (m, IH) , 6.88 (s, IH), 6.78 (d, 2H), 5.99 (d, IH) , 3.47 (s, 2H), 3.26 (m, 4H), 3.18 (s, 2H), 2.46 (m, 4H), 2.14 (br s, 3H), 2.08 (m, 4H), 1.78 (m, 4H) . EXAMPLE 283 This example was made by substituting EXAMPLE 282B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. - NMR (500 MHz, CDC13) 5 8.82 (d, IH), 8.68 (s, IH), 8.07 (dd, IH) , 7.65 (d, 2H), 7.49 (m, IH), 7.34 (m, 6H), 7.23 (m, IH), 6.90 (m, 2H) , 6.79 (d, 2H), 6.00 (d, IH), 3.41 (s, 2H), 3.26 (m, 4H), 3.18 (s, 2H), 2.46 (m, 4H), 2.14 (s, 3H), 2.08 (m, 4H), 1.78 (m, 4H). EXAMPLE 284 This example was made by substituting EXAMPLE 279C for 4-( ((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.76 (d, IH), 8.50 (m, 3H), 7.98 (dd, IH), 7.62 (d, 2H), 7.50 (m, 2H), 7.35 (m, 8H), 7.21 (m, 4H), 6.78 (d, 2H), 6.53 (d, IH), 4.01 (m, IH), 3.42 (s, 2H), 3.27 (m, 5H), 3.13 (d, 2H), 2.99 (m, IH), 2.48 (m, 4H). EXAMPLE 285A - 389 - WO2005/049594 PCT/US2004/037911 This example was made by substituting 2-bromo-3-bromomethylpyridine, prepared as described in J. Am. Chem. Soc, 1985, 107, 7487, for 2-bromobenzyl bromide in EXAMPLE 2A. EXAMPLE 285B This example was made by substituting EXAMPLE 285A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 285C This example was made by substituting EXAMPLE 285B for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 285D This example was made by substituting EXAMPLE 285C for EXAMPLE 1C in EXAMPLE ID. 1H NMR (300 MHz, DMSO-d6) 5 12.10 (s, IH), 8.70 (m, IH), 8.54 (d, IH), 8.29 (d, IH), 8.11 (m, IH), 7.86 (dd, IH), 7.76 (d, 2H), 7.58 (m, 5H), 7.16 (m, 6H), 6.94 (d, 2H) , 4.19 (m, IH), 3.54 (m, 4H), 3.39 (d, 2H), 3.13 (m, 4H), 2.75 (s, 3H), 2.74 (s, 3H) , 2.49 (m, 4H), 2.14 (m, 2H) . EXAMPLE 286 This example was made by substituting EXAMPLE 285C and 3-nitro-4-(2-phenylsulfanylethylamino)benzenesulfonamide, prepared as described in WO02/24636, For EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)-1- ( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR (300 MHz, CDC13) 6 8.83 (d, IH), 8.78 (d, IH), 8.67 (t, IH), 8.34 (d, IH) , 8.10 (dd, IH), 7.67 (d, IH), 7.52 (m, 3H) , 7.41 (m, 4H), 7.30 (m, 2H), 7.23 (m, IH), 6.82 (d, IH), 6.73 (d, - 390 - WO2005/049594 PCT/US2004/037911 2H), 4.35 (s, 2H), 3.57 (q, 2H), 3.47 (m, 4H), 3.20 (t, 2H) , 2.97 (m, 4H). EXAMPLE 287 This example was made by substituting EXAMPLE 285C and 4-(((1R)-3-(4-morpholinyl)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino) -3- nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (300 MHz, DMSO-d6) 6 8.70 (d, IH), 8.55 (d, IH), 8.30 (d, IH), 8.12 (m, IH), 7.87 (dd, IH), 7.76 (d, 2H), 7.57 (m, 5H), 7.16 (m, 6H), 6.94 (d, 2H), 4.19 (m, IH), 3.97 (d, 2H) , 3.58 (m, 7H), 3.38 (m, 5H), 3.19 (m, 4H), 3.01 (m, 4H),2.17 (m, 2H). EXAMPLE 288A This example was made by substituting phenylboronic acid and EXAMPLE 285A for 4-chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 288 This example was made by EXAMPLE 288A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 288C This example was made by substituting EXAMPLE 288B and 3-nitro-4-(2-phenylsulfanylethylamino)-benzenesulfonamide, prepared as described in WO02/24 636, for EXAMPLE 1C and 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE ID. H NMR - 391 - WO2005/049594 PCT/US2004/037911 (300 MHz, CDC13) 8 8.86 (d, IH) , 8.65 (m, 2H) , 8.14 (dd, l'H) , 7.91 (m, IH) , 7.60 (m, 4H), 7.43 (m, 5H), 7.28 (m, 4H), 6.80 (m, 3H), 3.56 (m, 4H), 3.31 (m, 4H), 3.21 (t, 2H), 2.51 (m, 4H) . EXAMPLE 289 This example was made by substituting EXAMPLE 288B and 4-(((lR)-3-(4-morpholinyl)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. lH NMR (300 MHz, CD3OD) 8 8.67 (d, IH), 8.49 (dd, IH), 8.07 (dd, IH), 7.88 (dd, IH), 7.78 (d, 2H), 7.48 (m, 6H),-7.26 (m, 2H), 7.12 (m, 3H), 6.95 (d, IH), 6.88 (d, 2H), 4.14 (m, IH), 3.66 (m, 4H), 3.53 (m, 2H), 3.25 (m, 6H), 2.51 (m, 1OH) , 2.13 (m, IH) , 1.92 (m, IH) . EXAMPLE 290 This example was made by substituting EXAMPLE 288B for EXAMPLE 2C in EXAMPLE 2D. 1R NMR (400 MHz, DMSO-d6) 8 8.56 (dd, IH), 8.44 (d, IH), 8.31 (d, IH), 7.94 (dd, IH), 7.79 (dd, IH) ,. 7.72 (d, 2H), 7.62 (m, 2H) , 7.43 (m, 5H) , 7.32 (m, 2H) , 7.25 (m, 2H), 7.17 (m, IH), 6.87 (d, IH), 6.79 (d, 2H), 4.05 (m, IH), 3.50 (s, 2H), 3.30 (m, 2H), 3.16 (s, 4H) , 2.43 (m, 4H), 2.35 (m, 6H), 2.01 (m, IH), 1.91 (m, IH). EXAMPLE 291A This example was made by substituting 4-(methylsulfanyl)phenylboronic acid and EXAMPLE 2 85A for 4- - 392 - WO2005/049594 PCT/US2004/037911 chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 29IB This example was made by substituting EXAMPLE 291A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 291C This example was made by substituting EXAMPLE 291B for EXAMPLE 2C in EXAMPLE 2D. XH NMR (300 MHz, CD3OD) 8 8.74 (dd, IH), 8.67 (d, IH), 8.42 (dd, 1H),'7.93 (dd, IH) , 7.74 (m, 3H) , 7.50 (d, 2H), 7.44 (d, 2H), 7.22 (m, 2H), 7.04 (m, 4H), 6.94 (d, 2H), 4.36 (s, 2H), 4.17 (m, IH), 3.43 (m, 5H), 3;24 (m, 3H), 3.04 (t, 4H), 2.87 (s, 6H), 2.51 (s, 3H), 2.24 (m, 2H). EXAMPLE 292A This example was made by substituting 4-methoxyphenylboronic acid and EXAMPLE 285A for 4-chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 292B This example was made by substituting EXAMPLE 292A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 292C This example was made by substituting EXAMPLE 292B for-EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 5 8.55 (dd, IH), 8.45 (d, IH), 8.33 (d, IH), 7.91 (dd, IH), 7.78 (dd, IH), 7.73 (d, 2H), 7.63 (d, 2H), 7.33 (m, 3H), 7.21 (m, 3H), 7.01 (d, 2H), 6.86 (d, IH), 6.80 (d, 2H), 4.04 (mf IH) , 3.79 - 393 - WO2005/049594 PCT/US2004/037911 (s, 3H), 3.50 (s, 2H), 3.18 (s, 4H), 3.00 (d, 2H) , 2.68 (ra, 2H), 2.45 (m, 4H), 2.33 (s, 6H), 1.95 (m, 2H). EXAMPLE 293A This example was made by substituting 4-dimethylaminophenylboronic acid and EXAMPLE 285A for 4-chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 293B This example was made by substituting EXAMPLE 293A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 293 This example was made by substituting EXAMPLE 293B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, CD3OD) 8 8.66 (d, IH), 8.46 (dd, IH), 8.08 (dd, IH) , 7.94 (dd, IH) , 7.75 (d, 2H), 7.42 (m, 3H), 7.24 (m, 2H), 7.08 (m, 3H), 6.96 (d, IH) , 6.91 (d, 2H), 6.84 (d, 2H), 4.14 (m, IH), 3.64 (s, 2H), 3.38 (m, 4H), 3.23 (m, 4H), 3.00 (s, 6H) , 2.86 (s, 7H), 2.54 (m, 4H), 2.22 (m, 2H). EXAMPLE 294A This example was made by substituting 4-fluorophenylboronic acid and EXAMPLE 285A for 4-chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 294B This example was made by substituting EXAMPLE 294A for EXAMPLE 2B in EXAMPLE 2C. - 394 - WO2005/049594 PCT/US2004/037911 EXAMPLE 294 This example was made by substituting EXAMPLE 294B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, CD3OD) 8 8.74 (dd, IH), 8.67 (d, IH), 8.37 (dd, IH), 7.93 (dd, IH), 7.73 (m, 3H), 7.60 (m, 2H), 7.31 (m, 2H), 7.22 (m, 2H), 7.03 (m, 4H), 6.95 (d, 2H), 4.39 (s, 2H), 4.17 (m, IH), 3.47 (m, 4H), 3.38 (m, IH), 3.23 (m, 3H), 3.08 (m, 4H), 2.86 (s, 6H), 2.24 (m, 2H). EXAMPLE 295A This example was made by substituting 4-(methanesulphonyl)phenylboronic acid and EXAMPLE 285A for 4-chlorophenylboronic acid and EXAMPLE 2A, respectively, in EXAMPLE 2B. EXAMPLE 295B This example was made by substituting EXAMPLE 295A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 295C This example was made by substituting EXAMPLE 295B for EXAMPLE 2C in EXAMPLE 2D. XR NMR (300 MHz, CDC13) 8 8.62 (m, 3H), 8.02 (d, 2H) , 7.89 (m, 3H), 7.80 (m, 3H), 7.32 (m, 3H), 7.19 (m, 3H), 6.73 (m, 3H), 4.06 (m, IH), 3.46 (s, 2H) , 3.24 (m, 4H), 3.12 (d, 2H), 2.85 (m, 3H), 2.59 (s, 6H) , 2.51 (m, 5H), 2.19 (m, IH), 2.08 (m, IH). EXAMPLE 205A This example was made by substituting 2-bromoethylamine hydrobromide for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 296A - 395 - WO2005/049594 PCT/US2004/037911 This example was made by substituting pyridin-4-yl-methanethiol for 2-mercaptoimidazole in EXAMPLE 205B. EXAMPLE 296B This example was made by substituting 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide for 4-(((IR)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.87 (d, IH), 8.62 (m, IH), 8.42 (d, 2H), 8.19 (dd, IH), 7.62 (d, 3H), 7.35 (m, 7H), 7.15 (d, 2H), 6.92 (d, IH), 6.77 (d, 2H), 3.70 (q, 2H) , 3.54 (s, 2H), 3.32 {m, 6H), 2.53 (m, 4H) . EXAMPLE 297A This example was made by substituting 4-(methanesulphonyl)phenylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. EXAMPLE 297B This example was made by substituting EXAMPLE 297A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 297C This example was made by substituting EXAMPLE 297B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 6 8.66 (d, IH), 8.57 (d, IH), 7.96 (d, 2H), 7.80 (m, 3H), 7.66 (d, 2H), 7.49 (m, IH), 7.38 (m, 2H), 7.29 (m, 2H), 7.19 (m, 4H), 6.71 (m, 3H), 4.04 (m, IH), 3.38 (s, 2H) , 3.18 (m, 4H), 3.10 (m, 6H), 2.85 (m, 2H), 2.58 (s, 6H), 2.45 (m, 4H), 2.20 (m, IH), 2.07 (m, IH). EXAMPLE 2 98 - 396 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 297B and 4-(((lR)-3-(4-morpholinyl)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 6 8.55 (d, IH) , 8.29 (d, IH), 8.01 (d, 2H), 7.87 (dd, IH), 7.76 (d, 2H), 7.67 (d, 2H), 7.55 (m, 2H) , 7.37 (d, IH), 7.23 (m, 2H), 7.15 (m, 4H), 6.93 (s, 2H), 4.19 (m, IH), 3.95 (s, 2H), 3.54 (m, 12H), 3.40 (d, 2H), 3.26 (s, 3H), 3.19 (m,.4H), 3.02 (m, 2H), 2.17 (m, 2H). EXAMPLE 299A EXAMPLE 19C (0.938 g) in dichloromethane (10 mL) at 25°C was treated with di(tert-butyl) dicarbonate (0.873 g) , stirred for 24 hours, and concentrated. The concentrate was flash chromatographed on silica gel with 20-60% ethyl acetate/hexanes. EXAMPLE 299B This example was prepared by substituting EXAMPLE 299A for EXAMPLE 67A in EXAMPLE 67B. EXAMPLE 299C This example was prepared by substituting EXAMPLE 299B for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 299D This example was prepared by substituting EXAMPLE 299C for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 299E - 397 - WO2005/049594 PCT/US2004/037911 EXAMPLE 299D (0.485 g) at 25°C was treated with 1M borane-THF (8 mL), stirred for 16 hours, treated with methanol (5 mL), and concentrated. The concentrate was refluxed in methanol/12M HC1 (30 mL/6 mL) for 8 hours and concentrated. The concentrate was flash chromatographed on silica gel with 1-20% methanol/NH3-saturated dichloromethane. EXAMPLE 299F This example was prepared by substituting EXAMPLE 299E for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, CDC13) 5 8.80 (d, 1H), 8.41 (d, 1H), 8.07 (dd, 1H), 7.77 (d, 2H), 7.63 (dd, 3H), 7.46 (m, 3H), 7.34 (m, 6H), 7.24 (m, 1H) , 7.00 (d, 1H) , 6.78 (d, 2H), 4.54 (m, 1H), 3.69 (mr 4H) , 3.45 (d, 2H) , 3.41 (s, 2H), 3.26 (m, 4H), 2.47 (m, 6H), 2.34 (m, 3H), 2.20 (m, 2H), 1.86 (m, 2H). EXAMPLE 300A This example was made by substituting 4-dimethylaminophenylboronic acid for 4-chlorophenylboronic acid in EXAMPLE 2B. EXAMPLE 300B This example was made by substituting EXAMPLE 300A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 30OC This example was made by substituting EXAMPLE 300B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 8.46 (d, 1H), 8.20 (d, 1H), 7.81 (dd, 1H), 7.72 (m, 2H), 7.50 (m, 1H), 7.30 (m, 6H), 7.24 (m, 4H), 6.90 (d, 1H), 6.79 (m, 4H) , 4.07 (m, 1H), 3.43 (s, .2H) , 3.21 (m, 8H) , 2.92 (s, 6H), 2.56 (s, 6H), 2.43 (m, 4H), 2.05 (m, 2H). - 398 - WO2005/049594 PCT/US2004/037911 EXAMPLE 301A This example was prepared by substituting EXAMPLE 18C for EXAMPLE 19C in EXAMPLE 299A. EXAMPLE 30IB This example was prepared by substituting EXAMPLE 301A for EXAMPLE 67A in EXAMPLE 67B. EXAMPLE 301C This example was prepared by substituting EXAMPLE 301B for EXAMPLE 272B in EXAMPLE 272C. EXAMPLE 30ID This example was prepared by substituting EXAMPLE 301C for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 30IE This example was made by substituting EXAMPLE 301D for 4- (((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 5 8.51 (m, 2H), 7.90 (dd, IH), 7.76 (d, 2H), 7.58 (dd, 2H), 7.50 (m, 6H), 7.38 (m, 4H), 7.23 (m, 2H), 6.90 (d, 2H), 4.70 (m, IH), 4.17 (m, IH), 3.76 (m, IH), 3.43 (s, 2H), 3.25 (m, 4H), 2.94 (m, IH) , 2.88 (s, 3H) , 2.77 (m, 4H) , 2.42 (m, 4H) . EXAMPLE 302A This example was prepared by substituting 3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester, - 399 - WO 2005/(149594 PCT7US2004/037911 prepared as described in J. Org. Chem., 1997, 62, 4197, for (S)-2-amino-butan-l-ol in EXAMPLE 267A. EXAMPLE 302B This example was made by substituting EXAMPLE 302A for EXAMPLE 21C in EXAMPLE 2ID. EXAMPLE 302C This example was made by substituting EXAMPLE 302B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 302D This example was prepared by substituting EXAMPLE 302C for EXAMPLE 272B in EXAMPLE 272C. 1H NMR (300 MHz, CD3OD) 8 8.78 (d, IH), 7.94 (dd, IH), 7.74 (m, 3H), 7.55 (m, 7H), 7.36 (m, 7H), 6.96 (d, 2H), 6.75 (d, IH), 4.51 (m, IH), 4.44 (s, 2H), 4.02 (m, 2H), 3.86 (q, IH), 3.49 (m, 2H), 3.43 (m, 2H), 3.35 (m, 2H), 3.14 (m, 4H). EXAMPLE 303 This example was made by substituting pyridine-4-thioi for isopropylamine in EXAMPLE 35B. 1H NMR (400 MHz, CD3OD) 6 8.64 (m, IH), 8.23 (m, 2H), 7.83 (m, 3H), 7.50 (m, IH), 7.36 (m, 7H), 7.23 (m, 5H), 7.11 (m, 3H), 6.85 (d, 2H), 6.78 (d, IH), 4.14 (m, IH), 3.60 (m, IH) , 3.47 (s, 2H) , 3.21 (m, 6H) , 3.10 (m, IH), 2.46 (m, 4H), 2.26 (m, IH), 2.12 (m, IH). EXAMPLE 304A A mixture of 3-bromo-4-methylpyridine (1.34 g) and NCS (1.43 g) in CC14 (10 mL) at reflux was stirred for 21 hours - 400 - WO2005/049594 PCT/US2004/037911 and filtered. The filtrate was dried (MgSO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 304B This example was prepared by substituting EXAMPLE 304A for 2-bromobenzyl bromide in EXAMPLE 2A. EXAMPLE 304C This example was prepared by substituting EXAMPLE 304B for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 304D This example was prepared by substituting EXAMPLE 304C for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 304E This example was prepared by substituting EXAMPLE 304D for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 5 12.09 (d, IH), 9.33 (d, IH), 8.69 (d, IH), 8.54 (d, IH), 8.29 (d, IH), 7.87 (dd, IH), 7.75 (m, 3H), 7.57 (d, 2H), 7.48 (d, 2H), 7.17 (m, 6H), 6.94 (d, 2H), 4.18 (m, IH), 3.39 (d, 2H), 3.13 (m, 4H), 2.75 (m, 3H), 2.73 (m, 3H), 2.14 (m, 2H). EXAMPLE 305 This example was prepared by substituting EXAMPLE 304D and 3-nitro-4-((2- (phenylsulfanyl)ethyl)amino)benzenesulfonamide for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl) amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (500 MHz, CDC13) 5 8.83 (d, IH) , 8.75 (d, IH), 8.66 (ra, 2H), - 401 - WO2005/049594 PCT/US2004/037911 8.11 (dd, IH), 8.08 (d, IH), 7.66 (d, 2H), 7.51 (d, 2H) , 7.40 (d, 2H), 7.27 (m, 5H), 6.81 (d, IH), 6.78 (d, 2H) , 3.90 (s, 2H), 3.57 (m, 2H), 3.42 (m, 4H) , 3.20 (t, 2H) , 2.75 (m, 4H) . EXAMPLE 306A 2-Bromo-cyclopent-l-enecarbaldehyde, prepared as described in Collect. Czech. Chem. Commun., 1961, 26, 3059-3073, (1.5 g), 4-piperazin-l-yl-benzoic acid ethyl ester (2 g) in ethanol (10 mL) at 25°C was treated with sodium cyanoborohydride (0.36 g), pH was adjusted to 5-6 with acetic acid, stirred for 18 hours, filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 5-10% ethyl acetate/hexanes. EXAMPLE 306B This example was made by substituting EXAMPLE 306A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 306C This example was made by substituting EXAMPLE 306B for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 306D This example was prepared by substituting EXAMPLE 306C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 12.10 (m, IH), 8.54 (d, IH), 8.28 (d, IH), 7.86 (dd, IH) , 7.78 (d, 2H), 7.32 (d, 2H), 7.28 (d, 2H), 7.22 (d, 2H), 7.14 (m, 4H), 6.97 (d, 2H), 4.18 (m, IH), 3.90 (m, 4H), 3.54 (m, 4H) , 3.39 (d, 2H), 3.14 (m, 4H), 2.92 (m, 2H), 2.76 (s, 6H), 2.64 (m, 2H), 2.15 (m, 2H), 1.96 (m, 2H). EXAMPLE 307A - 402 - WO2005/049594 PCT/US2004/037911 This example was prepared by substituting 2-bromo-cyclohex-1-enecarbaldehyde, prepared as described in Collect. Czech. Chem. Commun., 1961, 26, 3059, for 2-bromo-cyclopent-1-enecarbaldehyde in EXAMPLE 306A. EXAMPLE 307B This example was made by substituting EXAMPLE 307A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 307C This example was made by substituting EXAMPLE 307B for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 307D This example was made by substituting EXAMPLE 307C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 8.29 (d, IH), 8.03 (d, IH) , 7.61 (dd, IH), 7.53 (d, 2H), 7.15 (d, 2H), 6.97 (m, 2H), 6.89 (m, 6H), 6.70 (d, 2H), 3.93 (m, IH), 3.37 (m, 4H), 3.13 (m, 4H), 2.89 (m, 4H) , 2.49 (s, 6H), 2.24 (s, 2H), 1.98 (d, 4H), 1.89 (q, 2H), 1.43 (m, 4H). EXAMPLE 308A This example was made by substituting EXAMPLE 306A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 308B This example was made by substituting EXAMPLE 308A for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 6 9.48 (s, IH), 8.50 (d, IH), 8.25 (d, IH), 7.83 (dd, IH), 7.77 (d, 2H), 7.17 (m, 3H), 7.09 (m, 4H), 6.98 (d, 2H) , 4.14 (m, IH) , 3.80 (s, 2H), 3.35 (d, 2H), 3.28 (m, 4H), 3.11 (m, 4H), 2.70 (s, 6H), 2.64 (m, 2H), 2.41 (m, 2H), 2.10 (q, 2H), 1.93 (m, 2H). - 403 - WO2005/049594 PCT/US2004/037911 EXAMELE 79 This example was made by substituting EXAMPLE 307C and 4- (((lR)-3-(4-morpholinyl)- 1-((phenylsulfany1)methyl)propyl)amino)-3- nitrobenzenesulfonamide for EXAMPLE 2C and 4-(((lR)-3- (dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (300 MHz, DMSO-d6) 6 8.50 (d, IH) , 8.37 (d, IH) , 7.80 (dd, IH) , 7.72 (d, 2H), 7.37 (d, 2H), 7.28 (m, 2H), 7.17 (m, 5H), 7.04 (d, IH), 6.85 (d, 2H), 4.14 (s, IH), 3.53 (m, 4H), 3.36 (m, 4H), 3.21 (m, 4H), 2.80 (s, 2H), 2.45 (m, 2H), 2.34 (m, 5H), 2.19 (m, 5H), 2.01 (m, IH), 1.87 (m, IH), 1.67 (m, 4H). EXAMPLE 310 This example was made by substituting EXAMPLE 307C and EXAMPLE 18F for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (500 MHz, DMSO-d6) 6 7.80 (d, IH) , 7.63 (m, 3H), 7.24 (m, 6H), 7.12 (m, IH), 7.02 (d, 2H), 6.70 (d, 2H), 6.58 (d, IH), 5.74 (s, IH), 3.76 (m, IH), 3.16 (m, 6H), 3.07 (m, 4H), 2.90 (m, 2H), 2.68 (s, 2H), 2.41 (m, 2H), 2.19 (m, 4H), 2.10 (m, 4H) , 1.95 (m, 2H), 1.57 (m, 4H) . EXAMPLE 311A This example was made by substituting EXAMPLE 307A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 31IB This example was made by substituting EXAMPLE 311A for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 5 8.55 (d, - 404 - WO2005/049594 PCT/US2004/037911 1H), 8.29 (d, 1H), 7.87 (dd, 1H), 7.81 (d, 2H), 7.21 (m, 3H), 7.12 (m, 3H), 7.03 (d, 2H), 4.19 (m, 1H), 3.89 (s, 2H) , 3.30 (m, 8H), 3.15 (m, 4H), 2.74 (s, 6H), 2.56 (m, 2H), 2.25 (m, 2H), 2.15 (q, 2H), 1.68 (m, 4H). EXAMPLE 312A A mixture of DMF (10 mL) and chloroform (200 mL) at 5°C was treated with PBr3 (10 mL) , stirred at 25°C for 40 minutes, treated with tetrahydropyran~4-one (5 g) in chloroform (50 mL) at 0°C, stirred at 25°C for 18 hours, poured onto ice, treated with sodium bicarbonate, and extracted with diethyl ether. The extract was washed with saturated sodium bicarbonate and brine and dried (MgSO4) , filtered and concentrated. The concentrate was flash chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 312B This example was prepared by substituting 312A for 2-bromo-cyclopent-1-enecarbaldehyde in EXAMPLE 306A. EXAMPLE 312C This example was made by substituting EXAMPLE 312B for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 312D This example was made by substituting EXAMPLE 312C for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 312E This example was made by substituting EXAMPLE 312D for EXAMPLE 2C in EXAMPLE 2D. lti NMR (500 MHz, DMSO-d6) 5 8.29 (d, 1H), 8.03 (d, 1H), 7.61 (dd, 1H), 7.52 (d, 2H), 7.19 (d, 2H) , - 405 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 313B for EXAMPLE 2C in EXAMPLE 2D. 1HNMR (500 MHz, DMSO-d6) 8 8.55 (d, IH), 8.29 (d, IH), 7.87 (dd, IH), 7.79 (d, 2H), 7.23 (m, 2H), 7.15 (m, 8H) , 6.96 (d, 2H), 4.19 (m, IH), 3.86 (m, 4H), 3.60 (s, 2H) , 3.39 (d, 2H), 3.15 (m, 4H), 2.77 (m, 8H) , 2.27 (s, 2H), 2,22 (s, 2H), 2.15 (q, 2H), 1.72 (s, 4H) . EXAMPLE 315A This example was made by substituting EXAMPLE 307A and phenylboronic acid for EXAMPLE 2A and 4-chlorophenylboronic acid, respectively, in EXAMPLE 2B. EXAMPLE 315B This example was made by substituting EXAMPLE 315A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 315C This example was made by substituting EXAMPLE 315B for EXAMPLE 2C in EXAMPLE 2D. 1HNMR (400 MHz, DMSO-d6) 5 8.54 (d, IH), 8.29 (d, IH), 7.87 (dd, IH), 7.78 (d, 2H), 7.36 (m, 2H), 7.28 (m, IH), 7.21 (m, 2H), 7.13 (m, 6H) , 6.95 (d, 2H) , 4.19 (s, IH), 3.87 (s, 2H), 3.62 (m, 4H), 3.39 (d, 2H), 3.15 (m, 4H), 2.74 (m, 8H), 2.29 (s, 2H), 2.22 (s, 2H), 2.14 (q, 2H), 1.72 (m, 4H). EXAMPLE 316A This example was prepared by substituting 2-bromo-cyclooct-1-enecarbaldehyde for 2-bromo-cyclopent-1-enecarbaldehyde in EXAMPLE 306A. EXAMPLE 316B - 407 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 316A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 316C This example was made by substituting EXAMPLE 316B for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 316D This example was made by substituting EXAMPLE 316C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 8 8.54 (d, IH) , 8.30 (d, IH) , 7.86 (dd, IH), 7.78 (d, 2H), 7.43 (d, 2H), 7.17 (m, 8H), 6.95 (d, 2H), 4.19 (m, 5H), 3.89 (m, 2H), 3.64 (s, 2H), 3.39 (m, 4H), 3.13 (m, 4H), 2.75 (s, 3H), 2.74 (s, 3H), 2.46 (m, 2H), 2.14 (q, 2H), 1.66 (m, 2H), 1.54 (m, 4H), 1.41 (m, 2H). EXAMPLE 317A This example was made by substituting EXAMPLE 312B and 4-methylthiophenylboronic acid for EXAMPLE 2A and 4-chlorophenylboronic acid, respectively, in EXAMPLE 2B. EXAMPLE 317B This example was made by substituting EXAMPLE 317A for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 317C This example was made by substituting EXAMPLE 317B for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 8 8.54 (d, IH), 8.29 (d, IH), 7.86 (dd, IH), 7.79 (d, 2H), 7.22 (m, 4H) , 7.11 (m, 6H), 6.95 (d, 2H), 4.17 (m, IH), 3.90 (m, 4H) , 3.65 (m, 4H), 3.39 (d, 2H), 3.12 (m, 4H), 2.75 (s, 3H) , 2.74 (s, 3H) , 2.45 (s, 3H) , 2.24 (m, 4H), 2.14 (q, 2H), 1.71 (m, 4H) . - 408 - WO2005/049594 PCT/US2004/037911 EXAMPLE 318A This example was prepared by substituting 2-bromo-cyclohept-1-enecarbaldehyde for 2-bromo-cyclopent-1-enecarbaldehyde in EXAMPLE 306A. EXAMPLE 318B This example was made by substituting EXAMPLE 318A for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 318C This example was made by substituting EXAMPLE 318B for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 318D This example was made by substituting EXAMPLE 318C for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 8.54 (d, IH), 8.29 (d, IH), 7.86 (dd, IH), 7.78 (d, 2H), 7.40 (d, 2H), 7.22 (m, 2H), 7.14 (m, 6H), 6.95 (d, 2H), 4.19 (m, IH), 3.87 (s, 2H), 3.61 (m, 2H), 3.39 (m, 4H), 3.15 (m, 4H), 2.75 (m, 8H), 2.46 (m, 4H), 2.14 (m, 2H), 1.80 (m, 2H), 1.56 (m, 4H). EXAMPLE 319 This example was made by substituting EXAMPLE 318C and 4- (((1R)-3-(4-morpholinyl)- 1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide for EXAMPLE 2C and 4-(((lR)-3- (dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. H NMR (400 MHz, DMSO-d6) 5 8.55 (d, IH) , 8.29 (d, IH) , 7.87 (dd, IH), 7.78 (d, 2H), 7.40 (d, 2H) , 7.22 (m, 3H) , 7.14 (m, 6H) , 6.93 (d, 2H), 4.20 (m, IH), 3.91 (m, 4H), 3.39 (m, 6H) , 3.18 (m, - 409 - WO2005/049594 PCT/US2004/037911 6H), 3.03 (m, 2H) , 2.79 (m, 2H), 2.45 (m, 4H), 2.16 (q, 2H), 1.81 (m, 2H), 1.56 (m, 4H). EXAMPLE 320A This example was made by substituting 4,4-dimethyl-cyclohexanone for tetrahydro-pyran-4-one in EXAMPLE 312A. EXAMPLE 32OB This example was prepared by substituting 320A for 2-bromo-cyclopent-l-enecarbaldehyde in EXAMPLE 306A. EXAMPLE 32OC This example was made by substituting EXAMPLE 320B for EXAMPLE 2A in EXAMPLE 2B. EXAMPLE 320D This example was made by substituting EXAMPLE 32OC for EXAMPLE 2B in EXAMPLE 2C. EXAMPLE 320E This example was made by substituting EXAMPLE 320D for EXAMPLE 2C in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 8.54 (d, IH), 8.28 (d, IH), 7.86 (dd, IH), 7.79 (d, 2H), 7.41 (m, 2H) , 7.23 (m, 2H), 7.14 (m, 6H), 6.95 (d, 2H), 4.19 (m, IH) , 3.90 (m, IH), 3.39 (d, 2H), 3.15 (s, 6H), 2.74 (m, 8H), 2.54 2.22 (m, 2H), 1.29 (d, 9H). EXAMPLE 374 This example was made by substituting piperidine for isopropylamine in example 35B. •'"H NMR (300 MHz, DMSO-d6) 8 12.10 (m, IH) , 10.95 (m, IH), 9.97 (m, IH), 8.53 (d, IH) , 8.28 (d, IH), 8.04 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H), 7.54 (m, 4H), 7.23 (m, 8H), 6.93 (d, 2H), 4.35 (m, 2H) , 4.22 (m, IH), 3.88 (m, 2H), 3.40 (m, 2H), 3.27 (m, 6H), 3.10 (m, 2H) , 2.81 (m, 6H), 2.22 (m, 2H) , 1.75 (m, 4H) , 1.35 (m, 2H). EXAMPLE 375 This example was made by substituting 4-hydroxypiperidine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12.10 (m, IH) , 10.85 (m, IH), 9.98 (m, IH), 8.53 (d, IH), 8.28 (d, IH), 8.04 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H), 7.54 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H), 4.22 (m, IH), 3.93 (m, 3H), 3.27 (m, 6H), 3.10 (m, 2H), 2.87 (m, 4H), 2.22 (m, 2H), 1.91 (m, 4H), 1.70 (m, 2H). EXAMPLE 376 This example was made by substituting 1-acetylpiperazine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12.10 (m, IH), 10.69 (m, IH), 8.53 (d, IH), 8.28 (d, IH), 7.99 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H), 7.54 (m, 4H), 7.23 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H), 4.22 (m, IH), 3.92 (m, 2H), 3.41 (m, 4H), 3.27 (m, 6H), 3.00 (m, 2H), 2.85 (m, 6H), 2.22 (m, 2H), 2.02 (s, 3H). EXAMPLE 377 - 434 - WO2005/049594 PCT/US2004/037911 EXAMPLE 370 This example was made by substituting cylcobutylamine for isopropylamine in example 35B. -"H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH) , 10.88 (m, IH) , 9.04 (m, IH) , 8.53 (d, IH) , 8.27 (d, IH), 8.04 (m, IH), 7.86 (dd, IH), 7.78 (d, 2H) , 7.53 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.35 (m, 3H), 3.88 (m, 2H), 3.61 (m, 2H), 3.27 (m, 6H), 2.86 (m, 4H), 2.71 (m, IH), 2.11 (m, 4H), 1.76 (m, 2H). EXAMPLE 138 This example was made by substituting diethylamine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH), 10.99 (m, IH) , 10.08 (m, IH), 8.53 (d, IH) , 8.29 (d, IH), 8.06 (m, IH), 7.86 (dd, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.24 (m, 8H) , 6.93 (d, 2H), 4.34 (m, 3H), 3.88 (m, 2H), 3.39 (m, 2H), 3.27 (m, 6H), 3.08 (m, 4H), 2.81 (m, 2H), \ 2.15 (m, 2H), 1.17 (m, 6H). EXAMPLE 372 This example was made by substituting N-methylisopropylamine for isopropylamine in example 35B. H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH) , 10.89 (m, IH) , 9.96 (m, IH), 8.53 (d, IH), 8.29 (m, IH), 8.04 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.34 (m, 3H), 3.88 (m, 2H), 3.42 (m, 2H), 3.27 (m, 6H), 2.86 (m, 2H), 2.60 (m, 3H), 2.15 (m, 2H), 1.19 (m, 6H). EXAMPLE 373 This example was made by substituting N-methyl-tert-butylamine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12.10 (m, IH), 10.84 (m, IH), 9.70 (m, IH), 8.53 (d, IH), 8.30 (t, IH), 8.03 (m, IH), 7.85 (dd, IH), 7.78 - 433 - WO2005/049594 PCT/US2004/037911 This example was made by substituting thiomorpholine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12-10 (m, IH), 10.69 (m, IH), 10.55 (m, IH), 8.53 (d, IH), 8.28 (d, IH), 7.99 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.25 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H), 4.25 (m, IH), 3.90 (m, 2H), 3.64 (m, 4H), 3.41 (m, 4H) , 3.17 (m, 9H) , 2.82 (m, 4H), 2.22 (m, 2H). EXAMPLE 378 This example was made by substituting 4-(2-aminoethyl)morpholine for isopropylamine in example 35B. H NMR (300 MHz, DMSO-d6) 5 12.11 (m, IH) , 10.63 (m, IH) , 9.26 (m, IH), 8.53 (d, IH), 8.29 (d, IH), 7.99 (m, IH), 7.86 (dd, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.25 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H) , 4.25 (m, IH) , 3.90 (m, 2H) , 3.77 (m, 2H) , 3.41 (m, 4H), 3.27 (m, 6H), 3.05 (m, 6H), 2.82 (m, 4H), 2.17 (m, 2H). EXAMPLE 379A This example was made by substituting tert-butyl 1-piperazinecaboxylate for isopropylamine in example 35B. EXAMPLE 379B This example was made by substituting EXAMPLE 379A for EXAMPLE 27B in EXAMPLE 29A. 1H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH), 10.90 (m, IH), 9.50 (m, IH), 8.53 (d, IH), 8.30 (d, IH) , 8.04 (m, IH), 7.84 (dd, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.22 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H), 4.27 (m, IH), 3.90 (m, 2H), 3.40 (m, 6H), 3.17 (m, 1OH), 2.86 (m, 2H) , 2.23 (m, 2H) . EXAMPLE 380 - 435 - WO2005/049594 PCT/US2004/037911 This example was made by substituting (S)-3-hydroxypyrrolidine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH) , 10.73 (m, IH) , 10.26 (m, IH), 8.53 (d, IH), 8.29 (d, IH), 8.04 (m, IH), 7.85 (m, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.35 (m, 3H), 3.88 (m, 2H) , 3.38 (m, 4H) , 3.17 (m, 6H) , 3.03 (m, IH), 2.87 (m, 4H), 2.17 (m, 2H), 1.91 (m, 2H). EXAMPLE 381A This example was made by substituting 3(R)-(tert-butoxycarbonylamino)pyrrolidine for isopropylamine in example 35B. EXAMPLE 38IB This example was made by substituting EXAMPLE 381A for EXAMPLE 27B in EXAMPLE 29A. 1H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH) , 11.09 (m, IH) , 10.92 (m, IH)', 8.53 (d, IH) , 8.47 (m, IH), 8.30 (d, IH), 8.04 (m, IH), 7.85 (m, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.23 (m, 8H), 6.93 (d, 2H), 4.35 (m, 3H) , 3.88 (m, 2H) , 3.40 (m, 4H) , 3.27 (m, 6H) , 3.08 (m, IH) , 2.86 (m, 4H), 2.22 (m, 2H), 2.05 (m, 2H). EXAMPLE 382 This example was made by substituting 3-hydroxyazetidine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-de) 8 12.10 (m, IH), 10.73 (m, IH) , 10.23 (m, IH) , 8.53 (d, IH) , 8.27 (d, IH), 8.00 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H) , 7.52 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.35 (m, 2H), 4.26 (m, 3H), 4.04 (m, IH), 3.88 (m, 2H), 3.71 (m, 2H), 3.24 (m, 8H), 2.86 (m, 2H), 1.98 (m, 2H). EXAMPLE 383 - 436 - WO2005/049594 PCT/US2004/037911 This example was made by substituting 1-methylpiperazine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 5 12.11 (m, IH), 10.91 (m, IH), 8.53 (d, IH), 8.31 (d, IH), 8.04 (m, IH), 7.85 (dd, IH), 7.78 (d, 2H) , 7.54 (m, 4H), 7.24 (m, 8H), 6.93 (d, 2H), 4.34 (m, 2H), 4.26 (m, IH), 3.88 (m, 2H) , 3.40 (m, 6H), 3.27 (m, 8H), 2.86 (m, 4H), 2.80 (s, 3H), 2.21 (m, 2H) . EXAMPLE 384 This example was made by substituting thiomorpholine 1,1-dioxide, prepared as described in J. Med. Chem 1994, 37, 913-933, for isopropylamine in example 35B. 2H NMR (300 MHz, DMSO-d6) 5 12.08 (m, IH), 10.97 (m, IH), 8.53 (d, IH), 8.31 (d, IH), 8.04 (m, IH), 7.86 (dd, IH), 7.77 (d, 2H),.7.53 (m, 4H), 7.23 (m, 8H), 6.93 (d, 2H), 4.35 (m, 2H), 4.26 (m, 2H) , 3.88 (m, 2H), 3.55 (m, 5H), 3.24 (m, 8H), 2.89 (m, 4H), 1.98 (m, 2H) . EXAMPLE 385 This example was made by substituting 3,4-methylenedioxyaniline for isopropylamine in example 35B.1HNMR (400 MHz, DMSO-d6) 6 12.09 (m, IH), 11.29 (m, IH), 8.53 (d, IH), 8.28 (d, IH), 8.12 (m, IH), 7.82 (dd, IH), 7.77 (d, 2H) , 7.53 (m, 4H) , 7.24 (m, 9H) , 6.93 (m, 4H) , 6.07 (s, 2H), 4.35 (m, 2H), 4.26 (m, 2H), 3.28 (m, 9H), 2.85 (m, 4H), 2.15 (m, 2H) . EXAMPLE 386 This example was made by substituting 3,4-methylenedioxybenzylamine for isopropylamine in example 35B. XH NMR (400 MHz, DMSO-d6) 5 12.10 (m, IH) , 11.29 (m, IH), 9.26 (m, IH), 8.53 (d, IH), 8.26 (d, IH), 8.11 (m, IH), 7.86 - 437 - WO2005/049594 PCT/US2004/037911 (dd, IH), 7.77 (d, 2H), 7.53 (m, 4H), 7.24 (m, 9H), 6.90 (m, 4H), 6.02 (s, 2H), 4.34 (m, 3H), 3.98 (m, 2H), 3.87 (m, 2H), 3.61 (m, 2H), 3.28 (m, 4H), 2.91 (m, 4H), 2.16 (m, 2H). EXAMPLE 387 This example was made by substituting 2-aminomethylpyridine for isopropylamine in example 35B. H NMR (500 MHz, DMSO-d6) 6 12.11 (m, IH) , 11.57 (m, IH), 9.46 (m, 3H), 8.53 (d, IH), 8.26 (d, IH), 8.11 (m, IH), 7.86 (m, IH), 7.78 (d, 2H), 7.51 (m, 4H), 7.24 (m, 9H), 6.93 (d, 2H), 4.33 (m, 2H), 4.26 (m, IH), 3.87 (m, 2H), 3.39 (m, 4H), 3.25 (m, 4H), 2.84 (m, 4H), 2.22 (m, 2H). EXAMPLE 388 This example was made by substituting 2-aminoethylpyridine for isopropylamine in example 35B. H NMR (400 MHz, DMSO-d6) 8 12.10 (m, IH) , 11.36 (m, IH), 9.29 (m, 3H) , 8.62 (d, IH) , 8.53 (d, IH), 8.28 (d, IH), 8.13 (m, IH), 7.86 (d, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.18 (m, 9H), 6.93 (d, 2H), 4.33 (m, 2H), 3.87 (m, 2H), 3.31 (m, 7H) , 3.05 (m, 4H), 2.84 (m, 4H), 2.18 (m, 2H). EXAMPLE 389 This example was made by substituting 4-aminomethylpyridine for isopropylamine in example 35B. lti NMR (400 MHz, DMSO-d6) 5 12.08 (m, IH) , 11.30 (m, IH) , 9.85 (m, 2H), 9.17 (m, IH), 8.76 (d, IH), 8.53 (d, IH), 8.27 (d, IH), 8.11 (m, IH), 7.85 (d, IH), 7.78 (d, 2H), 7.53 (m, 4H) , 7.19 (m, 9H), 6.93 (d, 2H), 4.33 (m, 2H), 4.23 (m, IH) , 3.87 (m, 2H), 3.29 (m, 6H), 3.05 (m, 2H), 2.84 (m, 4H), 2.23 (m, 2H). EXAMPLE 390 - 438 - WO2005/049594 PCT/US2004/037911 This example was made by substituting 4-aminomorpholine for isopropylamine in example 35B. 1H NMR (500 MHz, DMSO-dg) 5 12.09 (m, IH), 11.55 (m, IH), 9.39 (m, 3H), 8.54 (d, IH), 8.32 (d, IH), 8.11 (m, IH), 7.87 (d, IH), 7.77 (d, 2H), 7.51 (m, 4H), 7.24 (m, 8H) , 6.92 (d, 2H) , .4.33 (m, 2H) , 4.23 (m, IH) , 4.00 (m, IH), 3.87 (m, 2H), 3.31 (m, 9H), 3.05 (m, 4H), 2.84 (m, 4H), 2.33 (m, 2H). EXAMPLE 391 This example was made by substituting N-methyl-4-aminopyridine for isopropylamine in example 35B. 1H NMR (300 MHz, DMSO-d6) 5 12.11 (m, IH) , 10.83 (m, IH) , 8.68 (m, 3H) , 8.52 (d, IH), 8.19 (t, 2H), 8.01 (m, IH), 7.83 (d, IH), 7.77 (d, 2H), 7.52 (m, 4H), 7.25 (m, 8H), 7.01 (d, IH), 6.93 (d, 2H), 6.74 (m, 2H), 4.33 (m, 2H), 4.24 (m, 2H), 3.87 (m, 3H), 3.36 (m 4H), 3.26 (m, 4H), 2.83 (d, 3H), 2.33 (m, 2H). EXAMPLE 392 This example was made by substituting 3-aminopyridine for isopropylamine in example 35B. -"H NMR (300 MHz,. DMSO-d6) S 12.11 (m, IH), 10.80 (m, IH) , 8.72 (m, 3H) , 8.52 (d, IH) , 8.22 (d, 2H), 7.99 (m, IH), 7.83 (d, IH), 7.77 (d, 2H), 7.52 (m, 4H) , 7.19 (m, 8H), 7.02 (d, IH), 6.93 (d, 2H), 6.59 (m, IH), 4.52 (m, 2H), 4.33 (m, 2H), 4.12 (m, IH), 3.87 (m, 2H), 3.36 (m 4H), 3.26 (m, 2H), 2.85 (d, 2H), 2.40 (m, 2H). EXAMPLE 393 This example was made by substituting 2, 6-dimethylpiperidine for isopropylamine in example 35B. H NMR (300 MHz, DMSO-d6) 5 12.09 (m, IH), 10.62 (m, IH), 9.74 (m, IH), 8.64 (m, IH), 8.50 (d, IH), 8.30 (d, IH), 7.99 (m, IH), 7.86 (d, IH), 7.77 (d, 2H), 7.5 2 (m, 4H), 7.24 (m, 8H), 6.93 - 439 - WO2005/049594 PCT/US2U04/037911 (d, 2H), 4.36 (m, 2H) , 3.88 (m, 2H), 3.31 (m 9H), 2.85 (d, 4H), 2.15 (m, 2H), 1.79 (m, 2H), 1.64 (m, 4H), 1.26 (m, 6H). EXAMPLE 394 This example was made by substituting cis-2,6-dimethylpiperidine for isopropylamine in example 35B. H NMR (300 MHz, DMSO-d6) 5 12.10 (m, IH) , 10.78 (m, IH) , 9.80 (m, IH), 8.74 (m, IH), 8.50 (d, IH), 8.30 (d, IH), 8.01 (m, IH), 7.86 (d, IH) , 7 .'77 (d, 2H) , 7.52 (m, 4H) , 7.24 (m, 8H) , 6.93 (d, 2H), 4.35 (m, 2H), 3.88 (m, 2H), 3.31 (m 9H), 2.85 (d, 4H), 2.15 (m, 2H), 1.79 (m, 2H) , 1.64 (m, 4H), 1.26 (m, 6H). EXAMPLE 395 This example was made by substituting 1-aminopyrrolidine for isopropylamine in example 35B. 1R NMR (300 MHz, DMSO-d6) 5 . 12.12 (m, IH), 10.86 (m, IH), 8.73 (a, IH), 8.54 (d, IH) , 8.32 (d, IH), 8.02 (m, IH), 7.86 (d, IH), 7.77 (d, 2H) , 7.52 (m, 4H), 7.25 (m, 8H), 6.93 (d, 2H), 4.36 (m, 2H), 4.22 (m, IH), 3.88 (m, 2H) , 3.31 (m 1OH), 2.85 (d, 4H), 2.32 (m, 2H), 2.11 (m, 4H). EXAMPLE 396A A mixture of tert-butyl 4-oxo-l-piperidinecarboxylate (2 g), methoxylamine hydrochloride (0.85 g), and potassium acetate (0.98 g) in ethanol(40 mL) was stirred at reflux for 18 hours and concentrated. The concentrate was treated with ethyl acetate (200 mL), washed with water and brine, and dried (Na2SO4), filtered, and concentrated. The concentrate was used without further purification. EXAMPLE 396B - 440 - WO2005/049594 PCT/US2004/037911 A mixture of EXAMPLE 396A (2.1 g) and TFA (10 mL) in dichloromethane (10 mL) at 25°C was stirred for 4 hours and concentrated. EXAMPLE 396C This example was made by substituting EXAMPLE 396B for isopropylamine in EXAMPLE 35B. 1H NMR (300 MHz, DMSO-d6) 5 8.51 (d, IH), 7.82 (dd, IH), 7.72 (d, 2H), 7.52 (m, 4H), 7.32 (m, 1OH), 6.87 (d, 2H), 4.17 (m, IH), 3.71 (s, 3H), 3.32 (m 1OH), 2.73 (m, 2H), 2.40 (m, 6H), 2.25 (m, 4H), 1.91 (m, 2H). EXAMPLE 397 A mixture of EXAMPLE 367 (80 mg), sodium azide (33 mg), and ammonium chloride (27 mg) in DMF (2 mL) at 110°C was stirred for 18 hours, treated with ethyl acetate (100 mL), washed with water and brine, dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 3% methanol/dichloromethane. H NMR (300 MHz, DMSO-d6) 5 12.09 (m, IH), 10.15 (m, IH), 8.52 (d, IH), 8.32 (d, IH), 7.82 (dd, IH), 7.78 (d, 2H), 7.52 (m, 4H), 7.24 (m, 8H) , 6.93 (d, 2H), 4.37 (m, 2H), 4.20 (m, IH), 3.71 (s, 3H), 3.28 (m, 5H), 2.98 (t, 2H), 2.83 (m, 2H), 2.23 (m, 2H) . EXAMPLE 398A This example was made by substituting 4-bromo-3-trifluoromethylbenzenesulfonamide for 4-(((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 398B A mixture of EXAMPLE 27B (2 g) and diethylamine (5 mL) in THF (20 mL) at 25°C was stirred for 18 hours and concentrated. - 441 - WO2005/049594 PCT/US2004/037911 The concentrate was flash chromatographed on silica gel with 3% (7M NH3 in methanol)/dichloromethane. EXAMPLE 398C This example was made by substituting EXAMPLE 398A and EXAMPLE 398B for EXAMPLE 164B and 164A, respectively, in EXAMPLE '164C. EXAMPLE 398D This example was made by substituting EXAMPLE 398C for EXAMPLE 27D in EXAMPLE 27E. I EXAMPLE 398E This example was made by substituting EXAMPLE 398D for EXAMPLE 27E in EXAMPLE 34. EXAMPLE 398F This example was made by substituting EXAMPLE 398E for EXAMPLE 34 in EXAMPLE 35A. EXAMPLE 398G This example was made by substituting EXAMPLE 398F and diisopropylamine for EXAMPLE 35A and isopropylamine, respectively, in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 8 11.94 (m, IH), 11.07 (m, IH), 9.25 (m, IH), 8.06 (m, IH), 7.93 (d, IH), 7.82 (dd, IH), 7.74 (d, 2H), 7.51 (m, 4H), 7.27 (m, 8H), 6.93 (t, 2H), 6.08 (d, IH), 4.33 (m, 2H), 4.00 (m, IH), 3.87 (m, 2H), 3.55 (m, 4H), 3.28 (m, 4H), 2.90 (m, 4H), 2.17 (m, 2H), 1.22 (m, 12H) . EXAMPLE 399 - 442 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 398F for EXAMPLE 35A in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 5 11.95 (m, IH), 11.11 (m, IH), 8.74 (m, IH), 8.06 (m, IH), 7.94 (d, IH), 7.91 (s, IH), 7.81 (dd, IH), 7.74 (d, 2H), 7.51 (m, 4H), 7.26 (m, 6H), 6.96 (d, IH), 6.91 (d, 2H), 5.99 (d, IH) , 4.33 (m, 2H) , 4.03 (m, IH) , 3.'87 (m, 2H) , 3.31 (m, 5H), 2.88 (m, 6H), 2.07 (m, 2H), 1.18 (m, 6H). EXAMPLE 400 This example was made by substituting diethanolamine for isopropylamine in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 6 8.58 (d, IH), 8.30 (m, IH), 8.01 (s, IH), 7.93 (dd, IH), 7.82 (d, 2H), 7.41 (m, 11H), 7.10 (d, IH), 6.93 (d, 2H), 4.50 (m, IH), 4.23 (m, IH), 3.75 (m, 4H), 3.49 (m, 4H), 3.28 (m, 4H), 3.33 (m, 7H), 2.59 (m, 2H), 2.23 (m, 2H). EXAMPLE 401A A mixture of l-bromo-2-(trifluoromethoxy)benzene (5 g) and chlorosulfonic acid (30 mL) at 85°C were stirred for 18 hours, treated with crushed ice, and extracted with ethyl acetate. The extract was washed with water and brine and dried (Na2SO4), filtered, and concentrated. The concentrate in IPA (200 mL) at 0°C was treated with 38% ammonium hydroxide (50 mL), stirred for 18 hours and concentrated. The concentrate was treated with ethyl acetate (200 mL) and water. The extract was washed with water and brine and dried (Na2SO4) , filtered, and concentrated. EXAMPLE 401B This example was made by substituting EXAMPLE 401A for EXAMPLE 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. - 443 - WO2005/049594 PCI7US2004/037911 EXAMPLE 401C This example was made by substituting EXAMPLE 401B for EXAMPLE 164B in EXAMPLE 164C. 1H NMR (500 MHz, DMSO-d6) 8 11.92 (m, IH), 11.12 (m, IH), 10.18 (m, IH), 7.92 (d, IH), 7.56 (d, 2H), 7.31 (m, 4H), 7.08 (m, 6H), 6.73 (d, 2H) , 5.86 (d, IH) , 4.15 (m, 2H), 3.68 (m, 2H), 3.59 (m, IH), 3.09 (m, 4H), 2.91 (m, 4H), 2.66 (m, 2H), 2.31 (m, 6H), 1.95 (m, 2H). EXAMPLE 402 This example was made by substituting EXAMPLE 398F and methylisopropylamine for EXAMPLE 35A and isopropylamine, respectively, in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 8 11.96 (m, IH), 11.40 (m, IH), 10.39 (m, IH), 8.14 (m, IH), 7.95 (d, IH), 7.81 (d, IH), 7.76 (d, 2H), 7.53 (m, 4H), 7.28 (m, 7H), 6.93 (m, 3H), 6.03 (m, IH), 4.33 (m, 2H), 4.02 (m, IH), 3.87 (m, 2H) , 3.32 (m, 6H) , 3.04 (m, 2H) , 2.86 (m, 2H) , 2.57 (m, 3H), 2.19 (m, 2H), 1.19 (m, 6H). EXAMPLE 403 This example was made by substituting EXAMPLE 398F and diethylamine for EXAMPLE 35A and isopropylamine, respectively, in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 5 11.96 (m, IH), 11.28 (m, IH), 10.30 (m, IH), 8.11 (m, IH), 7.94 (s, IH) , 7.81 (d, IH), 7.76 (d, 2H), 7.53 (m, 4H), 7.28 (m, 7H), 6.93 (m, 3H), 6.06 (m, IH), 4.33 (m, 2H), 4.02 (m, IH), 3.87 (m, 2H), 3.24 (m, 4H), 3.14 (m, 2H), 3.04 (m, 4H), 2.88 (m, 4H) , 2.13 (m, 2H), 1.17 (m, 6H). EXAMPLE 404 This example was made by substituting 2,5-dimethylpyrrolidine for isopropylamine, in EXAMPLE 35B. 1H - 444 - WO2005/049594 PCT/US2004/037911 NMR (500 MHz, DMSO-d6) 8 12.10 (m, IH), 11.41 (m, IH), 10.55 (m, IH), 9.88 (m, IH), 8.54 (s, IH), 8.31 (d, IH), 8.14 (m, IH), 7.86 (dd, IH), 7.77 (d, 2H), 7.53 (m, 4H) , 7.24 (m, 8H), 6.93 (d, 2H), 4.33 (m, 2H) , 3.88 (in, 2H) , 3.26 (m, 7H) , 2.83 (d, 2H), 2.16 (m, 4H), 1.65 (m, 2H), 1.36 (m, 6H). EXAMPLE 405 This example was made by substituting EXAMPLE 398F and 7M NH3 in methanol for EXAMPLE 35A and isopropylamine, respectively, in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 5 7.92 (s, IH), 7.87 (d, IH), 7.72 (d, 2H), 7.51 (dd, IH), 7.29 (m, 7H), 6.77 (m, 2H), 6.69 (m, IH), 4.40 (m, IH), 3.87 (m, 2H), 3.38 (m, 4H), 3.12 (m, 4H), 2.84 (t, 2H), 2.40 (m, 2H), 1.99 (m, 2H). EXAMPLE 406A This example was made by substituting 4-bromo-2-trifluoromethylbenzenesulfonamide for 4-(((1R)-3-(dimethylami.no) -1- ( (phenylsulfanyl)methyl) propyl) amino) -3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 406B this example was made by substituting EXAMPLE 406A for EXAMPLE 164B in EXAMPLE 164C. 1H NMR (500 MHz, DMSO-d6) 5 7.87 (d, IH), 7.79 (d, 2H), 7.48 (dd, IH), 7.26 (m, 11H), 6.78 (m, 3H), 6.56 (m, 2H), 3.64 (m, 2H), 3.12 (m, 5K), 3.06 (m, 2H), 2.80 (m, 4H), 2.36 (m, 6H), 2.01 (m, 2H), 1.74 (m, 2H). EXAMPLE 407A This example was made by substituting 4-bromo-3-fluorobenzenesulfonamide for 4-(((1R)-3-(dimethylamino)-- 445 - WO2005/049594 PCT/LS2004/037911 1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 407B This example was made by substituting EXAMPLE 407A for EXAMPLE 164B in EXAMPLE 164C. 1HNMR (500 MHz, DMSO-d6) 8 7.69 (d, 2H), 7.48 (dd, IH), 7.42 (d, IH), 7.25 (m, 12H), 6.77 (m, 2H), 6.44 (t, IH), 5.90 (d, IH), 3.63 (m, 2H), 3.10 (m, 9H), 2.79 (m, 4H), 2.36 (m, 6H), 1.98 (m, IH) , 1.87 (m, IH). EXAMPLE 847398A This example was made by substituting 4-bromo-2-trifluoromethoxybenzenesulfonamide for 4-{((lR)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 847398B This example was made by substituting EXAMPLE 847398A for EXAMPLE 164B in EXAMPLE 164C. 1H NMR (500 MHz, DMSO-d6) S 7.73 (d, 2H) , 7.62 (d, IH), 7.51 (d, IH), 7.31 (m, 12H), 6.81 (m, 2H), 6.39 (m, 2H), 3.61 (m, 2H), 3.39 (m, 2H), 3.17 (m, 6H), 3.09 (m, 4H), 2.79 (m, IH), 2.40 (m, 6H), 1.98 (m, IH), 1.87 (m, IH). EXAMPLE 409A This example was made by substituting 4-bromo-2,5-difluorobenzenesulfonamide for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 4 09B - 446 - WO2005/049594 PCT7US2004/U37911 This example was made by substituting EXAMPLE 409A for EXAMPLE 164B in EXAMPLE 164C. 1HNMR (500 MHz, DMSO-d6) 8 7.73 (d, 2H), 7.51 (d, IH), 7.31 (m, 1OH), 6.80 (d, 2H), 6.20 (m, 2H) , 6.10 (m, 2H), 3.59 (m, IH), 3.39 (m, 4H), 3.14 (m, 6H), 2.94 (m, 2H), 2.85 (m, 2H), 2.40 (m, 6H), 2.01 (m, IH), 1.90 (m, IH). EXAMPLE 410A This example was made by substituting 4-bromo-3-methylbenzenesulfonamide for 4-(((1R)-3-(dimethylamino)-l-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 410B This example was made by substituting EXAMPLE 410A for EXAMPLE 164Bin EXAMPLE 164C. 1H NMR (500 MHz, DMSO-d6) 8 7.72 (d, 2H), 7.51 (d, IH), 7.29 (m, 1OH), 6.83 (d, 2H) , 6.34 (d, 2H), 5.75 (s, 2H), 5.52 (d, IH), 3.72 (m, IH), 3.39 (m, 2H), 3.15 (m, 8H), 2.64 (m, 2H), 2.54 (m, 2H), 2.40 (m, 6H), 2.05 (s, 3H) , 1.98 (n IH), 1.87 (m, IH) . EXAMPLE 411 This example was made by substituting EXAMPLE 307C and EXAMPLE 29D for EXAMPLE 2C and 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 8 8.44 (s, IH) , 8.14 (m, IH) , 7.81 (m, IH) , 7.71 (d, 2H), 7.25 (m, 7H), 6.94 (d, IH), 6.77 (d, 2H), 4.11 (m, IH), 3.58 (m, 2H), 3.19 (m, 6H), 2.76 (s, 2H), 2.22 (m, 8H), 1.66 (m, 4H), 1.19 (m, 12H), 0.89 (m, 4H). EXAMPLE 412 - 447 - WO2005/049594 PCT/US2004/037911 This example was made by substituting (2R,5R)-(-)-trans-2,5-dimethylpyrrolidine, prepared as described in J. Org. Chem. 1999,64, 1979.-1985, for isopropylamine in EXAMPLE 35B. lH NMR (500 MHz, DMSO-d6) 8 8.45 (d, IH), 8.17 (m, IH) , 7.84 (dd, IH), 7.72 (d, 2H), 7.51 (d, IH), 7.27 (m, 8H), 6.99 (d, IH), 6.79 (d, 2H), 4.14 (m, 2H), 3.88 (m, 2H), 3.74 (m, IH), 3.38 (s, 2H), 3.28 (m, 6H), 2.87 (m, 2H), 2.40 (m, 6H) , 2.09 (m, 4H), 1.24 (m, 4H). EXAMPLE 413 This example was made by substituting (2S,5S)-(+)-trans-2,5-dimethylpyrrolidine, prepared as described in J. Org. Chem. 1999,64, 1979-1985, for isopropylamine in EXAMPLE 35B. 1H 'NMR (500 MHz, DMSO-d6) 8 8.45 (d, IH), 8.17 (m, IH) , 7.84 (dd, IH), 7.72 (d, 2H), 7.51 (d, IH), 7.27 (m, 8H) , 6.94 (m, IH), 6.79 (d, 2H), 4.11 (m, 2H), 3.88 (m, 2H), 3.74 (m, IH), 3.38 (s, 2H) , 3.27 (m, 6H) , 2.87 (m, 2H) , 2.40 (m, 6H) , 2.09 (m, 4H), 1.24 (m, 4H). EXAMPLE 414 This example was made by substituting (2S,5R)-cis-2, 5-dimethylpyrrolidine, prepared as described in J. Org. Chem. 1999,64, 1979-1985, for isopropylamine in EXAMPLE 35B. 1H NMR (500 MHz, DMSO-d6) 8 8.46 (d, IH) , 8.16 (m, IH), 7.83 (dd, IH), 7.72 (d, 2H), 7.51 (d, IH) , 7.27 (m, 8H), 6.97 (m, IH) , 6.80 (d, 2H), 4.12 (m, 2H), 3.49 (m, IH), 3.39 (s, 2H), 3.28 (m, 8H), 2.40 (m, 6H), 2.12 (m, 4H), 1.57 (m, 2H), 1.21 (m, 4H). EXAMPLE 415A A mixture of 4-bromo-3-(trifluoromethyl)benzenesulfonyl chloride (0.46 g), concentrated sulfuric acid (6 mL), and 90% nitric acid (3 mL) at 110°C were stirred for 18 hours, - 448 - WO2005/049594 PCT/US2004/037911 poured into ice water and extracted with ethyl acetate. The extract was washed with water and brine, dried (Na2SO4) , filtered, and concentrated. EXAMPLE 415B EXAMPLE 415A (0.5 g) in IPA (25 mL) and THF (25 mL) at -78°C was treated with 38% ammonium hydroxide (10 mL), stirred for 3 hours, acidified with 12M HC1, and concentrated. The concentrate was treated with ethyl acetate and water. The extract was washed with water and brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 25% ethyl acetate/hexane. EXAMPLE 415C A mixture of EXAMPLE 415B (0.235 g), EXAMPLE 164A (0.224 g) and DIEA (1 mL) in dimethylacetamide (10 mL) at 50°C was stirred for 18 hours, treated with ethyl acetate, washed with aqueous NaHCO3, water, and brine, and dried (MgSO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 50% ethyl acetate/NH3~ saturated dichloromethane. EXAMPLE 415D This example was made by substituting EXAMPLE 415C for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6)5 8.41 (d, IH), 8.20 (d, IH), 7.83 (dd, IH), 7.75 (d, 2H), 7.51 (dd, IH), 7.37 (m, 8H), 7.06 (d, 2H), 6.79 (d, 2H), 6.50 (m, IH), 3.39 (s, 2H), 3.29 (m IH), 3.05 (m, 7H) , 2.63 (m, 4H), 2.40 (m, 6H), 2.07 (m, 2H). - 449 - WO2005/049594 PCT/LS2004/037911 EXAMPLE 416 This example was made by substituting EXAMPLE 415C and EXAMPLE 307C. for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 5 8.31 (d, IH) , 8.10 (d, IH), 7.65 (d, 2H), 7.27 (d, 2H), 7.04 (m, 8H), 6.68 (d, 2H), 6.44 (m, IH), 3.04 (m, 4H), 2.82 (m, IH), 2.69 (m, 2H), 2.41 (m, 6H), 2.20 (m, 4H), 2.08 (m, 4H), 1.98 (m, 2H), 1.56 (m, 4H) . EXAMPLE 417 This example was made by substituting EXAMPLE 415C and EXAMPLE 318C for 4-(((1R)-3-(dimethylamino)-1-( (phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 6 8.18 (d, IH) , 7.98 (d, IH), 7.52 (d, 2H), 7.15 (d, 2H), 6.94 (m, 8H), 6.56 (d, 2H), 6.42 (m, IH), 2.90 {m, 4H), 2.69 (m, IH), 2.56 (m, 2H), 2.29 (m, 6H), 2.19 (m, 4H), 2.10 (m, 4H), 1.82 (m, IH), 1.74 (m, IH), 1.56 (m, 4H), 1.48 (m, 2H), 1.32 (m, 4H). EXAMPLE 418A 3-Fluoro-4-nitrobenzenesulfonyl chloride (1 g) in IPA (50 mL) at -15°C was treated with 38% NH4OH (10 mL), stirred for 18 hours and concentrated. The concentrate was partitioned between ethyl acetate and water. The water layer was extracted with ethyl acetate. The extract was washed with water and brine and dried (Na2SO4), filtered, and concentrated. EXAMPLE 418B - 450 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 418A and EXAMPLE 164A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 21C, respectively, in EXAMPLE 21D. EXAMPLE 418C This example was made by substituting EXAMPLE 418B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 8 7.99 (d, IH), 7.95 (d, 2H), 7.60 (s, IH), 7.51 (dd, IH), 7.37 (m, 4H), 7.30 (d, 4H), 7.24 (dd, IH), 7.14 (t, 2H), 7.08 (t, IH), 7.02 (dd, IH), 6.79 (d, 2H), 4.13 (m, IH), 3.49 (dd, IH), 3.39 (d, 2H), 3.36 (dd, IH) , 3.13 (m, 4H), 3.04 (m, 2H), 2.63 (m, 4H), 2.40 (m, 6H), 2.10 (m, 2H) . EXAMPLE 419A This example was made by substituting 4-bromo-3,5-difluorobenzenesulfonyl chloride for 3-fluoro-4-nitr'obenzenesulfonyl chloride in EXAMPLE 418A. •EXAMPLE 419B This example was made by substituting EXAMPLE 419A for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. EXAMPLE 419C This example was made by substituting EXAMPLE 419B for EXAMPLE 164B in EXAMPLE 164C. 1H NMR (500 MHz, DMSO-d6) 5 12.10 (m, IH), 11.43 (m, IH), 10.48 (m, IH), 8.55 (m, IH) , 8.14 (m, 2H), 7.77 (m, 2H), 7.33 (m, - 451 - WO2005/049594 PCT/US2004/037911 12H) , 6.93 (m, 2H) , 6.03 (d, 2H) , 4.34 (m 1H) , 3.88 (m, 2H) ,■ 3.36 (m, 4H), 3.13 (m, 2H) , 2.84 (m, 2H) , 2.70 (m, 6H) , 2.08 (m, 2H) . EXAMPLE 420A A mixture of 2-chloro-3-nitrobenzoic acid (5 g) and chlorosulfonic acid (30 mL) at 150°C was stirred for 72 hours, treated with ice, and extracted ethyl acetate. The extract was washed with water and brine, dried (Na2SO4), filtered, and concentrated. The concentrate in 1:1 IPA/THF (200 mL) at -78°C was treated with 38% ammonium hydroxide (30 mL), stirred for 2 hours, acidified with 12M HCl, and concentrated. The concentrate was treated with water and ethyl acetate. The extract was washed with water and brine and dried (Na2S(>4) , filtered, and concentrated. EXAMPLE 420B EXAMPLE 420A (4.5 g) in methanol (300 mL) was treated with concentrated sulfuric acid (3 mL), stirred at reflux for 18 hours, and concentrated. The concentrate was treated with water and ethyl acetate. The extract was washed with water and brine and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 20% ethyl acetate/hexane. EXAMPLE 42OC This example was made by substituting EXAMPLE 420B and EXAMPLE 164A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 21C, respectively, in EXAMPLE 21D. EXAMPLE 4 20D - 452 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 42OC and EXAMPLE 307C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1H NMR (500 MHz, DMSO-d6) 6 8.34 (s, IH) , 8.28 (d, IH), 7.72 (d, 2H), 7.36 (d, 2H), 7.13 (m, 7H), 6.76 (d, 2H), 3.80 (s, 3H), 3.10 (m, 4H), 2.75 (m, 2H), 2.27 (m, 4H), 2.18 (m, 6H), 1.99 (m, 2H), 1.88 (m, 2H), 1.65 (m, 4H). EXAMPLE 421 This example was made by substituting EXAMPLE 42OC for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. aH NMR (500 MHz, DMSO-d6) 8 8.27 (s, IH) , 8.20 (d, IH) , 7.66 (d, 2H), 7.43 (d, 2H), 7.16 (m, 11H), 6.71 (d, 2H), 3.74 (s, 3H), 3.05 (m, 6H), 2.82 (m, 2H), 2.49 (m, 6H), 2.32 (m, 4H) , 1.95 (m, 2H), 1.85 (m, 2H). EXAMPLE 422 EXAMPLE 421 (60 mg) in THF (1 mL), methanol (1 mL), and water (1 mL) was treated with lithium hydroxide monohydrate (10 mg) , stirred at 25°C for 18 hours, and concentrated. The concentrate was purified by high pressure liquid chromatography on a Waters Symmetry Cg column (25 mm * 100 mm, 7um particle size) with 10-100% acetonitrile/0.1% aqueous TFA over 8 minutes at a flow rate of 40 mL/minute. 1H NMR (500 MHz, DMSO-d6) 5 9.55 (m, IH), 9.13 (m, IH), 8.46 (s, IH), 8.33 (s, IH), 7.79 (d, 2H), 7.72 (m, IH), 7.52 (m, 4H), 7.49 (m, 2H), 7.33 (m, 2H), 7.09 (m, 4H), 6.99 (m, 2H), 6.93 (d, 2H), 4.21 (m, IH), 3.17 (m, 6H), 2.93 (m, 2H), 2.79 (m, 6H), 2.12 (m, 2H), 2.05 (m, 2H). - 453 - WO2005/049594 PCT/US2004/037911 EXAMPLE 423 This example was made by substituting EXAMPLE 420D for EXAMPLE 421 in EXAMPLE 422. 1H NMR (500 MHz, DMSO-d6) 8 9.57 (m, IH), 9.21 (m, IH), 8.47 (s, IH), 8.33 (s, IH), 7.80 (d, 2H), 7.40 (m, 4H), 7.15 (d, 2H), 7.09 (m, 4H), 7.01 (m, 2H), 6.95 (d, 2H), 3.17 ' (m, 6H), 2.79 (m, 6H), 2.26 (m, 4H), 2.21 (m, 4H), 2.14 (m, 2H), 2.03 (m, 2H), 1.70 (m, 4H). EXAMPLE 424 EXAMPLE 420D (100 mg) in 7M NH3 in methanol at 70°C was stirred for 48 hours in a sealed vial, and concentrated. The concentrate was purified by high pressure liquid chromatography on a Waters Symmetry Ca column (25 mm * 100 mm, 7um particle size) with 10-100% acetonitrile/0.1% aqueous TFA over 8 minutes at a flow rate of 40 mL/minute. H NMR (500 MHz, DMSO-d6) 5 9.46 (m, IH), 8.52 (m, IH), 8.45 (d, IH), 7.99 (s, IH), 7.87 (s, IH), 7.79 (d, 2H), 7.41 (m, 4H), 7.16 (d, 2H), 7.13 (m, 4H), 6.96 (d, 2H), 3.90 (m, IH), 3.59 (m, 2H), 3.35 (m, 4H), 3.27 (m, 4H), 3.17 (m, 6H), 2.77 (m, 6H), 2.26 (m, 4H), 2.21 (m, 4H) , 2.10 (m, 2H), 1.71 (m, 4H). EXAMPLE 425 This example was made by substituting EXAMPLE 421 for EXAMPLE 420D in EXAMPLE 424. 1HNMR (500 MHz, DMSO-d6) 8 9.42 (m, IH), 8.52 (m, IH), 8.46 (d, IH), 7.99 (s, IH), 7.87 (s, IH), 7.78 (d, 2H), 7.53 (m, 4H), 7.41 (d, 2H), 7.34 (m, IH), 7.14 (m, 4H), 6.94 (d, 2H), 3.91 (m, IH), 3.36 (m, 4H) , 3.28 (m, 4H), 3.16 (m, 6H), 2.77 (m, 6H), 2.11 (m, 2H). EXAMPLE 426A - 454 - WO2005/049594 PCT/US2004/037911 2-Fluoro-3-(trifluoromethyl)benzoic acid (5 g) in concentrated sulfuric acid (50 mL) at 0°C was treated with urea nitrate, prepared as described in Textbook of Practical Organic Chemistry; 1971, page 442, (5 g), stirred for 30 minutes and at 25°C for 12 hours, poured onto crushed ice and extracted with ethyl acetate. The extract was washed with water and brine, dried (Na2SO4) , filtered, and concentrated. The concentrate in methanol (300 mL) and concentrated sulfuric acid (3 mL) was refluxed for 18 hours and concentrated. The concentrate was treated with water and ethyl acetate, and the organic layer was washed with water and brine, and dried (Na2SO4) , filtered, and concentrated. EXAMPLE 426B EXAMPLE 426A (6 g) and 10% palladium on carbon (0.6 g) in ethyl acetate (200 mL) at 25°C were shaken under H2 (60 psi) for 2 hours, filtered and concentrated. EXAMPLE 426C This example was made by substituting EXAMPLE 426B for EXAMPLE 848090A in EXAMPLE 848090B. EXAMPLE 426D This example was made by substituting EXAMPLE 426C and EXAMPLE 164A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 21C, respectively, in EXAMPLE 21D. EXANPLE 426E This example was made by substituting EXAMPLE 426D and EXAMPLE 307C for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in - 455 - WO2005/049594 PCT/US2004/037911 EXAMPLE 2D. 1HNMR (400 MHz, DMSO-d6) 8 8.39 (d, IH) , 8.16 (d, IH), 7.72 (d, 2H), 7.36 (d, 2H), 7.30 (m, IH), 7.20 (d, 2H), 7.12 (m, 4H), 6.77 (d, 2H) , 3.81 (s, 3H), 3.62 (m, IH), 3.12 (m, 8H), 2.95 (m, 2H) , 2.77 (m, 2H), 2.61 (m, 6H), 2.28 (m, 4H), 2.18 (m, 4H), 2.10 (m, 2H), 1.91 (m, 2H), 1.66 (m, 4H). EXAMPLE 427 This example was made by substituting EXAMPLE 426D and EXAMPLE 312D for 4-{((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1H NMR (400 MHz, DMSO-d6) 8 8.39 (d, IH) , 8.15 (d, IH), 7.72 (d, 2H), 7.40 (d, 2H) , 7.30 (m, IH), 7.20 (m, 4H) , 7.12 (m, 2H), 6.77 (d, 2H), 4.16 (s, 2H), 3.81 (s, 3H), 3.79 (t, 2H), 3.62 (m, IH), 3.12 (m,' 8H), 2.95 (m, 2H), 2.88 (m, 4H), 2.60 (m, 6H) , 2.30 (m, 4H), 2.05 (m, 2H), 1.91 (m, 2H). EXAMPLE 428 This example was made by substituting EXAMPLE 426D for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. lH NMR (400 MHz, DMSO-d6) 8 8.40 (d, IH), 8.16 (d, IH), 7.73 (d, 2H), 7.50 (d, 2H), 7.47 (m, 4H), 7.24 (m, 6H), 6.79 (d, 2H), 3.81 (s, 3H), 3.61 (m, IH), 3.38 (s, 2H), 3.12 (m, 8H), 2.95 (m, 2H) , 2.61 (m, 6H), 2.40 (m, 4H) , 2.10 (m, 2H), 1.91 (m, 2H). EXAMPLE 429A This example was made by substituting Fmoc-D-Glu(0-tert-butyl)-OH for Fmoc-D-Asp(O-tert-butyl)-OH in EXAMPLE 27A. EXAMPLE 429B - 456 - WO2005/049594 PCT/LS2004/037911 This example was made by substituting EXAMPLE 429A for EXAMPLE 27A in EXAMPLE 27B. EXAMPLE 429C This example was made by substituting EXAMPLE 429B for EXAMPLE 27B in EXAMPLE 29A. EXAMPLE 429D This example was made by substituting EXAMPLE 429C and (2S,5R)-cis-2,5-dimethylpyrrolidine, prepared as described in J. Org. Chem. 1999,64, 1979-1985, for EXAMPLE 29A and diisopropylamine, respectively, in EXAMPLE 29B. EXAMPLE 429E This example was made by substituting EXAMPLE 429D for EXAMPLE 27B in EXAMPLE 398B. EXAMPLE 429F This example was made by substituting EXAMPLE 429E for EXAMPLE 18E in EXAMPLE 18F. EXAMPLE 429G This example was made by substituting EXAMPLE 429F for EXAMPLE 21C in EXAMPLE 21D. EXAMPLE 429H This example was made by substituting EXAMPLE 429G and EXAMPLE ,307C for 4- ( { (1R) -3- (dimethylamino) -1-((phenylsulfanyl)methyl)propyl)amino) -3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1HNMR (300 MHz, DMSO-d6) 5 12.11 (m, IH) , 10.17 (m, IH), 9.01 (m, IH), 8.53 (d, IH), 8.32 (d, IH), 7.87 (dd, - 457 - WO2005/049594 PCT/US2004/037911 IH), 7.79 (d, 2H), 7.41 (d, 2H), 7.18 (m, 6H), 6.96 (d, 2H), 4.18 (m, IH), 3.90 (m, 2H), 3.60 (m, 2H), 3.09 (m, 2H), 2.78 (m, 2H) , 2.2.6 (m, 4H) , 2.09 (m, 2H) , 1.68 (m, 8H) , 1.28 (d, 6H) . EXAMPLE 430 This example was made by substituting EXAMPLE 429G and EXAMPLE 312D for 4-(((1R) -3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide and EXAMPLE 2C, respectively, in EXAMPLE 2D. 1H NMR (300 MHz, DMSO-d6) 8 12.11 (m, IH) , 10.54 (m, IH), 9.00 (m, IH), 8.53 (d, IH) , 8.32 (d, IH) , 7.88 (dd, IH) , 7.78 (d, 2H), 7.45 (d, 2H) , 7.18 (m, 6H) , 6.96 (d, 2H) , 4.38 (s, 2H), 4.18 (m, IH), 3.84 (t, 2H), 3.66 (m, 2H) , 3.09 (m, 2H), 2.75 (m, 2H), 2.4 6 (m, 4H), 2.09 (m, 2H), 1.68 (m, 8H), 1.28 (d, 6H) . EXAMPLE 431 This example was made by substituting 2-tert-butoxycarbonylaminobenzoyl chloride for 2-bromobenzoyl chloride in EXAMPLE 106B. 1H NMR (500MHz, DMSO-d6) 8 9.48 (s, IH), 9.28 (brs, IH), 8.55 (d, IH) , 8.28 (d, IH), 7.88 (dd, IH), 7.77 (d, 2H), '7.24 (d, 2H) , 7.16 (dd, 2H) , 7.12 (d, IH) , 6.96 (d, 2H), 6.63 (d, IH), 6.58 (s, IH), 6.50 (d, IH) , 4.18 (m, IH), 3.40 (m, 4H), 3.35 (m, 2H), 3.20-3.08 (m, 4H), 2.73 (s, 6H), 2.54 (s, 2H), 2.14 (m, 2H) , 1.48 (s, 9H) . EXAMPLE 432 This example was made by substituting 2-dimethylaminobenzoyl chloride for 2-bromobenzoyl chloride in EXAMPLE 106B. XR NMR (500MHz, DMSO-d6) 5 9.26 (br s, IH) , 8.55 (d, IH), 8.28 (d, IH), 7.87 (dd, IH) , 7.77 (d, 2H) , 7.23 (d, - 458 - WO2005/049594 PCT/US2004/037911 2H), 7.15 (dd, 2H), 7.11 (d, IH), 6.96 (d, 2H) , 6.79 (d, IH), 6.69 (s, IH), 6.65 (d, IH), 4.17 (m, IH), 3.40 (m, 4H), 3.35 (m, 2H), 3.15 (m, 4H), 2.91 (s, 6H), 2.74 (s, 6H), 2.54 (s, 2H), 2.14 (m, 2H). EXAMPLE 433A This example was made by substituting (2S,4R)-3-((benzyloxy)carbonyl)-4-methyl-2-phenyl-l,3-oxazolidin-5-one, (prepared as described in Helv. Chim. Acta 1991, for (2R,4S)-3-((benzyloxy)carbonyl)-4-methyl-2-phenyl-l,3-oxazolidin-5-one in EXAMPLE 25A. EXAMPLE 433B This example was made by substituting EXAMPLE 433A for EXAMPLE 25A in EXAMPLE 2IB. EXAMPLE 433C This example was made by substituting EXAMPLE 433B for EXAMPLE 25B in EXAMPLE 21C. EXAMPLE 433D This example was made by substituting EXAMPLE 433C for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 433E This example was made by substituting EXAMPLE 433D for EXAMPLE 25D in EXAMPLE 21H. EXAMPLE 433F This example was made by substituting EXAMPLE 433E for EXAMPLE 25E in EXAMPLE 21F. EXAMPLE 433G - 459 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 433F for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 433H This example was made by substituting EXAMPLE 433G for EXAMPLE 25G in EXAMPLE 25H. EXAMPLE 4331 This example was made by substituting EXAMPLE 433H for EXAMPLE 1C in EXAMPLE ID. 1H NMR (500MHz, DMSO-d6) 8 8.51 (d, IH), 8.31 (s, IH), 7.92 (dd, IH), 7.81 (d, 2H), 7.60 (d, IH), 7.47 (m, 4H), 7.42 (m, 3H), 7.32 (m, 4H), 7.16 (dd, 2H), 7.08 (dd, IH), 6.86 (d, 2H), 4.25 (m, IH), 3.77 (d, 2H), 3.45 (d, IH), 3.21 (m, 4H), 2.95 (m, IH), 2.67 (s, 6H), 2.54 (m, IH) , 2.45 (m, 4H), 2.27 (m, IH), 1.59 (s, 3H). EXAMPLE 434 This example was made by substituting EXAMPLE 25H for EXAMPLE 1C in EXAMPLE ID. 1H NMR (500MHz, DMSO-d6) 8 10.20 (br s, IH), 8.48 (d, IH), 8.26 (s, IH), 7.87 (dd, IH), 7.78 (d, 2H), 7.56 (d, IH), 7.42 (m, 4H), 7.38 (m, 3H), 7.29 (d, IH), 7.25 (m, 3H), 7.05 (dd, 2H), 6.97 (dd, IH), 6.83 (d, 2H), 3.74 (m, IH), 3.45 (s, 2H), 3.39 (d, IH), 3.28 (m, IH), 3.20 (m, 4H), 3.16 (m, IH), 2.97 (m, IH), 2.67 (s, 6H), 2.54 (m, IH) , 2.40 (m, 4H), 2.25 (m, IH), 1.54 (s, 3H). EXAMPLE 435A 2-fluorobenzohitrile (0.325 mL) in isoindoline/NMP (1 mL/2 mL) at 180°C was stirred for 10 minutes in a microwave reactor, poured into diethyl ether (50 mL) and washed with 1M HC1 and brine. The solution was dried (Na2SO4) , filtered, and concentrated. - 460 - WO2005/049594 PCT/US2004/037911 EXAMPLE 435B EXAMPLE 435A (200 mg) in toluene (5 mL) at 25°C was treated with IM DIBAL in dichloromethane (1.1 mL), stirred for 30 minutes, treated with methanol (3 mL), poured into IM HCl (50 mL), and extracted with ethyl acetate. The extract was washed with brine and dried (Na2SO4) , filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 435C This example was made by substituting EXAMPLE 435B for EXAMPLE 130D in EXAMPLE 130E. 1H NMR (500MHz, DMSO-d6) 6 10.05 (br s, IH), 8.45 (d, 1H),.8.21 (d, IH), 7.81 (dd, IH), 7.73 (d, 2H), 7.34 (m, 4H), 7.23 (m, 4H), 7.18 (m, 2H), 7.07 (m, IH), 6.89 (m, 2H), 6.81 (d, 2H), 4.62 (AB quartet, 4H), 4.09 (m, IH), 3.62 (s, IH) , 3.34 (m, 2H), 3.28 (m, IH), 3.20 (m, 2H), 2.91 (dd, 2H), 2.84 (m, IH), 2.67 (s, 6H) , 2.55 (m, 4H) , 2.09 (m, IH), 2.02 (m, IH), 1.71 (m, IH). EXAMPLE 436A This example was made by substituting cyclohexylamine for isoindoline in EXAMPLE 435A. EXAMPLE 436B This example was made by substituting EXAMPLE 436A for EXAMPLE 435A in EXAMPLE 435B. EXAMPLE 436C This example was made by substituting EXAMPLE 436B for 2-(methylsulfanyl)benzaldehyde in EXAMPLE 128E. 1H NMR (400MHz, DMSO-d6) 5 9.70 (br s, IH), 8.52 (d, IH), 8.22 (d, IH), 7.84 - 461 - WO2005/049594 PCT/US2004/037911 EXAMPLE 438C This example was made by substituting EXAMPLE 438B for 2-(methylsulfanyl)benzaldehyde in EXAMPLE 128E. 1HNMR (400MHz, DMSO-d6) 5 10.18 (br s, IH), 8.52 (d, IH), 8.25 (d, IH) , 7.84 (dd, IH), 7.78 (d, 2H), 7.37 (d, 2H), 7.29 (dd, 2H), 7.24 (m, 2H), 7.19 (m, 2H), 7.12 (m, 3H), 7.07 (m, IH), 6.95 (d, 2H), 6.56 (dd, IH), 6.52 (d,.IH), 4.35 (s, 2H), 4.25 (m, IH) , 3.39 (d, 2H), 3.35 (m, 4H), 3.18 (m, IH), 3.05 (m, 8H), 2.68 (s, 6H) , 2.51 (m, IH), 2.19 (m, 2H). EXAMPLE 439A This example was made by substituting piperidine for isoindoline in EXAMPLE 435A. EXAMPLE 439B This example was made by substituting EXAMPLE 439A for EXAMPLE 435A in EXAMPLE 435B. EXAMPLE 439C This example was made by substituting EXAMPLE 439B for 2-(methylsulfanyl)benzaldehyde in EXAMPLE 128E. 1H NMR (400MHz, DMSO-d6) 8 8.49 (d, IH), 8.19 (m, IH), 7.82 (dd, IH), 7.75 (d, 2H), 7.41 (m, IH), 7.35 (m, IH), 7.30 (d, 2H), 7.22 (m, 3H), 7.15 (m, IH), 7.02 (m, 2H), 6.87 (d, IH), 4.12 (m, IH) , 3.60 (m, 2H), 3.42 (m, IH), 3.37 (d, 2H), 3.31 (m, 5H), 3.22 (m, 2H) , 3.08 (m, 2H), 2.82 (m, 4H), 2.69 (s, 6H), 2.59 (m, 2H), 2.10 (m, 2H), 1.65 (m, 4H), 1.51 (m, 2H), 1.21 (m, 4H). EXAMPLE 440 This example was made by substituting 4-cyclohexylamino-3-nitro-benzenesulfonamide, prepared as described in WO02/24636, for 4-(((1R)-3-(dimethylamino)- - 463 - WO2005/049594 PCT/US2004/037911 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500MHz, DMSO-d6) 5 11.90 (brs, IH), 8.61 (d, IH) , 8.60 (dd, IH), 7.94 (dd, IH), 7.74 (d, 2H), 7.59 (d, IH), 7.41 (dd, 2H), 7.38 (m, 4H), 7.25 (d, IH), 7.22 (d, IH), 6.89 (d, 2H), 3.58 (m, 2H), 3.25 (m, 3H), 2.47 (m, 4H), 1.85 (d, 2H), 1.69 (m, 3H), 1.61 (m, 2H), 1.19 (m, 4H), 0.99 (m, 2H). EXAMPLE 441 This example was made by substituting 4-cyclohexylmethylamino-3-nitrobenzenesulfonamide, prepared as described in WO02/24636, for 4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE ID. 1H NMR (500MHz, DMSO-d6) 5 11.90 (br s, IH), 8.70 (d, IH), 8.36 (dd, IH), 7.99 (dd, IH), 7.78 (d, 2H), 7.50 (d, IH), 7.45 (dd, 2H), 7.42 (m, 4H), 7.35 (d, IH), 7.32 (d, IH), 6.94 (d, 2H), 3.76 (m, 2H), 3.69 (m, 2H), 3.38 (m, IH), 2.58 (m, 4H), 1.99 (d, 2H), 1.74 (m, 3H), 1.62 (m, 2H), 1.45 (m, 6H), 1.29 (m, 2H). EXAMPLE 442 This example was prepared by substituting EXAMPLE 9OC and 4-( ((lR)-3-(4-morpholinyl)-1-((phenylsulfanyl)methyl)propyl)amino)-3- nitrobenzenesulfonamide, prepared as described in WO 02/24636, for EXAMPLE 2C and 4-(( (1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. 1H NMR (400MHz, DMSO-d6) 5 11.43 (br s, IH) , 8.54 (d, IH), 8.38 (d, IH), 7.83 (dd, IH), 7.79 (d, 2H), 7.41 (dd, 2H), 7.35 (m, 2H), 7.28 (m, 6H), 7.17 (m, 4H), 6.80 (d, 2H) , 4.19 (m, IH), 3.62 (m, 4H), 3.39 (m, 2H), 3.30 (m, 2H), 3.02 (s, 3H), 2.90 - 464 - WO 20<>5/<>49594 PCT/US2004/037911 (s, 2H), 2.85 (dd, 2H) , 2.65 (m, 6H), 2.08 (m, IH), 1.98 (m, IH) , 1.47 (d, 2H) , 1.18 (m, 2H) . EXAMPLE 443 This example was prepared by substituting EXAMPLE 9OC and 3-nitro-4-((2-(phenylsulfanyl)ethyl)amino)benzenesulfonamide, prepared as described in WO 02/24 636, for EXAMPLE 2C and 4-(((1R)-3- (dimethylamino)- I7((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide, respectively, in EXAMPLE 2D. 1H NMR (400MHz, DMSO-d6) 5 11.95 (br s, IH) , 8.75 (dd, IH) , 8.60 (d, IH), 7.91 (dd, IH), 7.79 (d, 2H), 7.41 (dd, 2H), 7.36 (m, 3H), 7.28 (m, 6H), 7.17 (m, 3H), 6.80 (d, 2H), 3.66 (m, 2H), 3.39 (m, 2H), 3.29 (m, 2H), 3.02 (s, 3H), 2.90 (s, 2H), 2.86 (dd, 2H), 1.45 (m, 2H), 1.18 (m, 2H). EXAMPLE 444A 4-chloro-3-(trifluoromethyl)benzenesulfonyl chloride (5 g) in THF (100 mL) was treated with saturated NH4OH at 0°C, stirred for 30 minutes and concentrated. The concentrate in ethyl acetate was washed with water and brine, and dried (Na2SO4), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with 30% ethyl acetate in hexanes. EXAMPLE 444B A mixture of EXAMPLE 444A (1.5 g) and 2-(phenylsulfanyl)ethanamine (1.06 g) in DMSO (17 mL) was treated with TEA (0.97 mL), heated at 145°C for 18 hours, cooled to 25°C, poured into ethyl acetate, washed with water, brine, dried (Na2SO4) , filtered, and concentrated. The - 465 - WO2005/049594 PCT/US2004/037911 concentrate was flash chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 444C This example was made by substituting EXAMPLE 4 44B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. -H NMR (500MHz, DMSO-d6) 8 7.88 (d, IH), 7.77 (d, IH), 7.73 (dd, 2H), 7.51 (d, IH) , 7.49 (s, 4H), 7.40 (dd, 2H), 7.35 (m, 4H), 7.21 (m, 2H), 6.78 (d, 2H), 6.70 (d, IH), 3.41 (m, 2H), 3.39 (s, IH), 3.16 (m, 2H), 3.13 (m, 4H), 2.50 (s, IH), 2.40 (m, 4H). EXAMPLE 445A This example was made by substituting EXAMPLE 444A for 4-fluoro-3-nitrobenzenesulfonamide, prepared as described in WO02/24636, in EXAMPLE 20D. EXAMPLE 445B This example was made by substituting EXAMPLE 445A for EXAMPLE 18E in EXAMPLE 18F. EXAMPLE 445C This example was made by substituting EXAMPLE 445B for 4-(((1R)-3-(dimethylamino)- 1-((phenylsulfanyl)methyl)propyl) amino)-3-nitrobenzenesulfonamide in EXAMPLE 2D. lH NMR (500MHz, DMSO-d6) 5 10.90 (br s, IH), 7.94 (d, IH), 7.79 (d, IH) , 7.74 (d, 2H), 7.53 (d, IH), 7.47 (s, 4H), 7.38 (m, 2H) , 7.32 (m, 2H), 7.26 (m, 3H), 7.19 (m, IH), 6.87 (d, 3H), 3.99 (m, IH), 3.42 (s, 2H), 3.29 (m, 2H), 3.17 (m, 4H), 3.02 (m, 4H), 2.40 (m, 4H), 2.16 (m, 2H), 1.89 (m, 4H), 1.28 (m, 2H). - 466 - WO2005/049594 PCT/US2004/037911 EXAMPLE 446A 4-chloronicotinic acid (5 g) in 1:1 methanol/ethyl acetate (200 itiL) was treated with 2M trimethylsilyldiazomethane (25 mL) and concentrated. EXAMPLE 446B A mixture of EXAMPLE 446A (4.88 g), 4-chlorobenzeneboronic acid (5.15 g), KF (5.45 g), Pd2(dba)3 (260 mg) , and tri-tert-butylphosphine in THF (80 mL) at 25°C was stirred for 3 days, filtered and concentrated. The concentrate was flash chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE 446C EXAMPLE 4 4 6B (3.4 g) in THF (50 mL) at 0°C was treated with IM LiAlH4 in THF (14 mL), stirred at 25°C for 1 hour, quenched with water (5 mL) and IM NaOH (20 mL), filtered, and concentrated. The concentrate was flash chromatographed on silica gel with ethyl acetate. EXAMPLE 446D EXAMPLE 446C (530 mg) in acetonitrile (15 mL) at 0°C was treated with pyridine (0.315 mL) and dibromotriphenylphosphorane (1.32 g), stirred at 25°C for 1 hour, and poured into saturated Na2C03 (100 mL) and ethyl acetate. The extract was washed with brine and dried (Na2SO4), filtered, and concentrated. The concentrate was- flash chromatographed on silica gel with 1:1 ethyl acetate/hexanes. EXAMPLE 446E - 4 67 - WO2005/049594 PCT/US2004/037911 This example was made by substituting EXAMPLE 446D for 2-bromobenzyl bromide in EXAMPLE 2A. EXAMPLE 446F This example was made by substituting EXAMPLE 44 6E for EXAMPLE IB in EXAMPLE 1C. EXAMPLE 446G This example was made by substituting EXAMPLE 446F for EXAMPLE 1C in EXAMPLE ID. 1H NMR (500MHz, DMSO-d6) 5 8.64 4 PCT7US2004/037911 N(R12)2/ C(O)NH2, C(O)NHR12, C(O)N(R12)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R12 is R13, R14, R15 or R16; R13 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R13A; R13A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R14 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl, 1,2,3-triazolyl, each of which is unfused or fused with benzene; R15 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R16 is Ca-alkyl, C2-alkyl, C3-7alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl; - 493 - WO2005/049594 PCT/US2004/037911 Z1 is R26 or R2.7, each of which is substituted with R2B, R or R , each of which is substituted wxth CI, Br, CH2R , C(R31) (R31A) (R37), C(O)R37, OR37, SR37, S(O)R37, SO2R37 orNHR37; R2 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R27 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R28 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R29 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R30 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, C6-cycloalkyl, C6-cycloalkyl, C10-cycloalkyl, C11-cycloalkyl, C12-cycloalkyl, C13-cycloalkyl, C14-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl, Ce-cycloalkenyl, Ca-cycloalkenyl or C10-4cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, - 494 - WO2005/049594 PCT/US2004/037911 C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R31 and R31R are independently F, CI, Br, C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl or are taken together and are C2-spiroalkyl, C3-spiroalkyl, C4-spiroalkyl or C5-spiroalkyl; ' R37 is R38, R39 or R40, each of which is substituted with F, CI, Br, I, R41, OR41, NHR41, N(R41)2, NHC(O)OR41, SR41, S (O) R41 or SO2R41; R38 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R39 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R40 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C7-cycloalkyl, Ce-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl, C6-cycloalkenyl, C7-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R41 is R42, R43, R44 or R45; R42 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, - 495 - WO2005/049594 PCT/US2004/0379» pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine, 1,2,3-triazole or R42A; R42A is C4-cycloalkane, C5-cycloalkane, C6-cycloalkane, C4-cycloalkene, C5-cycloalkene or C6-cycloalkene, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; R43 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1, 2, 3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R44 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenyl, C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2, 3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R45 is Cx-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl C6-alkyl, C2-alkenyl, C3-alkenyl, C4-alkenyl, C5-alkenyl C6-alkenyl, C2-alkynyl, C3-alkynyl, C4-alkynyl, C5-alkynyl or C6-alkynyl, each of which is unsubstituted or substituted with one or two independently selected R , OR , NHR , N(R )2r C(O)NH2, C(O)NHR46, C(O)N(R46)2, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R46 is R47 , R48 or R49 ; - 496 - WO2005/049594 PCT7US2004/037911 R47 is phenyl which is unfused or fused with benzene, furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine or 1,2,3-triazole; R48 is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2, 3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thienyl, triazinyl or 1,2,3-triazolyl, each of which is unfused or fused with benzene; R49 is C3-cycloalkyl, C4-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, C4-cycloalkenylr C5-cycloalkenyl or C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(O), S, S(O), SO2 or NH and one or two CH moieties unreplaced or replaced with N; wherein the moieties represented by B and Y together are substituted with C2-alkyl, C3-alkyl or C4-alkyl, each of which is substituted with one or two independently selected SR or 55 55 N (R )2 substituents, wherein R is independently selected phenyl or C1-alkyl; the moieties' represented by R2 , R3 and R4 are unsubstituted or substituted with one or two independently selected R50, OR50, SR50, SO2R5°, CO(O)R50 or OCF3 substituents, wherein R is phenyl, C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl; 8 9 10 the moieties represented by R , R and R are unsubstituted or substituted with one or two independently selected R50, OR50, C (O) NHSO2R5°, CO(O)R50, C(O)R50, C(O)OH, C(O)NHOH, OH, NH2, F, Cl, Br or I substituents, wherein R50 is phenyl, tetrazolyl or R54, wherein R54 is C1-alkyl, C2-alkyl or - 497 - WO2005/049594 PCT/US2004/037911 C3-alkyl, each of which is unsubstituted or substituted with phenyl; the moieties represented by R26 and R27 are further unsubstituted or substituted with one or two independently selected F, Br, CI or I substituents; the moieties represented by R , R and R are further unsubstituted or substituted with OR , wherein R is C1-alkyl or C2-alkyl, each of which is unsubstituted or substituted with N(R55)2 or R56, wherein R55 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, and R is C5-cycloalkyl or C6-cycloalkyl, each having one or two CH2 moieties replaced with independently selected O or NH and one CH moiety unreplaced or replaced with N; the moieties represented by R38 , R39 and R40 are further unsubstituted or substituted with one or two independently selected C1-alkyl, F, Br, CI or I substituents; and the moieties represented by R42 , R43 , R44 and R are unsubstituted or substituted with one or two independently selected R50f OR50, SR50, N(R50)2f SO2R50, CN, CF3, F, CI, Br or substituents, wherein R50 is phenyl or R54 , wherein R54 is C1-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with N(C1-alkyl)2 or C6-cycloalkyl having one CH2 moiety replaced with O and one CH moiety replaced with N. 4. The compound of formula (I) according to claim 3, wherein A1 is C(A2); A2 is H, F, CN, C(O)OHf C(O)NH2 or C(O)OCH3; B1 is R1, OR1, NHR1, N(R1)2 or NR1C (O) N (R1) 2; - 498 - WO2005/049594 PCT/US2004/037911 D1 is H, F, CI or CF3; E1 is H, F or CI; Y1 is H, CN, NO2, F, CI, CF3, OCF3/ NH2, C(O)NH2, or B and Y , together with the atoms to which they are attached, are imidazole or triazole; R1 is phenyl, pyrrolyl, C5-cycloalkyl, C6-cycloalkyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl or R ; R5 is C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl or C6-alkyl, each of which is unsubstituted or substituted with one or two or three independently selected C4-spiroalkyl, C5-spiroalkyl, R7, OR7, SR7, SO2R7, NHR7, N(R7)2, C(O)R7, C(O)NH2, C(O)NHR7, NHC(O)R7, NHSO2R7, NHC(O)OR7, NHC(O)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, OH, C(O)OH or NH2 substituents; R7 is phenyl, furanyl, imidazolyl, pyridinyl, tetrazolyl, thiazolyl, thienyl, 1,3-benzoxazolyl, 1,3-benzodioxolyl, 1,3-benzothiazole, C3-cycloalkyl, C-cycloalkyl, C5-cycloalkyl, C6-cycloalkyl, azetidinyl, morpholinyl, piperazinyl, piperidinyl, thiomorpholinyl, thiomorpholinyl sulfone 7-azabicyclo[2.2.1]heptanyl, 8-azabicyclo[3.2.1]-octanyl, 4,5-dihydro-lH-imidazolyl 2-oxa-5-azabicyclo-[2.2.l]heptanyl, 1,4,5,6-tetrahydropyrimidinyl or R1 ; Rn is C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl, each of which is unsubstituted or substituted with one or two or three independently selected R12, OR12, N(R12)2, C(O)N(R12)2, OH, C(O)OH, NH2, CF3/ F, CI, Br or I substituents; 12 R is 1,3-benzodioxolyl, pyridinyl, morpholinyl or C1-alkyl; - 499 - WO2005/049594 PCT/US2004/037911 Z1 is phenyl or pyridinyl, each of which is substituted with C6-cycloalkenyl, piperazinyl, piperidinyl, 1,2,3, 6-tetrahydropyridinyl or octahydropyrrolo[3,4-c]pyrrolyl, each of which is substituted with CH2R , C(C2-spiroalkyl) (R37) or C(O)R37; R37 is phenyl, naphthyl, imidazolyl, pyrazolyl, pyridinyl, C5-cycloalkenyl, C6-cycloalkenyl, C7~cycloalkenyl, Ce-cycloalkenyl or 3,6-dihydro-2H-pyranyl, each of which is substituted with F, CI, Br, I, R41, NHR41, N(R41)2, NHC(O)OR41 or SR41; R41 is phenyl, naphthyl, cyclohexyl, morpholinyl, piperidinyl, thienyl, pyridinyl, quinolinyl, benzofuranyl, 1,3-benzodioxolyl, isoindolinyl, 1,3-oxazolidin-2-onyl or R ; R45 is C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl, each of which is unsubstituted or substituted with phenyl; wherein the moieties represented by B and Y together are substituted with C2-alkyl, C3-alkyl or C4-alkyl, each of which is substituted with one or two independently selected SR or N(R )2 substituents, wherein R is independently selected phenyl or C1-alkyl; the moieties represented by R are unsubstituted or substituted with one or two independently selected R , OR °, SR50, SO2R5°, CO(O)R50 or OCF3 substituents, wherein R50 is phenyl, C1-alkyl, C2-alkyl, C3-alkyl or C4-alkyl; the moieties represented by R are unsubstituted or substituted with one or two independently selected R , OR , C(O)NHSO2R5O, CO(O)R50, C(O)R5°, C(O)OH, C(O)NHOH, OH, NH2, F, CI, Br or I substituents, wherein R is phenyl, tetrazolyl or - 500 - WO2005/049594 PCT/US2004/037911 R54, wherein R54 is C1-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with phenyl; the phenyl and pyridinyl moieties of Z are further unsubstituted or substituted with one or two independently selected F, Br, CI or I substituents; the C6-cycloalkenyl, piperazinyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl and octahydropyrrolo[3,4-c]pyrrolyl moieties of Z are further unsubstituted or substituted with OR54, wherein R54 is Chalky 1 or C2-alkyl, each of which is unsubstituted or substituted with N (C1-alkyl)2, morpholinyl, piperidinyl or piperidinyl; the moieties represented by R are further unsubstituted or substituted with one or two independently selected C1-alkyl, F, Br, CI or I substituents; and ; the moieties represented by R are unsubstituted or substituted with one or two independently selected R , OR , SR50, N(R50)2, SO2R50, CN, CF3, F, Cl, Br or I substituents, wherein R is phenyl or R54, wherein R is Ca-alkyl, C2-alkyl or C3-alkyl, each of which is unsubstituted or substituted with N(C1-alkyl)2 or morpholinyl. 5. A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer,lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer, said composition - 501 - WO2005/049594 PCT/US2004/037911 comprising an excipient and a therapeutically effective amount of the compound of claim 1. 6. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compound of claim 1. 7. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer,lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4-chloro (1,1'-biphenyl)-2- yl)methyl)piperazin-l-yl)benzoyl)-4-({(1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof. 8. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer,lymphoblastic leukemia, follicular - 502 - WO2005/049594 PCT/US2004/037911 lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of claim 1 and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. 9. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of N-(4-(4-((4-chloro(1,l1-biphenyl)-2-yl)methyl)piperazin-l-yl)benzoyl)-4-(((1R)-3-{dimethylamino)-1-((phenylsulfanyl)methyl)-propyl)amino)-3- nitrobenzenesulfonamide, or a therapeutically acceptable salt, prodrug or salt of a prodrug thereof, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. I - 503 -